---
document_datetime: 2023-12-08 11:36:37
document_pages: 137
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/zilbrysq-epar-public-assessment-report_en.pdf
document_name: zilbrysq-epar-public-assessment-report_en.pdf
version: success
processing_time: 92.1807779
conversion_datetime: 2025-12-26 20:47:47.593579
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

14 September 2023 EMA/CHMP/439661/2023 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Zilbrysq

International non-proprietary name: Zilucoplan

Procedure No. EMEA/H/C/005450/0000

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                              | ..............................................8                                                           |
|-------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier....................................................................................      | 8                                                                                                         |
| 1.2. Legal basis, dossier content.................................................................................      | 8                                                                                                         |
| 1.3. Information on paediatric requirements.................................................................            | 8                                                                                                         |
| 1.4. Information relating to orphan market exclusivity                                                                  | ................................................... 8                                                     |
| 1.4.1. Similarity                                                                                                       | ....................................................................................................... 8 |
| 1.4.2. New active substance status                                                                                      | ............................................................................. 8                           |
| 1.5. Scientific advice................................................................................................. | 9                                                                                                         |
| 1.6. Steps taken for the assessment of the product                                                                      | ....................................................... 9                                                 |
| 2. Scientific discussion                                                                                                | ..............................................................................10                          |
| 2.1. Problem statement...........................................................................................       | 10                                                                                                        |
| 2.1.1. Disease or condition.......................................................................................      | 10                                                                                                        |
| 2.1.2. Epidemiology                                                                                                     | ................................................................................................ 10       |
| 2.1.3. Aetiology and pathogenesis.............................................................................          | 11                                                                                                        |
| 2.1.4. Clinical presentation, diagnosis and stage/prognosis...........................................                  | 11                                                                                                        |
| 2.1.5. Management.................................................................................................      | 11                                                                                                        |
| 2.2. About the product ............................................................................................     | 12                                                                                                        |
| 2.3. Type of application and aspects on development...................................................                  | 13                                                                                                        |
| 2.4. Quality aspects ................................................................................................   | 13                                                                                                        |
| 2.4.1. Introduction .................................................................................................   | 13                                                                                                        |
| 2.4.2. Active substance                                                                                                 | ........................................................................................... 13            |
| 2.4.3. Finished medicinal product..............................................................................         | 17                                                                                                        |
| 2.4.4. Discussion on chemical, and pharmaceutical aspects                                                               | .......................................... 19                                                             |
| 2.4.5. Conclusions on the chemical, pharmaceutical and biological aspects                                               | ..................... 19                                                                                  |
| 2.4.6. Recommendations for future quality development ..............................................                    | 19                                                                                                        |
| 2.5. Non-clinical aspects..........................................................................................     | 20                                                                                                        |
| 2.5.1. Introduction .................................................................................................   | 20                                                                                                        |
| 2.5.2. Pharmacology...............................................................................................      | 20                                                                                                        |
| 2.5.3. Pharmacokinetics                                                                                                 | .......................................................................................... 21             |
| 2.5.4. Toxicology....................................................................................................   | 24                                                                                                        |
| 2.5.5. Ecotoxicity/environmental risk assessment........................................................                | 29                                                                                                        |
| 2.5.6. Discussion on non-clinical aspects....................................................................           | 30                                                                                                        |
| 2.5.7. Conclusion on the non-clinical aspects..............................................................             | 32                                                                                                        |
| 2.6. Clinical aspects                                                                                                   | ................................................................................................ 32       |
| 2.6.1. Introduction                                                                                                     | ................................................................................................. 32      |
| 2.6.2. Clinical pharmacology ....................................................................................       | 34                                                                                                        |
| 2.6.3. Discussion on clinical pharmacology .................................................................            | 51                                                                                                        |
| 2.6.4. Conclusions on clinical pharmacology                                                                             | ............................................................... 55                                        |
| 2.6.5. Clinical efficacy                                                                                                | ............................................................................................. 55          |
| 2.6.6. Discussion on clinical efficacy                                                                                  | .......................................................................... 90                             |
| 2.6.7. Conclusions on the clinical efficacy...................................................................          | 97                                                                                                        |
| 2.6.8. Clinical safety ...............................................................................................  | 97                                                                                                        |
| 2.6.9. Discussion on clinical safety                                                                                    | ...........................................................................118                            |

<div style=\"page-break-after: always\"></div>

2.6.10. Conclusions on the clinical safety ..................................................................  121

2.6.11. Safety concerns  ..........................................................................................  122

2.6.12. Pharmacovigilance plan ...............................................................................  122

2.6.13. Risk minimisation measures .........................................................................  123

2.6.14. Conclusion  .................................................................................................  124

2.7. Pharmacovigilance...........................................................................................  124

2.7.1. Pharmacovigilance system  .............................................................................  124

2.7.2. Periodic Safety Update Reports submission requirements ...................................  124

2.8. Product information  .........................................................................................  124

2.8.1. User consultation..........................................................................................  124

2.8.2. Additional monitoring  ....................................................................................  124

3. Benefit-Risk Balance............................................................................  125

3.1. Therapeutic Context ........................................................................................  125

3.1.1. Disease or condition......................................................................................  125

3.1.2. Available therapies and unmet medical need ....................................................  125

3.1.3. Main clinical studies  ......................................................................................  126

3.2. Favourable effects  ...........................................................................................  126

3.3. Uncertainties and limitations about favourable effects ..........................................  128

3.4. Unfavourable effects  ........................................................................................  129

3.5. Uncertainties and limitations about unfavourable effects .......................................  129

3.6. Effects Table ..................................................................................................  130

3.7. Benefit-risk assessment and discussion ..............................................................  132

3.7.1. Importance of favourable and unfavourable effects ...........................................  132

3.7.2. Balance of benefits and risks  ..........................................................................  134

3.7.3. Additional considerations on the benefit-risk balance .........................................  134

3.8. Conclusions  ....................................................................................................  134

4. Recommendations ...............................................................................  134

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| AChR      | Anti-acetylcholine receptor                                                                            |
|-----------|--------------------------------------------------------------------------------------------------------|
| ADA       | Anti-drug antibodies                                                                                   |
| ADME      | Absorption, distribution, metabolism, and excretion                                                    |
| AE        | Adverse events                                                                                         |
| AIC       | Akaike information criterion                                                                           |
| ALS       | Amyotrophic lateral sclerosis                                                                          |
| ANCOVA    | Analysis of covariance                                                                                 |
| APA       | Anti-PEG antibodies                                                                                    |
| ARDs      | Adverse drug reactions                                                                                 |
| AUC       | Area under the drug concentration versus time curve                                                    |
| AUC last  | Area under the plasma concentration-time curve from zero to last measure                               |
| AUC 0-24  | Area under the plasma concentration-time curve from zero to 24 hours after administration              |
| AUC 0- τ  | Area under the concentration-time curve at steady state over the dosing interval (from time zero to τ) |
| AUC 0-inf | Area under the concentration-time curve from time zero to infinity                                     |
| BMI       | Body mass index                                                                                        |
| C5        | Complement component 5                                                                                 |
| CBL       | Change from baseline                                                                                   |
| CCK       | Cholecystokinin                                                                                        |
| CHMP      | Committee for Medicinal Products for Human Use                                                         |
| CI(s)     | Confidence interval(s)                                                                                 |
| CL/(F)    | (apparent) Clearance                                                                                   |
| CNS       | Central nervous system                                                                                 |
| C max     | Maximum plasma concentration                                                                           |
| CQA       | Critical quality attribute                                                                             |
| CSP       | Clinical study protocol                                                                                |
| DDI       | Drug-drug interaction                                                                                  |
| DSC       | Differential scanning calorimetry                                                                      |
| EFD       | Embryofetal development                                                                                |
| ePPND     | Enhanced pre-postnatal development                                                                     |
| ERCP      | Endoscopic retrograde cholangiopancreatography                                                         |
| FT-IR     | Fourrier transform infrared spectroscopy                                                               |
| GC-MS     | Gas chromatography mass spectrometry                                                                   |
| GD        | Gestation day                                                                                          |
| HDPE      | High density polyethylene                                                                              |
| hERG      | human ether-a-go-go-related gene                                                                       |

<div style=\"page-break-after: always\"></div>

| HI        | Hepatic impairment                                                                                                    |
|-----------|-----------------------------------------------------------------------------------------------------------------------|
| HPLC      | High performance liquid chromatography                                                                                |
| IC 50     | half maximal inhibitory concentration                                                                                 |
| ICE       | Intercurrent event                                                                                                    |
| ICH       | International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use |
| ICP-MS    | Inductively coupled plasma mass spectrometry                                                                          |
| IMNM      | Immune-mediated necrotising myopathy                                                                                  |
| IMP       | Investigational medicinal product                                                                                     |
| IPD       | Individual patient data                                                                                               |
| IVIG      | Intravenous immunoglobulin                                                                                            |
| J2R       | Jump-to-reference                                                                                                     |
| LC-MS/MS  | Liquid chromatography-tandem mass spectrometry                                                                        |
| LS(M)     | least squares (means)                                                                                                 |
| LOCF      | Last-observation-carried-forward                                                                                      |
| MAC       | Membrane attack complex                                                                                               |
| MAH       | Marketing authorisation holder                                                                                        |
| MAR       | Missing at random                                                                                                     |
| MD        | Multiple dose                                                                                                         |
| MedDRA    | Medical Dictionary for Regulatory Activities                                                                          |
| (g)MG     | Generalised myasthenia gravis                                                                                         |
| MG-ADL    | Myasthenia gravis activities of daily living                                                                          |
| MGC       | Myasthenia gravis composite                                                                                           |
| MGFA      | Myasthenia Gravis Foundation of America                                                                               |
| MG-QOL15r | Myasthenia Gravis-Quality of Life 15-item scale revised                                                               |
| MGTX      | Myasthenia gravis patients receiving prednisone                                                                       |
| MMRM      | Mixed model with repeated measures                                                                                    |
| (m)ITT    | (modified) Intent-to-treat                                                                                            |
| MTP       | Multiple testing procedure                                                                                            |
| NAb       | Neutralising antibodies                                                                                               |
| NHP       | Non-human primate                                                                                                     |
| NMJ       | Neuromuscular junction                                                                                                |
| NMR       | Nuclear magnetic resonance                                                                                            |
| NOAEL     | No-observed-adverse-effect level                                                                                      |
| NOR       | Normal operating range                                                                                                |
| OLE       | Open label extension                                                                                                  |
| OR        | Odds ratio                                                                                                            |
| OX        | Orexin                                                                                                                |

<div style=\"page-break-after: always\"></div>

| PAR      | Proven acceptable range                              |
|----------|------------------------------------------------------|
| PB       | Placebo                                              |
| PBT      | Persistence bioaccumulation and toxicity             |
| PD       | Pharmacodynamic                                      |
| PDE      | Permitted daily exposure                             |
| PEG      | Polyethylene glycol                                  |
| PFS      | pre-filled syringe                                   |
| Ph. Eur. | European Pharmacopoeia                               |
| PK       | Pharmacokinetic                                      |
| PLEX     | Plasma exchange                                      |
| PNH      | Paroxysmal nocturnal haemoglobinuria                 |
| PP       | Polypropylene                                        |
| PT       | Preferred term                                       |
| popPK    | population Pk                                        |
| Q        | Intercompartmental CL                                |
| QMG      | Quantitative myasthenia gravis                       |
| QSAR     | Quantitative structure-activity relationship         |
| QTcF     | QT corrected using the Fridericia method             |
| QTPP     | Quality target product profile                       |
| QWBA     | Quantitative whole-body autoradiography              |
| (s)RBC   | (sheep) Red blood cell                               |
| RH       | Relative humidity                                    |
| RMP      | Risk management plan                                 |
| RNS      | rigid needle shield                                  |
| RP-HPLC  | Reverse phase high performance liquid chromatography |
| SAD      | Single-ascending dose                                |
| SAP      | Statistical analysis plan                            |
| SC       | Subcutaneous(ly)                                     |
| SmPC     | Summary of product characteristics                   |
| SMQ      | Standardized MedDRA query                            |
| SOC      | System organ class                                   |
| SPPS     | solid phase peptide synthesis                        |
| t max    | Time to maximum plasma concentration                 |
| t ½      | Terminal half-life                                   |
| TEAEs    | Treatment-emergent adverse events                    |
| TGA      | Thermo-gravimetric analysis                          |
| TK       | Toxicokinetic                                        |

<div style=\"page-break-after: always\"></div>

| TMDD   | Target mediated drug disposition                             |
|--------|--------------------------------------------------------------|
| UTI    | Urinary tract infection                                      |
| UV     | Ultraviolet                                                  |
| Vc(/F) | (Apparent) volume of distribution of the central compartment |
| Vp     | Volume of distribution of the peripheral compartment         |
| VPCs   | Visual predictive checks                                     |
| ZLP    | zilucoplan                                                   |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

The applicant UCB Pharma S.A. submitted on 31 August 2022 an application for marketing authorisation to the European Medicines Agency (EMA) for Zilbrysq, through the centralised procedure falling within the Article 3(1) and point 3 of Annex of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 19 September 2019.

Product name Zilbrysq was designated as an orphan medicinal product EU/3/22/2650 on 2022-07-18 in the following condition: Treatment of myasthenia gravis.

The applicant applied for the following indication: the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive and require treatment in addition to steroids or non-steroidal immunosuppressants.

## 1.2. Legal basis, dossier content

## The legal basis for this application refers to:

Article 8.3 of Directive 2001/83/EC - complete and independent application

The application submitted is composed of administrative information, complete quality data, non-clinical and  clinical  data  based  on  the  applicants'  own  tests  and  studies  and/or  bibliographic  literature substituting/supporting certain test(s) or study(ies).

## 1.3. Information on paediatric requirements

Pursuant  to  Article  7  of  Regulation  (EC)  No  1901/2006,  the  application  included  EMA  Decision(s) P/0143/2021 on the agreement of a paediatric investigation plan (PIP).

At  the  time  of  submission  of  the  application,  the  PIP  P/0143/2021  was  not  yet  completed  as  some measures were deferred.

## 1.4. Information relating to orphan market exclusivity

## 1.4.1. Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did submit a critical report addressing the possible similarity with authorised orphan medicinal products.

## 1.4.2. New active substance status

The applicant requested the active substance zilucoplan contained in the above medicinal product to be considered as a new active substance, as the applicant claims that it is not a constituent of a medicinal product previously authorised within the European Union.

<div style=\"page-break-after: always\"></div>

## 1.5. Scientific advice

The applicant received the following protocol assistance on the development relevant for the indication subject to the present application:

| Date             | Reference                                   | SAWP co-ordinators                               |
|------------------|---------------------------------------------|--------------------------------------------------|
| 29 May 2019      | EMEA/H/SA/3949/2/2019/SME/III               | Professor de Andres Trelles, Dr Marion Haberkamp |
| 17 June 2019     | EMEA/H/SA/3949/2/2019/SME/III clarification | Professor de Andres Trelles, Dr Marion Haberkamp |
| 10 December 2020 | EMEA/H/SA/3949/3/2020/I                     | Ms Audrey Sultana and Dr Cristina Migali         |

The protocol assistance pertained to the following quality, non-clinical, and clinical aspects:

The applicant received scientific advice on the development of zilucoplan for treatment of generalised myasthenia gravis from the CHMP on 29 May 2019 EMEA/H/SA/3949/2/2019/SME/III and clarification on the 17 June 2019. The scientific advice pertained to the following pre-clinical development, Clinical development, Phase III, Methodology, Statistical Analysis, Safety.

The applicant received scientific advice on the development of zilucoplan for treatment of generalised myasthenia gravis from the CHMP on 10 December 2020 (EMEA/H/SA/3949/3/2020/I). The scientific advice  pertained  to  the  following  quality  aspects:  starting  materials,  manufacturing  sites,  process validation for finished product.

## 1.6. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur: Kristina Dunder Co-Rapporteur:  Alexandre Moreau

| The application was received by the EMA on                                                                                                      | 31 August 2022    |
|-------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| The procedure started on                                                                                                                        | 29 September 2022 |
| The CHMP Rapporteur's first Assessment Report was circulated to all CHMP and PRAC members on                                                    | 14 December 2022  |
| The CHMP Co-Rapporteur's first Assessment Report was circulated to all CHMP and PRAC members on                                                 | 3 January 2023    |
| The PRAC Rapporteur's first Assessment Report was circulated to all PRAC and CHMP members on                                                    | 3 January 2023    |
| The CHMP agreed on the consolidated List of Questions to be sent to the applicant during the meeting on                                         | 26 January 2023   |
| The applicant submitted the responses to the CHMP consolidated List of Questions on                                                             | 19 April 2023     |
| The CHMP Rapporteurs circulated the CHMP and PRAC Rapporteurs Joint Assessment Report on the responses to the List of Questions to all CHMP and | 30 May 2023       |

<div style=\"page-break-after: always\"></div>

| PRAC members on                                                                                                                                                                          |                   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                                                                                                 | 08 June 2023      |
| The CHMP agreed on a list of outstanding issues <in writing and/or in an oral explanation> to be sent to the applicant on                                                                | 22 June 2023      |
| The applicant submitted the responses to the CHMP List of Outstanding Issues on                                                                                                          | 8 August 2023     |
| The CHMP Rapporteurs circulated the CHMP and PRAC Rapporteurs Joint Assessment Report on the responses to the List of Outstanding Issues to all CHMP and PRAC members on                 | 31 August 2023    |
| The CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a marketing authorisation to Zilbrysq on | 14 September 2023 |
| The CHMP adopted a report on similarity of Zilbrysq with Vyvgart and Soliris on (see Appendix on similarity)                                                                             | 14 September 2023 |
| Furthermore, the CHMP adopted a report on New Active Substance (NAS) status of the active substance contained in the medicinal product (see Appendix on NAS)                             | 14 September 2023 |

## 2. Scientific discussion

## 2.1. Problem statement

## 2.1.1. Disease or condition

Myasthenia gravis (MG) is a rare disease characterised by the production of autoantibodies targeting proteins that are critical for the normal transmission of neurotransmitter signals from nerves to muscles.

## 2.1.2. Epidemiology

The prevalence of MG globally is estimated to be 12.4 (range 10.6 to 14.5) per 100,000 persons (Salari et al, 2021), hence, MG affects up to approximately 760,000 people worldwide. MG most commonly affects  young  adult  women  (under  40)  and  older  men  (over  60),  but  it  can  occur  at  any  age. Epidemiological studies reveal an increasing prevalence over the past 50 years, due in part to an increase in  the  frequency  of  diagnosis  in  the  elderly  (Sanders  et  al,  2016).  As  the  population  has  aged,  the average age at onset has increased correspondingly.

The prevalence of MG in Europe (EU) is estimated to be 1 per 5,000 population (Orphanet).

<div style=\"page-break-after: always\"></div>

## 2.1.3. Aetiology and pathogenesis

MG is an antibody-directed, complement-mediated autoimmune disease characterised by the production of autoantibodies  targeting  acetylcholine  receptors  or  to  functionally  related  molecules  in  the postsynaptic membrane at the neuromuscular junction (NMJ). Approximately 80% of patients with MG are acetylcholine receptor (AChR) antibody positive (Howard, 2018). In these patients, binding of antiAChR auto-antibodies (mainly immunoglobulin [Ig]G1 and IgG3) to AChR results in uncontrolled and inappropriate  activation  of  the  classical  complement  pathway.  The  immune  complex  formed  by  the autoantibody-antigen complex activates the C1 component of the classical complement pathway. This leads to a series of enzymatic cleavage steps, culminating in the cleavage of complement component 5 (C5) into C5a and C5b and deposition of the cytolytic membrane attack complex (C5b-9, MAC) on the post-synaptic membrane of the NMJ and subsequent injury to the neuromuscular endplate, leading to failure of neuromuscular transmission.

## 2.1.4. Clinical presentation, diagnosis and stage/prognosis

In  approximately  15%  of  patients  with  MG,  symptoms  remain  confined  to  the  ocular  muscles.  In approximately 85% of patients, MG affects multiple muscle groups throughout the body, a condition that is typically referred to as generalised myasthenia gravis (gMG). Patients with gMG present with muscle weakness  that  characteristically  becomes  more  severe  with  repeated  use  and  recovers  with  rest. Symptoms are typically at their mildest in the morning, when overnight inactivity enables replenishment of acetylcholine levels in presynaptic motor neurons and worsen during the course of the day. Muscle weakness can be localised to specific muscles, but often progresses to more diffuse muscle weakness (Gilhus and Verschuuren, 2015; Gilhus, 2016).

Generalised MG symptoms can become life-threatening when muscle weakness involves the diaphragm and  intercostal  muscles  in  the  chest  wall  that  are  responsible  for  breathing.  The  most  dangerous complication of gMG, known as myasthenic crisis, requires hospitalisation, intubation, and mechanical ventilation. Approximately 15% to 20% of patients with gMG will experience a myasthenic crisis within 2 years of diagnosis (Shanker and Ramizuddin, 2014). The diagnosis of MG is based on medical history, evidence of clinical  signs  and  symptoms,  autoantibodies,  electrophysiological  studies  (e.g,  repetitive nerve  stimulation,  single  fibre  electromyography),  imaging  (e.g,  computed  tomography  scan)  and differential diagnosis with other neurological disorders including NMJ disorders (Gilhus et al, 2019).

## 2.1.5. Management

The most common target of autoantibodies in gMG is the nicotinic AChR, located at the NMJ, the point at which a motor neuron transmits chemical signals to a skeletal muscle fibre. Most therapies for gMG focus on either augmenting the AChR signal or non-specifically suppressing the autoimmune response. First-line  therapy  for  symptomatic  gMG  is  treatment  with  acetylcholinesterase  inhibitors  such  as pyridostigmine.  Although  sometimes  adequate  for  control  of  mild  ocular  symptoms,  pyridostigmine monotherapy is usually insufficient for the treatment of generalised weakness, and dosing is often limited by  cholinergic  side  effects.  Therefore,  in  patients  who  remain  symptomatic  despite  pyridostigmine therapy, corticosteroids with or without systemic immunosuppressants are used off label (Riedemann et al, 2002; Sanders et al, 2016). Immunosuppressants used frequently in gMG include azathioprine and mycophenolate mofetil. Cyclosporine, methotrexate, tacrolimus, cyclophosphamide, and rituximab are also  used  occasionally.  These  immunosuppressants  have  multiple  established  short-  and  long-term toxicities.

<div style=\"page-break-after: always\"></div>

Well-controlled,  randomised,  efficacy  studies  for  these  agents  are  sparse,  and  these  agents  are  not widely  approved.  Surgical  removal  of  the  thymus  may  be  recommended  in  patients  with  nonthymomatous gMG and moderate to severe symptoms, in an effort to reduce the production of AChR autoantibodies (Wachtman and Mansfield 2012; Wolfe et al, 2016). Intravenous immunoglobulin (IVIG) and plasma exchange (PLEX) are typically used short-term to manage worsening MG symptoms and in patients with myasthenic crisis or life-threatening signs such as respiratory insufficiency or dysphagia (Riedemann et al, 2002; Sanders et al, 2016). However, some patients with severe disease and multiple exacerbations may eventually require chronic IVIG or PLEX.

Inhibition of C5 for the treatment of gMG has already been shown to be effective in 2 clinical studies with the C5-blocking antibody, eculizumab (Howard et al, 2013; Howard et al, 2017), which established that inhibition of the terminal complement cascade by blocking cleavage of C5 is a clinically validated approach for treating gMG. Eculizumab is approved in the EU, Japan, and the US for treatment of adult patients with refractory gMG who are anti-AChR antibody positive. In addition, ravulizumab is approved in the US and EU for the treatment of adult patients with gMG who are anti-AChR positive (ravulizumabcwvz; ULTOMIRIS® US Prescribing Information).

The most recent additions to the MG treatment regimen, with a new mechanism of action, has been the introduction of efgartigimod (Vyvgart®), an IgG1 Fc fragment that targets neonatal Fc receptor (FcRn), leading to reduced overall IgG recycling.

A large population of patients with MG with high unmet medical need and severe disease burden exists despite standard of care therapies (Cutter et al, 2019); this may be because of poor efficacy of existing agents; inability to receive adequate standard of care therapies due to adverse effects; perceived or actual high treatment burdens; or denial of access to a specific treatment by insurance companies due to  its  high  cost.  The  high  unmet  medical  need  for  new  therapies  due  to  insufficiencies  of  current treatment options continues to be strongly felt by the MG patient community as well. Based on these considerations, a high unmet medical need continues to persist for improved therapeutic options, and in particular a more accessible and convenient C5 inhibitor such as zilucoplan for patients with gMG.

## 2.2. About the product

Zilucoplan (ZLP) is a 15-amino acid macrocyclic peptide complement inhibitor designed for the treatment of conditions in which inappropriate activation of C5 has been demonstrated to play a role. Zilucoplan has been developed for the treatment of gMG in adult patients who are anti-AChR antibody positive.

Zilucoplan is provided as a single-use prefilled syringe with a needle safety device and is formulated as a sterile, preservative-free solution administered via SC injection. Zilucoplan targets C5, a component of the terminal complement activation pathway. Zilucoplan binds to C5 with high affinity and prevents its cleavage by C5 convertases into the cleavage products C5a and C5b which results in a downregulation of the assembly and cytolytic activity of the membrane attack complex (MAC). Additionally, by binding to the C5b moiety of C5, zilucoplan sterically hinders binding of C5b to C6, which prevents the subsequent assembly and activity of the MAC, should any C5b be formed.

The initially proposed indication was the following:

- For  the  treatment  of  generalised  myasthenia  gravis  (gMG)  in  adult  patients  who  are  antiacetylcholine receptor (AChR) antibody positive and require treatment in addition to steroids or non-steroidal immunosuppressants.

The proposed posology is weight-based and is 16.6 mg (&lt;56 kg), 23.0 mg ( ≥ 56-&lt;77 kg) or 32.4 mg ( ≥ 77 kg) of zilucoplan given as daily subcutaneous injection. This corresponds to approximately 0.3 mg/kg (effective dose 0.2-0.4 mg/kg depending on the weight band). The proposed posology with flat

<div style=\"page-break-after: always\"></div>

dose within weight bands has been studied in the clinical programme and it is what is meant when a dose of 0.3 mg/kg is referred to.

## 2.3. Type of application and aspects on development

The clinical  development programme for zilucoplan in patients with gMG and acetyl choline receptor antibodies includes three clinical studies, MG0009 (phase II), MG00010 (RAISE) and MG00011 (RAISEXT). Further, a model-informed analysis was submitted to estimate the maintenance of efficacy effect versus placebo.

Scientific advice and protocol assistance were provided as the following procedures: EMEA/H/SA/3949/1/2018/PA/SME/III,  EMEA/H/SA/3949/2/2019/SME/III,  EMEA/H/SA/3949/3/2020/I, EMEA/H/SA/3949/2/2019/SME/III  (Clarification  letter),  and  a  national  scientific  advice  in  November 2021 at the Swedish Medicinal products Agency. See above further details for centralised SA procedures.

## 2.4. Quality aspects

## 2.4.1. Introduction

The finished product is presented as solution for injection in pre-filled syringe in three different dose presentations (16.6 mg, 23.0 mg and 32.4 mg) with zilucoplan as active substance. The product contains the sodium salt.

Other ingredients are sodium dihydrogen phosphate monohydrate, disodium phosphate (anhydrous), sodium chloride and water for injections.

The product is available in a prefilled syringe (type I glass) with a 29G ½' thin wall needle closed with a grey fluoropolymer laminated bromobutyl rubber plunger stopper. The needle is protected with a rigid needle shield consisting of a thermoplastic elastomer needle shield and a polypropylene rigid shield. Each prefilled syringe is pre-assembled with a needle safety device, a finger grip and a coloured plunger:

- Zilbrysq 16.6 mg solution for injection in pre-filled syringe - 0.416 mL solution for injection in pre -filled syringe with rubine red plunger:
- Zilbrysq  23 mg solution for injection in pre-filled  syringe  -  0.574 mL  solution  for  injection  in pre -filled syringe with orange plunger;
- Zilbrysq 32.4 mg solution for injection in pre-filled syringe - 0.810 mL solution for injection in pre -filled syringe with dark blue plunger.

## 2.4.2. Active substance

## 2.4.2.1. General information

The chemical name of zilucoplan sodium is N 2 -Acetyl-L-lysyl-L-valyl-Lα -glutamyl-L-arginyl-Lphenylalanyl-Lα -aspartyl-N-methyl-Lα -aspartyl-3-methyl-L-valyl-L-tyrosyl-3-(1H-pyrrolo[2,3b]pyridin-3-yl)-L-alanyl-Lα -glutamyl-L-tyrosyl-L-prolyl(2S)-2-cyclohexylglycyl-N 6 -(3-{ ω[( Nhexadecanoyl-Lγ -glutaminyl)amino]-tetracosakis(oxyethylene)}-propanoyl)-L-lysine (6 → 1 6 )-lactam, tetra sodium corresponding to the molecular formula C172H274N24O55Na4.. The sodium salt has a relative molecular mass of 3650.10 and the following structure:

<div style=\"page-break-after: always\"></div>

Figure 1: Active substance structure

<!-- image -->

Zilucoplan  active  substance  is  a  synthetic  peptide  conjugated  with  an  ethylene  glycol  moiety.  The chemical structure of zilucoplan sodium was elucidated by a combination of spectroscopic evaluation and physical measurements including near UV spectroscopy, 1D- and 2D-NMR ( 1 H/ 13 C/ 15 N), GC-MS-based chiral amino acid analysis, amino acid analysis, MS sequencing, optical rotation and solubility. The higher order structure of the active substance was evaluated by techniques such as far UV circular dichroism spectroscopy,  FT-IR  spectrometry,  fluorescence  spectroscopy  and  differential  scanning  calorimetry (DSC). The solid state properties of the active substance were measured by x-ray powder diffraction, thermogravimetric analysis (TGA) and water vapor sorption.

The active substance is a white to off-white, low-density very hygroscopic powder. The aqueous solubility of zilucoplan undergoes a sharp transition from low to high solubility, across the iso-electric point, above pH 5.

Zilucoplan exhibits stereoisomerism due to the presence of 16 chiral centres, all located at the amino acid α -carbons and having L-configuration. Data provided from chiral amino acid analyses demonstrate low or undetectable amounts of D-amino acids indicating that zilucoplan active substance consists of Lamino acids. Stereochemical control is achieved by a combination of starting material selection (L-aa) and starting material specifications, and process design aiming at epimerisation suppression. The peptide synthesis  contributes  to  impurity  control,  as  do  the  capping  procedures  as  well  as  chromatographic purifications and control of input material.

Polymorphism has not  been  observed  for  zilucoplan  sodium.  The  solid  form  was  analysed  by  X-ray diffraction and determined to be amorphous; the solid material was also characterised using DSC and TGA: the sample was heated from 25 to 250 ℃ , no significant phase transition was observed.

## 2.4.2.2. Manufacture, characterisation and process controls

The active substance is obtained from two manufacturers.

Zilucoplan consists of two major units: a cyclic peptide and an ethylene glycol moiety. In the final process steps, the cyclic peptide and the ethylene glycol moiety are conjugated, and the substance is thereafter purified and lyophilised.

<div style=\"page-break-after: always\"></div>

1The proposed starting materials are found acceptable and in line with given scientific advice as well as ICH Q11 expectations. None of the proposed starting materials are claimed to be a commodity in a nonpharmaceutical context.

Critical process parameters and in-process controls are clearly described for the synthesis of zilucoplan. Adequate in-process controls are applied during the synthesis. The overall active substance synthesis includes four defined intermediates. The specifications and control methods for intermediate products, starting materials and reagents have been presented.

No design space is proposed, and the manufacturing process is operated at target set-point or normal operating  ranges  (NOR)  for  all  parameters.  Set  points/NORs  have  been  defined  for  all  relevant parameters. Variation of one parameter within a proven acceptable range (PAR), whilst keeping all other parameters at setpoint or within NOR, is considered acceptable for a given unit operation. During the procedure a major objection (MO) was raised requesting applicant to describe more clearly how the proposed reaction conditions and controls were established. In response, scientifically based justifications,  supported  by  analytical  batch  data  complying  with  relevant  acceptance  values,  were provided. The identified CQAs are considered relevant for the active substance and were used to guide the process development in a rational way. The applicant has provided an acceptable presentation of the manufacturing process development, describing how in house experience and knowledge were combined with justified assumptions and experimental results to define and establish the process conditions. The available development data, the proposed control strategy and batch analysis data from commercial scale batches fully support the proposed PARs.

The active substance is supplied as a non-sterile material.

The commercial manufacturing process for the active substance was developed in parallel with the clinical development programme. The initial process 1.0 was further optimised to process 2.0 and then process 2.1. Changes introduced have been presented in sufficient detail and have been justified. The batch release, characterisation, and stability data demonstrate that the manufacturing sites, scale changes, and  process  improvements  implemented  during  the  development  of  the  zilucoplan  manufacturing process had no negative impact on the impurity profile and/or physico-chemical properties of zilucoplan active substance.

The characterisation of the active substance and its impurities are in accordance with the EU guideline on chemistry of new active substances. Potential and actual impurities were well discussed with regards to their origin and characterised.

The active substance is packaged in high density polyethylene (HDPE) bottles with polypropylene (PP) screw cap which complies with Commission Regulation (EU) 10/2011, as amended.

## 2.4.2.3. Specification

The  active  substance  specification  includes  tests  for:  appearance  (visual  inspection),  appearance  in solution  (Ph.  Eur.),  identity  (MS,  structural  analysis,  UHPLC),  assay  (liquid  chromatography),  water content (KF), sodium content (Ph. Eur.), purity (liquid chromatography), residual solvents (GC), bacterial endotoxins (Ph. Eur.) and microbial enumeration (Ph. Eur.).

The specifications cover the expected tests for the active substance and ensure robust and consistent quality is obtained. Acceptable justifications for the compendial tests, water content, and sodium content are presented. Residual solvents used in the last process step are controlled at their ICH Q3C limits which is fully endorsed.

<div style=\"page-break-after: always\"></div>

As the active substance is a synthetic peptide, Ph. Eur. monograph Substances for pharmaceutical use apply rather than ICH Q3A. During the procedure a MO was raised requesting toxicological data to be provided to support limits for other specified impurities above the qualification threshold as per the Ph. Eur. monograph for Substances for pharmaceutical use ( ≤ 1.0%). In response, the applicant presented interspecies data to toxicologically support the proposed specification limits for the specified impurities. The proposed limits have been acceptably qualified.

The analytical methods used have been adequately described and non-compendial methods appropriately validated in accordance with the ICH guidelines. Satisfactory information regarding the reference standards used for assay and impurities testing has been presented.

Analytical data from a relatively large number of batches is presented, including batches made to early development process. The manufacturing process history is described in S.2.6, with adequate details.

- process 1.0, used during early development: Data from eight batches are presented; one of the batches was considered non-GMP.
- process 2.0: Data from six batches are presented.
- process 2.1: Data from twelve batches are presented.

It is clearly stated that each batch was tested and released according to the current specification at that time. In the dossier, data is consistently presented against the proposed commercial specification, with comments explaining deviations from acceptance criteria. Generally, the historical batches comply with the current limits. Any deviations are acceptably explained.

## 2.4.2.4. Stability

Stability  data  from  13  commercial  scale  batches  of  active  substance  from  both  the  proposed manufacturers stored in a container closure system representative of that intended for the market for up to 48 months under long term conditions (-20±5ºC), for up to 48 months under accelerated conditions (5±3°C) and for up to 48 months under accelerated conditions (25±2°C/60±5% RH) according to the ICH guidelines were provided.

The parameters tested are the same as for release, with the exception of identity, sodium content and residual solvents, which is acceptable as they are not stability indicating. The active substance is stable under the studied conditions. Assay and impurity levels remain stable in the included batches, and upon comparison between the batches, similar results are revealed.

Photostability testing following the ICH guideline Q1B was performed on two batches. Degradation of the active substance was observed under the conditions tested for samples exposed to direct light and for samples stored in primary packaging but were still within the commercial specification for purity and total impurities. No significant degradation of zilucoplan was observed for samples stored in both primary and secondary packaging confirming that the current packaging (i.e., primary and secondary) is suitable to protect zilucoplan active substance from photo-induced degradation.

Results on stress conditions: thermal stress, acid/base stress and peroxide stress were also provided on one batch. Based on available information, the analytical methods are accepted as stability indicating.

The  stability  results  indicate  that  the  active  substance  manufactured  by  the  proposed  suppliers  is sufficiently stable. However, no retest period is accepted. Therefore, to ensure the quality of the active substance and finished product, the applicant should test the active substance according to approved specifications prior to each use in finished product manufacture. The quantity of zilucoplan needed for

<div style=\"page-break-after: always\"></div>

finished product manufacturing will be calculated based on the assay from the active substance certificate (CoA). In the future, a variation can be submitted to introduce a retest period.

## 2.4.3. Finished medicinal product

## 2.4.3.1. Description of the product and pharmaceutical development

The finished product is supplied as a sterile, preservative-free solution in a 1 mL long Type I glass prefilled syringe. Each single-use syringe contains zilucoplan active substance (40 mg/mL) in an iso-osmotic buffered  solution.  Other  ingredients  are  sodium  dihydrogen  phosphate  monohydrate,  disodium phosphate (anhydrous), sodium chloride and water for injections.

The finished product is provided in 3 dose presentations (16.6 mg, 23.0 mg and 32.4 mg) accomplished by varying the syringe fill volume.

The  pharmaceutical  development  is  extensively  described.  Critical  quality  attributes  (CQAs)  were identified  based  on  the  quality  target  product  profile  (QTPP),  knowledge  of  the  zilucoplan  active substance, and information gained during process development and manufacture.

All  excipients  are  compendial  grades.  Anhydrous  disodium  phosphate  (dibasic  sodium  phosphate anhydrous), sodium chloride and water for injection complies with respectively Ph. Eur. monograph. Sodium dihydrogen phosphate monohydrate (monobasic sodium phosphate monohydrate) complies with USP. All excipients are tested for bacterial endotoxins. There are no novel excipients used in the finished product formulation. The list of excipients is included in section 6.1 of the SmPC.

The primary packaging consists of a single-use 1 mL long glass (Type I) syringe with a 29G, ½' thin wall needle. The syringe is closed using a fluoropolymer-laminated bromobutyl rubber plunger stopper and a rigid needle shield (RNS) consisting of a thermoplastic elastomeric needle shield and a polypropylene rigid shield. Each pre-filled syringe is preassembled with the safety syringe components.

A colour-coded plunger rod and carton will help differentiate each dose strength: rubine red for low, orange for medium and dark blue for high dose.

The same formulation (40 mg/mL) and the same pre-filled syringe has been used in clinical studies since Phase 1 except for the clinical study UP0112 where vials instead of pre-filled syringes were used. The manufacturing  process  was  transferred  for  Phase  3  clinical  studies.  Sufficient  data  are  provided demonstrating  that  both  manufacturing  sites  are  comparable  and  provide  the  finished  product  with consistent quality.

The commercial dose presentations (16.6 mg, 23.0 mg and 32.4 mg) are developed by varying the syringe fill volume to allow dose variation and a daily dose of 0.3 mg/kg. The commercial presentations are used in the clinical studies. In some Phase 2 studies additional dose presentations (6.0 mg, 8.8 mg and 12.4 mg) were also used to achieve the clinical daily dose of 0.1 mg/kg.

There is no overage, however, the pre-filled syringes are filled with a slight overfill in order to ensure that the nominal dose volume.

Extractables and leachables are sufficiently studied. None of the extractables or leachables detected is considered associated with any patient safety concerns.

A valid Notified Body Opinion (NBOp) is provided confirming compliance with relevant General Safety and Performance Requirements (GSPRs) set out in Annex I of Regulation (EU) 2017/745.

<div style=\"page-break-after: always\"></div>

## 2.4.3.2. Manufacture of the product and process controls

The manufacturing process consists of following steps: dissolution of zilucoplan active substance in buffer solution, sterilisation, filling in pre-filled syringes and packaging.

The  syringe,  including  needle  and  the  rigid  needle  shield,  is  sterilised  by  the  supplier.  The  plunger stoppers are sterilised by the supplier. The sterilisation methods for the primary container (syringe and plunger stopper) are sufficiently described.

Major steps of the manufacturing process have been validated by a number of studies. Process validation has been performed on five consecutive process performance qualification (PPQ) batches covering the proposed batch size.

The maximum filling time for the finished product solution into the syringes is sufficiently justified. It has been  demonstrated  that  the  manufacturing  process  is  capable  of  producing  the  finished  product  of intended  quality  in  a  reproducible  manner.  The  in-process  controls  are  adequate  for  this  type  of manufacturing process and pharmaceutical form.

## 2.4.3.3. Product specification

The  finished  product  release  specifications  include  appropriate  tests  for  this  kind  of  dosage  form: appearance (Ph. Eur.), pH (Ph. Eur.), osmolality (Ph. Eur.), extractable volume (Ph. Eur.), identity (UV, UHPLC), assay (liquid chromatography), degradation products (liquid chromatography), visible particles (Ph. Eur.), sterility (Ph. Eur.), bacterial endotoxin (Ph. Eur.) and container closure integrity test (Ph. Eur.).

The specifications for the assembled safety syringes contain tests for: extractable volume (Ph. Eur.), shield removal force, maximum break-loose force, maximum gliding force, activation force, resistance to compression force, separation force, visibility of drug compartment and lock-out confirmation.

Release and shelf-life specifications for pre-filled syringes includes relevant test parameters. In addition, the final assembled safety syringes are tested for extractable volume and relevant functionality tests. The analytical methods are sufficiently described and validated.

The potential presence of elemental impurities in the finished product has been assessed following a riskbased approach in line with the ICH Q3D Guideline for Elemental Impurities. Batch analysis data on 5 batches using a validated ICP-MS method was provided, demonstrating that each relevant elemental impurity was not detected above 30% of the respective PDE. Based on the risk assessment and the presented batch data it can be concluded that it is not necessary to include any elemental impurity controls in the finished product specification. The information on the control of elemental impurities is satisfactory.

A risk assessment concerning the potential presence of nitrosamine impurities in the finished product has been performed considering all suspected and actual root causes in line with the 'Questions and answers  for  marketing  authorisation  holders/applicants  on  the  CHMP  Opinion  for  the  Article  5(3)  of Regulation  (EC)  No  726/2004  referral  on  nitrosamine  impurities  in  human  medicinal  products' (EMA/409815/2020) and the 'Assessment report- Procedure under Article 5(3) of Regulation EC (No) 726/2004- Nitrosamine  impurities  in  human  medicinal  products'  (EMA/369136/2020).  Based  on  the information provided, it is accepted that there is no risk of nitrosamine impurities in the active substance or the related finished product. Therefore, no specific control measures are deemed necessary.

The analytical methods used have been adequately described and appropriately validated in accordance with the ICH guidelines. Satisfactory information regarding the reference standards used for assay and impurities testing has been presented.

<div style=\"page-break-after: always\"></div>

Batch analysis results are provided for 20 commercial scale batches confirming the consistency of the manufacturing process and its ability to manufacture to the intended product specification.

The  finished  product  is  released  on  the  market  based  on  the  above  release  specifications,  through traditional final product release testing.

## 2.4.3.4. Stability of the product

Stability studies has been performed on all three dose presentations (16.6 mg, 23.0 mg and 32.4 mg) at long-term conditions (5°C±3°C), accelerated conditions (25°C±2°C / 60%±5% RH and 30°C±2°C / 75%±5%  RH)  and  stressed  conditions  (40°C±2°C  /  75%±5%  RH).  Forced  degradation  and photostability studies has also been performed.

Long-term data are provided for up to 42 months of clinical batches and up to 30 months of primary registration stability batches manufactured by the commercial manufacturer. All data complies with the finished product specification.

Stability  data  at  stressed  conditions  support  the  storage  conditions  to  keep  to  pre-filled  syringes protected from light and that temperatures down to -20°C, which may occur during shipping, do not impact the finished product quality.

The provided stability data supports the proposed shelf-life of 3 years when stored in a refrigerator (28°C) and that the pre-filled syringes may be stored for a single period of maximum 3 months up to 30°C within the 3-years shelf-life as stated in sections 6.3 and 6.4 of the SmPC.

## 2.4.3.5. Adventitious agents

No excipients derived from animal or human origin have been used.

## 2.4.4. Discussion on chemical, and pharmaceutical aspects

Information on development, manufacture and control of the active substance and finished product has been presented in a satisfactory manner. During the procedure two MOs, one on the active substance manufacturing process development and one on the toxicological qualification of specified impurity limits, were adequately addressed by the applicant (as discussed above). The claimed retest period was not agreed; therefore, the applicant should test the active substance according to approved specifications prior to each use in finished product manufacture. The results of tests carried out indicate consistency and uniformity of important product quality characteristics, and these in turn lead to the conclusion that the product should have a satisfactory and uniform performance in clinical use.

## 2.4.5. Conclusions on the chemical, pharmaceutical and biological aspects

The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the SmPC. Physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way.

## 2.4.6. Recommendations for future quality development

Not applicable.

<div style=\"page-break-after: always\"></div>

## 2.5. Non-clinical aspects

## 2.5.1. Introduction

Zilucoplan (occasionally referred to as RA101495) is a 15-amino acid macrocyclic peptide complement inhibitor  designed  for  the  treatment  of  conditions  in  which  inappropriate  activation  of  C5  has  been demonstrated to play a role.

## 2.5.2. Pharmacology

## 2.5.2.1. Primary pharmacodynamic studies

Zilucoplan exerts a rapid and strong association with C5 followed by a slow dissociation from the same. Zilucoplan inhibits cleavage of C5 into C5a and C5b, in a dose-dependent manner, measured by the inhibition of downstream MAC formation. Furthermore, this potency correlates with the potency to inhibit blood cell haemolysis, suggesting that the primary mechanism of zilucoplan for blocking complementmediated  haemolysis  is  through  the  inhibition  of  C5  cleavage.  Zilucoplan  inhibits  downstream  MAC assembly induced by the classical, alternative and lectin complement pathways.

The  effects  of  zilucoplan in  vivo are  mainly  assessed  by  analysis  of  inhibition  of  haemolysis;  this haemolysis  is  a  consequence  of  inhibition  of  C5b.  In  contrast,  the  inhibition  of  C5a  has  only  been characterised in vitro .

Data shows that zilucoplan have the potential to be effective in patients with C5 R885H mutations (a polymorphism  that  results  in  the  individuals  having  no  activity  of  the  C5  monoclonal  antibody eculizumab).

Zilucoplan demonstrated similar potent inhibition of complement-induced red blood cell (RBC) lysis in serum and/or plasma from non-human primate and human. In samples from pigs the activity was &gt;30 lower  than  cynomolgus  macaque.  Very  weak  activity  was  observed  in  rat  (&gt;150  times  lower  than cynomolgus macaque) and little to no activity was seen in other species such as mice, guinea pigs, dogs, or rabbits.

Three  potential  metabolites  of  special  interest  have  been  assessed  for  its  activities,  these  being RA102758, RA103488, and RA106009. Results from haemolysis assays indicate that RA102758 exhibits minimal activity mediated by the activation of classical complement pathway as compared to zilucoplan. On the other hand, RA103488 and RA106009 inhibit complement-mediated haemolysis of erythrocytes when  activated  by  either  the  classical  or  alternative  pathway  with  similar  half  maximal  inhibitory concentration (IC50) values as zilucoplan in both complement pathways examined.

Plasma drug levels at or above 2.5 μ g/ml in monkeys achieves &gt;90% inhibition of haemolysis. At a dose of 4 mg/kg/day, haemolysis was essentially completely inhibited to below 1% throughout dosing and remained  below  3%  48  hours  after  the  last  dose.  This  indicates  a  strong  relationship  between  the concentration of zilucoplan in monkey plasma and haemolysis.

## 2.5.2.2. Secondary pharmacodynamic studies

Zilucoplan demonstrates weak binding to C4 and human serum albumin. Data also shows that zilucoplan has no binding to C3, C3d, C4, C5, C6, C7 or CA II. Biotinylated analogues of RA101495 selectively isolate  complement C5 from human serum in pulldown experiments. These results demonstrate the selectivity of RA10495 binding to C5 in human serum.

<div style=\"page-break-after: always\"></div>

At concentrations ~10-fold higher than the plasma concentrations expected in the clinical setting (30 μ M) RA101495 and RA102758 did not show agonist activity of a selection of peptide liganded G-protein coupled receptors including cholecystokinin 1 (CCK1), cholecystokinin 2 (CCK2), glucagon and secretin receptors. At concentrations ~3-fold higher than plasma concentrations expected in the clinical setting (10μ M) RA101495 and RA102758 did not show antagonism of any of the receptors tested.

35  targets  known  to  be  associated  with  abuse  liability  were  evaluated  in  binding  assays  at  30 μ M (zilucoplan) or 3 μ M (RA102758 and RA103488). The metabolites did not show any significant binding on any of the 35 targets. However, two targets were found to interact with zilucoplan, these being orexin1 and GABA transporter. These two targets were further evaluated in a concentration-response was determined using binding assays (for both targets) as well as in functional assays (agonist/antagonist) for OX1. In binding assays, the IC50 of zilucoplan was 33 μ M for orexin 1 (OX1) and 11 μ M for the GABA transporter. In addition, zilucoplan exhibited an antagonistic activity on O receptors with an IC50 of 44 μ M, which is &gt;1000-fold above the free plasma therapeutic concentration.

## 2.5.2.3. Safety pharmacology programme

The safety pharmacology of zilucoplan was investigated regarding both the central nervous (CNS)-, the respiratory- and the cardiovascular systems and the studies were GLP compliant.

CNS safety was evaluated as a part of the 4-week repeat toxicology study in cynomolgus monkeys. No neurological alterations observed following treatment with zilucoplan up to 4mg/kg/day, corresponding to maximum plasma concentrations of 65.7 μ g/mL for males and 62.8 μ g/mL for females (this study, 20074710, is assessed in toxicology section.).

Respiratory and cardiovascular safety was evaluated in a dedicated in  vivo study where cynomolgus macaques (n=4/group) were administered with either 2 or 10 mg/kg zilucoplan (SC) 8 days after being injected with vehicle on day 1. The doses used should provide complete inhibition of C5 activity. 10 mg/kg should correspond to ~30-fold clinical exposure and approximately twice the exposure compared to  high  dose  in  the  toxicology  study.  No  finding  relating  to  either  electrocardiology,  blood  pressure, respiratory parameters, nor body temperature were noted. In addition, an in vitro human ether-a-gogo-related gene (hERG) study was also conducted. Zilucoplan did not inhibit hERG-mediated current at the maximum (and only) tested concentration of 300 μ M, corresponding to 1.07 mg/mL unbound drug, showing in contrast an increase in hERG-mediated current by 39.2±7.7%, versus hERG current inhibition of 0.4±1.2% (n=3) in the control.

Furthermore, electrocardiology was also investigated as part of the 4-, 13-, and 39-week GLP toxicology studies in cynomolgus macaques. In line with the results found in the dedicated safety pharmacology study, there were no zilucoplan-related electrocardiographic findings.

## 2.5.2.4. Pharmacodynamic drug interactions

Rituximab  is  used  for  treatment  of  gMG.  One  of  the  mechanisms  of  action  for  B-cell  depletion  by rituximab is through complement-dependent cytotoxic effect of rituximab. This complement-dependent cytotoxic effect of rituximab has a potential interaction with the C5 inhibitory effects of zilucoplan.

## 2.5.3. Pharmacokinetics

Pharmacokinetic studies and method validation

The pharmacokinetic (PK) profile of zilucoplan was characterised using both in vivo and in vitro studies. In vivo studies consisted of studies using Sprague-Dawley rats and cynomolgus monkeys.

<div style=\"page-break-after: always\"></div>

Toxicokinetic  (TK)  profiles  were  characterised  according  to  GLP  in  in  repeat-dose  toxicology  studies conducted in rats (up to 4 weeks) and monkeys (up to 39 weeks) after daily SC administration, in a male fertility study and in a combined embryofoetal and enhanced pre-postnatal development (ePPND) study in  monkeys for zilucoplan. No validation according to GLP standards have been provided for the TK characterisation of major metabolite.

For the detection of zilucoplan-related material in the whole  body  or  in biological  samples, [14C]zilucoplan was used and measured by liquid scintillation counting and autoradiographic techniques with  quantitative  imaging.  In  quantitative  whole-body  autoradiography  (QWBA)  study  16863  [14C] zilucoplan labelled on lipid/palmitoyl side chain; in QWBA study C18038, [14C] zilucoplan was labelled on the terminal lysine residue, adjacent to the polyethylene glycol (PEG)-lipid tail. Zilucoplan levels in plasma from rat and monkey were determined using protein precipitation followed by high-performance liquid chromatography with tandem mass spectrometry analysis. The assays were sufficiently validated for intra- and inter assay accuracy, precision, linearity, quantification range and limit of quantification as well as storage stability. The ELISA method was used to detect anti-drug antibodies (ADA) in monkeys. The data validation data presented in AR6187 seem sufficient to adequately quantify ADA titres.

Anti-zilucoplan antibodies were evaluated in cynomolgus monkeys in the 4-, 13-, and 39-week toxicology studies  and  in  the  combined  embryofetal  and  ePPND  studies.  ADA  positive  animals  had  sufficient exposure for Zilucoplan with no significant effect reported on PD parameters. However, the presence of APA has not been investigated.

## Absorption

Plasma  PK  parameters  of  zilucoplan  was  investigated  in  male  Sprague-Dawley  rat  and  Cynomolgus monkey after a single IV, PO, or SC dose.

In  rats,  zilucoplan  was  very  poorly  absorbed  after  single  PO,  with  a  bioavailability  of  approximately 0.42%. Following SC administration in rats, the mean area under the plasma concentration-time curve from zero to last measure (AUClast) and maximum plasma concentration (Cmax) of the 1 mg/kg dose were calculated to be 10.02% and 11.6% of the 10mg/kg dose, respectively. Thus, exposures to zilucoplan seem dose proportional  following  single  dose  administrations  from  1  -10  mg/kg.  The  mean  time  to maximum plasma concentration (tmax) ranged from 4.67 to 5.33h. The extrapolated area was low (1 mg/kg dose: 0.27% and 10 mg/kg dose: 0.12%).

SC single dose administration in monkeys resulted in a bioavailability ranging between 73-79% indicating good absorption following SC administration. In repeat dose studies in monkeys, exposures to zilucoplan were slightly less than dose proportional from 0.21 to 4.2mg/kg. Steady state was reached by Day 4 of dosing. Low accumulation was observed after 7-daily dosing of zilucoplan in monkeys as the area under the drug concentration versus time curve (AUC) ratio ranged from approximately 1.6- to 1.8-fold when administered daily, and when given every 3rd day even lower.

## Distribution

Plasma protein binding capacity of zilucoplan and two predominant metabolites RA102758 and RA103488 was also investigated in rat, monkey, and human plasma. The results jointly indicate high protein binding of zilucoplan, RA102758 and RA103488, all three &gt;99%. Zilucoplan was found to be predominantly in the plasma fraction and did not show significant distribution into the erythrocyte fraction.

The organ distribution studies in rat jointly show a rapid distribution of radioactivity and a slow decay with no significant distribution to melanin. Data point to a distribution to mainly kidney, but also to liver, lungs, trachea, GI-tract (mucosa and wall). Low placental penetration of zilucoplan was shown in an ex vivo model and was not affected by the presence of human C5 protein. However, transplacental transfer of metabolites, especially major metabolite RA102758, has not been evaluated. Although demonstrating

<div style=\"page-break-after: always\"></div>

brain penetration of zilucoplan in monkey, the levels are far less than those observed in plasma (approx. &lt; 250-fold lower). However, none of the metabolites seem to penetrate to brain.

## Metabolism

The in  vitro metabolic  profile  of  zilucoplan  was  evaluated  in  rat,  monkey,  and  human  hepatocytes. Zilucoplan was stable in human and monkey plasma as no metabolite was detected after an up to 8hour incubation. Hydrolysis was detected as the predominant metabolic pathway. Six metabolites were observed in monkey and human hepatocytes where no human unique metabolite was observed. In rat hepatocytes, no oxidation metabolites were detected, and parent drug remained as the major component in  rat  hepatocytes,  along  with  seven  hydrolysis  metabolites.  The in  vitro studies  indicate  that  the monkey, in terms of the metabolite profiles, qualifies as a good species to investigate efficacy and safety where both metabolites of potential interest, RA102758 and RA103488, are present.

RA103488 is a ω -oxidation product of zilucoplan. This metabolite is present of monkey and humans, but not in rat. Pharmacologically it has similar activity as zilucoplan. However, RA103488 is representing 9.4% AUC of zilucoplan in human plasma, and therefore it is agreed that RA103488 is not considered to contribute substantially to the overall pharmacological activity.

RA102758 is a hydrolysis product of zilucoplan and is considered a major metabolite in humans and is present  in  humans,  monkeys,  and  rats;  however,  it  does  not  have  a  pharmacologic  effect  on  the complement system and demonstrated no affinity for the C5 binding site occupied by zilucoplan.

Other  than  RA102758  and  RA103488,  RA103933  (a ω -oxidation  product  of  RA102758  or  hydrolysis product of RA103488) is the only metabolite with AUC near or above 10% of parent AUC in monkey plasma; however, data shows that the exposure of RA103933 was below 2.5% of zilucoplan AUC in human plasma following the last administration of once-daily dosing at 0.2mg/kg for 7 days. Therefore, RA103933 is considered as a minor metabolite in human, and it is agreed that no further studies are needed for this metabolite.

In liver, zilucoplan levels were dose dependent and compared to plasma levels, liver values ranged from 0-14% of plasma levels. Low levels of parent drug were observed in bile collected at terminal sacrifice, suggesting that this is not a major route of elimination of the parent drug. In contrast, RA1012758 was found at high concentrations in the bile, consistent with this being a major route of elimination for the metabolite.

## Excretion

Hepatobiliary excretion played an important role in the elimination of drug-derived radioactivity from rat (~17%  in  faeces),  with  less  found  in  urine  (~9%).  It  was  further  confirmed  that  the  remained radioactivity in rat tissue was related to radiolabelled palmitic acid, indicating the likely incorporation of this moiety into the endogenous metabolic cycle. However, in study C18038, the main excretion route of radioactivity was through urine (~50% of total radioactivity). The difference between these studies is explained by the fact that in study 16863, labelling was done on the lipid side chain, whereas in study C18038 zilucoplan was labelled in the lysine moiety. The difference between the above two studies is due  to  the 14 C  labelling  position  and  the  involvement  of  labelled  moieties  in  different  endogenous metabolic  cycles  and  the  associated  elimination  route.  When  labelled  on  the  lysine  residue,  more radioactivity was excreted in urine, which in turn seems reasonable considering that lysine is commonly excreted this way.

<div style=\"page-break-after: always\"></div>

## 2.5.4. Toxicology

The toxicology programme conducted for zilucoplan includes SC repeat-dose toxicology studies in rats and cynomolgus macaques, a battery of genotoxicity assays, reproductive and developmental toxicology studies  in  cynomolgus  macaques,  and in vitro and in vivo safety  pharmacology.  Based  on pharmacological activity, similarity in metabolite profile, and ratio of metabolites to parent drug, the cynomolgus macaque is considered to be the most relevant animal species for toxicology testing. Adverse effects were observed in monkeys at subtherapeutic exposure. In common for many of the observed pathologies  in  various  locations  were  vesicular  degeneration  of  epithelial  cells  and  mononuclear  cell infiltrates in surrounding tissues. The applicant suggests that all, or most, test-article related findings in the repeat-dose toxicity studies in cynomolgus monkeys are attributed to opportunistic infection, but no direct evidence is provided, and a clinical relevance cannot be dismissed.

## 2.5.4.1. Single dose toxicity

No single-dose toxicity studies were conducted with zilucoplan. However, in the safety pharmacology study a single dose at 10mg/kg was well tolerated in cynomolgus macaques. No adverse effects or injection site findings were reported.

## 2.5.4.2. Repeat dose toxicity

Repeat-dose  toxicity  of  zilucoplan  was  evaluated  in  one  4-week  study  in  rats  and  three  studies  in cynomolgus macaque (4-, 13-, and 39-weeks). As the pharmacological effect of zilucoplan is very week in rats compared to humans and non-human primates, the studies in cynomolgus are considered to be of  most  pharmacological  relevance.  In  rats,  zilucoplan-related  findings  were  mainly  limited  to  the injection sites. However, findings of increased fibrinogen, reticulocytes, and neutrophiles in rats given 40 mg/kg/day, together with a significantly decreased food consumption in rats given ≥ 10 mg/kg/day, may be suggestive of a systemic effect of zilucoplan also in rats. Although the pharmacological activity of zilucoplan is weak in this model (&gt;100 times lower than in cynomolgus macaque and humans), a longer rat study may have revealed potential off-target systemic toxicity.

In  the  cynomolgus  macaque,  the  main  findings  in  toxicity  studies  were  epithelial  mononuclear  cell infiltrates and vesicular degeneration with associated secondary sequelae including epithelial erosions. These were present in several locations in various tissues and organs. Also, pancreatic and hepatobiliary events were observed, including pancreatitis and elevation of liver- and pancreas enzymes. The NoObserved-Adverse-Effect Level (NOAEL) was considered by the applicant to be 2 mg/kg/day in the 13week study, which was also considered to be the highest tolerated dose in the 39-week study. At this dose,  the  mean  area  under  the  plasma  concentration-time  curve  from  zero  to  24  hours  after administration (AUC0-24) was 541 ug.h/mL which gives an exposure margin of ~2.0 to the predicted AUC0-24  seen  in  the  phase  3  clinical  studies.  However,  the  increase  in  liver  and  pancreas  enzymes, pancreatic  acinar  degeneration,  and  immune  cell  infiltrations  seen  consistently  in  the  cynomolgus studies, already at the lowest dose given, would suggest that a NOAEL cannot be established.

## Pharmacologic inhibition of C5 and dose-dependency of toxicity findings

In  all  three  repeat-dose  toxicity  studies  in  non-human  primate  (NHPs),  complement  activity  was determined in plasma samples using an in vitro RBC lysis assay. All control samples exhibited high levels of  haemolysis,  indicating  no  effect  of  the  vehicle  on  complement  activity.  All  animals  treated  with Zilucoplan (regardless of dose) showed high level of suppression of complement activity from within 2 hours post first dose throughout the entire duration of the studies. The suppressive effect was high (&gt;80%) already at the lowest dose of zilucoplan tested (0.25 mg/kg/day) and increased further with

<div style=\"page-break-after: always\"></div>

increasing dose (&gt;90% suppression in the 1 and 2 mg/kg/day groups, and &gt;95% suppression in the 4 and 6 mg/kg/day groups). Complement activity returned to baseline during the recovery in all groups. Many of the findings in the repeat-dose toxicity studies were not obviously dose-dependent. As the complement activity assay suggests almost full pharmacological activity of zilucoplan already at the lowest dose, the lack of a dose-response relationship may argue that such findings are secondary to C5 inhibition  and  opportunistic  infection  or  other  event  preferably  affecting  animals  with  a  supressed complement system. However, presence of inflammatory cells in multiple organs are dose-dependently increased in incidence and severity. Also other findings had a tendency to be more frequent in animals given the highest dose of zilucoplan. As nearly full C5 inhibition is achieved already at the lowest dose, findings caused by e.g. opportunistic infections would be expected to be equally common in all dose groups. Opportunistic infection is used by the applicant to explain most, or all, test-article related findings in the NHP studies, yet no attempts were made to identify any causative pathogens. In fact, the lack of clear  changes in haematology parameters such as neutrophil or monocyte count may argue against frequent occurrence of opportunistic infection in zilucoplan-treated animals.

## Mortality

Three cynomolgus macaque in the 39-week study were euthanised early due to developments attributed to zilucoplan. The primary causes of early euthanasia were multifocal skin erosions and ulcerations in two animals given 4 and 6 mg/kg/day, and colitis in one animal given the lowest dose (0.25 mg/kg/day). Although colitis was considered by the applicant to be a stress-exacerbated pre-existing condition, both this animal and the two additional early euthanised animals had histopathological findings in the pancreas of inflammation and acinar degeneration/degranulation (discussed in more detail below). Histopathological findings in the animal with colitis of decreased cellularity of the thymus, mild cortical hyperplasia  of  the  adrenal  gland,  and  moderate  chronic  atrophy  of  the  adipose  tissue  of  the  heart epicardium are all in line with a chronic stress response that could have caused the colitis. Both animals euthanised early because of skin erosions had additional test article-related findings that contributed to their  decline,  e.g.,  liver  fibrosis,  lung  oedema,  mononuclear  cell  infiltrates  and  epithelial  vesicular degeneration  of  several  organs,  and  uterine  endometrial  degeneration.  Pancreatic  findings  of  acinar degeneration and inflammation in all three early euthanised animals (including the low dose monkey with colitis) is curious and mechanisms alternative to opportunistic infection cannot be excluded.

## Clinical signs

Test article-related clinical signs were seen only in the 39-week study, and in three males given the highest  dose  (10  mg/kg/day)  in  the  13-week  study,  and  included  reddened  skin  (both  local  and generalised), ocular discharge and swelling in abdomen, penis, tail, or eyelid. These clinical signs were not clearly dose-related but affected a fraction of animals in all dose groups, which could be in line with an  infectious  aetiology.  However,  no  attempts  were  made  to  identify  any  ongoing  infection  and alternative zilucoplan-related mechanisms behind the clinical signs are possible.

## Pancreatic and hepatobiliary changes

In the NHP studies, signs of pancreatic and/or hepatobiliary toxicity were consistently reported. In the 4-week study, they were limited to minimally increased bile acids and lipase starting at 2 mg/kg/day. After 13 weeks of 10 mg/kg/day, one animal showed clear signs of pancreatitis including abdominal pain, acinar degeneration, and ductular hyperplasia and all animals had elevated liver and pancreas enzymes indicative of pancreatic and hepatobiliary toxicity. Mild degeneration of acinar cells was seen after 13 weeks also in two animals given 1 and 2 mg/kg/day respectively. In the 39-week study, minimally to mildly  increased  amylase  and  lipase  was  noted  and  considered  Zilucoplan-related.  Histopathologic findings were made in the pancreas of all three early euthanised animals and one additional animal in the 2.0 mg/kg/day dose group. In the 0.25 mg/kg/day dose group, the animal that was euthanised on day  245  due  to  weight  loss  and  abdominal  pain,  in  addition  to  colitis,  showed  moderate  pancreatic

<div style=\"page-break-after: always\"></div>

ductular degeneration/regeneration with acinar atrophy. The animals in the 4 and 6 mg/day/kg groups, euthanised for skin manifestations on days 52 and 203 respectively, were both found to have severe pancreatic and hepatobiliary changes: bridging portal fibrosis with biliary hyperplasia, portal mononuclear cell infiltrates,  and  oedema  of  the  liver  as  well  as  pancreatic  acinar  degeneration  with bridging fibrosis. The pancreatic events seen in all three studies in cynomolgus monkeys are of particular interest because elevated pancreas enzymes were noted also in the clinical studies and a few cases of pancreatitis were reported. A clinical relevance of the non-clinical findings cannot be dismissed but they call for a close follow-up of pancreatic events and epithelial degeneration post-approval.

## Epithelial tissues

Epithelial mononuclear cell infiltrates and vesicular degeneration of epithelial cells were some of the main findings in the two cynomolgus studies of longer duration (13 and 39 weeks). After 13 weeks of 10 mg/kg/day zilucoplan, moderate vesicle formation in the mucosa of the tongue as well as rupture of the tongue epithelia were seen in two animals. In the 39-week study, vesicular degeneration that in some cases progressed to epithelial erosions were seen in epithelial tissues of tongue, oesophagus, cervix, and vagina.  Similar  vesicular  degeneration  and  hydropic  change  of  the  epithelial  cells  of  the  skin, accompanied with epidermal erosion/ulceration, were seen microscopically in the skin lesions present at multiple locations on the body in the early euthanasia animals. Vesicular degeneration of epithelial cells at various locations on the body could be secondary to pathogen reactivation or de novo infection not translatable to humans. No skin infections have been observed in the clinical studies, and it is possible that differences in the background microbiome, stress, hygiene, etc between monkeys and humans can explain this difference. However, alternative zilucoplan-related mechanisms cannot be excluded as there is no direct evidence linking any pathogen to the observed findings.

## Thymus

Lymphoid hyperplasia (described variously as lymphoid hypercellularity, increased lymphoid aggregates, or increased lymphoid follicles) was observed sporadically in the thymus of some animals in all dose groups already in the 4- and 13-week cynomolgus studies. In the 39-week study, lymphoid follicles were described as active secondary follicles indicative of an ongoing immune (B-cell) response. The applicant suggests that this is an adaptive immune response to opportunistic pathogen proliferation, colonisation and  infection  secondary  to  pharmacologic  inhibition  of  C5,  and  that  such  infections  are  not  directly translatable  to  human.  However,  there  is  no  direct  evidence  linking  any  pathogen  to  the  observed findings or to dismiss the clinical relevance and alternative zilucoplan-related mechanisms behind the thymic findings must be considered.

## Uterus

In the 39-week cynomolgus study, mild endometrial degeneration was noted in one female given 1.0 mg/kg/day zilucoplan. In the animal in the 6.0 mg/kg/day dose group that was euthanised early for skin manifestations, endometrial degeneration was noted as marked, with loss of glandular mucosal structure replaced by loose fibrovascular stroma and mononuclear cell infiltrates.

## Mononuclear cell infiltrates

Animals in all dose groups in the 13- and 39-week cynomolgus studies had inflammatory cells infiltrating the tissue in multiple organs (pancreas, kidney, tongue, oesophagus, salivary gland, thyroid, rectum, ileum, stomach, and urinary bladder). Although increased compared with control animals already at the lowest dose of 0.25 mg/kg/day, the incidence and severity of these infiltrates increased further with increasing dose. The applicant suggests that this finding is due to inflammation caused by opportunistic infections. However, as nearly full C5 inhibition is achieved already at the lowest dose, the clear doserelationship in frequency and severity of mononuclear cell infiltrates may argue against that notion and alternative explanations must be considered.

<div style=\"page-break-after: always\"></div>

## 2.5.4.3. Genotoxicity

Zilucoplan is not considered to have genotoxic potential. The genotoxic test battery consists of a bacterial reverse mutation tests (Ames), an in vitro mammalian chromosome aberration tests in human peripheral blood lymphocytes and in vivo genotoxicity testing utilising a rat bone marrow erythrocyte micronucleus assay. All assays were negative.

## 2.5.4.4. Carcinogenicity

No dedicated rodent carcinogenicity studies have been performed for zilucoplan, which is acceptable. A weight of evidence assessment concerning zilucoplan carcinogenic potential has been performed since the treatment is likely to be chronic. The weight of evidence discussion is based on non-clinical studies, available clinical data, and literature.

Zilucoplan was not genotoxic in standard genotoxicity studies, impurities were negative in quantitative structure-activity relationship (QSAR), and there were no pro-tumorigenic off-targets identified. There are  two  existing  similar  C5-related  products  that  so  far  have  not  been  linked  to  an  increased carcinogenicity risk. The complement pathway is also not associated with tumorigenicity.

That being said, the two other products are of a different nature (monoclonal antibody versus small synthetic peptide) and dissimilar toxicity profile which makes such a direct product comparison difficult. Mild vesicular degeneration/hyperplasia of epithelial cells was noted in several tissues in the monkey repeat-dose toxicity studies. These findings are of uncertain clinical relevance provided that they could possibly be influenced by monkey specific infections.

However, considering the totality of data included in the carcinogenicity weight of evidence, most notably the lack of genotoxic potential and hyperplasia ranging from mild to moderate in severity, there is a low concern for carcinogenic potential.

## 2.5.4.5. Reproductive and developmental toxicity

The reproductive and developmental programme for zilucoplan consists of an ePPND and a male fertility study, both performed in cynomolgus monkeys.

## Fertility study in male cynomolgus monkeys

A male fertility study with zilucoplan was performed in sexually mature cynomolgus monkeys using SC administration which is the intended clinical route. The monkeys (n=6/group) were treated daily for 13 weeks, and a recovery period of 8 weeks was included for some of the animals (n=2/group). Dosing with the  high  dose  (4mg/kg/day)  resulted  in  approximately  7  times  exposure  margin  when  compared  to clinical exposure.

Overall, zilucoplan was well tolerated with no mortalities or treatment related clinical signs. No clear effects on body weight development, clinical pathology and organ weights were reported. It can be noted that 1/6 males administered high dose showed a decrease of testicular size during the dosing phase and a reduced testicular weight at necropsy. Given that the testicular effects were seen in a single animal the relevance is uncertain.

Analysis of spermatogenic stages indicated complete spermatogenesis with all stages present in all dose groups but there were animals that were scored as having reduced spermatogenesis stages.

There were histopathological testicular changes observed in all dose groups when compared to control. Minimal to slight unilateral or bilateral degeneration/depletion of germ cells was seen in 4/6 monkeys in all zilucoplan dose groups (1, 2, or 4 mg/kg) and also present in recovery animals. This can be compared

<div style=\"page-break-after: always\"></div>

to the study controls where none of the control animals (0/6) showed signs of germ cell changes. In 1/6 low dose and 1/6 high dose animal, minimal unilateral fibrosis was seen. Degeneration/depletion of germ cells in the testicular tubules was characterised by various combinations of tubular dilatation, tubular vacuolation, reduced height of germinal epithelium, reduced spermatogenesis stages, and tubuli with sertoli  cells  only.  No  testicular  effects  were  reported  in  the  repeat-dose  toxicity  studies.  There  were immunological  changes  within  the  thymus  of  high  dose  monkeys.  Minimal  overall  decrease  in number/distribution of CD3, CD4, and CD8+ T- cells, also seen in recovery animals, was evident in monkeys administered 4 mg/kg, but not at lower doses. This was coupled to various degrees of increase in the incidence and degree of thymic involution/atrophy/lymphoid depletion in high dose monkeys. No clear effects were noted in when it comes to CD20+ and CD45+ T-cells.

## ePPND study in cynomolgus monkeys

Potential  reproductive  and  developmental  toxicity  was  evaluated  in  an  ePPND  study  conducted  in pregnant  cynomolgus  monkeys.  Zilucoplan  was  daily  administered  subcutaneously  (intended  clinical route) with 1, 2 or 4 mg/kg. The study included a embryofetal development (EFD) part which used 4 pregnant females/group and a postnatal part with 16 pregnant females /group. The monkeys were dosed from  gestation  day  (GD)  20  to  100  or  to  end  of  pregnancy.  The  pregnancy  loss,  embryofetal development, survival, growth, and postnatal development of the offspring were assessed up to postpartum Day 91±1.

Dosing  with  the  high  dose  (4mg/kg/day)  resulted  in  approximately  4,5  times  exposure  margin  in maternal animals when compared to clinical exposure. Maximum complement inhibition of around 6070% was already reached with the low dose on GD58 and similar levels of inhibition were observed on GD90 and GD142. Zilucoplan was not detected in maternal plasma or infant plasma on post-partum day 21 nor in the milk samples collected on post-partum on day 28. Given that no TK measurements were performed in prenatal animals or directly after birth, it is unknown whether placental passage occurred in  the  study. An ex vivo closed-circuit human placental transfer model (described in the PK section) suggested low transfer rate of zilucoplan (0.5-1.0%) in the fetal compartment. The transfer rate of 0.5% was  observed  at  a  steady  state  plasma  concentration  of  10  µg/mL  zilucoplan,  corresponding  to  a therapeutic dose of 0.3 mg/kg. The relevance of the ex vivo placental transfer model to the human situation  is  unknown  and  it  should  be  noted  that  it  only  investigated  transfer  of  zilucoplan  parent compound and not metabolites.

Prenatal losses: Increased prenatal loss was noted in zilucoplan-treated ePPND phase maternal animals (dosed GD 20 to delivery). Prenatal loss was noted for 1/16 (6.25%) control animals, 5/16 (31.25%) animals administered 1.0 mg/kg, 4/16 (25.0%) animals administered 2.0 mg/kg, and 5/16 (31.25%) animals administered 4.0 mg/kg. For the high dose group there was also an increase when compared to historical controls. The corresponding prenatal loss values for the EFD phase maternal animals (dosed to GD 100) were 0/4 (control), 0/4 (1mg/kg), 1/4 (25%, 2mg/kg) and 0/4 (4mg/kg). The applicant has provided data that support that the prenatal losses in the study controls in the ePPND part was unusually low when compared to historical control groups. This is acknowledged and given that there was no correlation with complement inhibition and that spontaneous pregnancy losses can be high and variable in cynomolgus monkeys, the increase in prenatal losses is most likely not clinically relevant.

Embryo-fetal effects: Reddening of some organs was observed in 1/4 fetuses of a low dose maternal animal and 2/4 fetuses from high dose maternal animals. The clinical relevance is unclear.

Kinked  tails  were  seen  in  0/4,  1/4,  0/3,  and  2/4  fetuses  at  doses  of  0,  1,  2,  and  4  mg/kg/day, respectively. Skeletal fetal findings included a misaligning of vertebrae 53 to 54 in 1/4 fetuses of a low dose mother and a misaligning of the zygostyle (caudal vertebrae) in 2/4 fetuses of high dose maternal animals. Given that no skeletal findings were noted in the in the X-rayed postnatal groups, the findings are considered most likely not related to treatment.

<div style=\"page-break-after: always\"></div>

Postnatal effects: The incidences of infant deaths in zilucoplan groups were within the normal range of the concurrent control and reference data. A heart finding, possible the cause of death, was reported in one of the high dose infants found dead on day 16. According to the historical background data of the test site, heart findings are rare (12 cases in 947 control fetuses/infants). The applicant still considers the heart finding to be incidental with no dose-relationship which is a poor argument in this case since the finding occurred in the high dose group and maximum complement inhibition was already seen with the lowest dose. That said, given that this a single case, the toxicological relevance is uncertain. Two infants  of  the  group  administered  1.0  mg/kg  had  shortened  thumbs  on  both  hands.  This  finding  is considered incidental.

## 2.5.4.6. Toxicokinetic data

TX evaluation of zilucoplan has been performed in 4-week repeated dose in rats, and in 4-Week-, 13Week-, 39-Week repeated dose studies, together with male fertility and ePPND studies, all of these in monkeys. Major metabolite RA102758 was measured in monkeys in the 4- and 13-week, but not in the 39-week repeat-dose toxicology studies.

In  the  39  weeks  repeat  dose  study  in  monkey,  doses  were  approximately  dose  proportional. Furthermore, there were no signs of accumulation and there were no sex-related differences in the TK. Protein binding was similar between monkeys and humans, thus there is no concern whether free fraction or total exposure have been used for calculation of exposure margins. Dose proportionality was also shown in rats and in reproductive toxicology (fertility, EFD/ePPND) studies in monkeys.

Adverse effects were observed in monkeys at subtherapeutic exposure. Overall, exposure margins to human exposure levels were low in the toxicity studies. In monkeys, a daily dose of 1 mg/kg gave an exposure that was similar to the clinical AUC and adverse events were observed already in animals given 0.25 mg/kg/day.

## 2.5.4.7. Other toxicity studies

Impurities are mainly peptidic-like ethylene glycol-related oligomer impurities of zilucoplan or isomers of  zilucoplan.  Peptidic  ethylene  glycol  structures  are  negative  for  mutagenicity  based  on  QSAR.  The specified impurities have been qualified in the non-clinical toxicity studies.

## 2.5.5. Ecotoxicity/environmental risk assessment

Zilucoplan  PECsurfacewater  value  is  below  the  action  limit  of  0.01  µg/L  and  is  not  a  persistence bioaccumulation and toxicity (PBT) substance as log Kow does not exceed 4.5. Zilucoplan is not expected to pose a risk to the environment.

Table 1: Summary of main study results

| Substance (INN/Invented Name): Zilucoplan (RA101495)   | Substance (INN/Invented Name): Zilucoplan (RA101495)   | Substance (INN/Invented Name): Zilucoplan (RA101495)   | Substance (INN/Invented Name): Zilucoplan (RA101495)   |
|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|
| CAS-number (if available): 1841136-73-9                | CAS-number (if available): 1841136-73-9                | CAS-number (if available): 1841136-73-9                | CAS-number (if available): 1841136-73-9                |
| PBT screening                                          |                                                        | Result                                                 | Conclusion                                             |
| Bioaccumulation potential- log K ow                    | *                                                      | -2,52                                                  | Potential PBT: No, <4,5                                |
| PBT-assessment                                         | PBT-assessment                                         | PBT-assessment                                         | PBT-assessment                                         |
| Parameter                                              | Result relevant for conclusion                         |                                                        | Conclusion                                             |
| Bioaccumulation                                        | log K ow                                               | < 4.5                                                  | not B                                                  |
| Bioaccumulation                                        | BCF                                                    |                                                        | not B                                                  |

<div style=\"page-break-after: always\"></div>

| Persistence                                                         | DT50 or biodegradability                       | ready                                          | not P                                          |
|---------------------------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|
| Toxicity                                                            | NOEC or CMR                                    |                                                | not T                                          |
| PBT-statement:                                                      | The compound is not considered as PBT nor vPvB | The compound is not considered as PBT nor vPvB | The compound is not considered as PBT nor vPvB |
| Phase I                                                             |                                                |                                                |                                                |
| Calculation                                                         | Value                                          | Unit                                           | Conclusion                                     |
| PEC surfacewater , default or refined (e.g. prevalence, literature) | 0,00162                                        | µ g/L                                          | > 0.01 threshold: No                           |
| Other concerns (e.g. chemical class)                                |                                                |                                                | No                                             |

## 2.5.6. Discussion on non-clinical aspects

## Pharmacology

The applicant has shown that zilucoplan has strong and dose-dependent binding to C5 and that it inhibits the cleavage of C5 into C5a and C5b, both KD and IC50 in the low nM range. Markedly, a slow dissociation (Kd: 2.1x10 -4 s -1 ) from C5 is observed.

Inhibition  of  cleavage  of  C5  correlates  with  complement-mediated  haemolysis,  and  it  is  agreed  that therefore haemolysis is used to measure the potency of the inhibition of C5 cleavage. When C5 is cleaved an assembly of MAC is initiated, which in turn kills the pathogen. The applicant shows that zilucoplan inhibits  the  formation  of  MAC  regardless  of  whether  it  is  classic,  alternative  or  lectin  that  initiates cleavage of C5 in the complement system, also here with IC50 values in the low nM range. The effects of zilucoplan in  vivo are  mainly  assessed  by  analysis  of  inhibition  of  haemolysis;  haemolysis  is  a consequence of C5b activity. In contrast, the inhibition of C5a activity in vivo has not been demonstrated. There is a lack of in vivo data confirming that the C5 molecule cannot disintegrate over time and release C5a. The theorised role of elevated levels of active C5a in toxicological findings remains unclear.

Although not studied clinically, it is agreed that zilucoplan has the potential to be effective in patients with C5 R885H mutations. It also is agreed that the selection of cynomolgus macaque as test species for the safety studies is relevant.

The applicant has investigated off-target binding to various complement system components, peptide ligand G-protein coupled receptors and a battery of targets associated with addiction, all of these without any  notable  findings.  Although  a  broader  secondary  pharmacological  screen  is  missing,  this  lack  of information is, considering the available clinical data, not a cause for further concern .

No concerns are noted regarding the safety pharmacology. An increased hERG current upon exposure to test article is noted, with unclear clinical relevancy. The assessment of the increase in hERG current is hampered by the lack of dose-response evaluation and the clinical relevance of this data is unknown. However,  there  is  no  general  concern  regarding  hypothesised  QT  prolongation  as  this  has  been investigated in vivo without notable findings.

## Pharmacokinetics

Validated methods according to GLP for the detection of zilucoplan can be found in the dossier.

There are no non-clinical measurements of anti-PEG antibodies (APA). Formation of APA could potentially reduce toxicity in the non-clinical species. Based on the absence of altered pharmacokinetic/dynamic activity and the absence of immune-mediated findings, the likelihood of an anti-PEG antibody-mediated reduction of toxic potential in the non-clinical toxicology studies is deemed to be low.

<div style=\"page-break-after: always\"></div>

The monkey is considered the central animal model for evaluating safety in vivo . After SC administration in monkeys a bioavailability of ~70-80%, an approximate dose proportionality and some accumulation is shown. Steady state was reached after approximately 4 days.

Two QWBA studies was conducted; the difference between the studies is that radiolabelling was done at two different places - one on the palmitic acid and one on the lysine that joints the peptide with PEG. The organ distribution studies jointly show a rapid distribution of radioactivity and a slow decay with no significant distribution to melanin. Regardless of labelling site, there is a high distribution to mainly the kidney. The studies differ regarding retention in a few organs; in the study with palmitic acid labelling there is retention in fat and endocrine tissue, which seem reasonable for a fat chain. However, this is not found in the study with labelling on the lysine. On the contrary this study shows even higher levels and retention in the kidney, in line with what is expected for lysine excretion. However, since zilucoplan does not bind C5 in rats, there is some uncertainty about the distribution in a species where zilucoplan binds to its intended target.

It is agreed that it seems that metabolism plays a major role in zilucoplan elimination, as indicated by the low quantities in bile and urine. This is consistent with the findings where low levels of parent drug were observed in bile collected at terminal sacrifice, also suggesting that this is not a major route of elimination of the parent drug. As for the metabolite RA102758, data show that the primary elimination route is hepatobiliary. However, data is also indicating excretion of this metabolite through urine.

## Toxicology

The  applicant's  suggestion  that  all,  or  most  zilucoplan-related  findings  in  cynomolgus  monkeys  are attributed  to  opportunistic  infections  is  not  supported  by  data  or  identification  of  any  causative pathogens. In fact, the lack of clear changes in haematology parameters such as neutrophil or monocyte count may argue against common occurrence of opportunistic infection in zilucoplan-treated animals and alternative mechanisms behind the observed findings cannot be excluded. Consistently in the repeatdose toxicity studies vesicular degeneration of epithelial cells and mononuclear cell infiltrates were noted in various tissues at clinically relevant exposure.

Of particular interest in the repeat-dose toxicity studies is the consistent finding of pancreas-related toxicity, especially since elevated pancreas enzymes were noted also in the clinical studies and a few cases of pancreatitis were reported clinically. The mechanisms behind this are not clear, but a role for direct cleavage and activation of C5 by extrinsic proteases, not typically associated with complement, cannot be  excluded.  In  the  protease-producing  pancreas  it  is  known  that  C5  can  in  some  cases  be activated by trypsin, and as a consequence of the increased plasma C5 concentration after zilucoplan treatment, increased C5a and C5b locally in the pancreas can be envisioned. However, the difficulties in identifying the exact mechanism(s)  behind the observed pathologies beyond speculation are acknowledged.

## Toxicokinetics

Generally, toxicokinetic evaluation has done adequately. However, major metabolite RA102758 was not measured the 39-week repeat-dose toxicology studies. Despite this, the risk of RA102758 accumulation or  insufficient  exposure  in  the  39-week  repeat-dose  toxicology  is  deemed  low  owing  to  similar AUCmet/AUCparent ratios between the 4-week and 13-week monkey studies. Furthermore, based on plasma exposure of RA102758 metabolite (AUC0-24h=1040 μ g.h/mL) at the highest tested dose of 10mg/kg/day in the 13-week study, an exposure multiple of 38 was obtained compared to the human plasma exposure measured (AUC0-24h=27.1 μ g.h/mL at 0.3mg/kg/day) which further indicates a low risk of insufficient exposure to RA102758 in the 39 week study.

Zilucoplan PEC surfacewater value is below the action limit of 0.01 µ g/L, and is not a PBT substance as log Kow does not exceed 4.5. Therefore, zilucoplan is not expected to pose a risk to the environment.

<div style=\"page-break-after: always\"></div>

## 2.5.7. Conclusion on the non-clinical aspects

Assessment  of  the  non-clinical  dossier  of  zilucoplan  revealed  no  major  objections  to  marketing authorisation. There are no objections to marketing authorisation from a non-clinical point-of-view.

## 2.6. Clinical aspects

## 2.6.1. Introduction

## GCP aspects

The Clinical trials were performed in accordance with GCP as claimed by the applicant.

The applicant has provided a statement to the effect that clinical trials conducted outside the Community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

## · Tabular overview of clinical studies

Table 2: Summary of studies supporting the clinical pharmacokinetics of zilucoplan

| Study number                             | Study objectives                                                                                                                                                     | Number participants, levels                                                                                                                                                        | of dose                                  | PopPK PK/PD                              | or                                       | PD                                          | PK sampling/ immunogencity               |
|------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|---------------------------------------------|------------------------------------------|
| Initial PK/Tolerability, Phase 1 studies | Initial PK/Tolerability, Phase 1 studies                                                                                                                             | Initial PK/Tolerability, Phase 1 studies                                                                                                                                           | Initial PK/Tolerability, Phase 1 studies | Initial PK/Tolerability, Phase 1 studies | Initial PK/Tolerability, Phase 1 studies | Initial PK/Tolerability, Phase 1 studies    | Initial PK/Tolerability, Phase 1 studies |
| UP0112 (RA101495- 1001)                  | First-in-human study to evaluate the safety, tolerability, PK, and PD of single escalating doses of ZLP and multiple doses of ZLP administered once daily for 7 days | SAD: ZLP 0.05mg/kg ZLP 0.1mg/kg ZLP 0.2mg/kg ZLP 0.4mg/kg PBO (N=8) MD: ZLP 0.2mg/kg (N=4) PBO (N=2) Dose by BW                                                                    | (N=2) (N=4) (N=4) (n=4)                  | Yes                                      |                                          | Yes Assays: sRBC lysis, total C5, MAC, CH50 | Intensive/ADA                            |
| UP0113 (RA101495- 01.102)                | To evaluate safety and tolerability in healthy Japanese study participants and compared them with healthy Caucasian study participants                               | SD ZLP Caucasian (N=4) Japanese (N=4) SD ZLP 0.3mg/kg: Caucasian (N=4) Japanese (N=4) MD ZLP 0.3mg/kg Caucasian (N=6) Japanese (N=6) PBO Caucasian (N=4) Japanese (N=4) Dose by BW | 0.1mg/kg:                                | Yes                                      |                                          | Yes Assays: sRBC lysis, total C5, MAC       | Intensive/NA                             |
| UP0093 (RA101495- 02.101)                | To study of the effects of supratherapeutic dose of ZLP on cardiac repolarisation in healthy adult study participants                                                | ZLP 0.6mg/kg: Group 1 (N=32) PBO: Subgroup 2A (N=16) Subgroup 2B (N=17)                                                                                                            |                                          | Yes                                      |                                          | Yes Assay: Total C5                         | Intensive/NA                             |

<div style=\"page-break-after: always\"></div>

| Study number                               | Study objectives                                                                                                                                                           | Number of participants, dose levels                                                                                                                                               | PopPK PK/PD                                | PD                                         | PK sampling/ immunogencity                 |                                            |
|--------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|
|                                            |                                                                                                                                                                            | Dose by BW                                                                                                                                                                        |                                            |                                            |                                            |                                            |
| UP0094 (RA101495- 02.102)                  | To assess the PK profile of single-dose ZLP and its metabolites in study participants with moderate hepatic impairment and study participants with normal hepatic function | SD ZLP 0.3mg/kg: Moderate HI (N=8) Normal (N=8) Dose by weight bracket                                                                                                            | Yes                                        | Yes Assays: sRBC lysis, total C5           | Intensive/NA                               |                                            |
| UP0114 (RA101495- 03.101)                  | To assess the PK profile and safety of single-dose ZLP and its metabolites in participants with severe renal impairment and in participants with normal renal function     | SD ZLP 0.3mg/kg: Severe renal impairment (N=8) Normal renal function (N=8) Dose by weight bracket                                                                                 | Yes                                        | Yes Assay: Total C5                        | Intensive/NA                               |                                            |
| UP0115 b                                   | To evaluate the relative bioavailability, PD, safety, and tolerability of a single SC injection of ZLP at different administration sites                                   | ZLP 0.3mg/kg Group A: Treatment Sequence 1: AC (N=4) Treatment Sequence 2: CA (N=4) Group B: Treatment Sequence 3: BD (N=4) Treatment Sequence 4: DB (N=4) Dose by weight bracket | Yes                                        | Yes Assay: sRBC lysis                      | Intensive/NA                               |                                            |
| Phase 2 efficacy and safety studies in gMG | Phase 2 efficacy and safety studies in gMG                                                                                                                                 | Phase 2 efficacy and safety studies in gMG                                                                                                                                        | Phase 2 efficacy and safety studies in gMG |                                            |                                            |                                            |
| MG0009 (RA101495- 02.201)                  | To assess the safety, tolerability, and preliminary efficacy of ZLP in study participants with gMG                                                                         | ZLP 0.1mg/kg (N=15) ZLP 0.3mg/kg (N=15) PBO (N=15) Dose by weight bracket                                                                                                         | Yes                                        | Yes Assay: sRBC lysis, total C5            | Sparse/NA c                                |                                            |
| Phase 3 efficacy and safety studies in gMG | Phase 3 efficacy and safety studies in gMG                                                                                                                                 | Phase 3 efficacy and safety studies in gMG                                                                                                                                        | Phase 3 efficacy and safety studies in gMG | Phase 3 efficacy and safety studies in gMG | Phase 3 efficacy and safety studies in gMG | Phase 3 efficacy and safety studies in gMG |
| MG0010 (RA101495- 02.301)                  | To confirm safety, tolerability, and efficacy of ZLP in study participants with gMG                                                                                        | ZLP 0.3mg/kg (N=86) PBO (N=88) Dose by weight bracket                                                                                                                             | Yes                                        | Yes Assays: sRBC lysis, total C5           | Sparse/ADA                                 |                                            |
| MG0011 (RA101495- 02.302 Ongoing study     | To evaluate the long-term efficacy, safety, and tolerability of ZLP in study participants with gMG                                                                         | PBO/ZLP 0.1mg/kg/0.3mg/kg (N=5) PBO/ZLP 0.3mg/kg (N=90) ZLP 0.1mg/kg/ 0.1mg/kg/0.3mg/kg (N=12) ZLP 0.3mg/kg/0.3mg/kg (N=92)                                                       | Yes                                        | Assays: sRBC lysis, total C5               | Sparse/ADA                                 |                                            |

<div style=\"page-break-after: always\"></div>

| Study number   | Study objectives   | Number of participants, dose levels   | PopPK PK/PD   | PD   | PK sampling/ immunogencity   |
|----------------|--------------------|---------------------------------------|---------------|------|------------------------------|
|                |                    | Dose by weight bracket                |               |      |                              |

CH50=total haemolytic component; C5=complement component 5; MAC=membrane attack complex; sRBC=sheep red blood cell; ZLP=zilucoplan b   Treatment Sequence 1 (AC): Abdomen A at Treatment Period 1 followed by Arm at Treatment Period 2; Treatment Sequence 2 (CA): Arm at Treatment Period 1 followed by Abdomen A at Treatment Period 2; Treatment Sequence 3 (BD): Abdomen B at Treatment Period 1 followed by Thigh at Treatment Period 2; Treatment Sequence 4 (DB): Thigh at Treatment Period 1 followed by Abdomen B at Treatment Period 2.

c  The assay used for ADA assessment was considered not fit for purpose.

## 2.6.2. Clinical pharmacology

Zilucoplan (ZLP, RA101495) is a new chemical entity, and the PK studies should thus aim at describing the  absorption,  distribution,  metabolism,  and  excretion  (ADME)  characteristics  and  also  to  identify subgroups  where  an  altered  exposure  can  be  expected  based  on  the  pharmacokinetic  properties. Potential interactions should also be evaluated.

Zilucoplan is a synthetic peptide conjugated with an ethylene glycol moiety. Zilucoplan binds to C5 and is designed for the treatment of gMG. The proposed posology is weight-based and is 16.6 mg (&lt;56 kg), 23.0 mg ( ≥ 56-&lt;77 kg) or 32.4 mg ( ≥ 77 kg) of zilucoplan given as daily SC injection. This corresponds to approximately 0.3 mg/kg (effective dose 0.2-0.4 mg/kg depending on the weight band). The proposed posology with flat dose within weight bands has been studied in the clinical programme and it is what is meant when a dose of 0.3 mg/kg is referred to. Dose strength variation is accomplished by varying the syringe fill volume.

To support this marketing application, the PK of zilucoplan and its metabolites, RA102758 and RA103488, is investigated in 9 clinical studies. A numerous of in vitro studies is also performed. All PK studies were conducted according to GCP.

The qualitative and quantitative composition of the formulation used in first-in-man and all subsequent clinical studies has remained unchanged throughout the full development.

As a peptide, zilucoplan is expected to be degraded into small peptides and amino acids via catabolic pathways. CYP4F2 contributes to a minor part of the metabolism. One major metabolite, RA102758 (inactive), is evident in human plasma. RA103488 is an active metabolite, with a similar potency as parent compound, but its contribution to the overall efficacy is considered low.

## 2.6.2.1. Pharmacokinetics

## Methods

## Quantification of zilucoplan, RA102758 and RA103488

Total zilucoplan and its metabolites, RA102758 (major metabolite) and RA103488, were quantified by liquid  chromatography-tandem  mass  spectrometry  (LC-MS/MS)  using  validated  methods  in  human K2EDTA plasma, urine and faeces. Two different methods were used for analysis of the total plasma concentrations of zilucoplan (Method 1 was used in the single-ascending dose (SAD) and multiple-dose (MD) study, UP0112, and Method 2 was used in the in the other clinical studies). No cross-validation was performed between these two methods.

A validated LC-MS/MS method was also used for quantification of unbound zilucoplan in human K2-EDTA Plasma: Phosphate Buffered Saline.

<div style=\"page-break-after: always\"></div>

## Immunogenicity

A tiered approach to detect ADA and APA was applied.

The development of an assay to detect neutralising antibodies (NAb) was unsuccessful as issues with C5 target tolerance could not be circumvented.

Three ADA methods were developed to optimise drug tolerance, and full validations were carried out for each method.

- The initial method employed to support UP0112 detecting human ADAs was a ligand binding assay with biotinylated zilucoplan as a capture reagent and use of a labelled detection reagent. This assay showed a limited drug tolerance of 5 µg/mL of zilucoplan at PC antibody levels of 100 ng/mL.  Although  adequate  for  study  UP0112,  the  assay  was  subsequently  found  to  have insufficient drug tolerance to accommodate expected therapeutic levels of zilucoplan.
- The second-generation assay, used for study MG0009 showed insufficient drug tolerance and results were not reported.
- A third-generation assay was developed for use in the Phase 3 clinical studies and consists of an immunoassay with upfront acid dissociation. Biotinylated zilucoplan was used for the capture and detection by use of a mixture of labelled reagents.

The APA assay consists of a immunoassay, similar to the 3rd generation ADA assay, with upfront acid dissociation, capture with, and detection with a mixture of labelled reagents.

## Pharmacokinetic data analysis

Non-compartmental methods and population PK (popPK) analysis were used to evaluate the PKs.

## Population pharmacokinetic modelling

A popPK analysis was performed using PK data from studies UP0112 (SAD-MD), UP0113 (Japanese SDMD), UP0114 (RI; only data from HV included in popPK analysis), UP0093 (TQT), MG0009 (gMG; Phase 2), and MG0010 (gMG; Phase 3).

Of the collected samples, 7.7% had a concentration below the limit of quantification and were excluded from the analysis. In total, 2174 zilucoplan concentrations from 200 individuals were used to fit the models.

A preliminary zilucoplan target mediated drug disposition (TMDD) population PKPD model had previously been developed using data from Phase 1 and Phase 2 studies (gMG patients and studies in paroxysmal nocturnal  haemoglobinuria  patients).  The  model  was  simultaneously  fitted  to  zilucoplan  and  C5 complement concentration data and was considered too complex to be adequately supported by the sparse data collected in the Phase 3 study (MG0010). The preliminary model was therefore simplified by applying the quasi-steady-state approximation to the TMDD equations and by assuming a constant total (bound + unbound) C5 complement concentration in plasma. Thereby allowing the model to be fitted using only total zilucoplan concentration data.

The final popPK model is a 2-compartment model with first order absorption, followed by the simplified TMDD model (Figure 2). It includes estimated allometric coefficients to describe the effect of body weight on  the  linear  zilucoplan  PK  parameters  of  clearance  (CL),  intercompartmental  CL  (Q),  volume  of distribution of the central compartment (Vc), and volume of distribution of the peripheral compartment (Vp).

<div style=\"page-break-after: always\"></div>

Figure 2: Schematic description of the final zilucoplan population PK model

<!-- image -->

C5=complement component 5; PK=pharmacokinetic ; Rmax=maximum target density; SC=subcutaneous; ZLP=zilucoplan

A covariate analysis was performed to evaluate the potential effect of additional demographic covariates (age, sex, race, and population [healthy volunteers vs. gMG patients]) on CL and on the (constant) total C5 complement concentration (Rmax; maximum target density). The effects of single covariates on the respective  parameter  were  implemented  in  separate  NONMEM  models.  Since  the  95%  confidence intervals (CIs) of the estimated single covariate effects were all including 1 (i.e., were not statistically significant at p=0.05), the base model, without additional covariates (body weight was included a priori ), was considered the final model.

Parameter estimates for the final popPK model are presented in table below. The model was fitted using the  FOCE  estimation  method  with  interaction  in  NONMEM  (v.  7.5.0).  Provided  are  also  parameter estimates derived using sampling importance resampling, as implemented in Perl-speaks-NONMEM (PsN; v.  4.6.0),  where  the  values  correspond  to  the  50 th   (point  estimate),  and  2.5 th   and  97.5 th   (95%  CI) percentiles of the estimated distributions.

Table  3:  Parameter  estimates  for  the  final  population  PK  model,  derived  using  NONMEM  and  using sampling importance resampling, respectively

| Parameter                                | NONMEM Estimate (95% CI)                                          | NONMEM IIV     | SIR Estimate (95% CI)                                          | SIR IIV   | Shrinkage a   |
|------------------------------------------|-------------------------------------------------------------------|----------------|----------------------------------------------------------------|-----------|---------------|
| ka (1/h)                                 | 1.22 (0.809/1.85)                                                 | 41.5%          | 1.22 (0.939/1.66)                                              | 41.7%     | 29.6%         |
| CL (L/h)                                 | 0.0845 (0.0815/0.0875)                                            | 16.8%          | 0.0845 (0.0817/0.0877)                                         | 16.8%     | 13.5%         |
| Vc (L)                                   | 3.51 (3.31/3.71)                                                  | 15.7%          | 3.51 (3.33/3.72)                                               | 15.8%     | 39.3%         |
| Q (L/h)                                  | 0.566 (0.494/0.638)                                               | 39.4%          | 0.567 (0.488/0.647)                                            | 39.6%     | 58.7%         |
| Vp (L)                                   | 3.45 (3.19/3.72)                                                  | 0% Fixed       | 3.45 (3.17/3.75)                                               |           |               |
| Kss (ng/mL)                              | 63.3 (13.4/113)                                                   | 0% Fixed       | 62.4 (33.0/107)                                                |           |               |
| Kint (1/h) Rmax (ng/mL) Allometric WT    | 0.00320 (0.00262/0.00379) 1780 (1610/1960) on 0.715 (0.604/0.825) | 0% Fixed 21.5% | 0.00321 (0.00275/0.00363) 1780 (1630/1980) 0.716 (0.621/0.807) | 21.8%     | 49.4%         |
| CL and Q Allometric WT on                | 0.452 (0.335/0.569)                                               |                | 0.454 (0.350/0.544)                                            |           |               |
| Vc and Vp slope of logarithm of ka on WT | -1.01 (-1.38/-0.643)                                              |                | -1.01 (-1.25/-0.783)                                           |           |               |
| Proportional (%)                         | RUV 9.26 (8.41/10.1)                                              |                | 9.27 (8.85/9.64)                                               |           | 9.6%          |
| Additive (ng/mL)                         | RUV 63.3 (16.5/110)                                               |                | 64.0 (46.6/87.9)                                               |           | 9.6%          |

<div style=\"page-break-after: always\"></div>

CI=confidence interval; CL=clearance; ka=absorption rate constant; IIV=inter-individual variability Kint=internalisation rate constant; Kss=quasi-stationary  constant;  OFV=  objective  function  value;  Q=inter  24%compartmental  clearance;  Rmax=maximum  target density; RUV=residual unexplained variability; Vc=central volume; Vp=peripheral volume; WT=weight a Shrinkage calculated using the standard deviation from NONMEM estimates

Goodness of fit plots and visual predictive checks (VPCs) were used to ascertain the ability of the final popPK model to adequately describe the observed zilucoplan concentrations. VPCs stratified by dose (not shown), by body weight (not shown), single and multiple dose (Figure 3), and population (HV/gMG patient;  Figure  4)  were  provided.  All  figures  demonstrate  that  there  was  adequate  correspondence between  the  2.5 th ,  50 th   (median),  and  97.5 th   percentiles  of  the  observed  data  and  corresponding simulated quantiles for zilucoplan concentrations.

Figure 3: Visual predictive checks for the final population PK model for zilucoplan, stratified by single and multiple dose

<!-- image -->

popPK=population pharmacokinetic; VPCs=visual predictive checks; ZLP=zilucoplan

Red lines=observed ZLP quantiles (2.5 th , 50 th , 97.5 th ); black lines=median of ZLP (2.5 th , 50 th , 97.5 th ) across simulated trials; blue and red shaded areas=95% of the ZLP quantiles (2.5 th , 50 th , 97.5 th ) across simulated trials; red circles=observations

<div style=\"page-break-after: always\"></div>

Figure 4: Visual predictive checks for the final population PK model for zilucoplan, stratified by population

<!-- image -->

popPK=population pharmacokinetic; VPCs=visual predictive checks; ZLP=zilucoplan

Red lines=observed ZLP quantiles (2.5 th , 50 th , 97.5 th ); black lines=median of ZLP (2.5 th , 50 th , 97.5 th ) across simulated trials; blue and red shaded areas=95% of the ZLP quantiles (2.5 th , 50 th , 97.5 th ) across simulated trials; red circles=observations

## Absorption

Cmax of zilucoplan is generally reached 3-6 hours after both single and repeated SC administration. Single dose PK in healthy volunteers are shown in Table 4.

Table 4: Pharmacokinetics of zilucoplan following a single SC injection of zilucoplan in healthy volunteers

| Study no   | ZLP dose         | ZLP PK parameter (geometric mean and geometric CV %) a   | ZLP PK parameter (geometric mean and geometric CV %) a   | ZLP PK parameter (geometric mean and geometric CV %) a   | ZLP PK parameter (geometric mean and geometric CV %) a   | ZLP PK parameter (geometric mean and geometric CV %) a   |
|------------|------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|
| Study no   | ZLP dose         | C max (ng/mL)                                            | t max a) (h)                                             | AUC (0-last) (h*ng/mL)                                   | AUC (0-inf) (h*ng/mL)                                    | t 1/2 a) (h)                                             |
| UP0112     | 0.05 mg/kg, N=2  | 1010 (1.4)                                               | 4.5 (3, 6)                                               | 179,800 (1.8)                                            | 190,700 (1.6)                                            | 164 (156, 171)                                           |
| UP0112     | 0.1 mg/kg, N=4   | 1540 (13)                                                | 3.0 (3, 24)                                              | 373,000 (13)                                             | 405,900 (14)                                             | 186 (178, 193)                                           |
| UP0112     | 0.2 mg/kg, N=4   | 2958 (11)                                                | 4.5 (3, 48)                                              | 647,800 (17)                                             | 692,200 (20)                                             | 170 (144, 204)                                           |
| UP0112     | 0.4 mg/kg, N=4   | 5860 (7.6)                                               | 4.6 (3, 6)                                               | 816,500 (14)                                             | 855,900 (15)                                             | 158 (139, 168)                                           |
| UP0113     | C: 0.1mg/kg, N=4 | 1700 (4.4)                                               | 3.0 (3.0, 3.0)                                           | 401,000 (4.7)                                            | 439,000 (6.2)                                            | 174 (7.4)                                                |
| UP0113     | J: 0.1mg/kg, N=4 | 1580 (14)                                                | 3.0 (3.0, 6.0)                                           | 428,000 (13)                                             | 480,000 (13)                                             | 201 (2.2)                                                |
| UP0113     | C: 0.3mg/kg, N=4 | 3580 (8.8 )                                              | 6.0 (3.0, 6.0)                                           | 607,000 (21)                                             | 653,000 (23)                                             | 165 (11.8)                                               |
| UP0113     | J: 0.3mg/kg, N=4 | 3780 (5.1)                                               | 3.0 (3.0, 3.0)                                           | 737,000 (8.6)                                            | 808,000 (9.1)                                            | 183 (8.4)                                                |
| UP0094     | 0.3 mg/kg, N=8   | 5128 (19)                                                | 8.0 (2.0, 12)                                            | 769,900 (13)                                             | 787,000 (13)                                             | 163 (111, 164)                                           |
| UP0114     | 0.3 mg/kg, N=8   | 4830 (18)                                                | 4.0 (2.0, 12)                                            | 789,543 (18)                                             | 821,508 (20)                                             | 168 (150, 269)                                           |
| UP0093 b)  | 0.6 mg/kg, N=32  | 8372 (12)                                                | 4.0 (2.0, 8.1)                                           | 149,000 (9.3)                                            | NC                                                       | --                                                       |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Study no   | ZLP dose        | ZLP PK parameter (geometric mean and geometric CV %) a   | ZLP PK parameter (geometric mean and geometric CV %) a   | ZLP PK parameter (geometric mean and geometric CV %) a   | ZLP PK parameter (geometric mean and geometric CV %) a   |
|------------|-----------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|
|            |                 | C max (ng/mL)                                            | t max a) (h) AUC (0-last) (h*ng/mL)                      | AUC (0-inf) (h*ng/mL)                                    | t 1/2 a) (h)                                             |
| UP0115 c)  | 0.3 mg/kg, N=16 | Group A: Abdomen (A) (N=7)                               | Group A: Abdomen (A) (N=7)                               | Group A: Abdomen (A) (N=7)                               | Group A: Abdomen (A) (N=7)                               |
| UP0115 c)  |                 | 5180 (13)                                                | 6.0 (3.0, 8.2) 821,700 (6.5)                             | 858,200 (6.4)                                            | 181 (149, 203)                                           |
| UP0115 c)  |                 | Group A: Arm (C) (N=7)                                   | Group A: Arm (C) (N=7)                                   | Group A: Arm (C) (N=7)                                   | Group A: Arm (C) (N=7)                                   |
| UP0115 c)  |                 | 5187 (18)                                                | 4.0 (3.0, 8.1) 806,300 (5.3)                             | 841,300 (5.0)                                            | 183 (161, 198)                                           |
| UP0115 c)  |                 | Group B: Abdomen (B) (N=8)                               | Group B: Abdomen (B) (N=8)                               | Group B: Abdomen (B) (N=8)                               | Group B: Abdomen (B) (N=8)                               |
| UP0115 c)  |                 | 5905 (18)                                                | 6.0 (3.0, 8.1) 903,400 (16)                              | 942,400 (18)                                             | 178 (132, 219)                                           |
| UP0115 c)  |                 | Group B: Thigh (D) (N=8)                                 | Group B: Thigh (D) (N=8)                                 | Group B: Thigh (D) (N=8)                                 | Group B: Thigh (D) (N=8)                                 |
| UP0115 c)  |                 | 5103 (15)                                                | 6.1 (4.0, 24.0) 876,300 (16)                             | 916,300 (18)                                             | 180 (123, 229)                                           |

CV=coefficient of variation; NC=not calculated; ZLP=zilucoplan

J=Japanese, C=Caucasian

a  median (minimum, maximum) for tmax and t1/2; in UP0113: geo mean and geo CV%

b  Only data from the first day of treatment are shown

c  Group A study participants received 1 injection in either the abdomen or arm in a randomised order. Group B study participants received 1 injection in either the abdomen or thigh in a randomised order.

Source: Modified Table 5-1 in clinical pharmacology summary

No bioequivalence study has been performed.

A study was performed to investigate the effect on different injection sites on the relative bioavailability of  zilucoplan  (UP0115,  Table  4).  The  systemic  exposures  of  ZLP,  in  terms  of  Cmax  and  AUC0-t,  were comparable following a single SC injection in the abdomen as compared to the thigh and arm. No major differences in the geometric mean CL/F and t½; and median tmax were noted between the injection sites. Based  on  visual  inspection,  the  plasma  concentration-time  profiles  of  the  metabolites  seemed comparable between the injection sites.

## Distribution

The apparent volume of distribution of the central compartment (Vc/F) of zilucoplan (not bound to target) is approximately 3.5 L (popPK analysis).

The plasma protein binding for zilucoplan was &gt;99.8% (355-1, TR-0122). The two largest circulating metabolites in humans, RA103488 and RA102758, were also highly bound to plasma proteins (&gt;99%) (355-1).

The blood-to-plasma ratios ranged between 0.70 and 0.76 (TR-0123) indicating that zilucoplan does not partition into erythrocytes.

## Elimination

As a peptide, ZLP is expected to be degraded into small peptides and amino acids via catabolic pathways. CYP4F2 seems to contribute to a minor part of the metabolism.

The mean plasma t1/2 of ZLP was approximately 172 hours (range: 139 to 204 hours) in healthy study participants. The mean apparent clearance (CL/F) ranged between 0.26 to 0.47 ml/h/kg after a single SC dose in the range 0.05-0.4 mg/kg. A higher mean CL/F of 1.33 ml/h/kg was reported after repeated administration of 0.2 mg/kg/day for 7 days. The popPK estimate of CL/F of drug not bound to target was 0.085 L/h (95 % CI: 0.082-0.088 L/h). Based on popPK analysis, there is no difference in CL/F between healthy participants and participants with gMG.

<div style=\"page-break-after: always\"></div>

## Excretion

No mass-balance study has been performed. Following a single dose injection of unlabelled zilucoplan, excretion of zilucoplan, RA103488, and RA102758 into urine and faeces appears to be minimal (studies UP0114 and UP0094).

## Metabolism

The metabolism zilucoplan (RA101495) was investigated in in vitro studies with labelled ZLP and in vivo studies with unlabelled zilucoplan. The proposed metabolic pathways in human plasma are summarised in Figure 5.

Figure 5: Proposed metabolic pathways of zilucoplan in human plasma

<!-- image -->

Six  metabolites  (M2356/1,  RA103056,  M1780/1,  M2040/1,  M2169/1,  RA102758)  were  identified  in human hepatocytes, and no human unique metabolite was observed (16900). Peptide hydrolysis seems to be the predominant metabolic pathway. RA102758 was the abundant metabolite accounting for 28% and 7.2% of the total radioactivity in the 4-hr incubations with 1 and 10 µM [ 14 C]RA101495, respectively. M1780/1, M2040/1, and M2169/1 were co-eluted, accounting for approximately 31% and 13% of total radioactivity in the 1 and 10 µM incubations, in which the contribution of M2169/1 was 27% and 11% respectively.

Metabolite identification was performed in pooled plasma samples collected 24-hours after dosing at week 12 from patients  with  gMG  in  the  Phase  2  study,  MG0009  (18512).  In  addition  to  RA101495 (zilucoplan),  eighteen  metabolites,  including  palmitic  acid,  were  tentatively  identified  (Figure  5). RA106009 was not detected. The major metabolic pathways of RA101495 in human plasma involved: 1) proteolytic cleavage at different peptide bond in RA101495 and its mono-oxidation products; 2) monooxidation of RA101495 and its cleavage products; 3) amide hydrolysis at PEG linker.

<div style=\"page-break-after: always\"></div>

In  vitro studies  with  liver  microsomes  and  recombinant  CYP  enzymes  show  that  mainly  CYP4F2  is involved in the formation of the active metabolite, RA103488 ( ω -oxidation of RA101495) (TR-0160).

## Pharmacokinetics of the metabolites

Potential metabolites were evaluated in the 0.4 mg/kg single dose cohort and in the 0.2 mg/kg multiple dose  part  of  study  UP0112  (TR-0128).  Of  those  10  metabolites  evaluated,  two  larger  metabolites RA103488 and RA102758 were identified in the single dose cohort. Thereafter, RA102758, RA103488 and RA103933 (observed in higher proportions in non-clinical studies), were quantified in the MD study (Figure 6). Based on molar units, the total plasma exposure (AUC0-24) of RA102758 and RA103488 on the last day of treatment (day 7) were approximately 25% and 16% of parent AUC0-24, respectively. For RA103488 this metabolite-to-parent ratio was similar after the single as compared to repeated dosing, whereas for RA102758 the ratio was approximately 2-fold higher after repeated dosing. RA103488, is a pharmacologically  active  metabolite  with  a  similar  potency  as  parent  compound in  vitro ,  whereas RA102758 is not pharmacologically active.

Figure 6: Mean Plasma concentration vs time profile of ZLP (RA101495) and three metabolites during study of 7 daily subcutaneous doses at 0.20mg/kg

<!-- image -->

M1= RA102758, M9= RA103933, M10= RA103488 (study UP0112)

The PK of the metabolites were also studied after once daily SC injections of 0.3 mg/kg of ZLP for 14 days (UP0113). On day 14, the Cmax of RA102758 (geometric mean range: 1270-1610 ng/mL) and RA103488 (geometric mean range: 889-1110 ng/mL) were reached approximately 13-23 hours and 215 hours after dosing, respectively. At approximate steady state (day 14), the metabolite-to-parent plasma area under the concentration-time curve at steady state over the dosing interval (AUC0τ ) ratios were approximately 25% for RA102758 and 10% for RA103488. The geometric mean (CV%) t1/2 of RA102758 was estimated  to  92  h  (8.1%)  and  108  h  (9.3%)  in  Caucasians  and  Japanese  subjects, respectively. The geometric mean (CV%) t1/2 of RA103488 was estimated to 275 h (8.7%) and 288 h (6.1%) in Caucasians and Japanese subjects, respectively.

Following a single dose of 0.3 mg/kg to healthy subjects in the renal impairment study (UP0114), the mean t1/2 of RA102758 and RA103488 were estimated to 107 hours and 301 hours, respectively.

<div style=\"page-break-after: always\"></div>

## Dose proportionality and time dependencies

Following single-dose administration of 0.05 to 0.4 mg/kg ZLP in the SAD study (UP0112), the increase in Cmax was approximately dose proportional while the increase in AUC0-last and AUCinf was less than dose proportional (Table 4).

When  multiple  doses  of  0.6  mg/kg  were  given  in  the  TQT  study  UP0093,  a  faster  elimination  was observed,  however  limited  by  short  sampling  times.  Similar  was  observed  in  the  14-day  study  in Caucasian and Japanese participants (UP0113).

The accumulation ratio of zilucoplan was approximately 3 at doses of 0.2-0.6 mg/kg/dose (expressed as Cmax and AUC0-24 after a single injection as compared to repeated administration) (UP0093, UP0112, UP0113).

The terminal half-life (t1/2) of ZLP was consistent following single and repeated dosing (0.2 mg/kg SAD mean t1/2=172 hours [range: 144 to 204 hours]; 0.2 mg/kg MD mean Day 7 t1/2=162 hours [range: 142 to  177 hours]). The Vz/F of ZLP increased with administration of MD of ZLP (0.2 mg/kg SAD mean Vz/F=71.4 mL/kg; 0.2 mg/kg MD mean Day 7 Vz/F=312 mL/kg). However, the Day 7 Vz/F for ZLP was still less than total body water, suggesting that ZLP does not distribute into the extravascular space upon repeat SC administration.

## Immunogenicity

No positive ADA samples were observed in the multiple dose part of study UP0112, in which healthy participants were given SC injections of 0.2 mg/kg/day for 7 days.

Samples from studies MG0009 and IMNM01 are inconclusive due to poor drug tolerance of the secondgeneration assay.

ADA and APA samples were collected for all subjects in Phase III study, MG0010. Two study participants (of in total 86) in the ZLP 0.3 mg/kg treatment group were treatment-emergent ADA positive and had similar plasma concentrations of ZLP compared with ADA negative study participants. The ADA titres of these 2 study participants while treated with ZLP were 133 and 212.

Eight  study  participants  were  treatment-emergent  anti-PEG  positive.  The  titres  of  these  participants while under ZLP treatment ranged between &lt;100 (4 participants) and 1523.81 (one participant). Within this range 4 participants had titres between 100 and 750. Zilucoplan plasma concentrations of study participants who were anti-PEG positive were generally within the same range as the study participants who were anti-PEG negative, which includes n=5 baseline positive individuals.

The APA titres of the 2 additional study participants who became anti-PEG positive during MG0011 were low and close to the MRD. Combined ADA and APA data up to the MG0011 clinical data cutoff date of 08 Sep 2022 showing the number of participants that are ADA and APA positive are shown in Table 5.

<div style=\"page-break-after: always\"></div>

Table 5: ADA and APA classification in studies MG0010 and MG0011 by treatment arm

| ADAclassification                       | Anti-PEGantibodyclassification   | Anti-PEGantibodyclassification   | Anti-PEGantibodyclassification   | Anti-PEGantibodyclassification   | Anti-PEGantibodyclassification   | Anti-PEGantibodyclassification   | Anti-PEGantibodyclassification   | Anti-PEGantibodyclassification   |
|-----------------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|
|                                         | (%)                              | (%)                              | (%)                              | (%)                              | (%)                              | (%)                              | (%)                              | (%)                              |
|                                         | a                                | b                                | C                                | d                                | e                                | f                                | g                                | Total                            |
| Placebo/ZLP 0.3mg/kg (N=90)             |                                  |                                  |                                  |                                  |                                  |                                  |                                  |                                  |
| Pre ADA neg - treatment induced ADA neg | 53 (63.1)                        | 13 (15.5)                        | 0                                | 4 (4.8)                          | 2 (2.4)                          | 0                                | 0                                | 72 (85.7)                        |
| Pre ADA neg - treatment induced ADA pos | 2 (2.4)                          | 2 (2.4)                          | 0                                | 1 (1.2)                          | 0                                | 0                                | 0                                | 5 (6.0)                          |
| Pre ADA pos - treatment reduced ADA     | 0                                | 0                                | 0                                | 0                                | 0                                | 0                                | 0                                | 0                                |
| Pre ADA pos - treatment unaffected ADA  | 0                                | 0                                | 0                                | 0                                | 0                                | 0                                | 0                                | 0                                |
| Pre ADA pos - treatment boosted ADA pos | 0                                | 0                                | 0                                | 0                                | 0                                | 0                                | 0                                | 0                                |
| Inconclusive                            | 0                                | 0                                | 0                                | 0                                | 0                                | 0                                | 0                                | 0                                |
| Missing                                 | 0                                | 2 (2.4)                          | 0                                | 1 (1.2)                          | 0                                | 0                                | 4 (4.8)                          | 7 (8.3)                          |
| Total                                   | 55 (65.5)                        | 17 (20.2)                        | 0                                | 6 (7.1)                          | 2 (2.4)                          | 0                                | 4 (4.8)                          | 84 (100)                         |

| ADAclassification                       | Anti-PEGantibodyclassification   | Anti-PEGantibodyclassification   | Anti-PEGantibodyclassification   | Anti-PEGantibodyclassification   | Anti-PEGantibodyclassification   | Anti-PEGantibodyclassification   | Anti-PEGantibodyclassification   | Anti-PEGantibodyclassification   |
|-----------------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|
|                                         | (%)                              | (%)                              | (%)                              | (%)                              | (%)                              | (%)                              | (%)                              | (%)                              |
|                                         | a                                | b                                | C                                | d                                | e                                | f                                | g                                | Total                            |
| ZLP0.3mg/kg/ZLP0.3mg/kg (E6=N)          |                                  |                                  |                                  |                                  |                                  |                                  |                                  |                                  |
| Pre ADA neg - treatment induced ADA neg | 48 (58.5)                        | 13 (15.9)                        | 1 (1.2)                          | 2 (2.4)                          | 0                                | 1 (1.2)                          | 0                                | 65 (79.3)                        |
| Pre ADA neg - treatment induced ADA pos | 2 (2.4)                          | 2 (2.4)                          | 0                                | 0                                | 0                                | 0                                | 0                                | 4 (4.9)                          |
| Pre ADA pos - treatmentreduced ADA      | 0                                | 1 (1.2)                          | 0                                | 0                                | 0                                | 0                                | 0                                | 1 (1.2)                          |
| Pre ADA pos - treatment unaffected ADA  | 0                                | 0                                | 0                                | 0                                | 0                                | 0                                | 0                                | 0                                |
| Pre ADA pos - treatment boosted ADA pos | 0                                | 0                                | 0                                | 0                                | 0                                | 0                                | 0                                | 0                                |
| Inconclusive                            | 0                                | 0                                | 0                                | 0                                | 0                                | 0                                | 0                                | 0                                |
| Missing                                 | 0                                | 2 (2.4)                          | 0                                | 0                                |                                  | 1 (1.2)                          | 9 (11.0)                         | 12 (14.6)                        |
| Total                                   | 50 (61.0)                        | 18 (22.0)                        | 1 (1.2)                          | 2 (2.4)                          | 0                                | 2 (2.4)                          | 9 (11.0)                         | 82 (100)                         |

Note Antidrug and anti-PEG antibodies data are not considered for MG0009 participants. Only MG0010 participants are summarised.

A Pre anti-PEG ADA negative-treatment induced anti-PEG ADA negative

B Pre anti-PEG ADA negative-treatment induced anti-PEG ADA positive

C Pre anti-PEG ADA positive-treatment reduced anti-PEG ADA

D Pre anti-PEG ADA positive-treatment unaffected anti-PEG ADA

E Pre anti-PEG ADA positive-treatment boosted anti-PEG ADA positive

F Inconclusive: participants who are ADA positive at baseline and some (or all) post baseline samples are missing, while other (if presesent) posttreatment samples are ADA negative

G Missing pre ADA negative (or missing) - more than postdose treatment samples are missing, while other (if present) posttreatment samples are negative.

<div style=\"page-break-after: always\"></div>

## Intra- and inter-individual variability

Following a single injection of zilucoplan in healthy subjects, the inter-individual variability (expressed as CV%) in Cmax and AUC for zilucoplan were 1.4-19% and 1.6-23%, respectively. Based on individual parameter estimates from the popPK model, exposure metrics were derived for the gMG participants in the MG0010 study. These derived exposure metrics at steady state indicate an inter-individual variability (CV%) of 18-19% for Cmax and AUC.

## Pharmacokinetics in target population

The PK of zilucoplan and its metabolites, RA102758 and RA103488 were investigated in subjects with gMG. Relatively sparse PK sampling was use. PopPK analysis was used to derive population estimates of PK parameters and test the effect of various covariates. A brief summary of the systemic exposure in the studies in gMG patients are given below.

## MG0009

This  was  a  multicentre,  randomised,  double-blind,  placebo-controlled  study  to  evaluate  the  safety, tolerability,  and  preliminary  efficacy  of  ZLP  in  adult  study  participants  with  gMG.  Forty-five  study participants were enrolled in the study. Study participants were randomised in a 1:1:1 ratio to receive daily SC doses of ZLP 0.1 mg/kg, ZLP 0.3 mg/kg, or matching placebo. The first 12 weeks of the study (i.e., Main Portion) was placebo controlled. After 12 weeks, study participants in the placebo group were randomised to receive ZLP 0.1 mg/kg or 0.3 mg/kg and continued for an additional 12 weeks. The study was then extended for an additional 12 weeks, to have all study participants receive at least 24 weeks active  treatment.  At  some  point  after  24  weeks,  all  participants  in  the  0.1  mg/kg  dose  group  were switched to the 0.3 mg/kg dose group (i.e., Switchers). ZLP was provided in prefilled syringes for selfinjection using weight bracketed dosing.

Approximate steady state plasma concentrations of ZLP, RA102758 and RA103488 were observed after 4  weeks  of  treatment.  There  was  a  trend  towards  an  increase  in  geometric  mean  pre-dose  plasma concentrations of RA103488 with time over the 24 weeks of treatment.

At week 12, the geometric mean (CV%) pre-dose plasma concentrations of zilucoplan were 5143 ng/mL (26%) and 10134 ng/mL (18%) in dose groups 0.1 and 0.3 mg/kg, respectively. The increase in predose plasma concentrations were less than dose proportional.

At week 12 in the main study, for RA102758 the geometric mean metabolite-to-parent ratios of predose plasma concentrations (based on molar concentrations) were 0.16 and 0.30 at doses of 0.1 and 0.3 mg/kg/day, respectively. The corresponding values for RA103488 were 0.11 and 0.13, respectively.

## MG0010

This  was  a  multicentre,  randomised,  double-blind,  placebo-controlled  study  to  confirm  the  efficacy, safety, and tolerability of ZLP in study participants with gMG. Study participants were randomised in a 1:1 ratio to receive daily SC doses of ZLP 0.3 mg/kg/day or placebo. The posology was the same as proposed  in  the  SmPC.  A  total  of  174  study  participants  were  enrolled  and  166  study  participants completed  the  study.  The  total  duration  of  study  participation  for  all  study  participants  was  up  to approximately 16 weeks, including a Screening Period of up to 4 weeks and a 12-week Treatment Period.

Pre-dose concentrations of zilucoplan and its metabolites, RA103488 and RA102758, were measured in plasma. ADAs and APA were also measured in the study (see section Immunogenicity).

Geometric mean pre-dose plasma concentrations of ZLP, RA103488 and RA102758 are shown in Table 6. Plasma concentrations of zilucoplan, RA103488 and RA10275, seemed to reach steady state after 4 weeks and remained relatively stable through Week 12.

<div style=\"page-break-after: always\"></div>

Table 6: Geometric mean pre-dose (95% CI) plasma concentrations of ZLP, RA103488 and RA102758

|            | Geometric mean [95% CI] plasma concentration (ng/mL)   | Geometric mean [95% CI] plasma concentration (ng/mL)   | Geometric mean [95% CI] plasma concentration (ng/mL)   | Geometric mean [95% CI] plasma concentration (ng/mL)   | Geometric mean [95% CI] plasma concentration (ng/mL)   | Geometric mean [95% CI] plasma concentration (ng/mL)   | Geometric mean [95% CI] plasma concentration (ng/mL)   | Geometric mean [95% CI] plasma concentration (ng/mL)   |
|------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|
| Analyte    | Baseline                                               | Week 1                                                 | Week2                                                  | Week 4                                                 |                                                        | Week 8                                                 | Week 12                                                | Week 12                                                |
| Zilucoplan | 5.1 a [4.9, 5.2] (n=83)                                | 11431 [10911, 11975] (n=81)                            | 12460 [11879, 13071] (n=82)                            | 12982 [12270, (n=79)                                   | 13735]                                                 | 12433 [11767, 13137] (n=77)                            | 12545 [11922, (n=75)                                   | 13200]                                                 |
| RA103488   | 5.0 (n=83)                                             | 1055 [982.5, 1133] (n=81)                              | 1407 [1318, (n=82)                                     | 1503] 1553 [1449, (n=79)                               | 1664]                                                  | 1554 [1441, 1677] (n=77)                               | 1554 [1444, (n=75)                                     | 1673]                                                  |
| RA102758   | 5.0 (n=83)                                             | 1072 [997.5, 1152.5] (n=81)                            | 1694 [1572, (n=82)                                     | 1825] 2012 [1859, (n=79)                               | 2178]                                                  | 1891 [1735, 2060] (n=77)                               | 1866 [1711, (n=75)                                     | 2034]                                                  |

Note: Values BLQ are replaced by value of LLOQ/2 (=5 ng/mL) in calculations of the mean n=number of subjects

a  Measurable plasma concentrations were only observed in one subject

## MG0011

MG0011  is  an  ongoing,  multicentre,  open  label  extension  study  evaluating  the  long-term  safety, tolerability,  and  efficacy  of  zilucoplan  in  study  participants  with  gMG  who  previously  participated  in studies MG0009 and MG0010.

Study participants receive zilucoplan 0.3 mg/kg administered SC at the Day E1 Visit. Single-use, prefilled syringes in injection devices are provided for use during the study, using weight-bracketed dosing. At the time of the clinical cut-off date (18 Feb 2022), 199 study participants were enrolled. Sparse sampling for PK was collected during the study. The concentrations of zilucoplan, RA103488 and RA102758 were measured in plasma.

Geometric mean plasma concentrations of zilucoplan in the 0.3/0.3 mg/kg treatment group were stable from baseline through Week E24. Geometric mean plasma concentrations of zilucoplan in the PBO/0.3 mg/kg treatment group reached steady state by Week E4, following 4 weeks of daily zilucoplan 0.3 mg/kg  treatment,  and  remained  stable  up  to  Week  E24.  A  similar  pattern  was  observed  for  the metabolites, RA102758 and RA103488. The steady state pre-dose concentrations of zilucoplan and its metabolites seem to be in the same range as in study MG0010.

## Special populations

## Impaired renal function

In study UP0114, the impact of severe renal impairment on the PKs of zilucoplan and its metabolites, RA103488 and RA102758, was investigated after single of 0.3 mg/kg zilucoplan.  It  was  planned  to determine  unbound  concentrations,  however  the  bioanalysis  of  free  concentration  turned  out  to  be infeasible.

The  PK  profile  of  zilucoplan  following  SC  administration  was  generally  similar  between  healthy study participants and those with severe RI. The exposure of zilucoplan was slightly decreased in subjects with severe RI compared to subjects with normal renal function. RA102758 point estimates indicated

<div style=\"page-break-after: always\"></div>

decreased exposure in subjects with severe RI compared to subjects with normal renal function, the CIs were however wide.

The exposure of the active metabolite RA103488 in terms of Cmax and AUC0-last was approximately 1.5fold higher in subjects with severe RI compared to subjects with normal renal function. The area under the concentration-time curve from time zero to infinity (AUC0-inf) of RA103488 was approximately 1.4fold higher in subjects with severe renal impairment compared to subjects with normal renal function. However, in view of the much lower exposure of RA103488 compared to the parent compound zilucoplan in absolute terms (Cmax ~20x, AUC0-last and AUC0-inf ~6x to ~7x), the applicant expects the clinical impact of this increase in subjects with severe RI to be negligible.

Zilucoplan, RA103488, and RA102758 were minimally renally excreted in both the normal and severe renal impairment groups (&lt;1% of dose in total across all analytes) (sampling time 120 hours).

Overall, the applicant considers that no dose adjustment based on PK is necessary in patients with renal impairment.

## Impaired hepatic function

The PKs of zilucoplan was investigated after a single SC dose of 0.3 mg/kg in subjects with moderate hepatic impairment compared with study participants with normal hepatic function.

Overall,  3  study  participants  reported  5  treatment-emergent  adverse  events  (TEAEs),  with  mild  and moderate severity.

Unbound zilucoplan in plasma was only detected 4 hours post-dose. In UP0094 study report, a mean plasma concentration of unbound zilucoplan in moderate hepatic impairment (HI) is reported as 16.79 ng/mL, while in the corresponding bioanalysis report in table 4, the highest concentration in this whole study  was  13.3  ng/mL  in  plasma:PBS  1:1.  The  reported  geometric  mean  (CV%)  of  the  unbound zilucoplan  fraction  was  0.38%  (59)  in  the  moderate  HI  liver  function  study  participants.  The  mean unbound zilucoplan concentrations or fractions were not calculated in the normal liver function study participants  because  3/8  subjects  had  concentrations  below  lower  limit  of  quantitation.  The  median percent of unbound zilucoplan fraction (fu%) in the Normal arm was 0.37% (range:0.27 - 0.51 %).

Zilucoplan  AUC0-last  and  AUC0-inf  were  both  24%  lower  in  subjects  with  moderate  HI  liver  function compared with study participants with normal liver function. Zilucoplan Cmax was similar between groups. Moderate HI study participants had a 32% higher CL/F and ~36% higher Vz/F normalised to body weight (i.e., 0.11 L/kg in moderate HI study participants and 0.082 L/kg in study participants with normal liver function). As a consequence, the t1/2 remained similar (150 h vs. 162 h) between the 2 arms indicating that despite moderate hepatic impairment, the metabolic function of the liver did not impact PK of total zilucoplan.

For the 2 metabolites, systemic exposure based on AUC0-last and peak exposure based on Cmax were higher in study participants with moderate HI liver function compared with study participants with normal liver function.

Despite the decrease zilucoplan AUC, the PD analyses did not identify any meaningful differences in either total C5 plasma levels nor inhibition of sheep RBC (sRBC) lysis between moderate HI and normal study  participants.  The  applicant  considers  that  a  zilucoplan  dose  adjustment  in  participants  with moderately impaired liver function is not warranted.

The faecal samples were not weighed, and therefore the total amounts of zilucoplan and metabolites in faeces could not be assessed. Based on the concentrations of zilucoplan and metabolites in faeces and the estimated fraction excreted by the faecal route, zilucoplan was minimally excreted in both the normal and in the moderate HI study participants (&lt;1% of dose in total).

<div style=\"page-break-after: always\"></div>

## Gender

In the Phase 3 study (MG0010), approximately 60% of the participating patients were female and 40% were male. Sex was not a statistically significant covariate in the popPK analysis.

## Race

A single- and multiple-dose PK study was performed in Japanese and Caucasian subjects (UP0113). The subjects  were  given  a  single  injection  of  0.1  or  0.3  mg/kg  or  once  daily  injections  of  0.3  mg/kg  of zilucoplan for 14 days. There were no greater differences in the PK of zilucoplan between Japanese as compared to Caucasian subjects. In addition, race was not identified as a statistically significant covariate in the popPK analysis.

The PK of the metabolites were also investigated. At a dose of 0.3 mg/kg the following were observed:

There were trends towards higher AUC and/or Cmax of RA102758 in Japanese as compared to Caucasian subjects, but the CIs were wide or included 100%. However, the AUC τ was not determined in most of the subjects in the multiple-dose cohort. Following repeated injections for 14 days, there were no greater differences in pre-dose plasma concentrations of RA102758 between the races.

There were trends towards lower AUC and/or Cmax of RA103488 in Japanese as compared to Caucasian subjects,  but  after  repeated  injections  (day  14)  the  CI  included  100%  (indicating  no  difference  in exposure). However, the AUC τ was not determined in most of the subjects in the MD cohort. Following repeated injections for 14 days, the pre-dose concentrations of RA103488 tended to be lower in Japanese as compared to Caucasian subjects.

The effect on sRBC haemolysis or total C5 plasma levels, expressed as percent change from baseline (CBL), appeared to be relatively similar between Japanese and Caucasian participants.

## Body weight

In the Phase 3 study (MG0010), the body weight range among patients receiving zilucoplan was 49.6 to 145 kg. In the clinical studies, Zilucoplan was dosed by body weight, and body weight was also included as a covariate ( a priori ) in the popPK model, with estimated exponents. In a simulation analysis, the effect of the three dose categories on exposure measures was investigated as a function of body weight. The results for trough concentration at steady state are provided in Figure 7. These results suggest that the intended dosing schedule results in adequate correction of the impact of body weight on exposure to zilucoplan.

<div style=\"page-break-after: always\"></div>

Figure 7: Distribution of trough steady state zilucoplan concentration by weight using the final population PK model

<!-- image -->

Red line and blue area: median and 90% of simulated values for patients sampled from the NHANES DXA database. Orange circles: individual predicted values for gMG patients in MG0010, vertical black lines: weights (56 and 77 kg) where dose changes from 16.6 mg to 23 mg to 32.4 mg

## Age

In the Phase 3 study (MG0010), the age range among patients receiving zilucoplan was 20 to 75 years. Age was not a statistically significant covariate in the popPK analysis.

## Pharmacokinetic interaction studies

No in vivo drug-drug interaction (DDI) study has been performed.

## Pharmacokinetics using human biomaterials

In vitro studies were performed to investigate the DDI potential of zilucoplan and RA102758.

## Effect of other medicines on zilucoplan and RA102758

Zilucoplan is a peptide that is expected to be degraded into small peptides and amino acids via catabolic pathways. CYP4F2 contributes to a minor part of the metabolism.

Zilucoplan seems not to be a substrate of P-gp, BCRP, MRP2, MRP3, OATP1B1 and OATP1B3. There are some unclarities regarding the recovery in the BCRP and P-gp experiments, for which reason the results should be interpreted with caution. RA102758 is not a substrate of OATP1B1/B3.

## Effect of zilucoplan and RA102758 on other medicines

Zilucoplan and RA102758 seem not to be a direct or time-dependent inhibitor of CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 3A and CYP4F (only direct inhibition was studied) at clinically relevant concentrations.

<div style=\"page-break-after: always\"></div>

Zilucoplan does not inhibit the UGT enzymes, UGT 1A1, 1A3, 1A4, 1A6, 1A9, 2B7, and 2B15. In addition, zilucoplan seems not to induce CYP1A2, CYP2B6 and CYP3A4.

Inhibition of BCRP, P-gp, MATE1, MATE2-K, OAT1, OAT3, OCT1, OCT2, BSEP and NTCP (only investigated for  zilucoplan)  seems  unlikely in  vivo .  RA102758  does  not  inhibit  OATP1B1/B3  at  clinically  relevant concentrations, whereas Zilucoplan inhibited OATP1B1 and OATP1B3 with IC50 values of 2.4 and 2.1 µM, respectively. These values are close to the systemic DDI cut-off (1.7 µM). Zilucoplan seems not to be a clinically relevant inhibitor of MRP2. However, it cannot be excluded that zilucoplan inhibits MRP3 in vivo .

## Exposure relevant for safety evaluation

Following repeated SC injections of 0.3 mg/kg/day, the geometric mean Cmax and AUC0-24 of ZLP at steady state  were  12300  ng/mL  and  259000  ng*h/mL,  respectively  (UP0113).  The  corresponding  Cmax  and AUC0-24 of RA102758 were 1270 ng/mL and 287100 ng*h/mL, respectively.

## 2.6.2.2. Pharmacodynamics

## Mechanism of action

## Primary and Secondary pharmacology

## Thorough QT study (UP0093)

The thorough QT study UP0093 investigated the effects of 7 daily doses of zilucoplan 0.6 mg/kg SC on cardiac repolarisation. Sensitivity was demonstrated with moxifloxacin as an active control.

The geometric mean systemic exposure of total zilucoplan was higher on Day 7 compared with Day 1 for both Cmax (D1: 8372 and D7: 23940 ng/mL) and AUCT (D1: 149000 and D7: 459100 h*ng/mL), indicating accumulation  as  a  result  of  daily  dosing  and  reflecting  the  relatively  slow  clearance  of  zilucoplan. Compared with Day 1, the Cmax and AUCT on Day 7 had increased by a factor of approximately 3. The peak concentration was achieved at 4 hours post-dose after single and repeated dosing. The variability between the participants remained comparable between Day 1 and Day 7. The tmax remained constant between single and multiple dosing at 4 hours post-dose.

The systemic exposure of RA102758 was higher on Day 7 compared with Day 1 for both Cmax (D1: 119 and D7: 1680 ng/mL) and AUCT (D1: 1270 and D7: 35700 h*ng/mL). Compared with Day 1, the Cmax and AUCT on Day 7 had increased by factors of approximately 28 and 14, respectively. The tmax remained constant between single and multiple dosing at 24 hours post dose.

The systemic exposure of RA103488 was higher on Day 7 compared with Day 1 for both Cmax (D1: 174 and D7: 1610 ng/mL) and AUCtau (D1: 2070 and D7: 34000 h*ng/mL). Compared with Day 1, the Cmax and AUCT on Day 7 had increased by factors of approximately 9 and 17, respectively. The tmax was higher for the single dose compared with multiple dosing.

No trends were visible in the hysteresis analysis of Δ QTcF (QT corrected using the Fridericia method) under zilucoplan and under placebo ( ΔΔ QTcF) for any of zilucoplan or its metabolites.

In the by-time point analysis, mean ΔΔ HR was below 10 bpm for the zilucoplan group across all post dose time points, thereby demonstrating that ZLP has no relevant effect on heart rate.

The  relationship  between  plasma  concentrations  of  zilucoplan  and  its  metabolites  RA102758  and RA103488  and Δ QTcF  was  quantified  using  a  linear  mixed-effects  modeling  approach.  In  total,  7 concentration-QTc  (C-QTc)  models  were  evaluated:  the  full  model  with  zilucoplan,  RA102758,  and RA103488 (Model A), a model with zilucoplan and RA102758 (Model B), a model with zilucoplan and RA103488 (Model C), a model with RA102758 and RA103488 (Model D), a model with zilucoplan alone

<div style=\"page-break-after: always\"></div>

(Model E), a model with RA102758 alone (Model F), and a model with RA103488 alone (Model G). The model selection was based on the Akaike Information Criterion (AIC) and the t-value for the treatment effect-specific  intercept  estimator.  A  significant  treatment  effect-specific  intercept  is  not  biologically plausible and may indicate hysteresis or model misspecification.

The treatment effect-specific  intercepts  for  the  Models  A  through  G  were  not  statistically  significant (absolute t-value&lt;1.95). The model with zilucoplan alone (Model E) was chosen as the primary model, since it had the smallest AIC value among Models A through G.

The relationship between the individually observed plasma concentrations of zilucoplan and estimated ΔΔ QTcF for Model E (ZLP alone) are shown in Figure 8.

Figure 8 : Scatter plot of observed plasma concentrations (zilucoplan alone) and estimated ΔΔQTcF for Model E (PK/QTc Analysis Set; UP0093)

<!-- image -->

The solid red line with dashed red lines denotes the model-predicted mean ΔΔ QTcF with 90% CI, which was calculated from the equation ΔΔ QTcF(ms)=0.29(ms)+0.00011(ms per ng/mL)×zilucoplan plasma concentration (ng/mL). The plotted points denote the pairs of observed drug plasma concentrations and estimated ΔΔ QTcF by study participants for each active group and placebo group. The individually estimated ΔΔ QTcFi,k equals the individual Δ QTcFi,k for study participant i administered with active drug or placebo at time point k minus the estimation of the time effect at time point k

The estimated population slope of the C-QTc relationship was 0.00011 ms per ng/mL (90% CI: 0.000001 to  0.000220;  p=0.0961)  for  ZLP  with  a  small,  not  statistically  significant  treatment  effect  specific intercept of 0.29 ms (90% CI: -1.485, 2.069; p=0.7858). At the geometric mean Cmax of zilucoplan on Day 1 (8372 ng/mL) and Day 7 (23940 ng/mL), the effect on ΔΔ QTcF can be predicted to 1.2 ms (90% CI: -0.28 to 2.71) and 2.9 ms (90% CI: 0.73 to 5.10), respectively. Based on this C -QTc analysis, a QTcF  effect  ( ΔΔ QTcF)  exceeding  10  ms  can  be  excluded  within  the  observed  range  of  ZLP  plasma concentrations. It should be noted that the prediction results from all models (A-G) were similar and that all  concluded  that  a  QTc  effect  exceeding  10  ms  can  be  excluded  within  the  observed  plasma concentration ranges of zilucoplan, RA102758, and RA103488.

<div style=\"page-break-after: always\"></div>

Zilucoplan had no clinically relevant effect on cardiac conduction, i.e., the PR and QRS intervals, within the observed plasma concentration ranges.

## Relationship between plasma concentration and effect

Exposure-response models were developed for Myasthenia Gravis Activities of Daily Living (MG-ADL) score and quantitative myasthenia gravis (QMG) score, respectively. The models were fitted to data from the Phase 2 study (MG0009) and the Phase 3 study (MG0010), where most data were from placebo or the 0.3 mg/kg dose level (only about 6% of the data were on the 0.1 mg/kg dose level). Due to the limited nature of the data, and the limited importance of the models, these analyses are not further described.

## 2.6.3. Discussion on clinical pharmacology

MG is characterised by the production of autoantibodies targeting proteins that are critical for the normal transmission of neurotransmitter signals from nerves to muscles. This activates the classical complement pathway including cleavage of complement C5 into C5a and C5b and deposition of the cytolytic MAC (C5b-9) on the post-synaptic membrane of the NMJ.

Zilucoplan is a 15-amino acid peptide that binds to C5 with high affinity and prevents its cleavage into C5a and C5b. Inhibition of C5 cleavage prevents the downstream activity of the MAC. Zilucoplan binds to the portion of C5 that corresponds to C5b. In binding to this region of C5, should any C5b be formed, it will be blocked from binding to C6 by ZLP, which further prevents the subsequent assembly of the MAC (C5b-9).

## Pharmacokinetics

The applicant has performed several clinical pharmacology studies to describe the ADME characteristics of zilucoplan and to identify special populations or DDI with risk for altered exposure. The PK was also thoroughly investigated for the major metabolite, RA102758, and the active metabolite RA103488.

Referring  to  a  per  kilogram  dose  can  be  misleading  for  the  prescriber,  when  the  actual  doses administered during clinical trials were flat doses within body weight bands. For clarity, the applicant changed from '0.3 mg/kg' to 'recommended dose' throughout the SmPC as requested.

## Methods

## Quantification of zilucoplan, RA102758 and RA103488

Overall, the bioanalytical methods (LC-MS/MS) for analysis of ZLP, RA102758 and RA103488 in plasma and urine were adequately validated for their intended purpose, despite the lack of cross-validation between the two methods used for analysis of total concentrations of zilucoplan in plasma (methods 1 and 2). Method 1 was only used in the first study in humans, which included only a limited number of subjects (in total 18 subjects were dosed with ZLP), and therefore this issue was not further pursued.

The LC-MS/MS method that was used to determine ZLP, RA102758, and RA103488 in human faeces (study  UP0094)  has  not  been  assessed  since  there  were  limitations  in  the  collection  of  the  faeces samples.

The bioanalytical report for analysis of plasma concentrations of ZLP, RA102758 and RA103488 in the ongoing study, MG0011, was provided. The report included data up to and including 14 October 2022. The performance of the method seemed adequate. However, it was noted that multiple samples were analysed outside of the validated stability period of 367 days at -80°C. The clinical study is currently ongoing and the long-term stability in human plasma will be assessed after a period of ≥ 696 days to

<div style=\"page-break-after: always\"></div>

extend the current stability period. The applicant has committed to provide final bioanalytical report, including long term stability, when the clinical study is completed.

## Immunogenicity

All three ADA methods were fully validated, and cut-off points were determined in healthy subjects using state of the art procedures.

The  initial  method  has  adequate  drug  tolerance  to  be  used  for  the  analysis  of  samples  from  study UP0112. However, due to the poor drug tolerance using the second-generation assay, immunogenicity data from study MG0009 should be considered inconclusive. The drug and target tolerance of the third generation ADA method is sufficient for use in the phase 3 studies. No target interference is expected with total C5 levels.

The CHMP recommended that a bioanalytical report including immunogenicity data from study MG0011 is submitted once it is completed. The APA assay has insufficient sensitivity and drug tolerance at 100 ng/mL APAs, with a sensitivity of 200 ng/mL in the screening and 134 ng/mL in the confirmatory assay. The difference in sensitivity in the two tiers entails that some samples that could potentially be confirmed positive would not be tested as they would be screened negative. The applicant considers it unlikely that a significant number of additional positive sampled would be detected if the sensitivity of the screening and confirmatory assay were similar. Additionally, since there was no association of positive APA status with efficacy or safety, there would be no clinical relevance of these additional samples. This is agreed.

Regarding  the  NAb,  the  applicant's  view  that  the  assays  are  unsuitable  is  agreed,  since  significant interferences would be expected. Given the low incidence of ADAs, and current data indicating no impact on safety and efficacy, the absence of a reliable NAb assay is acceptable.

The bioanalytical reports from study samples indicate the within study validation was adequate.

## Population PK

The developed popPK model is used to describe the nonlinear PK of zilucoplan and it is used to support equal exposure across body weight, with the suggested weight bracketed doses. A thorough evaluation of the model has been conducted by the applicant, showing that the model appropriately describes data across dose, body weight, single and multiple dose, and population (HV/gMG patient).

## Absorption, distribution, metabolism and elimination

In general, the PK of zilucoplan and its metabolites, RA102758 and RA103488, have been sufficiently described.

No bioequivalence study has been performed. The to-be-marketed formulation (process 2.2) has not been tested clinically. Since the issues raised in the quality section are adequately solved, it is agreed that no clinical bioequivalence study is needed.

The AUC of zilucoplan increased less than proportional with an increase in dose. There seems to be a faster elimination after repeated as compared to single administration, indicating that the PK is likely driven  by  binding  to  the  target,  i.e.  once  the  target  is  saturated,  elimination  increases.  This  is  also supported by the popPK analyses. No time-dependency was observed.

As a peptide, ZLP is expected to be degraded into small peptides and amino acids via catabolic pathways.

In human hepatocytes, RA102758 and M2169/1, were the metabolites that accounted for the largest part  of  the  total  radioactivity  (16900).  The  applicant  clarified  that  M2169/1  is  a  minor  circulating metabolite in humans. RA102758 and RA103488 were the two largest metabolites identified in human plasma. RA102758 is inactive, whereas RA103488 is a pharmacologically active metabolite with a similar potency as parent compound in vitro (see non-clinical sections). RA102758 is considered to be a major

<div style=\"page-break-after: always\"></div>

metabolite, as its AUC (expressed in molar units) is approximately 25% of the parent AUC. RA103488, is mainly formed by CYP4F2, which only contributes to a minor part of the metabolism.

No  human  mass-balance  study  has  been  performed,  this  is  acceptable  considering  the  molecular structure of this peptide and that catabolic pathways are involved in the degradation of the compound. Based on unlabelled zilucoplan, it appears that excretion of zilucoplan, RA103488, and RA102758 into urine and faeces is minimal. However, the sampling was relatively short, compared to zilucoplan and its metabolites' half-lives. In addition, there were some problems with the faecal samples. Nevertheless, the provided analysis gives some indication that faecal excretion of zilucoplan and its metabolites is not a  major  route  of  elimination.  Overall,  it  can  be  concluded  that  the  excretion  pathways  have  been sufficiently characterised.

## Immunogenicity

The incidence of treatment-emergent ADA was low in the Phase III study (study MG0010) and remained low in the ongoing long-term efficacy and safety study, MG0011. No impact on the PK of zilucoplan was seen for ADAs and APAs. However, study MG0010 and MG0011 results indicate a higher incidence of treatment emergent APAs compared to ADAs, due to differences in sensitivity between the ADA and APA method. The ADA screening and confirmatory assays could only detect the APA positive control at higher concentrations (801 and 611 ng/mL, respectively), compared to a sensitivity in the 100 ng/mL range in the APA assay. This explains why the incidence of APAs is higher. Immunogenicity against PEG is in line with literature data.

The applicant provided summary tables with the ADA and APA status, presented by arm (placebo/ZLP vs ZLP/ZLP). Most patients were negative throughout for both ADA and APAs, 63% in the placebo arm and 59% in the ZLP arm. Consistent with the difference in sensitivity for APAs, the incidence of APA positive while ADA negative was 16% in both arms. Only 2 patients per arm (2.4%) were treatment induced ADA and APA positive, and additional 2 per arm were ADA positive but APA negative. Upon request, information on immunogenicity has been adequately moved to section 5.1 of the SmPC and updated to reflect Table 5.

## Special populations

A dedicated renal impairment study showed that the exposure of zilucoplan decreases in severe renal impairment subjects, compared to subjects with normal renal function. The exposure of the metabolite RA103488 increased when renal function decreased, while the exposure of RA102758 was more variable. Overall, it is agreed that there is no need for dose adjustment for patients with renal impairment, as the difference compared to normal renal function is small. The SmPC text has been revised and is acceptable.

A dedicated hepatic impairment study indicated a statistically significant decrease in ZLP in moderate hepatically impaired subjects, with the consequence of a small increase of its metabolites RA102758 and RA103488). The discrepancy between two tables was clarified as caused by the dilution factor. The fu in the two arms seems overlapping, thus it could be acceptable to focus the analysis on total concentration. The applicant argues that despite an AUC decreased by 24% in moderate HI patients, the Css,ave remains higher than the EC95 value of 4.45 mg/L, with no impact on the sRBC lysis. A 24% decrease of the trough concentration, compared to the geometric mean trough concentration observed at week 12 in the 0.3  mg/kg  dose  group  in  MG0009,  would  correspond  to  a  trough  concentration  of  7.68  mg/L.  This concentration is above both the predicted EC95 value, and the geometric mean trough concentration observed in the 0.1 mg/kg dose group in study MG0009 (5.14 mg/L). Based on the totality of data, it is agreed that there is no need for a dose adjustment for moderate HI patients. The proposed actionable recommendation for patients with severe HI in SmPC section 4.2 is acceptable.

There was no effect of age, race and gender on the PK of zilucoplan. There were no major differences in the systemic exposure of RA102758 between the races. However, the pre-dose plasma concentrations

<div style=\"page-break-after: always\"></div>

of RA103488 (active metabolite) tended to be lower in Japanese as compared to Caucasian subjects. This is not considered clinically relevant since the plasma concentrations of this metabolite are much lower than parent. Thus, no dose-adjustments are needed based on age, race or gender. The information in the SmPC is generally supported.

In the clinical studies, Zilucoplan was dosed by body weight, and body weight was also included as a covariate ( a priori ) in the popPK model (with estimated coefficients). Based on simulations, the proposed weight bracketed doses appear to result in comparable median exposure across body weight for subjects weighing 25 to 150 kg, while subjects weighing ≥150 kg have a lower simulated median exposure. The applicant argues that the simulated median trough concentration for subjects with a body weight of 200 kg, receiving 32.4 mg QD, is just below 9 mg/L (10 th  percentile just below 7 mg/L). This concentration is well above both the predicted EC95 value of 4.45 mg/L, and the geometric mean trough concentration observed in the 0.1 mg/kg dose group in study MG0009 (5.14 mg/L). Based on the totality of data, it is hence agreed that a higher dose of ZLP in patients ≥ 150 kg is not needed.

## Interactions

The DDIs for zilucoplan and its major metabolite, RA102758, have been thoroughly investigated. No clinical DDI study has been performed. For victim DDIs, this is acceptable considering that zilucoplan is a peptide that is expected to be degraded into small peptides and amino acids via catabolic pathways and CYP4F2 contributes only to a minor part of the metabolism.

## Zilucoplan and RA102758 as victim

Zilucoplan is not a substrate of MRP2, MRP3, OATP1B1 and OATP1B3. ZLP seems not to be a substrate for P-gp and BCRP. However, there are unclarities regarding the recovery in the P-gp and BCRP assays. Considering that ZLP is administered SC and that there appears to be a small amount excreted into faeces, this is not further pursued. The involvement of renal transporters was not investigated, which is acceptable  since  renal  excretion  of  ZLP  appears  to  be  minimal.  RA102758  is  not  a  substrate  of OATP1B1/B3.

## Zilucoplan and RA102758 as perpetrator

Inhibition of BCRP, P-gp, MATE1, MATE2-K, OAT1, OAT3, OCT1, OCT2, BSEP and NTCP seems unlikely in vivo . ZLP inhibited OATP1B1 and OATP1B3 with IC50 values of 2.4 and 2.1 µM, respectively. These IC50 values are close to the systemic cut-off (1.7 µM). The applicant provided information supporting that the experiment is conducted under linear conditions. Thus, a clinically relevant inhibition of OATP1B1 and OATP1B3 in vivo seems unlikely. Inhibition of MRP2 and MRP3 cannot be excluded. The applicant discussed the clinical relevance of these interactions. It is agreed that the IC50 for MRP2 is slightly above the systemic DDI cut-off and therefore inhibition of MRP2 can be excluded in vivo . For MRP3 it is agreed that substrate specificity overlaps with other transporters and that there are currently no examples of sensitive  MRP3  substrates,  it  is  nevertheless  a  signal.  Thus,  SmPC  section  5.2  includes  a  warning specifying that the clinical relevance is unknown. RA102758 does not seem to inhibit transporters known to be involved in clinically relevant in vivo drug interactions.

In vitro data  indicate  that  inhibition  of  the  major CYP  enzymes, including CYP4F, is unlikely in  vivo . Zilucoplan does not seem inhibit the UGT enzymes (UGT 1A1, 1A3, 1A4, 1A6, 1A9, 2B7, and 2B15) or induce  CYP1A2,  CYP2B6  and  CYP3A4  at  clinically  relevant  concentrations.  However,  several  of  the induction experiments indicated down-regulation of the mRNA, including the negative control. For both CYP2B6 and CYP3A4, a similar decrease in mRNA levels was observed in the negative control (flumazenil) as in the incubations with zilucoplan, and therefore down-regulation of the mRNA can be ruled out. For CYP1A2, since no concentration-dependent decrease in mRNA levels was evident, down-regulation of the mRNA seems unlikely, as suggested by the applicant. This issue is not further pursued.

<div style=\"page-break-after: always\"></div>

## Primary pharmacology

The primary PD of zilucoplan were studied throughout the clinical development programme using the sRBC  lysis  assay  and  determination  of  total  C5  plasma  levels.  These  PD  markers  are  relevant  to characterise the mode of action of Zilucoplan which is the inhibition of complement activation. Similar assays have been used to characterise the primary PD of C5-related products. However, it should be noted that, unlike these products, only total C5 plasma levels were determined in the zilucoplan clinical programme and not serum free C5 levels. A rapid and sustained reduction of cell lysis was seen after ZLP treatment. This effect was somewhat more pronounced and faster with the 0.3mg/kg dose than with the 0.1mg/kg dose.

## Secondary pharmacology

With an administration of 7 days of 0.6 mg/kg ZLP, ZLP and its metabolites seemed to reach steady state in study UP0093. The exposure following 0.6 mg/kg ZLP was supratherapeutic with regards to Cmax. The elimination was increased upon multiple doses of 0.6 mg/kg, compared to 0.3 mg/kg, showing some less than dose proportional increase in AUC. The exposure was however still higher than the therapeutic exposure from Phase III studies.

Given  the  relatively  flat  concentration-time  profile  of  ZLP  and  its  metabolites,  no  trends  could  be identified in the hysteresis analysis.

The study demonstrated sufficient sensitivity with moxifloxacin.

The applicant's conclusion that there was no meaningful effect of ZLP on cardiac function is agreed.

## 2.6.4. Conclusions on clinical pharmacology

The PK of zilucoplan and its major metabolite, RA102758, has been well described. No major concern has been identified. The risk of DDIs is low. The SmPC is acceptable.

The CHMP considers the following measures necessary to address the issues related to pharmacology:

- Submission of final immunogenicity data and bioanalytical reports for study MG0011 for ADA and APA.
- Submission of final bioanalytical report for zilucoplan, RA102758 and RA103488, including long term stability, for study MG0011.

## 2.6.5. Clinical efficacy

Efficacy was studied in one phase II dose-finding study (MG0009) and two phase III studies, one blinded and controlled (MG0010) and one open label (MG0011). Characteristics of these studies are presented in the table below.

<div style=\"page-break-after: always\"></div>

Table 7: Clinical efficacy studies

| Study ID a Countries Study Status                                                                                                     | Study Design                           | Study period              | Number of study receiving: ZLP                          | participants Placebo      | Maximum duration treatment                              | of                        |
|---------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------|---------------------------|---------------------------------------------------------|---------------------------|---------------------------------------------------------|---------------------------|
| Primary efficacy study                                                                                                                | Primary efficacy study                 | Primary efficacy study    | Primary efficacy study                                  | Primary efficacy study    | Primary efficacy study                                  | Primary efficacy study    |
| MG0010 RAISE (RA101495- 02.301) Canada, France, Germany, Italy, Japan, Norway, Poland, Spain, United Kingdom, United States           | Phase 3, MC, R, DB, PC                 | Treatment Period          | 0.3mg/kg SC once daily: 86                              | 88                        | 12 weeks                                                |                           |
| Supporting efficacy study                                                                                                             | Supporting efficacy study              | Supporting efficacy study | Supporting efficacy study                               | Supporting efficacy study | Supporting efficacy study                               | Supporting efficacy study |
| MG0009 (RA101495- 02.201) Canada, United States                                                                                       | Phase 2, MC, R, DB, PC                 | Main Portion              | 0.1mg/kg SC once daily: 15 0.3mg/kg SC once daily: 14   | 15                        | 12 weeks                                                |                           |
| Complete                                                                                                                              |                                        | Extension Portion         | 0.1mg/kg SC once daily: 22 b 0.3mg/kg SC once daily: 41 | NA                        | Approximately 4 years (as of the clinical cut-off date) |                           |
| Long-term study                                                                                                                       | Long-term study                        | Long-term study           | Long-term study                                         | Long-term study           | Long-term study                                         | Long-term study           |
| MG0011 RAISE-XT (RA101495-02.302) Canada, France, Germany, Italy, Japan, Norway, Poland, Spain, United Kingdom, United States Ongoing | Phase 3, MC, OLE for MG0009 and MG0010 | Treatment Period          | 0.3 mg/kg SC once daily: 199                            | NA                        | 3.9 years c                                             |                           |

b) Following implementation of Protocol Amendment 3.0, and upon appropriate reconsent, all study participants ongoing in the Extension Portion received the ZLP 0.3mg/kg dose that had been selected for MG0010 and were eventually enrolled (at variable times relative to the Baseline of MG0009) in the open-label extension study, MG0011 (RAISE-XT).

c) Maximum duration of treatment from start of the open-label extension at the time of interim data cut, 18 Feb 2022.

## 2.6.5.1. Dose response study

MG0009 was a Phase 2, multicentre, randomised, double-blind, placebo-controlled study to evaluate the safety,  tolerability,  and  preliminary  efficacy  of  ZLP  0.1mg/kg/day  and  0.3mg/kg/day  doses  in  study participants with gMG.

<div style=\"page-break-after: always\"></div>

Figure 9: Schematic diagram of Study MG0009

<!-- image -->

Note ZLP was named RA101495 previously in the development process

Note Following protocol version 3.0, all study participants received ZLP 0.3mg/kg/day during the extension portion.

Inclusion and exclusion criteria were similar to those in the main study MG0010.

## Sample size, randomisation, blinding/masking

Subjects who met all entry criteria were to be randomised in a 1:1:1 ratio to receive daily SC doses of 0.1 mg/kg ZLP, 0.3 mg/kg ZLP, or matching placebo. At randomisation subjects were stratified based on baseline QMG Score (≤ 17 versus ≥ 18).

This was a double-blind study. Study drug was to be provided in prefilled syringes for self-injection using weight bracketed dosing. Subjects and study staff were to remain blinded to treatment assignments during the extension portion until after the data from the main portion of the study had been cleaned, locked, and unblinded. Unblinding of treatment assignment prior to initiation of rescue therapy was not allowed, unless critical for reasons of subject safety.

The planned enrolment was approximately 36 study participants. With 12 subjects per treatment group, the study had a power of 81% to detect a difference of 4.5 between one of the active dose arms and placebo in CBL to Week 12 (Day 84) in QMG score based on a 1-sided type I error of 0.10 and assuming a standard deviation of 5.0.

Subjects who prematurely discontinued participation in the study could be replaced in order to obtain at least 12 evaluable subjects per treatment arm.

All subjects who completed the Day 84 visit had the option to continue treatment in an extension period. Subjects initially assigned to active treatment during the main study period were to continue the same dose of study drug. Subjects initially randomised to the placebo arm were randomised in a 1:1 ratio to 0.1 mg/kg ZLP or 0.3 mg/kg ZLP. This randomisation was to occur at the screening visit when a subject was initially randomised to the double-blind main study period.

## Statistical methods

The primary analysis of the study was to be performed when all subjects had completed the main portion.

The primary analysis population was the modified intention-to treat (mITT) including all subjects in the intention-to-treat (ITT) Population (all randomised) who had received at least 1 dose of study drug.

For  the  primary  efficacy  endpoint,  the  CBL  to  Week  12  (Day  84)  in  QMG  score,  treatment  group differences were to be assessed by an analysis of covariance (ANCOVA) model, with treatment as a factor and baseline QMG score as a covariate.

<div style=\"page-break-after: always\"></div>

The primary efficacy analysis was the comparison of the 0.3 mg/kg dose group versus the placebo dose group based on the ANCOVA model at a 1-sided 0.10 significance level.

The comparison of the 0.1 mg/kg dose group versus the placebo dose group was considered a secondary efficacy endpoint analysis tested at the 1-sided 0.10 level.

In addition, a test of linear trend across the 3 treatment groups was planned as was a test for treatment effect pooling the 0.1mg/kg and 0.3mg/kg dose groups versus placebo.

The secondary efficacy endpoints: Week 12 CBL in MG-ADL, Myasthenia Gravis-Quality of Life 15-item scale revised (MG-QOL15r), and MG Composite (MGC) were to be analysed by an ANCOVA model similar to the primary efficacy endpoint analysis. For the 'Subjects with ≥ 3 -point reduction in QMG score at Week 12' and 'Subjects requiring rescue therapy over the 12-week Treatment Period' secondary efficacy endpoints, the rate of subjects meeting the endpoint for each of the active treatment groups were to be compared with the placebo group using a Fisher's exact test at the 1-sided 0.10 level.

The primary method for handling missing data was last-observation-carried-forward (LOCF). For the LOCF algorithm, if a study participant was missing a value, the closest non missing endpoint value prior to the missing value was imputed for the missing value. This included the baseline value and values from unscheduled visits.

Additionally, if a subject received rescue therapy, efficacy endpoints that occurred after rescue therapy were censored and imputed using LOCF and the closest non-missing endpoint value prior to the initiation of rescue therapy.

There were no adjustments to the type I error rate for the multiple secondary efficacy analyses.

## Results

First study participant enrolled was 28 Nov 2017 and last study participant completed the study 19 Nov 2020. A total of 22 Investigators enrolled study participants at 29 sites, 26 sites in the United States and 3 sites in Europe.

Table 8: Disposition and discontinuation reasons - main portion (ITT Population) MG0009

| Category                           | Placebo N=15 n (%)                 | ZLP 0.1mg/kg/day N=15 n (%)        | ZLP 0.3mg/kg/day N=15 n (%)        | Total N=45 n (%)                   |
|------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|
| Completed Main Portion a           | 15 (100)                           | 15 (100)                           | 13 (86.7)                          | 43 (95.6)                          |
| Discontinued Main Portion          | 0                                  | 0                                  | 2 (13.3)                           | 2 (4.4)                            |
| Primary reason for discontinuation | Primary reason for discontinuation | Primary reason for discontinuation | Primary reason for discontinuation | Primary reason for discontinuation |
| Lost to follow up                  | 0                                  | 0                                  | 1 (6.7)                            | 1 (2.2)                            |
| Other                              | 0                                  | 0                                  | 1 (6.7)                            | 1 (2.2)                            |
| Enrolled in the Extension Portion  | 14 (93.3)                          | 15 (100)                           | 13 (86.7)                          | 42 (93.3)                          |

<div style=\"page-break-after: always\"></div>

Table 9: Demographic characteristics - overall (ITT Population) MG0009

| Characteristic         | Placebo N=15 n (%)   | ZLP 0.1mg/kg/day N=15 n (%)   | ZLP 0.3mg/kg/day N=15 n (%)   | Total N=45 n (%)   |
|------------------------|----------------------|-------------------------------|-------------------------------|--------------------|
| Sex, n (%)             |                      |                               |                               |                    |
| Female                 | 11 (73.3)            | 8 (53.3)                      | 5 (33.3)                      | 24 (53.3)          |
| Male                   | 4 (26.7)             | 7 (46.7)                      | 10 (66.7)                     | 21 (46.7)          |
| Age (years)            |                      |                               |                               |                    |
| N                      | 15                   | 15                            | 15                            | 45                 |
| Mean (SD)              | 48.4 (15.7)          | 45.5 (15.6)                   | 54.5 (14.9)                   | 49.5 (15.5)        |
| Median                 | 43.0                 | 52.0                          | 58.0                          | 54.0               |
| Min, max               | 23, 73               | 20, 65                        | 21, 76                        | 20, 76             |
| Age Group, n (%)       |                      |                               |                               |                    |
| <65 years              | 13 (86.7)            | 14 (93.3)                     | 11 (73.3)                     | 38 (84.4)          |
| ≥65 years to <75 years | 2 (13.3)             | 1 (6.7)                       | 3 (20.0)                      | 6 (13.3)           |
| ≥75 years              | 0                    | 0                             | 1 (6.7)                       | 1 (2.2)            |
| Weight (kg)            |                      |                               |                               |                    |
| N                      | 15                   | 15                            | 14                            | 44                 |
| Mean (SD)              | 85.27 (21.44)        | 93.71 (24.72)                 | 110.94 (30.79)                | 96.31 (27.38)      |
| Median                 | 79.10                | 87.50                         | 99.70                         | 91.15              |
| Min, max               | 56.4, 128.3          | 58.0, 140.3                   | 75.0, 171.1                   | 56.4, 171.1        |
| Min, max               | 21.46, 46.01         | 24.14, 43.79                  | 25.06, 55.87                  | 21.46, 55.87       |

<div style=\"page-break-after: always\"></div>

Table 10: Baseline disease characteristics (mITT Population) MG0009

| Characteristic                  | Placeb o N=15 n (%)       | ZLP 0.1mg/kg/ day N=15 n (%)   | ZLP 0.3mg/kg/ day N=14 n (%)   | Tota l N=4 4 n (%)        |
|---------------------------------|---------------------------|--------------------------------|--------------------------------|---------------------------|
| MGFA Class at Screening         | 15                        | 15                             | 14                             | 44                        |
| Class II                        | 7 (46.7)                  | 5 (33.3)                       | 5 (35.7)                       | 17 (38.6)                 |
| Class III                       | 8 (53.3)                  | 10 (66.7)                      | 5 (35.7)                       | 23 (52.3)                 |
| Class IV                        | 0                         | 0                              | 4 (28.6)                       | 4 (9.1)                   |
| Age at Disease Onset (years), n | 15                        | 15                             | 14                             | 44                        |
| Mean (SD)                       | 40.3 (17.8)               | 37.3 (16.0)                    | 46.9 (19.5)                    | 41.4 (17.8)               |
| Median                          | 31.0                      | 29.0                           | 53.5                           | 42.5                      |
| Min, max                        | 15, 64                    | 17, 63                         | 15, 69                         | 15, 69                    |
| Baseline QMG score, n (%)       | Baseline QMG score, n (%) | Baseline QMG score, n (%)      | Baseline QMG score, n (%)      | Baseline QMG score, n (%) |
| N                               | 15                        | 15                             | 14                             | 44                        |
| Mean (SD)                       | 18.7 (4.0)                | 18.7 (4.0)                     | 19.1 (5.1)                     | 18.8 (4.3)                |
| Median                          | 17.0                      | 18.0                           | 18.5                           | 18.0                      |
| Min, max                        | 14, 30                    | 13, 29                         | 12, 33                         | 12, 33                    |
| p-value                         | -                         | -                              | -                              | 0.9447                    |
| Baseline QMG score, n (%)       | Baseline QMG score, n (%) | Baseline QMG score, n (%)      | Baseline QMG score, n (%)      | Baseline QMG score, n (%) |
| N                               | 15                        | 15                             | 14                             | 44                        |
| ≤17                             | 8 (53.3)                  | 6 (40.0)                       | 6 (42.9)                       | 20 (45.5)                 |
| ≥18                             | 7 (46.7)                  | 9 (60.0)                       | 8 (57.1)                       | 24 (54.5)                 |
| Baseline MG-ADL score           | Baseline MG-ADL score     | Baseline MG-ADL score          | Baseline MG-ADL score          | Baseline MG-ADL score     |
| N                               | 15                        | 15                             | 14                             | 44                        |
| Mean (SD)                       | 8.8 (3.6)                 | 6.9 (3.3)                      | 7.6 (2.6)                      | 7.8 (3.2)                 |
| Median                          | 9.0                       | 7.0                            | 7.5                            | 7.0                       |
| Min, max                        | 3, 14                     | 0, 11                          | 2, 11                          | 0, 14                     |
| p-value                         | -                         | -                              | -                              | 0.2815                    |

## Outcomes and estimation

## Main portion of study MG0009

The primary efficacy endpoint was the CBL to Week 12 QMG score. Prespecified significance testing was performed at a 1-sided alpha of 0.10.

<div style=\"page-break-after: always\"></div>

Table 11: Change from baseline QMG score over time - main portion (mITT Population [LOCF Ancova]) MG0009

| MMRM ANCOVA Timepoint Variable   | Placebo N=15   | ZLP 0.1mg/kg/d ay N=15   | ZLP 0.3mg/kg/d ay N=14   | ZLP 0.1mg/kg/day + 0.3mg/kg/day N=29   |
|----------------------------------|----------------|--------------------------|--------------------------|----------------------------------------|
| Week 12                          |                |                          |                          |                                        |
| N                                | 15             | 15                       | 14                       | 29                                     |
| LS mean (SE) a                   | -3.2 (1.2)     | -5.5 (1.2)               | -6.0 (1.2)               | -5.8 (0.9)                             |
| 80% CI a                         | (-4.8, -1.6)   | (-7.0, -3.9)             | (-7.7, -4.4)             | (-6.9, -4.6)                           |
| LS mean difference (SE) b        | -              | -2.3 (1.7)               | -2.8 (1.7)               | -2.6 (1.5)                             |
| 80% CI b                         | -              | (-4.5, -0.1)             | (-5.1, -0.6)             | (-4.4, -0.6)                           |
| 1-sided p-value b                | -              | 0.0941                   | 0.0538                   | 0.0444                                 |

The continuous secondary efficacy variables (CBL to Week 12 in MG-ADL, MG-QOL15r, and MGC) were analysed similar to the primary efficacy endpoint analysis; each of the active doses were compared with the placebo group at the 1-sided 0.10 significance level.

Table  12:  Change from baseline MG-ADL score, MG-QOL15r score and MGC score over time - main portion (mITT Population [LOCF Ancova]) MG0009

| Timepoint Variable        | Placebo N=15   | ZLP 0.1mg/kg/da y N=15   | ZLP 0.3mg/kg/da y N=14   | ZLP 0.1mg/kg/day + 0.3mg/kg/day N=29   |
|---------------------------|----------------|--------------------------|--------------------------|----------------------------------------|
| Week 12 MG-ADL            |                |                          |                          |                                        |
| N                         | 15             | 15                       | 14                       | 29                                     |
| LS mean (SE) a            | -1.1 (0.9)     | -3.3 (0.9)               | -3.4 (0.9)               | -3.3 (0.6)                             |
| 80% CI                    | (-2.2, 0.1)    | (-4.4, -2.1)             | (-4.6, -2.2)             | (-4.2, -2.5)                           |
| LS mean difference (SE) b | -              | -2.2 (1.3)               | -2.3 (1.3)               | -2.3 (1.1)                             |
| 80% CI b                  | -              | (-3.9, -0.5)             | (-4.0, -0.6)             | (-3.7, -0.8)                           |
| 1-sided p-value b         | -              | 0.0470                   | 0.0392                   | 0.0233                                 |
| Week 12 MG-QOL15r         |                |                          |                          |                                        |
| N                         | 15             | 15                       | 14                       | 29                                     |
| LS mean (SE) a            | -2.1 (1.7)     | -7.4 (1.7)               | -5.9 (1.7)               | -6.6 (1.2)                             |
| 80% CI                    | (-4.3, 0.1)    | (-9.6, -5.2)             | (-8.1, -3.6)             | (-8.2, -5.1)                           |
| LS mean difference (SE) b | -              | -5.3 (2.4)               | -3.7 (2.4)               | -4.5 (2.0)                             |
| 80% CI b                  | -              | (-8.4, -2.1)             | (-6.9, -0.6)             | (-7.2, -1.8)                           |
| 1-sided p-value b         | -              | 0.0170                   | 0.0624                   | 0.0169                                 |
| Week 12 MGC               | Week 12 MGC    | Week 12 MGC              | Week 12 MGC              | Week 12 MGC                            |

<div style=\"page-break-after: always\"></div>

| N                         | 15           | 15           | 14           | 29           |
|---------------------------|--------------|--------------|--------------|--------------|
| LS mean (SE) a            | -3.3 (1.6)   | -5.3 (1.5)   | -7.4 (1.6)   | -6.3 (1.1)   |
| 80% CI                    | (-5.4, -1.3) | (-7.3, -3.3) | (-9.4, -5.3) | (-7.7, -4.9) |
| LS mean difference (SE) b | -            | -2.0 (2.2)   | -4.1 (2.2)   | -3.0 (1.9)   |
| 80% CI b                  | -            | (-4.9, 0.9)  | (-7.0, -1.1) | (-5.5, -0.5) |
| 1-sided p-value b         | -            | 0.1866       | 0.0391       | 0.0660       |

a) LS means, standard errors, CIs, and p-values were from an ANCOVA model on the change from Baseline efficacy score with a fixed factor for treatment, and Baseline score as a covariate.

b) p-values (tested at the 1-sided 0.10 significance level), LS mean differences and associated confidence intervals were presented for each ZLP dose group (and combined group) compared with the placebo group.

## Extension portion of study MG0009

In the Extension Portion of the study, study participants assigned to a ZLP dose group during the Main Portion of the study continued to receive the same dose of ZLP during the Extension Portion. Study participants assigned to the placebo arm during the Main Portion of the study were randomised in a 1:1 ratio  to  receive  ZLP  0.1mg/kg/day  or  ZLP  0.3mg/kg/day.  After  a  planned  interim  analysis  and  the implementation of Protocol Version 3, all study participants received the ZLP 0.3mg/kg/day dose for the remainder of the Extension Portion.

Change from baseline over time -24 weeks of active treatment.

Study participants were able to complete 24 weeks of active treatment in a combination of the Main Portion and first 12 weeks of the Extension Portion or during 24 weeks of the Extension Portion. This summary includes study participants in the active treatment dose group during the Main Portion, as well as study participants in the placebo arm during the Main Portion who switched to the active treatment dose group during the Extension Portion.

Table 13: Change from baseline QMG score over time - first 24 weeks of active treatment (ZLP Safety Population [LOCF]) MG0009

| Timepoint Variable   | ZLP 0.1mg/kg/da y N=22   | ZLP 0.1mg/kg/da y N=22   | ZLP 0.3mg/kg/da y N=21   | ZLP 0.3mg/kg/da y N=21   | ZLP 0.1mg/kg/day + 0.3mg/kg/day N=43   | ZLP 0.1mg/kg/day + 0.3mg/kg/day N=43   |
|----------------------|--------------------------|--------------------------|--------------------------|--------------------------|----------------------------------------|----------------------------------------|
|                      | Value                    | CFB                      | Value                    | CFB                      | Value                                  | CFB                                    |
| Week 24              | Week 24                  | Week 24                  | Week 24                  | Week 24                  | Week 24                                | Week 24                                |
| n                    | 22                       | 22                       | 20                       | 20                       | 42                                     | 42                                     |
| Mean (SD)            | 11.41 (5.36)             | -6.05 (5.31)             | 10.65 (5.42)             | -7.50 (5.24)             | 11.05 (5.34)                           | -6.74 (5.26)                           |
| Median               | 11.00                    | -5.50                    | 10.50                    | -6.50                    | 11.00                                  | -6.00                                  |
| Min, max             | 1.0, 24.0                | -14.0, 1.0               | 2.0, 23.0                | -20.0, -1.0              | 1.0, 24.0                              | -20.0, 1.0                             |

<div style=\"page-break-after: always\"></div>

Table 14: Change from baseline in secondary endpoints MG-ADL, MG-QOL15r and MCG score over time - first 24 weeks of active treatment (ZLP Safety Population [LOCF]) MG0009

| Timepoint Variable   | ZLP 0.1mg/kg/day N=22   | ZLP 0.1mg/kg/day N=22   | ZLP 0.3mg/kg/da y N=21   | ZLP 0.3mg/kg/da y N=21   | ZLP 0.1mg/kg/day + 0.3mg/kg/day N=43   | ZLP 0.1mg/kg/day + 0.3mg/kg/day N=43   |
|----------------------|-------------------------|-------------------------|--------------------------|--------------------------|----------------------------------------|----------------------------------------|
| Timepoint Variable   | Value                   | CFB                     | Value                    | CFB                      | Value                                  | CFB                                    |
| Week 24 MG-ADL       | Week 24 MG-ADL          | Week 24 MG-ADL          | Week 24 MG-ADL           | Week 24 MG-ADL           | Week 24 MG-ADL                         | Week 24 MG-ADL                         |
| n                    | 22                      | 22                      | 20                       | 20                       | 42                                     | 42                                     |
| Mean (SD)            | 4.23 (3.29)             | -2.68 (3.15)            | 4.00 (4.21)              | -3.25 (3.46)             | 4.12 (3.71)                            | -2.95 (3.28)                           |
| Median               | 4.00                    | -2.00                   | 2.00                     | -2.00                    | 3.50                                   | -2.00                                  |
| Min, max             | 0.0, 11.0               | -11.0, 3.0              | 0.0, 14.0                | -10.0, 0.0               | 0.0, 14.0                              | -11.0, 3.0                             |
| Week 24 MG-QOL15r    | Week 24 MG-QOL15r       | Week 24 MG-QOL15r       | Week 24 MG-QOL15r        | Week 24 MG-QOL15r        | Week 24 MG-QOL15r                      | Week 24 MG-QOL15r                      |
| n                    | 22                      | 22                      | 20                       | 20                       | 42                                     | 42                                     |
| Mean (SD)            | 8.6 (7.9)               | -8.5 (7.4)              | 9.2 (7.7)                | -6.1 (7.5)               | 8.9 (7.7)                              | -7.4 (7.5)                             |
| Median               | 5.5                     | -8.5                    | 8.0                      | -5.5                     | 7.5                                    | -8.0                                   |
| Min, max             | 0, 27                   | -22, 2                  | 0, 25                    | -26, 4                   | 0, 27                                  | -26, 4                                 |
| Week 24 MGC          | Week 24 MGC             | Week 24 MGC             | Week 24 MGC              | Week 24 MGC              | Week 24 MGC                            | Week 24 MGC                            |
| n                    | 22                      | 22                      | 20                       | 20                       | 42                                     | 42                                     |
| Mean (SD)            | 8.0 (5.8)               | -6.3 (6.7)              | 6.6 (5.9)                | -7.6 (7.8)               | 7.3 (5.9)                              | -6.9 (7.2)                             |
| Median               | 7.0                     | -5.0                    | 5.0                      | -7.5                     | 6.0                                    | -5.0                                   |
| Min, max             | 0, 21                   | -22, 6                  | 0, 21                    | -24, 5                   | 0, 21                                  | -24, 6                                 |

## 2.6.5.2. Main study

Study MG0010 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Confirm the Efficacy, Safety, and Tolerability of Zilucoplan in Subjects with Generalized Myasthenia Gravis

Protocol: RA101495-02.301 (RAISE) (UCB study MG0010)

## Methods

This  was  a  multicentre,  randomised,  double-blind,  placebo-controlled  study  to  confirm  the  efficacy, safety, and tolerability of 0.3 mg/kg zilucoplan in subjects with gMG. The study included a screening period of up to 4 weeks and a 12-week treatment period during which subjects were to return to the clinic at week 1, week 2, week 4, week 8, and week 12 to evaluate efficacy, safety, and tolerability.

## · Study Participants

## Inclusion criteria:

To be eligible for this study, study participants must have met all of the following inclusion criteria:

1. Male or female ≥ 18 years and &lt;75 years

<div style=\"page-break-after: always\"></div>

2. Able to provide informed consent, including signing and dating the informed consent form
3. Diagnosis of gMG [Myasthenia Gravis Foundation of America (MGFA) Disease Class II-IV] at Screening
4. Positive serology for AChR binding autoantibodies
5. MG-ADL score of ≥ 6 at Screening and Baseline
6. QMG score of ≥ 12 at Screening and Baseline (off acetylcholinesterase inhibitor therapy for at least 10 hours)
7. Four or more of the QMG test items must have been scored at ≥ 2 at Screening and Baseline
8. No change in corticosteroid dose for at least 30 days prior to baseline or anticipated to occur during the 12-week Treatment Period
9. No change in IST, including dose, for at least 30 days prior to baseline or anticipated to occur during the 12-week Treatment Period
10. Vaccination  with  a  quadrivalent  meningococcal  vaccine  and,  where  available,  meningococcal serotype B vaccine at least 14 days prior to the first dose of investigational medicinal product (IMP) at the Day 1 Visit. A booster vaccination should have also been administered as clinically indicated, according to the local standard of care, for study participants who had been previously vaccinated against Neisseria meningitidis.
11. Female study participants of childbearing potential must have had a negative serum pregnancy test at Screening and a negative urine pregnancy test within 24 hours prior to the first dose of IMP
12. Sexually active female study participants of childbearing potential (ie, women who were not postmenopausal or who had not had a hysterectomy, bilateral oophorectomy, or bilateral tubal ligation) and all male study participants (who had not been surgically sterilised by vasectomy) must have agreed to use effective contraception during the study and during the SFU Period of 40  days  after  the  last  dose  of  IMP.  Postmenopausal  women  were,  for  the  purposes  of  the protocol,  defined  as  women  who  had  not  had  menses  for  12  months  without  an  alternative medical cause. A high follicle stimulating hormone level in the postmenopausal range may have been used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy. However, in the absence of 12 months of amenorrhea, a single follicle stimulating hormone measurement was insufficient.

## Exclusion criteria

Study participants who met any of the following exclusion criteria must have been excluded from the study:

1. Thymectomy within 12 months prior to Baseline or scheduled to occur during the 12-week study
2. Abnormal thyroid function as determined by local standard
3. Known positive serology for muscle-specific kinase
4. Minimal Manifestation Status of gMG based on the clinical judgement of the Investigator
5. Fixed weakness ('burnt out' gMG) based on the clinical judgement of the Investigator
6. History of meningococcal disease

<div style=\"page-break-after: always\"></div>

7. Current or recent systemic infection within 2 weeks prior to Baseline or infection requiring iv antibiotics within 4 weeks prior to baseline
8. Pregnant, planning to become pregnant, or nursing female study participants
9. Recent surgery requiring general anaesthesia within 2 weeks prior to Screening or expected to have surgery requiring general anaesthesia during the 12-week Treatment Period
10. Prior treatment with a complement inhibitor
11. Treatment with an experimental drug within 30 days or 5 half-lives of the experimental drug (whichever was longer) prior to baseline
12. Treatment with rituximab within 12 months prior to Baseline or planned to occur during the 12week study (this exclusion criterion was implemented out of an abundance of caution, in the absence  of  data  showing  that  complement  inhibition  in  the  context  of  B-cell  elimination  by rituximab is safe)
13. Treatment with IVIG, SC immunoglobulin, or PLEX 4 weeks prior to Baseline
14. Active malignancy (except curatively resected squamous or basal cell carcinoma of the skin) requiring surgery, chemotherapy, or radiation within the prior 12 months (study participants with a history of malignancy who had undergone curative resection or otherwise not requiring treatment for at least 12 months prior to Screening with no detectable recurrence were allowed)
15. History of or current significant medical disorder, psychiatric disorder, or laboratory abnormality that  in  the  opinion  of  the  Investigator  would  make  the  study  participant  unsuitable  for participation in the study
16. Participation in another  concurrent  clinical  study  involving  an  experimental  therapeutic intervention (participation in observational studies and/or registry studies is permitted)
17. Unable or unwilling to comply with the requirements of the study
18. Hypersensitivity to ZLP, any of its excipients, or to placebo

## · Treatments

Study  participants  who  met  all  entry  criteria  were  randomised  to  receive  daily  SC  doses  of  ZLP 0.3mg/kg/day or placebo. IMP was provided in prefilled syringes for self-injection using weight-bracketed dosing.

Table 15: ZLP dose presentations by weight brackets

|   Minimum (nominal) target dose (mg/kg) |   Actual (mg) | dose   | Weight range (kg)   | Dose range (mg/kg)   |
|-----------------------------------------|---------------|--------|---------------------|----------------------|
|                                     0.3 |          16.6 |        | ≥43 to <56          | 0.30 to 0.39         |
|                                     0.3 |          23   |        | ≥56 to <77          | 0.30 to 0.41         |
|                                     0.3 |          32.4 |        | ≥77 to 150          | 0.22 to 0.42         |

All standard of care therapy medications for gMG should have been kept at the same dose throughout the study, including corticosteroids and IST drugs. If escalation of gMG therapy (ie, 'rescue therapy') became necessary due to major deterioration of a study participant's clinical status, or risk of MG crisis as per the Investigator's judgment, the study participant may have received IVIG or PLEX treatment as 'rescue therapy.'

<div style=\"page-break-after: always\"></div>

## · Objectives

The primary objective of MG0010 was to confirm the efficacy of ZLP in study participants with gMG.

The secondary objective of MG0010 was the following: Confirmation of the safety and tolerability of ZLP in study participants with gMG

## · Outcomes/endpoints

## Primary endpoint

The null statistical hypothesis for the primary endpoint was that the treatment difference between ZLP and placebo in CBL to Week 12 in MG-ADL score was zero. The alternative statistical hypothesis was that the treatment difference between ZLP and placebo in CBL to Week 12 in MG-ADL score was different from zero.

## Secondary endpoints

The key secondary endpoints were:

- CBL to Week 12 in the QMG score
- CBL to Week 12 in the MGC score
- CBL Week 12 in the MG-QOL15r score

The additional secondary endpoints were:

- Time to first administration of rescue therapy over the 12-week Treatment Period
- Achieving MSE, defined as an MG-ADL of 0 or 1, at Week 12 without rescue therapy
- Achieving a ≥ 3-point reduction in MG-ADL Score at Week 12 without rescue therapy
- Achieving a ≥ 5-point reduction in QMG Score at Week 12 without rescue therapy

## · Sample size

Initially the planned enrolment was approximately 130 subjects. The sample size estimation was based on the primary endpoint, CBL to week 12 in MG-ADL score, assuming a difference between treatment arms of 2.3 and a standard deviation of 3.4 based on the phase 2 study RA101495-02.201 (MG0009). With 65 subjects per treatment group, a 2-sided alpha of 0.05 and assumed rates of rescue and dropout of up to 10% and 5%, respectively, power was approximately 94%.

With global amendment 1 (Clinical study protocol (CSP) version 2.0, 18 December 2020) and statistical analysis plan (SAP) amendment 1 (01 February 2021) the total sample size was increased to account for a higher variability in the primary endpoint than what had originally been assumed and to maintain the power of the study. The new sample size calculation used a standard deviation of 3.7 and implied a total sample size of 156 subjects, 78 per treatment arm.

## · Randomisation and Blinding (masking)

Subjects who met all entry criteria were to be randomised in a 1:1 ratio at baseline (Day 1) to receive 0.3  mg/kg zilucoplan or  placebo  administered  SC.  Randomisation  was  to  be  performed  in  a  blinded fashion using a computerised randomisation algorithm and was stratified based on the baseline MG-ADL Score ( ≤ 9 versus ≥ 10), QMG Score ( ≤ 17 versus ≥ 18), and geographical region (North America, Europe, and Japan).

This  was  a  double-blind  study  and  subjects,  and  study  staff  was  to  remain  blinded  to  treatment assignments until after the data had been cleaned, locked, and unblinded. Randomised subjects were to

<div style=\"page-break-after: always\"></div>

receive 0.3 mg/kg zilucoplan or matching placebo administered SC at the Day 1 visit. Following in-clinic education and training, all subjects were to self-inject daily SC doses of blinded study drug, according to  randomised  treatment  allocation.  Single-use  pre-filled  syringes  in  injection  devices  were  to  be provided for use during the study. Matching placebo for the 0.3 mg/kg dose was to be provided in one presentation of 0.574 mL.

## · Statistical methods

Once all subjects had completed the Day 84 visit, the study database was to be locked (interim database lock), unblinded, and the analyses for the study performed. If necessary, a final database lock was to occur once all the subjects had completed the study after the safety follow-up visit.

The SAP version 1.0 was approved 6 Nov 2019. There were five SAP amendments. The last/latest version (version 5.0) was dated 06 Dec 2021.

## Primary estimand

The analysis of the primary efficacy endpoint utilised an estimand as follows:

Treatment: ZLP administered by daily SC injection (0.3mg/kg) versus placebo Target population: adults with gMG according to study inclusion and exclusion criteria Endpoint: CBL to Week 12 in MG-ADL score

## Intercurrent event (ICE) handling:

· Administration of rescue therapy (ICE1): It was assumed to be a treatment failure from the time of the ICE.

· Any death or myasthenic crisis (ICE2): It was assumed to be a treatment failure from the time of the ICE.

·  Any  other  monotone  missing  data  (ICE3)  were  assumed  to  be  missing  at  random  (MAR):  It  was assumed that the study participant had remained on their IMP throughout the study (i.e., a \"hypotheticalstrategy\" assuming study participants did not discontinue the study and remained on treatment).

## Primary analysis

The primary efficacy analysis population was the mITT Population including all randomised participants who received at least 1 dose of study drug and had at least 1 post-dosing/baseline assessment.

For the primary efficacy endpoint, CBL to week 12 in MG-ADL score, treatment group differences were assessed using a mixed model with repeated measures (MMRM) ANCOVA with treatment, baseline MGADL score, baseline QMG score, geographical region, treatment-by-visit, baseline MG-ADL score-by-visit as fixed effects and subject as a random effect. The MMRM ANCOVA was to include Weeks 1, 2, 4, 8, and 12. The least square means (LSMs) and standard errors of each treatment group, and the LSM differences between zilucoplan, and placebo were to be reported for the Week 12 Visit along with the corresponding 2-sided 95% CIs and p-values.

Missing or censored data was to be imputed by the baseline or the last available MG-ADL score (including unscheduled visit), whichever was worse from the time after a participant had received rescue therapy (ICE1) and after a participant had died or experienced a myasthenic crisis (ICE2). Any other monotone missing data (ICE3) were to be assumed to be MAR. If a MG-ADL assessment was performed on the rescue therapy visit, then this as to be considered as the last score available prior to rescue therapy.

Continuous secondary efficacy endpoints (i.e., week 12 CBL in QMG Score, MGC Score, and MG-QOL15r Survey) were analysed using a MMRM ANCOVA. Overall, the analysis model and the approach were to be similar as compared with the primary endpoint analysis. As for the primary endpoint, data after use

<div style=\"page-break-after: always\"></div>

of rescue therapy (ICE1) and death or myasthenic crisis (ICE2) were to be imputed by baseline or the last  available  corresponding  score  (including  unscheduled  visit),  whichever  was  worse.  Any  other monotone missing data (ICE3) were to be assumed to be MAR.

The dichotomous secondary efficacy endpoints: achieving MSE, defined as an MG-ADL of 0 or 1, at Week 12 without rescue therapy, a ≥ 3-point reduction in MG-ADL Score at Week 12 without rescue therapy, and a ≥ 5-point reduction in QMG Score at Week 12 without rescue therapy were to be analysed by a logistic regression. Multiple imputation was used to impute missing at random data. Intermittent missing data were to be imputed using Markov Chain Monte Carlo to obtain monotone missing pattern. Any monotone missing data was to be imputed using MAR assumption. Endpoints were then dichotomised at Week 12 from the imputed continuous endpoint. Participants who received rescue therapy or who had an event of death or myasthenic crisis were to be considered as non-responders.

Time to receive rescue therapy over the 12-week treatment period was analysed using Kaplan-Meier plots.  Subjects  who  did  not  take  rescue  therapy  were  censored  at  the  date  of  withdrawal/study completion. The treatment difference was tested using a log Rank test.

## Secondary Endpoints and multiplicity defined in SAP amendment 3 (dated 17 June 2021)

Control of the familywise type I error rate at a 2-sided alpha level of 0.05 was to be achieved using a parallel gatekeeping testing framework with different testing procedure for each of two endpoint families. Testing  of  secondary  endpoints  was  only  to  proceed  provided  the  primary  endpoint  was  statistically significant at a 2-sided type 1 error of 0.05.

Family  1  included  the  key  secondary  endpoints  and  testing  was  performed  using  a  fixed-sequential testing procedure in the following order:

1. CFB to Week 12 in the QMG score
2. CFB to Week 12 in the MGC score
3. CFB to Week 12 in the MG-QOL15r Survey

If all secondary endpoints in Family 1 were statistically significant at 2-sided type 1 error of 5%, family 2 was to be tested using a Holm procedure at 2-sided type 1 error of 0.05. Family 2 included the following secondary endpoints:

- Time to receive rescue therapy over the 12-week Treatment Period
- Achieving MSE, defined as an MG-ADL of 0 or 1, at Week 12 without rescue therapy
- Achieving a ≥ 3-point reduction in MG-ADL Score at Week 12 without rescue therapy
- Achieving a ≥ 5-point reduction in QMG Score at Week 12 without rescue therapy

## Sensitivity and supplementary analyses

Among the  pre-planned  sensitivity  analyses  was  a  MMRM  analysis  using  a  jump-to-reference  (J2R) approach and a Tipping point analysis.

Among pre-planned supplementary analyses was a MMRM analysis applying a treatment policy approach where all data were to be used regardless of any ICE (i.e., no data was to be censored). Any missing MG-ADL score was to be handled based on the maximum likelihood estimation method under the MAR assumption.

## Interim Analysis

Not Applicable.

<div style=\"page-break-after: always\"></div>

## Results

## · Participant flow

A total of 239 study participants were screened at 75 sites (37 sites in North America, 27 sites in Europe, and 11 sites in the East Asia) and were included in the study; 25 study participants were screened prior to  the  COVID-19  pandemic  period  and  214  study  participants  were  screened  during  the  COVID-19 pandemic period. Of the 239 study participants who were screened, 63 study participants (26.4%; 4 study participants prior to the COVID-19 pandemic period and 59 study during the COVID-19 pandemic period) were deemed ineligible and were screen failures. Two of the 239 study participants who were screened  (0.8%)  withdrew  prior  to  randomisation,  both  of  whom  withdrew  prior  to  the  COVID-19 pandemic  period.  The  remaining  174  study  participants  were  randomised  and  included  in  the  mITT Population.

Table 16: Disposition and primary discontinuation reasons - Overall (mITT Population) MG0010

| Category                                                      | Placebo N=88 n (%)   | ZLP 0.3mg/kg N=86 n (%)   | All study participants N=174 n (%)   |
|---------------------------------------------------------------|----------------------|---------------------------|--------------------------------------|
| Started study                                                 | 88 (100)             | 86 (100)                  | 174 (100)                            |
| Completed study                                               | 84 (95.5)            | 82 (95.3)                 | 166 (95.4)                           |
| Discontinued                                                  | 4 (4.5)              | 4 (4.7)                   | 8 (4.6)                              |
| Primary reason for discontinuation                            |                      |                           |                                      |
| Adverse event                                                 | 0                    | 2 (2.3)                   | 2 (1.1)                              |
| Lost to follow up                                             | 0                    | 0                         | 0                                    |
| Withdrawal by study participant                               | 2 (2.3)              | 1 (1.2)                   | 3 (1.7)                              |
| Physician decision                                            | 1 (1.1)              | 0                         | 1 (0.6)                              |
| Protocol violation                                            | 0                    | 0                         | 0                                    |
| Death                                                         | 1 (1.1)              | 1 (1.2)                   | 2 (1.1)                              |
| Safety reasons as determined by the Investigator or Sponsor 0 |                      | 0                         | 0                                    |
| Intolerability of IMP                                         | 0                    | 0                         | 0                                    |
| Other                                                         | 0                    | 0                         | 0                                    |
| Entered MG0011                                                | 84 (95.5)            | 81 (94.2)                 | 165 (94.8)                           |

## · Recruitment

First study participant was enrolled 17 Sep 2019 and last study participant completed 30 Dec 2021. The study was conducted at 75 sites (37 sites in North America [Canada and the United States], 27 sites in Europe [France, Germany, Italy, Norway, Poland, Spain, and the United Kingdom], and 11 sites in the East Asia [Japan]).

## · Conduct of the study

The original protocol (version 1.0) was dated 08 Apr 2019. There were 8 local amendments and one global  protocol  amendment:  protocol  amendment  version  2.0  (18  Dec  2020).  The  following,  among other, changes to the protocol were implemented:

<div style=\"page-break-after: always\"></div>

- The total sample size was increased from 130 study participants to 156 study participants to account for higher variability in the primary endpoint than originally assumed.
- An unblinded interim analysis was added to be performed after the final study participant had completed the Week 12 Visit, or after the final study participant had prematurely discontinued prior to reaching Week 12. The purpose of this interim analysis was to analyse all available data to prepare regulatory submissions for approval of the gMG target indication.
- COVID-19 related amendments
- Baseline data

Table 17: Demographic characteristics- Overall (mITT population) MG0010

| Variable Statistic                        | Placebo N=88   | ZLP 0.3mg/kg N=86   | All study participants N=174   |
|-------------------------------------------|----------------|---------------------|--------------------------------|
| Sex, n (%)                                |                |                     |                                |
| Female                                    | 47 (53.4)      | 52 (60.5)           | 99 (56.9)                      |
| Male                                      | 41 (46.6)      | 34 (39.5)           | 75 (43.1)                      |
| Race, n (%)                               |                |                     |                                |
| American Indian or Alaska Native          | 1 (1.1)        | 0                   | 1 (0.6)                        |
| Asian                                     | 14 (15.9)      | 7 (8.1)             | 21 (12.1)                      |
| Black                                     | 7 (8.0)        | 6 (7.0)             | 13 (7.5)                       |
| Native Hawaiian or other Pacific Islander | 0              | 0                   | 0                              |
| White                                     | 62 (70.5)      | 66 (76.7)           | 128 (73.6)                     |
| Other/Mixed                               | 0              | 0                   | 0                              |
| Missing                                   | 4 (4.5)        | 7 (8.1)             | 11 (6.3)                       |
| Ethnicity, n (%)                          |                |                     |                                |
| Hispanic or Latino                        | 5 (5.7)        | 7 (8.1)             | 12 (6.9)                       |
| Not Hispanic or Latino                    | 79 (89.8)      | 72 (83.7)           | 151 (86.8)                     |
| Missing                                   | 4 (4.5)        | 7 (8.1)             | 11 (6.3)                       |
| Region, n (%)                             |                |                     |                                |
| East Asia                                 | 9 (10.2)       | 7 (8.1)             | 16 (9.2)                       |
| Europe                                    | 33 (37.5)      | 34 (39.5)           | 67 (38.5)                      |
| North America                             | 46 (52.3)      | 45 (52.3)           | 91 (52.3)                      |
| Age (years)                               |                |                     |                                |
| N                                         | 88             | 86                  | 174                            |
| Mean (SD)                                 | 53.3 (15.7)    | 52.6 (14.6)         | 53.0 (15.1)                    |
| Median                                    | 55.5           | 54.5                | 55.0                           |
| Min, max                                  | 19, 75         | 21, 75              | 19, 75                         |
| Age group, n (%)                          |                |                     |                                |

<div style=\"page-break-after: always\"></div>

| ≤18 years             | 0             | 0              | 0              |
|-----------------------|---------------|----------------|----------------|
| 19 years to <65 years | 62 (70.5)     | 64 (74.4)      | 126 (72.4)     |
| ≥65 years             | 26 (29.5)     | 22 (25.6)      | 48 (27.6)      |
| Weight (kg)           |               |                |                |
| N                     | 88            | 86             | 174            |
| Mean (SD)             | 88.2 (26.58)  | 90.1 (22.87)   | 89.1 (24.77)   |
| Median                | 87.0          | 85.5           | 86.5           |
| Min, max              | 41, 169       | 50, 145        | 41, 169        |
| Weight (kg), n (%)    |               |                |                |
| <56                   | 6 (6.8)       | 5 (5.8)        | 11 (6.3)       |
| 56 to <77             | 25 (28.4)     | 21 (24.4)      | 46 (26.4)      |
| 77 to <150            | 54 (61.4)     | 60 (69.8)      | 114 (65.5)     |
| ≥150                  | 3 (3.4)       | 0              | 3 (1.7)        |
| Height (cm)           |               |                |                |
| N                     | 88            | 86             | 174            |
| Mean (SD)             | 169.52 (9.98) | 169.25 (10.51) | 169.39 (10.21) |
| Median                | 168.00        | 168.00         | 168.00         |
| Min, max              | 150.0, 200.0  | 147.6, 193.0   | 147.6, 200.0   |
| BMI (kg/m 2 )         |               |                |                |
| N                     | 88            | 86             | 174            |
| Mean (SD)             | 30.5 (8.02)   | 31.4 (7.22)    | 31.0 (7.63)    |
| Median                | 29.0          | 30.5           | 30.0           |
| Min, max              | 16, 54        | 19, 50         | 16, 54         |

There were no notable differences in demographics for the mITT Population by COVID-19 period. Baseline demographic characteristics for the per protocol set and safety set were consistent with those for the mITT Population.

Table 18: Baseline disease characteristics and gMG disease history - Overall (mITT Population) MG0010

| Variable Statistic             | Placebo N=88                   | ZLP 0.3mg/kg N=86              | All Study participants N=174   |
|--------------------------------|--------------------------------|--------------------------------|--------------------------------|
| MGFA class at Screening, n (%) | MGFA class at Screening, n (%) | MGFA class at Screening, n (%) | MGFA class at Screening, n (%) |
| Class II                       | 27 (30.7)                      | 22 (25.6)                      | 49 (28.2)                      |
| Class III                      | 57 (64.8)                      | 60 (69.8)                      | 117 (67.2)                     |
| Class IV                       | 4 (4.5)                        | 4 (4.7)                        | 8 (4.6)                        |
| Age at disease onset (years)   | Age at disease onset (years)   | Age at disease onset (years)   | Age at disease onset (years)   |
| N                              | 88                             | 85                             | 173                            |
| Mean (SD)                      | 44.02 (18.67)                  | 43.47 (17.35)                  | 43.75 (17.98)                  |

<div style=\"page-break-after: always\"></div>

| Median                        | 44.50          | 43.00         | 44.00          |
|-------------------------------|----------------|---------------|----------------|
| Min, max                      | 9.0, 73.0      | 13.0, 73.0    | 9.0, 73.0      |
| Duration of disease (years)   |                |               |                |
| N                             | 88             | 86            | 174            |
| Mean (SD)                     | 8.96 (10.43)   | 9.34 (9.47)   | 9.15 (9.94)    |
| Median                        | 4.75           | 5.55          | 5.00           |
| Min, max                      | 0.2, 51.9      | 0.1, 42.3     | 0.1, 51.9      |
| Symptoms at onset, n (%)      |                |               |                |
| Ocular                        | 34 (38.6)      | 28 (32.6)     | 62 (35.6)      |
| Generalised                   | 54 (61.4)      | 58 (67.4)     | 112 (64.4)     |
| Prior thymectomy, n (%)       | 37 (42.0)      | 45 (52.3)     | 82 (47.1)      |
| Prior MG crisis, n (%)        | 29 (33.0)      | 28 (32.6)     | 57 (32.8)      |
| Time since most recent crisis | (months) a     |               |                |
| N                             | 29             | 28            | 57             |
| Mean (SD)                     | 72.26 (109.76) | 75.61 (91.81) | 73.91 (100.45) |
| Median                        | 21.98          | 38.98         | 26.94          |
| Min, max                      | 1.4,469.8      | 1.4, 277.6    | 1.4, 469.8     |
| gMG refractory, n(%) b        | 44 (50.0)      | 44 (51.2)     | 88 (50.6)      |
| Baseline MG-ADL score         |                |               |                |
| N                             | 88             | 86            | 174            |
| Mean (SD)                     | 10.9 (3.4)     | 10.3 (2.5)    | 10.6 (3.0)     |
| Median                        | 10.5           | 10.0          | 10.0           |
| Min, max                      | 6, 19          | 6, 16         | 6, 19          |
| Baseline MG-ADL score, n (%)  |                |               |                |
| ≤9                            | 33 (37.5)      | 33 (38.4)     | 66 (37.9)      |
| ≥10                           | 55 (62.5)      | 53 (61.6)     | 108 (62.1)     |
| Baseline QMG score            |                |               |                |
| N                             | 88             | 86            | 174            |
| Mean (SD)                     | 19.4 (4.5)     | 18.7 (3.6)    | 19.1 (4.1)     |
| Median                        | 18.5           | 18.0          | 18.0           |
| Min, max                      | 13, 36         | 12, 31        | 12, 36         |
| Baseline QMG score, n (%)     |                |               |                |
| ≤17                           | 38 (43.2)      | 38 (44.2)     | 76 (43.7)      |
| ≥18                           | 50 (56.8)      | 48 (55.8)     | 98 (56.3)      |

a) Time since most recent crisis (months) was calculated as: (Date of Study Day 1-Date of crisis)/(365.25/12).

b) A study participant was considered 'gMG Refractory' if they met the following criteria:

(1)  Treatment  for  at  least  1  year  with  2  or  more  of  the  following  therapies:  prednisone,  azathioprine,  mycophenolate, cyclosporine, cyclophosphamide, methotrexate, tacrolimus, rituximab, eculizumab, or other corticosteroids, or

(2) History of treatment with at least 1 of the therapies listed in (1) for 1 year or more and required chronic plasma exchange or IVIG or SCIG at least every 3 months for the 12 months prior to enrolment.

<div style=\"page-break-after: always\"></div>

The usage of Baseline gMG-specific medications was generally balanced between treatment groups.

Table 19: Baseline gMG-specific medications (SS)

| Group Concomitant Preferred term      | Placebo N=88 n (%)   | ZLP 0.3mg/kg N=86 n (%)   | All study participants N=174 n (%)   |
|---------------------------------------|----------------------|---------------------------|--------------------------------------|
| Any gMG-specific Baseline medications | 83 (94.3)            | 84 (97.7)                 | 167 (96.0)                           |
| Group A                               | 51 (58.0)            | 59 (68.6)                 | 110 (63.2)                           |
| Prednisone for gMG                    | 33 (37.5)            | 38 (44.2)                 | 71 (40.8)                            |
| Prednisone                            | 33 (37.5)            | 38 (44.2)                 | 71 (40.8)                            |
| Other corticosteroids for gMG         | 18 (20.5)            | 21 (24.4)                 | 39 (22.4)                            |
| Prednisolone                          | 16 (18.2)            | 20 (23.3)                 | 36 (20.7)                            |
| Methylprednisolone                    | 2 (2.3)              | 1 (1.2)                   | 3 (1.7)                              |
| Group B                               | 35 (39.8)            | 30 (34.9)                 | 65 (37.4)                            |
| Azathioprine                          | 18 (20.5)            | 13 (15.1)                 | 31 (17.8)                            |
| Azathioprine                          | 18 (20.5)            | 13 (15.1)                 | 31 (17.8)                            |
| Mycophenolate                         | 17 (19.3)            | 17 (19.8)                 | 34 (19.5)                            |
| Mycophenolate mofetil                 | 17 (19.3)            | 17 (19.8)                 | 34 (19.5)                            |
| Group C                               | 0                    | 0                         | 0                                    |
| IVIG                                  | 0                    | 0                         | 0                                    |
| Immunoglobulins NOS                   | 0                    | 0                         | 0                                    |
| SCIG                                  | 0                    | 0                         | 0                                    |
| Immunoglobulins NOS                   | 0                    | 0                         | 0                                    |
| Group D                               | 0                    | 0                         | 0                                    |
| IVIG, SCIG, or PLEX                   | 0                    | 0                         | 0                                    |
| Immunoglobulins NOS                   | 0                    | 0                         | 0                                    |
| PLEX                                  | 0                    | 0                         | 0                                    |
| Group E                               | 15 (17.0)            | 12 (14.0)                 | 27 (15.5)                            |
| Cyclosporine                          | 7 (8.0)              | 6 (7.0)                   | 13 (7.5)                             |
| Ciclosporin                           | 7 (8.0)              | 6 (7.0)                   | 13 (7.5)                             |
| Cyclophosphamide                      | 0                    | 0                         | 0                                    |
| Cyclophosphamide                      | 0                    | 0                         | 0                                    |
| Methotrexate                          | 1 (1.1)              | 3 (3.5)                   | 4 (2.3)                              |
| Methotrexate                          | 1 (1.1)              | 3 (3.5)                   | 4 (2.3)                              |
| Tacrolimus                            | 7 (8.0)              | 3 (3.5)                   | 10 (5.7)                             |
| Tacrolimus                            | 7 (8.0)              | 3 (3.5)                   | 10 (5.7)                             |
| Rituximab                             | 0                    | 0                         | 0                                    |
| Rituximab                             | 0                    | 0                         | 0                                    |
| Group F                               | 73 (83.0)            | 74 (86.0)                 | 147 (84.5)                           |
| Cholinesterase inhibitors             | 73 (83.0)            | 74 (86.0)                 | 147 (84.5)                           |
| Ambenonium                            | 3 (3.4)              | 4 (4.7)                   | 7 (4.0)                              |
| Pyridostigmine                        | 70 (79.5)            | 70 (81.4)                 | 140 (80.5)                           |

gMG=generalised  myasthenia  gravis;  IVIG=intravenous  immunoglobulin;  NOS=not  otherwise  specified;  PLEX=plasma  exchange; SCIG=subcutaneous immunoglobulin; SS=Safety Set; ZLP=zilucoplan

Note: Baseline medications include any medications that started prior to dosing and continued after (classified as prior and concomitant medications).

<div style=\"page-break-after: always\"></div>

## · Numbers analysed

Table 20: Analysis sets

| Analysis set    | Placebo N=88 n (%)   | ZLP 0.3mg/kg N=86 n (%)   | All study participants N=174 n (%)   |
|-----------------|----------------------|---------------------------|--------------------------------------|
| RS              | 88 (100)             | 86 (100)                  | 174 (100)                            |
| mITT Population | 88 (100)             | 86 (100)                  | 174 (100)                            |
| CFS             | 81 (92.0)            | 77 (89.5)                 | 158 (90.8)                           |
| PPS             | 77 (87.5)            | 70 (81.4)                 | 147 (84.5)                           |
| SS              | 88 (100)             | 86 (100)                  | 174 (100)                            |
| PK-PPS          | 88 (100)             | 85 (98.8)                 | 173 (99.4)                           |
| PD-PPS          | 88 (100)             | 85 (98.8)                 | 173 (99.4)                           |

CFS=COVID-19 Free Set; COVID-19=coronavirus  disease  2019;  mITT=modified  Intent-to-Treat;  PD-PPS=Pharmacodynamic  PerProtocol Set; PK-PPS=Pharmacokinetic Per-Protocol Set; PPS=Per Protocol Set; RS=Randomised Set; SS=Safety Set; ZLP=zilucoplan

## · Outcomes and estimation

The  LSM  CBL  through  Week  12  in  MG-ADL  score  using  MMRM  ANCOVA  is  presented  for  the  mITT Population in the figure below. The changes from Baseline to Week 12 in the primary (MG-ADL) and key secondary (QMG, MGC, MG-QOL15r) efficacy endpoints are shown in the table below.

Figure 10: MG0010 - LS mean change from baseline to week 12 in MG-ADL score (mITT Population [MMRM ANCOVA])

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 21: MG0010 - change from baseline to week 12 in primary and key secondary efficacy endpoints (mITT Population [MMRM ANCOVA])

| Visit Statistic         | Placebo N=88   | ZLP 0.3mg/kg N=86   |
|-------------------------|----------------|---------------------|
| Week 12 MG-ADL          |                |                     |
| LS mean (SE)            | -2.30 (0.44)   | -4.39 (0.45)        |
| 95% CI                  | -3.17, -1.43   | -5.28, -3.50        |
| LS mean difference (SE) | -              | -2.09 (0.58)        |
| 95% CI                  | -              | -3.24, -0.95        |
| p-value                 | -              | <0.001              |
| Week 12 QMG             |                |                     |
| LS mean (SE)            | -3.25 (0.55)   | -6.19 (0.56)        |
| 95% CI                  | -4.32, -2.17   | -7.29, -5.08        |
| LS mean difference (SE) | -              | -2.94 (0.73)        |
| 95% CI                  | -              | -4.39, -1.49        |
| p-value                 | -              | <0.001              |
| Week 12 MGC             |                |                     |
| LS mean (SE)            | -5.42 (0.79)   | -8.62 (0.81)        |
| 95% CI                  | -6.98, -3.86   | -10.22, -7.01       |
| LS mean difference (SE) | -              | -3.20 (1.03)        |
| 95% CI                  | -              | -5.24, -1.16        |
| p-value                 | -              | 0.0023              |
| Week 12 MG-QOL15r       |                |                     |
| LS mean (SE)            | -3.16 (0.76)   | -5.65 (0.77)        |
| 95% CI                  | -4.65, -1.67   | -7.17, -4.12        |
| LS mean difference (SE) | -              | -2.49 (0.99)        |
| 95% CI                  | -              | -4.45, -0.54        |
| p-value                 | -              | 0.0128              |

Sensitivity and supplementary analyses - primary endpoint

When the primary efficacy endpoint was analysed using MMRM ANCOVA with the J2R approach, the LSM CBL to Week 12 in MG-ADL score was -4.47 in the ZLP 0.3mg/kg treatment group and -2.44 in the placebo treatment group, LSM difference of -2.03 (nominal p&lt;0.001).

When the primary efficacy endpoint was analysed using MMRM ANCOVA applying a treatment policy strategy, the LSM CBL to Week 12 in MG-ADL score was -4.56 in the ZLP 0.3mg/kg treatment group and -2.54 in the placebo treatment group, LSM difference of -2.02 (nominal p&lt;0.001).

Other secondary endpoints (Family 2)

The proportion of study participants in the ZLP 0.3mg/kg treatment group compared with the placebo treatment group was higher with odds ratios significantly favouring ZLP treatment over placebo for MG-

<div style=\"page-break-after: always\"></div>

ADL  responders  (73.1%  vs  46.1%,  respectively;  OR:  3.184;  95%  CI:  1.662  to  6.101)  and  QMG responders (58.0% vs 33.0%, respectively; odds ratio: 2.865; 95% CI: 1.518 to 5.409).

Figure 11: Forest plot of MG-ADL responders, QMG responders, and MSE at Week 12 (mITT Population) MG0010

Zilucoplan

<!-- image -->

The cumulative proportion of study participants receiving rescue therapy by Week 12 was lower in the ZLP  0.3mg/kg  treatment  group  (Day  84:  4  study  participants  [5%])  compared  with  the  placebo treatment group (Day 84: 10 study participants [12%]). This difference favoured ZLP numerically but was not statistically significant (p=0.1003).

Figure 12: Kaplan-Meier plot of time to rescue therapy (mITT Population) MG0010

<!-- image -->

Note: Circles represent censored study participants

## · Ancillary analyses

A summary of MG-ADL score and CBL is provided for the mITT Population by subgroup and by visit in the table below.

<div style=\"page-break-after: always\"></div>

Table 22: Subgroup analysis of change from Baseline to Week 12 in MG-ADL (mITT Population) MG0010

| Subgroup                          | Placebo N=88   | Placebo N=88   | ZLP 0.3mg/kg N=86   | ZLP 0.3mg/kg N=86   |
|-----------------------------------|----------------|----------------|---------------------|---------------------|
| Subgroup                          | n              | Mean CFB (SD)  | n                   | Mean CFB (SD)       |
| Overall CFB Week 12               | 85             | -2.85 (3.60)   | 84                  | -4.70 (3.93)        |
| Age                               |                |                |                     |                     |
| <65 years                         | 59             | -2.75 (3.83)   | 63                  | -4.56 (4.14)        |
| ≥65 years                         | 26             | -3.08 (3.07)   | 21                  | -5.14 (3.24)        |
| Gender                            |                |                |                     |                     |
| Male                              | 40             | -2.85 (3.62)   | 33                  | -5.12 (3.62)        |
| Female                            | 45             | -2.84 (3.62)   | 51                  | -4.43 (4.12)        |
| Duration of disease at Baseline   |                |                |                     |                     |
| <Median                           | 46             | -3.04 (3.71)   | 39                  | -3.92 (3.59)        |
| ≥Median                           | 39             | -2.62 (3.51)   | 45                  | -5.38 (4.12)        |
| MGFA disease class at Baseline    |                |                |                     |                     |
| Class II (IIa, IIb)               | 26             | -3.69 (3.60)   | 22                  | -4.23 (3.26)        |
| Class III (IIIa, IIIb)            | 55             | -2.42 (3.44)   | 58                  | -4.69 (3.96)        |
| Class IV (IVa or IVb)             | 4              | -3.25 (5.74)   | 4                   | -7.50 (6.45)        |
| Baseline MG-ADL                   |                |                |                     |                     |
| ≤9                                | 31             | -2.48 (2.97)   | 33                  | -3.88 (2.76)        |
| ≥10                               | 54             | -3.06 (3.93)   | 51                  | -5.24 (4.47)        |
| Baseline QMG                      |                |                |                     |                     |
| ≤17                               | 37             | -2.81 (3.93)   | 37                  | -4.19 (3.08)        |
| ≥18                               | 48             | -2.88 (3.37)   | 47                  | -5.11 (4.47)        |
| MG refractory                     |                |                |                     |                     |
| Yes                               | 42             | -2.26 (3.39)   | 44                  | -4.89 (4.09)        |
| No                                | 43             | -3.42 (3.75)   | 40                  | -4.50 (3.78)        |
| Ever had a crisis                 |                |                |                     |                     |
| Yes                               | 28             | -4.14 (4.01)   | 28                  | -5.54 (3.98)        |
| No                                | 57             | -2.21 (3.23)   | 55                  | -4.44 (3.74)        |
| Prior thymectomy                  |                |                |                     |                     |
| Yes                               | 36             | -2.78 (3.64)   | 43                  | -5.02 (4.32)        |
| No                                | 49             | -2.90 (3.61)   | 41                  | -4.37 (3.48)        |
| Prior steroid therapy             |                |                |                     |                     |
| Yes                               | 72             | -3.00 (3.74)   | 75                  | -4.88 (3.95)        |
| No                                | 13             | -2.00 (2.65)   | 9                   | -3.22 (3.60)        |
| Steroid therapy taken at Baseline |                |                |                     |                     |

<div style=\"page-break-after: always\"></div>

| Yes                                                  | 50                                                   | -2.80 (3.84)                                         | 59                                                   | -4.58 (3.59)                                         |
|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
| No                                                   | 35                                                   | -2.91 (3.28)                                         | 25                                                   | -5.00 (4.69)                                         |
| Prior immunosuppressive therapy (nonsteroidal)       | Prior immunosuppressive therapy (nonsteroidal)       | Prior immunosuppressive therapy (nonsteroidal)       | Prior immunosuppressive therapy (nonsteroidal)       | Prior immunosuppressive therapy (nonsteroidal)       |
| Yes                                                  | 31                                                   | -1.71 (3.47)                                         | 26                                                   | -4.62 (4.45)                                         |
| No                                                   | 54                                                   | -3.50 (3.54)                                         | 58                                                   | -4.74 (3.71)                                         |
| Immunosuppressive therapy (nonsteroidal) at Baseline | Immunosuppressive therapy (nonsteroidal) at Baseline | Immunosuppressive therapy (nonsteroidal) at Baseline | Immunosuppressive therapy (nonsteroidal) at Baseline | Immunosuppressive therapy (nonsteroidal) at Baseline |
| Yes                                                  | 15                                                   | -1.07 (2.25)                                         | 12                                                   | -3.83 (4.09)                                         |
| No                                                   | 70                                                   | -3.23 (3.73)                                         | 72                                                   | -4.85 (3.91)                                         |
| Prior history of IVIG or sc immunoglobulin or PLEX   | Prior history of IVIG or sc immunoglobulin or PLEX   | Prior history of IVIG or sc immunoglobulin or PLEX   | Prior history of IVIG or sc immunoglobulin or PLEX   | Prior history of IVIG or sc immunoglobulin or PLEX   |
| Yes                                                  | 62                                                   | -2.94 (3.97)                                         | 57                                                   | -4.93 (4.05)                                         |
| No                                                   | 23                                                   | -2.61 (2.41)                                         | 27                                                   | -4.22 (3.68)                                         |
| Diagnosed with thymoma                               | Diagnosed with thymoma                               | Diagnosed with thymoma                               | Diagnosed with thymoma                               | Diagnosed with thymoma                               |
| Yes                                                  | 18                                                   | -2.61 (4.00)                                         | 20                                                   | -5.80 (3.19)                                         |
| No                                                   | 67                                                   | -2.91 (3.52)                                         | 64                                                   | -4.36 (4.09)                                         |

Table 23: Subgroup analysis of change from baseline to week 12 in QMG (mITT Population) MG0010

| Subgroup Category              | Placebo N=88   | Placebo N=88   | ZLP 0.3mg/kg N=86   | ZLP 0.3mg/kg N=86   |
|--------------------------------|----------------|----------------|---------------------|---------------------|
|                                | n              | Mean CFB (SD)  | n                   | Mean CFB (SD)       |
| Overall CFB Week 12            | 84             | -3.38 (4.21)   | 83                  | -6.31 (4.92)        |
| Age                            |                |                |                     |                     |
| <65 years                      | 58             | -3.17 (4.15)   | 62                  | -6.35 (5.21)        |
| ≥65 years                      | 26             | -3.85 (4.37)   | 21                  | -6.19 (4.04)        |
| MGFA disease class at Baseline |                |                |                     |                     |
| Class II (IIa, IIb)            | 26             | -3.65 (3.88)   | 22                  | -5.86 (5.13)        |
| Class III (IIIa, IIIb)         | 54             | -3.24 (4.41)   | 57                  | -6.44 (4.83)        |
| Class IV (IVa or IVb)          | 4              | -3.50 (4.43)   | 4                   | -7.00 (6.27)        |
| Baseline MG-ADL                |                |                |                     |                     |
| ≤9                             | 30             | -2.87 (4.11)   | 33                  | -6.03 (4.91)        |
| ≥10                            | 54             | -3.67 (4.27)   | 50                  | -6.50 (4.96)        |
| Baseline QMG                   |                |                |                     |                     |
| ≤17                            | 37             | -2.43 (3.88)   | 37                  | -5.70 (3.98)        |
| ≥18                            | 47             | -4.13 (4.34)   | 46                  | -6.80 (5.56)        |

<div style=\"page-break-after: always\"></div>

Table 24: Subgroup analysis of change from baseline to week 12 in MGC (mITT Population) MG0010

| Subgroup Category              | Placebo N=88   | Placebo N=88   | ZLP0.3mg/kgN=86   | ZLP0.3mg/kgN=86   |
|--------------------------------|----------------|----------------|-------------------|-------------------|
|                                | n              | Mean CFB (SD)  | n                 | Mean CFB (SD)     |
| Overall CFB at Week 12         | 84             | -6.58 (6.46)   | 83                | -9.20 (6.35)      |
| Age                            |                |                |                   |                   |
| <65 years                      | 58             | -6.67 (6.53)   | 62                | -9.13 (6.81)      |
| ≥65 years                      | 26             | -6.38 (6.43)   | 21                | -9.43 (4.87)      |
| MGFA disease class at Baseline |                |                |                   |                   |
| Class II (IIa, IIb)            | 26             | -7.58 (5.68)   | 22                | -9.82 (7.20)      |
| Class III (IIIa, IIIb)         | 54             | -6.15 (6.84)   | 57                | -8.72 (5.98)      |
| Class IV (IVa or IVb)          | 4              | -6.00 (6.93)   | 4                 | -12.75 (6.95)     |
| Baseline MG-ADL                |                |                |                   |                   |
| ≤9                             | 30             | -5.43 (6.27)   | 33                | -7.97 (5.49)      |
| ≥10                            | 54             | -7.22 (6.53)   | 50                | -10.02 (6.78)     |
| Baseline QMG                   |                |                |                   |                   |
| ≤17                            | 37             | -5.57 (5.70)   | 37                | -7.97 (5.49)      |
| ≥18                            | 47             | -7.38 (6.95)   | 46                | -10.20 (6.88)     |

<div style=\"page-break-after: always\"></div>

Table 25: Subgroup analysis of change from baseline to week 12 in MG-QOL15r (mITT Population)

| Subgroup Category              | Placebo N=88   | Placebo N=88   | ZLP 0.3mg/kg N=86   | ZLP 0.3mg/kg N=86   |
|--------------------------------|----------------|----------------|---------------------|---------------------|
|                                | n              | Mean CFB (SD)  | n                   | Mean CFB (SD)       |
| Overall CFB at Week 12         | 83             | -3.93 (6.34)   | 82                  | -6.09 (7.10)        |
| Age                            |                |                |                     |                     |
| <65 years                      | 57             | -3.65 (6.59)   | 62                  | -7.02 (7.60)        |
| ≥65 years                      | 26             | -4.54 (5.83)   | 20                  | -3.20 (4.23)        |
| MGFA disease class at Baseline |                |                |                     |                     |
| Class II (IIa, IIb)            | 25             | -5.28 (6.54)   | 22                  | -4.95 (6.22)        |
| Class III (IIIa, IIIb)         | 54             | -3.56 (6.23)   | 57                  | -6.25 (7.12)        |
| Class IV (IVa or IVb)          | 4              | -0.50 (6.24)   | 3                   | -11.33 (12.58)      |
| Baseline MG-ADL                |                |                |                     |                     |
| ≤9                             | 29             | -3.79 (5.85)   | 33                  | -6.21 (5.38)        |
| ≥10                            | 54             | -4.00 (6.64)   | 49                  | -6.00 (8.11)        |
| Baseline QMG                   |                |                |                     |                     |
| ≤17                            | 36             | -4.61 (6.68)   | 37                  | -5.73 (7.02)        |
| ≥18                            | 47             | -3.40 (6.09)   | 45                  | -6.38 (7.23)        |

## Antidrug antibodies

By Week 12, 2 study participants each in the ZLP 0.3mg/kg treatment group and the placebo group were treatment-emergent ADA positive at 1 visit or more. In the 2 study participants in the ZLP 0.3mg/kg treatment group who were treatment-emergent ADA positive, the CBL in MG-ADL score was numerically greater compared with the study participants who were ADA negative.

## · Summary of main efficacy results

The  following  table  summarise  the  efficacy  results  from  the  main  study  supporting  the  present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

| Title: A phase 3, multicenter, randomized, double-blind, placebo-controlled study to confirm the safety, tolerability, and efficacy of Zilucoplan in subjects with generalized myasthenia gravis   | Title: A phase 3, multicenter, randomized, double-blind, placebo-controlled study to confirm the safety, tolerability, and efficacy of Zilucoplan in subjects with generalized myasthenia gravis   | Title: A phase 3, multicenter, randomized, double-blind, placebo-controlled study to confirm the safety, tolerability, and efficacy of Zilucoplan in subjects with generalized myasthenia gravis   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                   | MG0010 (Ra Pharmaceuticals, Inc. RA101495-02.301 [RAISE]) EUDRACT 2019-001564-30 NCT04115293                                                                                                       | MG0010 (Ra Pharmaceuticals, Inc. RA101495-02.301 [RAISE]) EUDRACT 2019-001564-30 NCT04115293                                                                                                       |
| Design                                                                                                                                                                                             | Multicentre, Randomised, Double-Blind, Placebo-Controlled                                                                                                                                          | Multicentre, Randomised, Double-Blind, Placebo-Controlled                                                                                                                                          |
|                                                                                                                                                                                                    | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                     | 12 weeks Screening Period of up to 4 weeks OLE in MG0011(Raise XT)                                                                                                                                 |
| Hypothesis                                                                                                                                                                                         | Superiority to placebo                                                                                                                                                                             | Superiority to placebo                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

## Title:  A phase 3, multicenter, randomized, double-blind, placebo-controlled study to confirm the  safety,  tolerability,  and  efficacy  of  Zilucoplan  in  subjects  with  generalized  myasthenia gravis

| Study identifier          | MG0010 (Ra Pharmaceuticals, Inc. RA101495-02.301 [RAISE]) EUDRACT 2019-001564-30 NCT04115293   | MG0010 (Ra Pharmaceuticals, Inc. RA101495-02.301 [RAISE]) EUDRACT 2019-001564-30 NCT04115293   | MG0010 (Ra Pharmaceuticals, Inc. RA101495-02.301 [RAISE]) EUDRACT 2019-001564-30 NCT04115293                                                                                                                                                                                                                                                                                                                                              |
|---------------------------|------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Treatments groups         | Zilucoplan                                                                                     | Zilucoplan                                                                                     | Zilucoplan 0.3 mg/Kg administered daily by SC injection for a duration of 12 weeks Number randomised = 86                                                                                                                                                                                                                                                                                                                                 |
| Treatments groups         | Placebo                                                                                        | Placebo                                                                                        | Placebo administered daily by SC injection for a duration of 12 weeks Number randomised =88                                                                                                                                                                                                                                                                                                                                               |
| Endpoints and definitions | Primary endpoint                                                                               | CFB to Week 12 in MG-ADL score                                                                 | The MG-ADL is a brief 8-item survey designed to evaluate MG symptom severity. Higher scores are associated with more severe symptoms of MG. A 2-point change in MG-ADL Score is considered clinically meaningful.                                                                                                                                                                                                                         |
| Endpoints and definitions | Key secondary endpoint                                                                         | CFB to Week 12 in the QMG score                                                                | The QMG test is a standardised quantitative strength scoring system and measures 13 items on a 0-3 scale, with 0 being the least severe. The total sum of the 13 items represents the QMG score. The QMG score can range from 0 (least severe) to 39 (most severe). A change in the QMG Score of 3 points may be considered clinically meaningful, in a typical clinical trial population of MG patients.                                 |
| Endpoints and definitions | Key secondary endpoint                                                                         | CFB to Week 12 in the MGC score                                                                | The MGC is a 10-item scale that has been used to measure the clinical status of patients with Myasthenia Gravis (MG) in order to evaluate treatment response. The MGC has 4-point Likert-type scale response options ranging from 0 to 2, 3, 4, 5, 6 or 9 according to the item (weighted response options). The total score is the sum of all items (range 0-50) where higher scores indicate more severe impairment due to the disease. |
| Endpoints and definitions | Key secondary endpoint                                                                         | CFB to Week 12 in MG- QOL15r score                                                             | The MG-QOL15r is a 15-item survey that was designed to assess quality of life in patients with MG. The MG-QoL has 3-point Likert Scale response options ranging from 0 to 2. The MGQoL15r score can range from 0 to 30, where higher scores indicate more severe impact of the disease on aspects of the patient's life                                                                                                                   |

Database lock

18-Jan-2022

| Results and Analysis                           | Results and Analysis                                                                                                                                                             | Results and Analysis                                                                                                                                                             | Results and Analysis                                                                                                                                                             | Results and Analysis                                                                                                                                                             |
|------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Analysis description                           | Primary Analysis                                                                                                                                                                 | Primary Analysis                                                                                                                                                                 | Primary Analysis                                                                                                                                                                 | Primary Analysis                                                                                                                                                                 |
| Analysis population and time point description | Comparison of zilucoplan 0.3 mg/kg treatment group versus placebo in CFB to Week 12 in MG-ADL Score at a 2-sided 0.05 significance level based on the mITT population using LSM. | Comparison of zilucoplan 0.3 mg/kg treatment group versus placebo in CFB to Week 12 in MG-ADL Score at a 2-sided 0.05 significance level based on the mITT population using LSM. | Comparison of zilucoplan 0.3 mg/kg treatment group versus placebo in CFB to Week 12 in MG-ADL Score at a 2-sided 0.05 significance level based on the mITT population using LSM. | Comparison of zilucoplan 0.3 mg/kg treatment group versus placebo in CFB to Week 12 in MG-ADL Score at a 2-sided 0.05 significance level based on the mITT population using LSM. |
| Descriptive statistics                         | Treatment group                                                                                                                                                                  | placebo                                                                                                                                                                          | zilucoplan                                                                                                                                                                       |                                                                                                                                                                                  |
| and                                            | Number of subject                                                                                                                                                                | 88                                                                                                                                                                               | 86                                                                                                                                                                               |                                                                                                                                                                                  |
| estimate variability                           | LS mean change                                                                                                                                                                   | -2.30                                                                                                                                                                            | -4.39                                                                                                                                                                            |                                                                                                                                                                                  |
|                                                | 95% CI                                                                                                                                                                           | -3.17, -1.43                                                                                                                                                                     | -5.28, -3.50                                                                                                                                                                     |                                                                                                                                                                                  |
| Effect estimate                                | Primary endpoint:                                                                                                                                                                | Comparison groups                                                                                                                                                                | Zilucoplan versus placebo                                                                                                                                                        |                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

## Title:  A phase 3, multicenter, randomized, double-blind, placebo-controlled study to confirm the  safety,  tolerability,  and  efficacy  of  Zilucoplan  in  subjects  with  generalized  myasthenia gravis

Study identifier

MG0010 (Ra Pharmaceuticals, Inc. RA101495-02.301 [RAISE]) EUDRACT 2019-001564-30

NCT04115293

per comparison

CFB  to  Week  12  in MG-ADL Score

LS mean difference

-2.09

95% CI

-3.24,-0.95

p-value

&lt;0.001

Notes

ICE handling:

- Administration of rescue therapy (ICE1): will be assumed to be a treatment failure from the time of the ICE.

- Any death or myasthenic crisis (ICE2) will be assumed to be a treatment failure from the time of the ICE.

- Any other monotone missing data (ICE3) will be assumed to be missing at random: it is assumed that the participant had remained on their treatment throughout the study (i.e., a \"Hypothetical strategy\" assuming participants did not discontinue the study and remained on treatment).

## Analysis description

Secondary analysis

Analysis population and time point description

Comparison of zilucoplan 0.3 mg/kg treatment group versus placebo in CFB to Week 12 in QMG Score at a 2-sided 0.05 significance level based on the mITT population using LSM.

Descriptive statistics and estimate variability

Treatment group

placebo

zilucoplan

Number of subject

88

86

LS mean change

-3.25

-6.19

95% CI

-4.32, -2.17

-7.29, -5.08

Effect estimate

Secondary endpoint:

Comparison groups

Zilucoplan versus placebo

per comparison

CFB  to  Week  12  in QMG Score

LS mean difference

-2.94

95% CI

-4.39,-1.49

p-value

&lt;0.001

## Analysis description

## Secondary analysis

Analysis population and time point description

Comparison of zilucoplan 0.3 mg/kg treatment group versus placebo in CFB to Week 12 in MGC Score at a 2-sided 0.05 significance level based on the mITT population using LSM.

Descriptive statistics and estimate variability

Treatment group

placebo

zilucoplan

Number of subject

88

86

LS mean change

-5.42

-8.62

95% CI

-6.98, -3.86

-10.22, -7.01

Effect estimate

Secondary endpoint:

Comparison groups

Zilucoplan versus placebo

per comparison

CFB  to  Week  12  in MGC Score

LS mean difference

-3.20

95% CI

-5.24,-1.16

p-value

0.0023

## Analysis description

## Secondary analysis

Analysis population and time point description

Comparison of zilucoplan 0.3 mg/kg treatment group versus placebo in CFB to Week 12 in MG-QOL15r Score at a 2-sided 0.05 significance level based on the mITT population using LSM.

Descriptive statistics and estimate variability

Treatment group

placebo

zilucoplan

Number of subject

88

86

LS mean change

-3.16

-5.65

<div style=\"page-break-after: always\"></div>

| Title: A phase 3, multicenter, randomized, double-blind, placebo-controlled study to confirm the safety, tolerability, and efficacy of Zilucoplan in subjects with generalized myasthenia gravis   | Title: A phase 3, multicenter, randomized, double-blind, placebo-controlled study to confirm the safety, tolerability, and efficacy of Zilucoplan in subjects with generalized myasthenia gravis   | Title: A phase 3, multicenter, randomized, double-blind, placebo-controlled study to confirm the safety, tolerability, and efficacy of Zilucoplan in subjects with generalized myasthenia gravis   | Title: A phase 3, multicenter, randomized, double-blind, placebo-controlled study to confirm the safety, tolerability, and efficacy of Zilucoplan in subjects with generalized myasthenia gravis   | Title: A phase 3, multicenter, randomized, double-blind, placebo-controlled study to confirm the safety, tolerability, and efficacy of Zilucoplan in subjects with generalized myasthenia gravis   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                   | MG0010 (Ra Pharmaceuticals, Inc. RA101495-02.301 [RAISE]) EUDRACT 2019-001564-30 NCT04115293                                                                                                       | MG0010 (Ra Pharmaceuticals, Inc. RA101495-02.301 [RAISE]) EUDRACT 2019-001564-30 NCT04115293                                                                                                       | MG0010 (Ra Pharmaceuticals, Inc. RA101495-02.301 [RAISE]) EUDRACT 2019-001564-30 NCT04115293                                                                                                       | MG0010 (Ra Pharmaceuticals, Inc. RA101495-02.301 [RAISE]) EUDRACT 2019-001564-30 NCT04115293                                                                                                       |
|                                                                                                                                                                                                    | 95% CI                                                                                                                                                                                             | -4.65, -1.67                                                                                                                                                                                       | -7.17, -4.12                                                                                                                                                                                       |                                                                                                                                                                                                    |
| Effect estimate                                                                                                                                                                                    | Secondary endpoint:                                                                                                                                                                                | Comparison groups                                                                                                                                                                                  | Zilucoplan versus placebo                                                                                                                                                                          |                                                                                                                                                                                                    |
| per comparison                                                                                                                                                                                     | CFB to Week 12 in MG-QOL15r Score                                                                                                                                                                  | LS mean difference                                                                                                                                                                                 | -2.49                                                                                                                                                                                              |                                                                                                                                                                                                    |
| per comparison                                                                                                                                                                                     |                                                                                                                                                                                                    | 95% CI                                                                                                                                                                                             | -4.45,-0.57                                                                                                                                                                                        |                                                                                                                                                                                                    |
| per comparison                                                                                                                                                                                     |                                                                                                                                                                                                    | p-value                                                                                                                                                                                            | 0.0128                                                                                                                                                                                             |                                                                                                                                                                                                    |

## 2.6.5.3. Clinical studies in special populations

In the controlled pivotal trial MG0010, 48 of 174 participants (27.6%) were aged ≥ 65years. In the controlled phase II trial MG009 7 of 45 participants (15.6%) were aged ≥ 65years. In the non -controlled OL trial MG0011, 57 of 200 participants (28.6%) were aged ≥ 65years (8 Sept data cut).

|                                            | Age 55-64 (Older subjects number /total number)   | Age 65-75 (Older subjects number /total number)   | Age 75+ (Older subjects number /total number)   |
|--------------------------------------------|---------------------------------------------------|---------------------------------------------------|-------------------------------------------------|
| Controlled Trials MG0010 N=45 MG0009 N=174 | 15/45 40/174                                      | 6/45 48/174                                       | 1/45 0/174                                      |
| Non Controlled trials MG0011 N=200         | 48/200                                            | 56/200                                            | 1/200                                           |

## 2.6.5.4. Analysis performed across trials (pooled analyses and meta-analysis)

## Overview

A Model-Informed Analysis was performed intended to estimate the maintenance of efficacy effect versus placebo for up to 24 weeks using indirect comparison through a Main-Analytical Approach and a set of sensitivity, supplementary and secondary analyses. The Main Analytical Approach of this Model-Informed Analysis was a 2-part combined analysis of 12-week double-blind data from MG0009, MG0010, 24-weeks data from MG0011 of patients initially randomised to ZLP in MG0010 within a Bayesian Framework using a linear model with log time.

Part 1 synthesised the information based on the summary data on PB response over time through a meta-regression model using aggregate data (SLR, MG-Registry, Thymectomy  Trial in NonThymomatous Myasthenia Gravis Patients Receiving Prednisone (MGTX)).

In Part 2, a combined Bayesian analysis of the MG0009 and MG0010 double-blind studies and of the MG0011 open-label extension was done, using the posterior distributions that resulted from the analysis in Part 1, as informative priors in this analysis - downweighed by 30% (to reflect the choice of model assumptions and to account for unexpected features (as compared to the features of external studies) of MG0009 and MG0010).

In summary, the analysis of the summary level data was combined with the IPD (individual patient data) through  a  Bayesian  framework  in  this  two-part  approach.  This  model  assumed  that  the  disease progression was similar over time in the PB and ZLP treatment groups.

<div style=\"page-break-after: always\"></div>

## Summary of methods

Multiple statistical methods were used to perform the model-informed analysis.

Regarding the external, historical data for placebo patients up to week 24, mixed models with repeated measures using an unstructured correlation structure (alt AR1) were used in patient-level data from external sources after using Inverse Probability Treatment Weighting (IPTW). Meta-regression on grouplevel data were applied to combine summary results from all external sources.

The primary analysis was a combined analysis of MG0009 and MG0010 within a Bayesian Framework using a linear model with log time based on down-weighted, informative priors from the analysis of external,  historical  data  of  placebo  patients  up  to  week  24.  This  model  assumed  that  the  disease progression was similar over time in the PB and ZLP treatment groups.

Bayesian statistics provided a formal mathematical method for combining prior information with current information observed in the clinical trial.  This  combined-studies analysis consisted of two parts; the meta-regression on PB summary data (sensitivity analyses were planned and included the use of vague prior) and the combined-IPD analysis informed by the results of the first part.

Part 1 synthesised the information based on the summary data on PB response over time through a meta-regression model using aggregate data. The outcome of this Bayesian meta-regression was the posterior distribution of the model parameters: the overall mean response (intercept), the slope of the response over time and the baseline effect.

In  Part  2,  a  combined  Bayesian  analysis  of  the  MG0009  and  MG0010  studies  was  done,  using  the posterior distributions that resulted from the analysis in Part 1, as informative priors in this analysis. In other words, the analysis of the summary level data was combined with the IPD through the Bayesian framework in this two-part approach.

## Primary results

At Week 24 the mean estimation of a population treatment effect for ZLP over placebo was -2.60 (95% CrI: [-3.70; -1.50]) on the MG-ADL scale as the primary endpoint. The probability that the posterior mean change from baseline in MG-ADL at Week 24 in zilucoplan is lower than the posterior mean CFB in MG-ADL in placebo was &gt; 99.9%. The probability that the difference in posteriors mean CFB in MG-ADL between  zilucoplan  and  placebo  is  lower  than  the  clinically  meaningful  threshold  of  -2  was  85.8%. Moreover, the Main-Analytical Approach produced Week 12 results that were consistent the significant results observed in MG0010 when using all data through 24 weeks.

## Sensitivity analysis, secondary analysis, supplemental analysis

A  wide  range  of  sensitivity,  supplementary  and  secondary  analyses  were  planned  to  assess  the robustness of the results to all the assumptions made in the primary analysis (historical or vague prior, confidence in the prior if use of historical prior, use of long-term data or not, statistical model used to fit the data, etc.). According to the applicant, all analyses gave results that are consistent with the primary analysis.

## 2.6.5.5. Supportive study

## Study MG0011

MG0011  is  an  ongoing,  multicentre,  open-label  extension  study  evaluating  the  long-term  safety, tolerability, and efficacy of ZLP in study participants with gMG who previously participated in a parent ZLP  study  (i.e.,  MG0009  or  MG0010).  To  be  eligible,  subjects  had  to  have  successfully  completed participation in a parent study. All subjects received ZLP 0.3mg/kg administered SC at the Day E1 Visit.

<div style=\"page-break-after: always\"></div>

Study  participants  or  caregivers  were  then  instructed  to  self-inject  daily  SC  doses  of  IMP  for  the subsequent doses. Weight-bracketed dosing strategy as in study MG0010 was applied.

The  primary  endpoint  pertained  to  safety.  Secondary  endpoints  were  MG-ADL,  QMG,  MGC  and  MGQOL15r.

It was expected that approximately 200 subjects would be enrolled from the parent studies, MG0009 and MG0010.

## Efficacy analysis

No statistical testing was planned. Changes from Baseline to Week E12 in MG-ADL score and QMG score were estimated using a MMRM ANCOVA with baseline MG-ADL score, baseline QMG score, geographical region, parent study factor, and baseline MG-ADL score-by-visit as fixed effects, and study participant as a random effect.

The MMRM ANCOVA included Week 1 to Week 12 (double-blind [parent study] Treatment Period) and Week E1 to Week E12 (open label [MG0011] Treatment Period) for groups of PB/ZLP 0.3mg/kg and ZLP 0.3/ZLP 0.3mg/kg. Separate models were fitted for each group.

The LSM of placebo/ZLP 0.3mg/kg and ZLP 0.3/ZLP 0.3mg/kg have been reported for all visits along with corresponding 2-sided 95% CIs. Statistical outputs such as LSM, and CI from Week 1 to Week E12 have been plotted in graphs.

Time to receive rescue therapy over the open-label treatment period was analysed as time-to-event, using Kaplan-Meier plots.

Missing total scores of QMG, MG-ADL, MGC, and MG-QOL15r were not imputed. In addition, data after rescue medication were not imputed.

The ITT Population was to include all enrolled subjects. The mITT Population was to include all subjects in the ITT population who had received study drug and had at least 1 post-dosing MG-ADL score.

Analyses were based on the randomised treatment in the parent study (i.e., MG0009 or MG0010) and the planned treatment in MG0011 (i.e., ZLP 0.3mg/kg) and have been displayed in summaries as follows:

- PB/ZLP 0.1/0.3mg/kg
- PB/ZLP 0.3mg/kg
- ZLP 0.1/ZLP 0.1/ZLP 0.3mg/kg
- ZLP 0.3/ZLP 0.3mg/kg
- All ZLP doses

## Results

At the time of the clinical data cut-off, 199 study participants had been enrolled in MG0011. This included study participants who transitioned from MG0009 and all study participants who completed MG0010, with the exception of 1 study participant whose data is not included in the clinical data cut-off, because having entered MG0011 after the clinical data cut-off for this interim case study report.

Of the 199 study participants enrolled in the study, 158 study participants (79.4%) had completed the Week E12 Visit, although they may have remained ongoing.

<div style=\"page-break-after: always\"></div>

Table 26: Disposition and discontinuation reasons (ITT Population) MG0011

| Category                                                    | Placebo/ZLP 0.1mg/kg/ 0.3mg/kg N=5 n (%)   | Placebo/ ZLP 0.3mg/kg N=90 n (%)   | ZLP 0.1mg/kg/ ZLP                  | ZLP 0.1mg/kg/ ZLP                  | All                                | ZLP                                |
|-------------------------------------------------------------|--------------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|
|                                                             |                                            |                                    | 0.1mg/kg/ 0.3mg/kg N=12 n (%)      | 0.3mg/kg/ 0.3mg/kg N=92 n (%)      | doses N=199 (%)                    | n                                  |
| Entered MG0011                                              | 5 (100)                                    | 90 (100)                           | 12 (100)                           | 92 (100)                           | 199 (100)                          |                                    |
| Completed MG0011 Week E12                                   | 5 (100)                                    | 68 (75.6)                          | 12 (100)                           | 73 (79.3)                          | 158 (79.4)                         |                                    |
| Ongoing                                                     | 4 (80.0)                                   | 74 (82.2)                          | 11 (91.7)                          | 84 (91.3)                          | 173 (86.9)                         |                                    |
| Discontinued                                                | 1 (20.0)                                   | 16 (17.8)                          | 1 (8.3)                            | 8 (8.7)                            | 26 (13.1)                          |                                    |
| Primary reason for discontinuation                          | Primary reason for discontinuation         | Primary reason for discontinuation | Primary reason for discontinuation | Primary reason for discontinuation | Primary reason for discontinuation | Primary reason for discontinuation |
| Adverse event                                               | 0                                          | 4 (4.4)                            | 0                                  | 0                                  | 4 (2.0)                            |                                    |
| Withdrawal by study participant                             | 0                                          | 7 (7.8)                            | 1 (8.3)                            | 0                                  | 8 (4.0)                            |                                    |
| Physician decision                                          | 0                                          | 3 (3.3)                            | 0                                  | 2 (2.2)                            | 5 (2.5)                            |                                    |
| Death                                                       | 0                                          | 1 (1.1)                            | 0                                  | 4 (4.3)                            | 5 (2.5)                            |                                    |
| Safety reasons as determined by the Investigator or Sponsor | 0                                          | 1 (1.1)                            | 0                                  | 0                                  | 1 (0.5)                            |                                    |
| Other                                                       | 1 (20.0)                                   | 0                                  | 0                                  | 2 (2.2)                            | 3 (1.5)                            |                                    |

## Efficacy outcomes

The LSM differences between Week E12 and Week 12 in the ZLP 0.3/ZLP 0.3mg/kg and PB/ZLP 0.3mg/kg treatment  groups  were  -2.25  (-3.41,  -1.10)  and  -3.39  (-5.85,  -0.93),  respectively,  showing  further reduction in MG-ADL score in both groups after Week 12 and the continued benefit of ZLP treatment.

<div style=\"page-break-after: always\"></div>

Table 27: Change from parent study baseline to week E12 in MG-ADL score (mITT Population [MMRM ANCOVA]) MG0011

| Visit Statistic                                         | Placebo/ ZLP 0.3mg/kg N=90   | ZLP 0.3/ 0.3mg/kg N=92   |
|---------------------------------------------------------|------------------------------|--------------------------|
| Week 12, n                                              | 90                           | 92                       |
| Mean (SE)                                               | -2.93 (0.38)                 | -4.79 (0.40)             |
| Median                                                  | -3.00                        | -5.00                    |
| Min, max                                                | -14.0, 4.0                   | -13.0, 4.0               |
| LS mean (SE)                                            | -2.93 (0.70)                 | -4.05 (0.54)             |
| 95% CI                                                  | [-4.31, -1.56]               | [-5.11, -2.98]           |
| Week E12, n                                             | 69                           | 71                       |
| Mean (SE)                                               | -6.22 (0.49)                 | -6.14 (0.43)             |
| Median                                                  | -6.00                        | -6.00                    |
| Min, max                                                | -14.0, 3.0                   | -15.0, 2.0               |
| LS mean (SE)                                            | -6.32 (0.84)                 | -6.30 (0.58)             |
| 95% CI                                                  | [-8.00, -4.65]               | [-7.44, -5.15]           |
| Difference between Week E12 versus parent study Week 12 | -3.39                        | -2.25                    |
| 95% CI                                                  | [-5.85, -0.93]               | [-3.41, -1.10]           |
| p-value a                                               | 0.0075                       | 0.0002                   |

a) The LSM difference presented was Open-Label Extension Weeks vs Double Blind Week in the parent study in MG0011.

Figure 13: Change from parent study baseline to week E12 in MG-ADL score (mITT Population) MG0011

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 28: Change from parent study baseline to week E12 in QMG, MGC and MG-QOL15r score (mITT Population [MMRM ANCOVA]) MG0011

| Visit Statistic                                         | Placebo/ ZLP 0.3mg/kg N=90 ZLP N=92   | 0.3/0.3mg/kg     |
|---------------------------------------------------------|---------------------------------------|------------------|
| Week 12 QMG , n                                         | 89                                    | 91               |
| LS mean (SE)                                            | -3.20 (0.82)                          | -7.04 (0.74)     |
| 95% CI                                                  | [-4.82, -1.58]                        | [-8.51, -5.58]   |
| Week E12, n                                             | 68                                    | 69               |
| LS mean (SE)                                            | -8.52 (1.19)                          | -8.87, (0.73)    |
| 95% CI                                                  | [-10.89, -6.16]                       | [-10.31, -7.42]  |
| Difference between Week E12 versus parent study Week 12 | -5.33                                 | -1.82            |
| 95% CI                                                  | [-8.54, -2.12]                        | [-3.60, -0.04]   |
| p-value                                                 | 0.0014                                | 0.0450           |
| Week 12 MGC , n                                         | 89                                    | 91               |
| LS mean (SE)                                            | -7.56 (1.39)                          | -9.34 (1.02)     |
| 95% CI                                                  | [-10.31, -4.81]                       | [-11.36, -7.32]  |
| Week E12, n                                             | 68                                    | 69               |
| LS mean (SE)                                            | -12.57 (1.70)                         | -11.92 (1.02)    |
| 95% CI                                                  | [-15.94, -9.20]                       | [-13.94, - 9.89] |
| Difference between Week E12 versus parent study Week 12 | -5.01                                 | -2.58            |
| 95% CI                                                  | [-10.07, 0.05]                        | [-5.21, 0.06]    |
| p-value                                                 | 0.0525                                | 0.0550           |
| Week 12 MG-QOL15r , n                                   | 88                                    | 90               |
| LS mean (SE)                                            | -2.36 (1.12)                          | -5.72 (1.10)     |
| 95% CI                                                  | [-4.56, -0.15]                        | [-7.89, -3.54]   |
| Week E12, n                                             | 68                                    | 68               |
| LS mean (SE)                                            | -8.52 (1.64)                          | -9.06 (1.12)     |
| 95% CI                                                  | [-11.76, -5.27]                       | [-11.28, -6.84]  |
| Difference between Week E12 versus parent study Week 12 | -6.16                                 | -3.35            |
| 95% CI                                                  | [-10.13, -2.19]                       | [-5.67, -1.02]   |
| p-value                                                 | 0.0027                                | 0.0053           |

In  the  ZLP  0.3/ZLP  0.3mg/kg  treatment  group  and  the  PB/ZLP  0.3mg/kg  treatment  group,  4  study participants (4.3%) and 3 study participants (3.3%), respectively, received rescue therapy from MG0011 Baseline through Week E12.

<div style=\"page-break-after: always\"></div>

## Subgroup analyses

Table 29: Subgroup analysis of change from MG0011 baseline to week E12 in MG-ADL. QMG, MGC and MG-QOL15r (mITT Population)

| Subgroup Category                 | Placebo/ ZLP 0.3mg/kg N=90        | Placebo/ ZLP 0.3mg/kg N=90   | ZLP 0.3/ 0.3mg/kg N=92   | ZLP 0.3/ 0.3mg/kg N=92   |
|-----------------------------------|-----------------------------------|------------------------------|--------------------------|--------------------------|
|                                   |                                   | Mean CfB (SD)                | n                        | Mean CfB (SD)            |
| Overall MG-ADL CFB at Week E12 69 | Overall MG-ADL CFB at Week E12 69 | -3.19 (3.86)                 | 71                       | -1.20 (2.90)             |
| Age                               |                                   |                              |                          |                          |
| <65 years                         | 47                                | -3.57 (4.31)                 | 54                       | -1.15 (3.25)             |
| ≥65 years                         | 22                                | -2.36 (2.56)                 | 17                       | -1.35 (1.37)             |
| Baseline MG-ADL                   |                                   |                              |                          |                          |
| ≤9                                | 46                                | -1.76 (2.39)                 | 59                       | -0.56 (2.16)             |
| ≥10                               | 23                                | -6.04 (4.66)                 | 12                       | -4.33 (4.01)             |
| Baseline QMG                      |                                   |                              |                          |                          |
| ≤17                               | 49                                | -2.43 (2.67)                 | 56                       | -0.50 (2.15)             |
| ≥18                               | 20                                | -5.05 (5.50)                 | 15                       | -3.80 (3.84)             |
| Overall QMG CFB at Week E12       | 68                                | -3.74 (4.86)                 | 69                       | -1.65 (3.33)             |
| Age                               |                                   |                              |                          |                          |
| <65 years                         | 46                                | -4.24 (5.30)                 | 53                       | -1.51 (3.50)             |
| ≥65 years                         | 22                                | -2.68 (3.68)                 | 16                       | -2.13 (2.75)             |
| Baseline MG-ADL                   |                                   |                              |                          |                          |
| ≤9                                | 45                                | -2.80 (3.06)                 | 58                       | -1.34 (3.32)             |
| ≥10                               | 23                                | -5.57 (6.92)                 | 11                       | -3.27 (3.04)             |
| Baseline QMG                      |                                   |                              |                          |                          |
| ≤17                               | 48                                | -2.69 (3.20)                 | 56                       | -1.07 (3.06)             |
| ≥18                               | 20                                | -6.25 (6.97)                 | 13                       | -4.15 (3.41)             |
| Overall MGC CFB at Week E12       | 68                                | -5.71 (7.27)                 | 69                       | -2.78 (5.29)             |
| Age                               |                                   |                              |                          |                          |
| <65 years                         | 46                                | -6.63 (8.04)                 | 53                       | -2.62 (5.51)             |
| ≥65 years                         | 22                                | -3.77 (4.93)                 | 16                       | -3.31 (4.60)             |
| Baseline MG-ADL                   |                                   |                              |                          |                          |
| ≤9                                | 45                                | -3.47 (4.19)                 | 58                       | -2.10 (4.95)             |
| ≥10                               | 23                                | -10.09 (9.77)                | 11                       | -6.36 (5.80)             |
| Baseline QMG                      |                                   |                              |                          |                          |
| ≤17                               | 48                                | -4.25 (4.86)                 | 56                       | -1.64 (4.48)             |
| ≥18                               | 20                                | -9.20 (10.48)                | 13                       | -7.69 (5.88)             |
| Overall MG-QOL15r CFB at Week E12 | 68                                | -4.96 (6.25)                 | 68                       | -2.63 (6.13)             |
| Age                               |                                   |                              |                          |                          |

<div style=\"page-break-after: always\"></div>

| <65 years       | 46   | -6.11 (6.82)   | 52   | -2.77 (6.55)   |
|-----------------|------|----------------|------|----------------|
| ≥65 years       | 22   | -2.55 (4.02)   | 16   | -2.19 (4.68)   |
| Baseline MG-ADL |      |                |      |                |
| ≤9              | 45   | -3.76 (4.74)   | 57   | -1.74 (5.06)   |
| ≥10             | 23   | -7.30 (8.09)   | 11   | -7.27 (8.97)   |
| Baseline QMG    |      |                |      |                |
| ≤17             | 48   | -4.38 (5.69)   | 55   | -1.82 (5.32)   |
| ≥18             | 20   | -6.35 (7.41)   | 13   | -6.08 (8.16)   |

## 2.6.6. Discussion on clinical efficacy

## Efficacy at 12 weeks in the main study MG0010

## Study participants

Study MG0010, the single pivotal phase 3 study, was a randomised double-blind placebo-controlled study comparing the efficacy of ZLP 0.3mg/kg with placebo. Patients included were to be Acetylcholine-receptor antibody positive, MGFA class II-IV, have at least an MG-ADL score of 6 and a QMG score of at least 12 with a score of at least 2 in at least 4 items. The requirements of the disease manifestations are strict and decreases the proportion of patients with mild disease. This can be seen in the baseline disease characteristics where more than 70% of participants had at least moderate weakness according to the MGFA classification, mean MG-ADL was 10.6 and mean QMG was 19.1.

For comparison, the baseline QMG ranged between 8.5 and 19.4 in the 27 MG studies analysed in the systematic literature report submitted by the applicant. The highest QMG score (19.4) was reported in a study by Liu et al (2010) and in the PB group of Study MG0010. The cohort of patients selected from the MG-registry for the external reference of study MG0011 (requirement of baseline MG-ADL ≥ 6), had a baseline QMG of 12.9 and baseline MG-ADL 7.4 before using Odds Weighting. The two cohorts from the MGTX study included in the modelling for the reference group, had an index mean QMG of 13.7 and mean MG-ADL of 8.0 before using Odds Weighting.

## Patients with MGFA class V were excluded.

## Sample size

The  initially  planned  enrolment  was  approximately  130  subjects  (65  subjects  per  arm)  assuming  a difference between treatment arm in CBL in MG-ADL score week 12 of 2.3. With global amendment 1 (CSP  version  2.0,  18  December  2020)  the  total  sample  size  was  increased  to  account  for  a  higher variability (standard deviation 3.7) in the primary endpoint than what had originally been assumed (3.4). The new sample size calculation implied a total sample size of 156 subjects (78 per treatment arm). No update or sample size re estimation (blinded or unblinded) had been pre-planned and no further details had been found shedding any light on what caused variability considerations. The Applicant clarified that no data from the study will have been used or known. Instead, the applicant will have conducted a literature review. The reason appears to have been a sanity check after the Ra Pharma acquisition.

Subjects who prematurely discontinued participation prior to the Day 84 visit may have been replaced. A similar approach was planned in the phase 2 study MG0009 (see below) and is not endorsed. Contrary phase 2 sample size, the study MG0010 sample size will have been accounted for not only an assumed dropout rate but also that approximately 5% of subjects were expected to use rescue. Details were lacking, and the applicant was requested to clarify whereafter the applicant confirmed that replacement

<div style=\"page-break-after: always\"></div>

had  been  allowed  as  per  study  MG0010  protocol  but  that  no  replacement  of  discontinued  study participants occurred.

In the end, more subjects (N=174) than planned within amendment 1 (N=156) were randomised into the study. Contrary to the applicant's statement in connection with the same 'issue' in the phase 2 study, no explanation had been offered for the phase 3 study. As was clarified by the applicant, this will have been due to the many sites recruiting patients, the safety margin applied before closure of screening to ensure the randomisation of at least 156 participants and, in the end, a slightly lower screen failure rate than initially expected.

## Randomisation and masking/blinding

Except for what currently appears to have been a protocol-defined opportunity to replace randomised subjects dropping out early, the randomisation procedure seems  to have been appropriate. Randomisation was performed using a 1:1 allocation ratio and subjects were stratified based on baseline MGADL Score (≤9 versus ≥10), QMG Score (≤17 versus ≥18), and geographical region (North America, Europe, and Japan).

Study MG0010 was to be performed under double-blind conditions. Subjects and study staff was to remain blinded to treatment assignments until after database lock and unblinding of data. Dosing was weight-based and according to the SmPC, there are three zilucoplan presentations implying pre-filled syringes of 0.416 mL, 0.574 mL, and 0.810 mL each containing a different amount of zilucoplan sodium. Matching placebo for the 0.3 mg/kg dose was to be provided in one presentation (0.574 mL). However, it had not been confirmed that active treatment was also to be provided in one presentation of 0.574 mL or if not, what other means were in place to achieve masking of treatments, e.g., whether the pre-filled syringes were in any way covered. Considering that primary and secondary endpoints relied on patient and  physician  reported  outcomes  success  in  concealment  of  treatment  assignment  is  vital  and  the applicant was requested to clarify. The initially missing piece of information will have been that to blind study  participants  and  site  personnel  to  the  small  differences  in  volumes/plunger  positions,  safety syringes were wrapped with a label which fully masked the prefilled syringe cartridge. Few subjects discontinued the study (&lt;5%) and not that many subjects needed rescue therapy although more subjects in the placebo group than in the zilucoplan group. This could be considered as one piece of evidence that masking of treatments was successful and maintained throughout the double-blind study period.

## Statistical analysis plan

Zilucoplan was initially developed by Ra Pharmaceuticals, Inc. (Ra Pharma), which was acquired by UCB on 02 Apr 2020. This may explain some of the changes introduced with the CSP version 2 as well as the changes made to the original SAP (approved 6 Nov 2019). There was one global amendment to the CSP forming protocol version 2.0 which led to SAP amendment 1 (01 Feb 2021). In total, there have been five amendments to the SAP, all of which have been submitted including a revision history. The last SAP version (version 5.0) was dated 06 Dec 2021.

For the definition of the primary estimand, three ICE had been identified all of which initially were to be considered using a hypothetical strategy. With SAP amendment 4 (dated 13 Oct 2021), the primary estimand was revised, and the definition of ICE was slightly amended (based on regulatory feedback (FDA)). Also, the strategy changed such as rescue therapy (ICE1), death and MG crisis (ICE2) were to be seen as treatment failures. This could be agreed. Study discontinuation for reasons other than death or a MG crisis (ICE3), was to be handled applying a hypothetical strategy which is considered aligned with the statistical analysis model based on an MMRM ANCOVA and for which monotone missing after ICE3 was considered MAR. This is seldom an appropriate assumption and concerned here for example study discontinuations due to an adverse event (AE).

<div style=\"page-break-after: always\"></div>

The approach to handle missing or censored data in case of rescue, death or an MG crisis was imputation of baseline or last available assessment (including unscheduled visits) whichever was worst.

The number of subjects with an ICE was 11/88 (12.5%) in the placebo arm and 6/86 (7.0%) in the zilucoplan arm. The most common ICE was use of rescue therapy concerning 10/11 subjects (placebo) and 4/6 subjects (zilucoplan) with an ICE. One subject in each arm died. Two subjects in the zilucoplan arm, none in the placebo arm, discontinued the study due to an AE. According to the presentation of ICEs, it was only one subject (zilucoplan) who experienced an event falling into the category ICE3.

In each treatment arm it was less than 5% of the subjects who did not complete the study: 4/88 (4.5%): placebo and 4/86 (4.7%): zilucoplan. The number of subjects with intermittently missing MG-ADL total scores (not attributed to an ICE) differed slightly across visits and comparing treatments but raise no major concern.

The primary efficacy analysis set was the mITT. The intention excluding subjects who did not receive any treatment or who did not provide any postbaseline efficacy assessment is not supported but since all randomised subjects were included in the mITT there is no need to pursue this further.

Besides the primary estimand, several supplementary and sensitivity analyses had been planned. Not all are agreed as sufficiently challenging but can be agreed to represent slightly different assumptions. Among the latter was the primary analysis repeated using J2R: among the former a treatment policy estimand where all data were to be used regardless of any ICE (i.e., data after rescue use was not censored).  Both  are  appreciated  and  both  showed  outcomes  not  that  dissimilar  compared  with  the primary  endpoint  primary  analysis.  Estimated  treatment  differences  were  slightly  smaller  but  (still) statistically significant. However, in the treatment policy analysis, any missing MG-ADL score was to be handled assuming MAR. It may be that not that many had missing scores week 12 but an additional treatment policy analysis without relying only on the MAR assumption was requested. This analysis (using J2R and assuming missing not at random) confirmed the outcome of the primary analysis of the primary endpoint.

In addition, the applicant has confirmed that none of the study participants in the mITT population who received rescue therapy discontinued the study; therefore, all were followed after initiation of rescue therapy.

Within SAP amendment 3 (17 June 2021) the multiplicity strategy for secondary endpoints was modified justified by the small number of events expected for the secondary endpoints in the lowest part of the hierarchy.  The  revision  of  the  multiple  testing  procedure  (MTP)  implied  the  implementation  of  two families of secondary endpoints where endpoint 1-3 with order of appearance kept, formed family 1 defined as key secondary endpoints that was to be tested in a fixed sequential order. Secondary efficacy endpoints 4-7 was then to form family 2 with multiplicity to be controlled with Holm's procedure using a gatekeeping approach. The modified version of the MTP is per se not objected to but since changed rather late into the study, and since it implied that not all of the secondary endpoints defined as forming family 2 failed, as will have been the case had the original version been kept, and since study MG0010 serves as the only confirmatory study submitted, the applicant was requested to provide more details on the process and what triggered the considerations leading to the modification of the testing strategy. During the procedure, not much new information was provided. The applicant claimed that for Family 2, including the last 4 secondary endpoints of the testing strategy (i.e., time to rescue therapy, achieving MSE (minimal symptom expression), MG-ADL response without rescue therapy, QMG response without rescue therapy), there was less clinical rationale to justify the hierarchy. In addition, as described also in the SAP, only a small number of events were expected for the secondary endpoints forming Family 2. The reasons are per se undisputable. The Ra Pharma acquisition is mentioned, however, if the change in the MTP was to pass as part of a sanity check of the SAP, it could have been expected to have been

<div style=\"page-break-after: always\"></div>

implemented earlier. However, no new concern has been raised. Importantly, and as also pointed out by the applicant, the revised MTP was implemented 7 months prior to unblinding.

The primary analysis of the study was performed when all subjects had completed the double-blind 12week treatment period. Database lock occurred on 18 Jan 2022.

## Primary efficacy endpoint

The effect of ZLP 0.3 mg/kg started early as measured with CBL in MG-ADL. A numerical difference between the placebo group and the ZLP group was seen already at week 1. The effect of PB and of ZLP stabilised after approximately four weeks with a steady difference up to week 12 at primary endpoint assessment.  A  statistically  significant  difference  to  PB  in  CBL  of  -  2.09  (p&lt;0.001)  was  found.  All sensitivity analyses showed highly significant treatment difference between PB and ZLP of slightly more than 2 points, which has been found clinically relevant (Muppidi et al, Muscle Nerve 44: 727-731, 2011).

## Secondary efficacy endpoints

As the primary efficacy endpoint, CBL in MG-ADL, is a score based on subjective change according to the study participant, the first secondary endpoint, CBL in QMG, is important as it is the result of a physical  examination  under  controlled  circumstances.  What  can  be  regarded  as  a  clinically  relevant change in QMG has been stated in the literature. Bahron et al 1998 found that a treatment must produce more than 2.6 units of QMG change to be of clinical significance. QMG score changes of up to 2.6 units are expected to occur due to variability of repeated observations. Katzberg et al 2014 concluded that the  minimal  clinically  important  difference  depends  on  baseline  QMG  and  if  QMG&gt;16,  the  minimal clinically important difference should be -2.75. According to MGFA, recent data support the use of a 2or 3- point of change in QMG as a criterion for minimal clinically significant change and depending on MG  severity;  in  mild  (QMG  0-9)  to  moderate  disease  (QMG  10-16),  a  2-point  change  is  clinically significant and a 3-point change is significant for severe MG (QMG &gt;16) (https://myasthenia.org/Professionals/Resources-for-Professionals  Jan  8,  2023).  The  result  of  Study MG0010 with a CBL and compared to PB of -2.94 (p&lt;0.001), can thus be regarded as clinically relevant in the studied population.

The  secondary  efficacy  endpoints  MGC  and  MG-QOL15r  further  support  the  efficacy  of  ZLP  with statistically  significant  results  at  12  weeks  in  the  studied  population  with  CFB  of  -3.20  and  -2.49 respectively.

The  maximal  improvement  was  obtained  during  the  first  4  to  8  weeks  of  treatment.  However,  a substantial number of study participants requires longer durations of treatment to respond, and it is therefore not possible to recommend a specific time period at which discontinuation of treatment should be considered in case of no or weak response to treatment.

## Supportive data from Study MG0009, efficacy at week 12

The phase II 12-week randomised DB placebo-controlled dose-finding study MG0009 investigated two ZLP dose levels (0.1 mg/kg and 0.3 mg/kg). Inclusion and exclusion criteria were similar to the phase III trial MG0010 and the included participants had similar baseline characteristics. Efficacy endpoints were assessed as CFB at 12 weeks with QMG as the primary endpoint. The sample size was very limited: based on the assumptions made, 12 subjects per arm were required and subjects who discontinued prior to  the  day  84  visit  could  be  replaced.  In  the  end,  45  instead  of  36  subjects  were  randomised  and according to the applicant the reason for this was 2-fold whereof one of the explanations will have been the fact that subjects could be replaced. This is not endorsed. Upon request, the applicant confirmed that although replacement was allowed per the study protocol, no replacement of discontinued study participants occurred. Blinding of randomised treatment was to be achieved using matching placebo. However, it remained to be confirmed that prefilled syringes matched irrespective of active dose-level

<div style=\"page-break-after: always\"></div>

or placebo. What appears to initially have been the missing piece of information was that to blind study participants and site personnel to the small differences in volumes/plunger positions, safety syringes were wrapped with a label which fully masked the prefilled syringe cartridge.

The primary analysis of the primary endpoint was the comparison between the 0.3 mg/kg zilucoplan group and the placebo group: the comparison versus the lower dose (0.1 mg/kg) and placebo was described as a secondary endpoint. There were no formal multiplicity considerations. In case of data missing last-observation-carried-forward was used. Testing was planned and performed using a onesided 0.10 significance level and outcomes were presented with two-sided 80% CIs.

For the primary and important secondary endpoints, 95% CIs was requested. The applicant provided new estimates and as could be expected, all 95% CIs included 0.

CBL in in the ZLP 0.3 mg/kg compared to placebo after 12 weeks was MG-ADL -2.3 (95% CI: -4.9, 0.3) , QMG -2.8 (95% CI: -6.3, 0.6), MGC -4.1 (95% CI: -8.6, 0.5 ) and MG-QOL15r -3.7 (95% CI: -8.6, 1.1).  Despite  a  lack  of  scientific  stringency,  these  results  may  lend  some  support  to  the  findings  of MG0010.

## Supportive data from Study MG0011, efficacy at week 12

Study MG0011 was an open label phase III study which included participants who had completed either of studies MG0009 or MG0010. As there is no PB control and participants knew that they received ZLP 0.3mg/kg,  efficacy  data  cannot  be  directly  compared  to  the  other  results  but  contribute  with  some information of interest. With conservative imputation participants who received ZLP in study MG0011 but had received PB in parent study MG0010, decreased their LSM MG-ADL score with 2.87 points after 12 weeks of ZLP treatment. In study MG0010 (ZLP treated participants) the CBL not corrected for the PB effect was -4.68. Corresponding data for QMG were MG0011 -3.77 and MG0010 -6.48, MCG MG0011 -5.56 and MG0010 -8.85, MG-QOL15r MG0011 -4.54 and MG0010 -6.21. These 12-week data support the findings of study MG0010.

## Main efficacy issues

## Study population

Inclusion criteria of studies MG009 and MG0010 for baseline disease severity were partly the same as in the studies of other recently approved products in gMG for MGFA (class II-IV) and MGADL (≥6), but the ZLP studies had two additional requirements: QMG ≥12 and at least a score of 2 in at least 4 items. These distort the study population towards the moderate-severe part of the disease severity distribution. Enrichment of patients displaying more signs and symptoms in order to increase the range of possible improvement in a clinical trial, may be acceptable. In the pivotal MG0010 a patient population with more disease manifestations than usually seen in gMG under standard of care has been enriched and patients with mild disease based on QMG, has not been included. This can be seen when comparing to baseline data of other clinical trials in the literature (please see above). Compared to recently approved medicinal products  in  gMG,  the  population  in  MG0010  is  most  similar  to  the  one  used  in  the  pivotal  trial  of eculizumab (EMA/410939/2017). Mean baseline QMG in study MG0010 is higher than in the pivotal trials of ravulizumab and efgartigimod (19.1, compared to 14.6 and 15.9, respectively) (EMA/686052/202, EMA/641081/2022).

In subgroup analyses of study MG0010, which should be interpreted with caution, there was a pattern of smaller magnitude of efficacy in participants with a milder disease. This pattern was also seen in the OL Study MG0011, with the largest difference between patients with mild and moderate-severe disease in participants assessed after the longer treatment duration of 24 weeks. Post hoc subgroup analyses used data imputation (scores after rescue therapy or any death or myasthenic crisis were imputed based on baseline score or on the last available score, whichever was worst, other missing scores, including

<div style=\"page-break-after: always\"></div>

discontinuation, were handled under the MAR assumption) in contrast to the original subgroup analyses. In explored subgroups (based on MG-ADL at baseline, QMG at baseline and MGFA at baseline), no clear correlation  was  observed  between  the  effect  size  (CBL,  responder  rate)  of  zilucoplan  and  disease severity. Efficacy can be extrapolated to patients not included in the pivotal study population (QMG &lt;12, still symptomatic despite standard of care), as it is considered that efficacy can be extrapolated based on the mechanism of action with reduced complement dependent cytotoxicity. This indication is also in line with of other authorised gMG products.

## Study duration

The DB phase of studies MG0009 and MG0010 was 12 weeks. Pivotal trials in gMG for other products, including products with similar mechanism of action, have all used at least 24 weeks for the controlled phase followed by an OL. This was also the advice given by the CHMP (EMEA/H/SA/3949/2/2019/SME/III)  and  the  recommendation  to  include  a  24-weeks  double-blind placebo-controlled period in the pivotal trial in order to demonstrate maintenance of effect and longterm  safety,  was  reiterated  in  the  follow  up  advice  EMEA/H/SA/3949/2/2019/SME/III.  In  a  national scientific  advice  meeting  with  the  Swedish  Medicinal  Products  Agency  in  November  2021,  it  was acknowledged that while there are no FDA nor EMA regulatory guidelines for drugs in the development for gMG, there is precedence of approved drugs with a study duration longer than 12 weeks. Longer studies  can  be  conducted  without  ethical  issue  as  patients  in  the  placebo  (PB)  group  are  receiving standard of care and it appears there are a sufficient number of patients to be included in a 24-week study. MPA raised the question if a 12-week study would be of sufficient duration, given that myasthenia gravis fluctuates over time and that a sufficient number of measurements of primary and secondary endpoints of MG-ADL and QMG will be needed to capture a difference over time vs placebo.

## 24 weeks and 60 weeks efficacy data MG0011

Participants who were treated with ZLP for 24 weeks improved their MG-ADL from the original baseline to week E12 and numerically from week 12 to week E12. The MG-ADL change between MG0010 baseline and week E12 (i.e. 24 weeks) with conservative imputation was -5.33 which is slightly larger than the result at week 12 (i.e. 12 weeks), -4.68, implying a difference of -0.65 points. Secondary endpoints QMG, MGC and MG-QOL15r, all showed numerically slight improvement at 24 weeks, difference between week 12 and week E12 being -0.62, -1.06 and -1.85 respectively. These data together with analyses of other factors contributing to efficacy estimates, may support 24 weeks efficacy. However, longer-term treatment with ZLP is anticipated and the applicant was requested to provide more data. To support long-term  efficacy,  a  more  recent  snapshot  of  MG0011  was  taken  on  11  May  2023  and  descriptive analyses restricted to study participants coming from MG0010 were performed. As of the new snapshot, 85.5% (142/166) of former MG0010 study subjects had completed 48 weeks of active treatment and 18.1% (30/166) of the subjects had used rescue therapy in MG0011. Analyses based on observed data showed an increase in CBL comparing data from week 12 and week 48 interpreted as to probably be due to responders remaining on trial. In an analysis in which subjects who discontinued the study or used rescue  therapy  were  counted  as  treatment  failures  and  subjects  who  died  were  assigned  the  worst possible score from the time of death, similar results weeks 12 and 48 were obtained. Together, these data suggest sustained efficacy at a clinically relevant magnitude over time.

## 24 weeks efficacy data Extension portion of study MG0009

Participants who completed the main portion of MG0009 could enter the OLE portion. The first 24 weeks of active treatment include data at week 12 of the Extension portion of participants treated with ZLP in the Main portion, and data at week 24 of the Extension portion of participants treated with PB in the main portion. Thus, all participants analysed had the same duration (24 weeks) of active treatment. QMG CBL at week 24 was numerically larger, -7.50 than at 12 weeks (-6.0). Secondary endpoints (MGADL, MGC and MG-QOL15r) all showed numerically similar, or slightly larger improvement at 24 weeks.

<div style=\"page-break-after: always\"></div>

## Model informed analysis

To overcome the lack of PB control the last 12 weeks (i e the 12 weeks of the MG0011 OL study), the applicant tried to obtain a reference of what CBL can be expected in patients treated with standard of care  (the  treatment  given  the  PB  participants  in  studies  MG0009  and  MG0010)  for  24  weeks.  The applicant made substantial effort to find appropriate and representative subjects with similar disease and patient characteristics as those included in studied MG0009 and MG0010. These external, historical data included group-level data from a systematic literature review (SLR, 6 studies with approx. 312 placebo patients) and patient-level data from the Swedish MG-Registry (Cohort 1A: 16 patients) and the MGTX trial (SOCb and T+SOC: 53 patients). The performed primary analysis was considered appropriate and  the  performed  Bayesian  analysis  in  terms  of  statistical  modelling  and  model  diagnostics  are supported. Considering the multiple options of modelling decisions required in these complex analyses, the efforts of the applicant to be transparent and pre-specify the statistical methods is acknowledged.

The major issues of the presented results include the potential for different kinds of bias. The applicant addressed these issues by providing comprehensive sensitivity, supplemental and secondary analyses. Although these additional analyses were consistent with and, therefore, support the primary results, it is unclear to what degree potential residual bias from unmeasured or unknown confounders or deviations from model assumptions remains. Therefore, the provided evidence is in principle considered inferior relative to a corresponding double-blinded, randomised controlled study.

This  means,  while  the  arguments  for  a  non-random  (cf.  statistically  significant),  clinically  relevant difference between the treated groups at week 24 seem convincing, the causal inference explaining the observed differences between groups exclusively as a treatment effect is less so.

Predicted efficacy (CBL MG-ADL) at week 24 was -4.66. In study 0011, the MG-ADL CBL at week 24 was -6.30. Predicted PB CBL was -2.06. As the efficacy magnitude was not predicted correctly, this casts doubt on the modelled analysis and the reliability of the predicted PB effect and the PB free efficacy magnitude of MG-ADL CBL.

The mechanism of action and the known long-term efficacy of products approved in gMG with similar mechanism  of  action  (C5  inhibitors  eculizumab  and  ravulizumab),  may  increase  the  probability  of maintained efficacy with ZLP treatment. The applicant has provided further analyses and a discussion including justification why it could be expected that the efficacy of ZLP will be maintained at a clinically relevant  magnitude  during  60  weeks  of  treatment.  Potential  sources  of  error  such  as  responders remaining on trial, use of rescue treatment and prohibited medications, placebo effect and spontaneous disease fluctuations were discussed and it can be concluded that there is effect of ZLP at 60 weeks, even if the treatment efficacy cannot be isolated, and the true treatment efficacy cannot be separated from e.g., subject-expectancy effect or spontaneous disease fluctuations.

## Age and age at disease onset

In  study  MG0011,  at  12  weeks,  there  is  a  numerical  difference  with  smaller  efficacy  magnitude  in participants ≥ 65 years of age in the former PB participants. The difference is minor in the MG-ADL score, but quite evident in the secondary efficacy endpoints. In Study MG0010, elderly participants seemed to benefit less than younger only when looking at the quality-of-life score, MG-QOL15, where the elderly participants even improved more in the PB group than the ZLP group (with 1.34 points) while the younger participants treated with ZLP improved more compared to PB with 3.37 points. To understand this better, analyses based on age at disease onset were performed. Lately, the division info three subgroups based on age at onset has shown purposeful, early &lt;50, late ≥ 50 to &lt;65 years, very late ≥ 65 years) (CortésVicente et al, 2020). Efficacy analyses with conservative imputation show that participants with very late onset display a large placebo effect as measured with MG-ADL and QMG. This may be due to regression to the mean in a study of patients with a fluctuating disease and strict inclusion criteria (Benatar et al

<div style=\"page-break-after: always\"></div>

2012). Subgroup analyses should always be interpreted with caution, some variability and findings by chance are  expected  in  case  of  multiple  analyses.  Efficacy  resulting  from  inhibition  of  CDC  in  AchR antibody mediated disease, should however be the same regardless of age or age at onset. Most data point to a fair effect in elderly patients and in patients with late and very late onset of disease and a restriction to the indication is not justified.

The  estimated  efficacy  in  participants  who  at  baseline  were  classified  as  treatment  refractory,  was numerically larger than in participants not classified as refractory. This may partly be due to confounding; there may be a correlation between severe disease manifestation and being treatment refractory, and between severe disease manifestation and larger efficacy magnitude. Nevertheless, treatment refractory participants seem to benefit to a relevant extent from ZLP treatment.

## 2.6.7. Conclusions on the clinical efficacy

Efficacy of ZLP 0.3 mg/kg in the treatment of gMG in the studied patient population is clinically relevant and statistically highly significant at 12 weeks. The primary efficacy endpoint of the pivotal study is supported  by  results  from  studies  MG0009  and  MG0011,  sensitivity  analyses,  secondary  efficacy endpoints, pharmacodynamic studies and mechanism of action. Thus, the efficacy at 12 weeks in the studied population can be regarded as robust and compelling.

Analyses on the open label data from study MG0011 including analyses of responders remaining in the trial, placebo effect, effect due to expectations and disease fluctuations, have been sufficiently reported and the results may support efficacy for 24 weeks. Based on a new, a more recent snapshot of MG0011 (11 May 2023) and additional analyses restricted to subjects coming from MG0010, also longer term efficacy can be considered supported in that these data suggest sustained efficacy at a clinically relevant magnitude over time. As of the new snapshot, 85.5% (142/166) of former MG0010 study subjects had completed 48 weeks of active treatment.

Subgroup analyses on efficacy in patients included in MG0010 and MG0011 show similar efficacy in participants with milder and more severe disease, indicating that the efficacy may be sufficient in patients with even milder disease manifestations. The indication is not restricted to the pivotal study population, who had QMG ≥ 12 and at least four QMG items of at least score 2. The CHMP considers that efficacy can be extrapolated to patients with less severe disease but who are still symptomatic despite standard of care, based on mechanism of action with reduced complement dependent cytotoxicity, and safety profile is likely similar.

## 2.6.8. Clinical safety

## 2.6.8.1. Introduction

The evaluation of the safety of zilucoplan in the treatment of patients with gMG is based on data from the 3 studies included in this application.

In addition, zilucoplan has been investigated for use in immune mediated necrotizing myopathy (IMNM) and several other diseases, of which the similar disease characteristics of IMNM allowed for pooling of safety data with the phase 2 study from this development programme to enlarge the safety pool.

<div style=\"page-break-after: always\"></div>

## 2.6.8.2. Patient exposure

## Exposure and patient populations studied

A  total  of  213  study  participants  with  gMG,  have  received  zilucoplan  in  the  clinical  development programme as of the clinical cutoff date 18 Feb 2022, including 212 study participants at the proposed therapeutic dose of 0.3mg/kg. A total of 138 gMG study participants were exposed at least 6 months (137 study participants at 0.3mg/kg dose) and 91 gMG study participants exposed for more than a year (87 study participants at 0.3mg/kg dose). A total of 154 study participants have been exposed to ZLP for more than a year in any indication (gMG, IMNM, paroxysmal nocturnal haemoglobinuria [PNH], and amyotrophic lateral sclerosis [ALS]) including 150 study participants at the 0.3mg/kg dose level.

The safety evaluation for ZLP primarily utilised 4 pools:

- Pool S1A: 12-week placebo-controlled safety pool including data from the Phase 2 and Phase 3 study  in  gMG  (115  study  participants  in  the  ZLP  0.1mg/kg+0.3mg/kg  group  with  26.4 participant-years at risk).
- Pool S2A: 8/12-week placebo-controlled safety pool including data from the Phase 2 and Phase 3  study  in  gMG  and  the  Phase  2  study  in  IMNM  (127  study  participants  in  the  ZLP 0.1mg/kg+0.3mg/kg group with 28.3 participant-years at risk).
- Pool S1B: long-term safety pool with data on all ZLP-exposed participants in gMG, from the placebo-controlled  Phase  2  and  Phase  3  study  in  gMG  and  their  OLE  studies  (213  study participants in the All ZLP group with 262.4 participant-years at risk).
- Pool S2B: long-term safety pool with data on all ZLP-exposed participants in gMG and IMNM, from the placebo-controlled Phase 2 and Phase 3 studies in gMG and their OLE studies (238 study participants in the All ZLP group with 275.2 participant-years at risk).

The pools including only gMG study participants (Pool S1A and S1B) are considered the primary pools for analysis unless otherwise stated.

The number of study participants in the ZLP 0.1mg/kg treatment group was limited compared with the number of study participants in the placebo and ZLP 0.3mg/kg treatment groups in the pooled analyses. For the gMG studies, the ZLP 0.1mg/kg dose was only used in the Phase 2 study (MG0009).

## Demographics

For Pool S1B, the mean (SD) age of study participants at first study entry was 52.4 years (15.3), with most of the study participants (74.2%) in the age category 18 to &lt;65 years of age. The majority of study participants were female (55.4%) and white (74.6%). The mean body weight and mean body mass index (BMI) were 90.50kg and 31.3kg/m 2 .

<div style=\"page-break-after: always\"></div>

Table 30: IMP duration and participant years of time at risk for pool S1A and pool S1B

|                                         | Pool S1A (placebo-controlled period, gMG studies)   | Pool S1A (placebo-controlled period, gMG studies)   | Pool S1A (placebo-controlled period, gMG studies)   | Pool S1A (placebo-controlled period, gMG studies)   | Pool S1B (long-term, gMG studies including open-label)   | Pool S1B (long-term, gMG studies including open-label)   | Pool S1B (long-term, gMG studies including open-label)   |
|-----------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|
|                                         | Placebo N=103                                       | ZLP 0.1mg/kg N=15                                   | ZLP 0.3mg/kg N=100                                  | ZLP 0.1mg/kg+ 0.3mg/kg N=115                        | ZLP 0.1mg/kg N=22                                        | ZLP 0.3mg/kg N=212                                       | All ZLP N=213                                            |
| IMP duration (days)                     | IMP duration (days)                                 | IMP duration (days)                                 | IMP duration (days)                                 | IMP duration (days)                                 | IMP duration (days)                                      | IMP duration (days)                                      | IMP duration (days)                                      |
| n                                       | 103                                                 | 15                                                  | 100                                                 | 115                                                 | 22                                                       | 212                                                      | 213                                                      |
| Mean (SD)                               | 81.7 (12.2)                                         | 82.8 (2.3)                                          | 82.0 (10.6)                                         | 82.1 (9.4)                                          | 357.8 (88.4)                                             | 406.6 (360.6)                                            | 441.7 (412.0)                                            |
| Median                                  | 84.0                                                | 84.0                                                | 84.0                                                | 84.0                                                | 388.5                                                    | 280.5                                                    | 288.0                                                    |
| Min, max                                | 1, 96                                               | 77, 87                                              | 15, 94                                              | 15, 94                                              | 104, 476                                                 | 14, 1517                                                 | 14, 1517                                                 |
| Duration of IMP                         | Duration of IMP                                     | Duration of IMP                                     | Duration of IMP                                     | Duration of IMP                                     | Duration of IMP                                          | Duration of IMP                                          | Duration of IMP                                          |
| ≥1 day n (%)                            | 103 (100)                                           | 15 (100)                                            | 100 (100)                                           | 115 (100)                                           | 22 (100)                                                 | 212 (100)                                                | 213 (100)                                                |
| ≥30 days n (%)                          | 101 (98.1)                                          | 15 (100)                                            | 98 (98.0)                                           | 113 (98.3)                                          | 22 (100)                                                 | 205 (96.7)                                               | 207 (97.2)                                               |
| ≥60 days n (%)                          | 99 (96.1)                                           | 15 (100)                                            | 96 (96.0)                                           | 111 (96.5)                                          | 22 (100)                                                 | 187 (88.2)                                               | 189 (88.7)                                               |
| ≥90 days n (%)                          | 4 (3.9)                                             | 0                                                   | 5 (5.0)                                             | 5 (4.3)                                             | 22 (100)                                                 | 180 (84.9)                                               | 182 (85.4)                                               |
| ≥6 months n (%)                         | -                                                   | -                                                   | -                                                   | -                                                   | 21 (95.5)                                                | 137 (64.6)                                               | 138 (64.8)                                               |
| ≥12 months n (%)                        | -                                                   | -                                                   | -                                                   | -                                                   | 12 (54.5)                                                | 87 (41.0)                                                | 91 (42.7)                                                |
| ≥18 months n (%)                        | -                                                   | -                                                   | -                                                   | -                                                   | 0                                                        | 55 (25.9)                                                | 57 (26.8)                                                |
| ≥24 months n (%)                        | -                                                   | -                                                   | -                                                   | -                                                   | 0                                                        | 38 (17.9)                                                | 39 (18.3)                                                |
| ≥36 months n (%)                        | -                                                   | -                                                   | -                                                   | -                                                   | 0                                                        | 15 (7.1)                                                 | 31 (14.6)                                                |
| ≥48 months n (%)                        | -                                                   | -                                                   | -                                                   | -                                                   | 0                                                        | 1 (0.5)                                                  | 1 (0.5)                                                  |
| Total IMP duration (participant- years) | 23.0                                                | 3.4                                                 | 22.4                                                | 25.8                                                | 21.6                                                     | 236.0                                                    | 257.6                                                    |
| Total time at risk (participant- years) | 23.4                                                | 3.4                                                 | 23.0                                                | 26.4                                                | 21.6                                                     | 240.7                                                    | 262.4                                                    |

Note: IMP duration is defined as (Date of Last Dose - Date of First Dose + 1)

Note: Time at risk is defined as the exposure duration (Date of End of Observation Period - Date of First Dose + 1) where the observation period includes the time up to the Safety Follow-up Visit or 40 days after the final dose, whichever is earliest.

Note: As participants may have received more than 1 ZLP dose level, the All ZLP column is not a total of the previous dose columns.

<div style=\"page-break-after: always\"></div>

Table 31: Cumulative duration of exposure (pool S2B)

|                          | All zilucoplan N=238   | All zilucoplan N=238   | All zilucoplan N=238   |
|--------------------------|------------------------|------------------------|------------------------|
| Duration of exposure     |                        | n (%)                  | Subject -years         |
| >= 1 day                 | 238                    | (100                   | 275.2                  |
| >= 30 days               | 237                    | （ 99.6)                | 275.2                  |
| >= 60 days               | 221                    | 92.9)                  | 272.9                  |
| >= 90 days               |                        | 210 (88.2)             | 270.6                  |
| >= 6 months (182 days)   | 151                    | 63.4)                  | 248.0                  |
| 12 months (365 days)     | 66                     | (41.6)                 | 212.7                  |
| >= 18 months (547 days)  |                        | 58(24.4)               | 163.2                  |
| >= 24 months (730 days)  |                        | 40 (16.8)              | 132.2                  |
| >= 36 months (1095 days) |                        | 32 (13.4)              | 114.5                  |
| 48 months (1460 days)    |                        | 0.4)                   | 4.2                    |

Note subject-years of exposure duration is defined as (date of end of observation period - date of first dose +1) where the observation period includes the time up to the safety follow-up visit or 40 days after the last dose, whichever is earliest

## 2.6.8.3. Adverse events

Differences in incidences between treatment groups are assessed as per the following criteria: similarity is stated for incidences varying by &lt;2.5%; a slight difference in incidence is stated for variations of ≥ 2.5% to &lt;5%; and differences are stated from ≥ 5% onwards.

<div style=\"page-break-after: always\"></div>

Table 32: Incidence of TEAEs - Overview (Pool S1A)

| Category                                         | Placebo N=103 n (%)[#]   | ZLP 0.1mg/kg N=15 n (%)[#]   | ZLP 0.3mg/kg N=100 n (%)[#]   | ZLP 0.1mg/kg+0.3mg/ kg N=115 n (%)[#]   |
|--------------------------------------------------|--------------------------|------------------------------|-------------------------------|-----------------------------------------|
| Any TEAEs                                        | 76 (73.8) [275]          | 15 (100) [58]                | 78 (78.0) [351]               | 93 (80.9) [409]                         |
| Serious TEAEs                                    | 16 (15.5) [18]           | 0                            | 16 (16.0) [21]                | 16 (13.9) [21]                          |
| Study participant. discontinuations due to TEAEs | 2 (1.9) [2]              | 0                            | 4 (4.0) [4]                   | 4 (3.5) [4]                             |
| Treatment-related TEAEs                          | 27 (26.2) [40]           | 8 (53.3) [22]                | 32 (32.0) [60]                | 40 (34.8) [82]                          |
| Severe TEAEs                                     | 14 (13.6) [17]           | 2 (13.3) [3]                 | 14 (14.0) [30]                | 16 (13.9) [33]                          |
| Deaths (TEAEs leading to death)                  | 1 (1.0) [1]              | 0                            | 1 (1.0) [2]                   | 1 (0.9) [2]                             |

AE=adverse event; ISS=Integrated Summary of Safety; TEAE=treatment-emergent adverse event; ZLP=zilucoplan

Note: n=number of participants reporting at least 1 TEAE in that category.

Note: [#] is the number of individual occurrences of the TEAE in that category.

Note: Treatment-related TEAEs are those defined as related by the Investigator.

Note:   There were no additional nontreatment-emergent AEs leading to death.

<div style=\"page-break-after: always\"></div>

Table 33: Incidence of common TEAEs reported in ≥5% of study participants by PT (Pool S1A)

| MedDRA SOC PT                                        | Placebo N=103 n (%)                                  | ZLP 0.1mg/kg N=15 n (%)                              | ZLP 0.3mg/kg N=100 n (%)                             | ZLP 0.1mg/kg+0.3mg/kg N=115 n (%)                    |                                                      |
|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
| Gastrointestinal disorders                           | Gastrointestinal disorders                           | Gastrointestinal disorders                           | Gastrointestinal disorders                           | Gastrointestinal disorders                           | Gastrointestinal disorders                           |
| Diarrhoea                                            | 3 (2.9)                                              | 1 (6.7)                                              | 10 (10.0)                                            | 11 (9.6)                                             |                                                      |
| Nausea                                               | 1 (1.0)                                              | 2 (13.3)                                             | 4 (4.0)                                              | 6 (5.2)                                              |                                                      |
| General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions |
| Injection site bruising                              | 10 (9.7)                                             | 2 (13.3)                                             | 14 (14.0)                                            | 16 (13.9)                                            |                                                      |
| Injection site pain                                  | 4 (3.9)                                              | 0                                                    | 8 (8.0)                                              | 8 (7.0)                                              |                                                      |
| Oedema peripheral                                    | 1 (1.0)                                              | 0                                                    | 5 (5.0)                                              | 5 (4.3)                                              |                                                      |
| Infections and infestations                          | Infections and infestations                          | Infections and infestations                          | Infections and infestations                          | Infections and infestations                          | Infections and infestations                          |
| Nasopharyngitis                                      | 3 (2.9)                                              | 1 (6.7)                                              | 5 (5.0)                                              | 6 (5.2)                                              |                                                      |
| Urinary tract infection                              | 4 (3.9)                                              | 1 (6.7)                                              | 7 (7.0)                                              | 8 (7.0)                                              |                                                      |
| Injury, poisoning and procedural complications       | Injury, poisoning and procedural complications       | Injury, poisoning and procedural complications       | Injury, poisoning and procedural complications       | Injury, poisoning and procedural complications       | Injury, poisoning and procedural complications       |
| Contusion                                            | 4 (3.9)                                              | 1 (6.7)                                              | 8 (8.0)                                              | 9 (7.8)                                              |                                                      |
| Investigations                                       | Investigations                                       | Investigations                                       | Investigations                                       | Investigations                                       | Investigations                                       |
| Amylase increased                                    | 3 (2.9)                                              | 0                                                    | 7 (7.0)                                              | 7 (6.1)                                              |                                                      |
| Lipase increased                                     | 3 (2.9)                                              | 0                                                    | 6 (6.0)                                              | 6 (5.2)                                              |                                                      |
| Nervous system disorders                             | Nervous system disorders                             | Nervous system disorders                             | Nervous system disorders                             | Nervous system disorders                             | Nervous system disorders                             |
| Headache                                             | 17 (16.5)                                            | 6 (40.0)                                             | 16 (16.0)                                            | 22 (19.1)                                            |                                                      |
| Myasthenia gravis                                    | 13 (12.6)                                            | 4 (26.7)                                             | 10 (10.0)                                            | 14 (12.2)                                            |                                                      |

ISS=Integrated  Summary  of  Safety;  MedDRA=Medical  Dictionary  for  Regulatory  Activities;  PT=Preferred  Term;  SOC=System Organ Class; TEAE=treatment-emergent adverse event; ZLP=zilucoplan

Note: n=number of participants reporting a TEAE in any study period.

The number of study participants in the ZLP 0.1mg/kg treatment group (N=15 [Pool S2A]) was limited compared with the number of study participants in the placebo (N=118 [Pool S2A]) and ZLP 0.3mg/kg (N=112 [Pool S2A]) treatment groups. Potential dose response is evaluated where possible in respective sections,  but  for  some  analyses,  the  numbers  were  too  small  to  draw  any  meaningful  conclusions. Overall, no dose response has been observed with respect to safety.

## Adverse Drug Reactions (ARDs)

Pool S2A includes randomised placebo-controlled study data in study participants with gMG and IMNM and was selected as the main pool to suggest potential ADRs as it is the largest placebo-controlled pool with no major differences in population characteristics or exposure to the product.

The identification of undesirable effects/ADRs was based upon a best evidence assessment of all collected safety data and other relevant evidence to the assessment of causality, severity, and frequency.

<div style=\"page-break-after: always\"></div>

Table 34: Adverse drug reactions for ZLP (incidences from Pool S2A)

| MedDRA SOC ADR                                       | Version 24.0 Placebo N=118 n (%)                     | ZLP N=127 n (%)                                      | Frequency Category a                                 |
|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
| General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions |
| Injection site reactions b                           | 17 (14.4)                                            | 32 (25.2)                                            | Very common                                          |
| Infections and infestations                          | Infections and infestations                          | Infections and infestations                          | Infections and infestations                          |
| Upper respiratory tract infections c                 | 8 (6.8)                                              | 17 (13.4)                                            | Very common                                          |
| Gastrointestinal disorders                           | Gastrointestinal disorders                           | Gastrointestinal disorders                           | Gastrointestinal disorders                           |
| Diarrhoea d                                          | 3 (2.5)                                              | 11 (8.7)                                             | Common                                               |
| Investigations                                       | Investigations                                       | Investigations                                       | Investigations                                       |
| Amylase increased e                                  | 3 (2.5)                                              | 8 (6.3)                                              | Common                                               |
| Lipase increased f                                   | 3 (2.5)                                              | 6 (4.7)                                              | Common                                               |
| Blood eosinophils increased g                        | 0                                                    | 1 (0.8)                                              | Uncommon                                             |
| Skin and subcutaneous tissue disorders               | Skin and subcutaneous tissue disorders               | Skin and subcutaneous tissue disorders               | Skin and subcutaneous tissue disorders               |
| Morphoea h                                           | 0                                                    | 0                                                    | Common                                               |

## TEAEs by duration of treatment

In Pools S1A and S2A, the incidence of any TEAEs reported over time in the ZLP 0.1mg/kg+0.3mg/kg group were higher for the interval ≤29 days [66.1%; 66.1%] compared with ≥30 days [56.6%; 52.8%] and the same trend was observed for the placebo group. The incidence of most common AEs were similar in the ZLP 0.1mg/kg+0.3mg/kg group compared with the placebo group with the following exceptions: in the time interval ≤29 days injection si te pain and diarrhoea were higher in the ZLP 0.1mg/kg+0.3mg/kg group compared with the placebo group; for the time interval of ≥30 days, amylase increased  was  higher  and  injection  site  bruising  and  headache  were  slightly  higher  in  the  ZLP 0.1mg/kg+0.3mg/kg group compared with the placebo group.

In Pool S1B and Pool S2B, respectively, the incidence of any TEAEs reported over time in the All ZLP group were generally similar for the time intervals up to ≤181 days (≤29 days [59.6%; 60.1%], 30 to ≤90 days [61.2%; 59.5%] and 91 to ≤181 days [59.2%; 59. 5%]) with higher incidences for the longer intervals: 182 to ≤364 days [67.4%; 66.7%], ≥365 days [69.1%; 70.4%].

Overall, there was no clinically meaningful difference in incidence of TEAEs by duration of treatment.

<div style=\"page-break-after: always\"></div>

## Withdrawal effects

Overall, a review of the events of myasthenia gravis after ZLP discontinuation were not suggestive of a rebound effect. Fluctuations in symptoms are expected throughout the disease course of myasthenia gravis and were evident in both study participants with TEAEs of myasthenia gravis before and after ZLP discontinuation. No apparent withdrawal effects after cessation of treatment have been observed in any ZLP study.

## 2.6.8.4. Serious adverse events, deaths, and other significant events

## Deaths

In the studies included in the pooled analysis, a total of 10 deaths were reported in ZLP-treated study participants, of which 1 involved a nontreatment emergent fatal AE.

In placebo-controlled periods, no imbalance was observed in the incidence of TEAEs leading to death between ZLP and placebo treatment groups (1 death occurred in each group, due to COVID-19 in the ZLP group and cerebral haemorrhage in the placebo group). Both of these deaths occurred in MG0010.

Nine deaths occurred in OLE periods (3 in MG0009, 5 in MG0011, and 1 in IMNM01), one of which involved a nontreatment-emergent fatal AE in MG0011. None of the deaths were considered treatmentrelated by the Investigator. An individual case review indicated that all deaths had predisposing factors and/or strong alternative explanations. Of the 5 deaths reported as cardiac arrest or with unknown cause, 1 participant experienced severe pneumonia 2 days before, 1 participant experienced bronchitis 3  days  before  and  the  cause  of  death  could  have  been  related  to  a  pneumonia  with  sepsis,  a cerebrovascular accident, or asthma attack; the nontreatment-emergent death was likely due to an underlying prostate or pancreatic carcinoma. The 2 remaining participants had major cardiovascular risk factors. The 4 other deaths were due to an accidental head injury, COVID-19 (2 study participants), and pancreatic carcinoma.

No deaths were reported in the Main portion of MG0009 or the main portion of IMNM01.

## Other serious adverse events

In Pool S1A, incidences of serious TEAEs were similar in the ZLP 0.1mg/kg+0.3mg/kg group (13.9%) and in the placebo group (15.5%) (Table 35). No serious TEAEs were reported in the ZLP 0.1mg/kg group.

<div style=\"page-break-after: always\"></div>

Table 35: Incidence of serious TEAEs by SOC and PT (Pool S1A)

| MedDRA v24.0 SOC PT                                                  | Placebo N=103 n (%) [#]   | ZLP 0.3mg/kg N=100 n (%) [#]   |
|----------------------------------------------------------------------|---------------------------|--------------------------------|
| Any serious TEAE                                                     | 16 (15.5) [18]            | 16 (16.0) [21]                 |
| Blood and lymphatic system disorders                                 | 0                         | 1 (1.0) [1]                    |
| Anaemia                                                              | 0                         | 1 (1.0) [1]                    |
| Gastrointestinal disorders                                           | 1 (1.0) [1]               | 1 (1.0) [1]                    |
| Vomiting                                                             | 1 (1.0) [1]               | 0                              |
| Aphthous ulcer                                                       | 0                         | 1 (1.0) [1]                    |
| General disorders and administration site conditions                 | 0                         | 1 (1.0) [1]                    |
| Systemic inflammatory response syndrome                              | 0                         | 1 (1.0) [1]                    |
| Infections and infestations                                          | 4 (3.9) [5]               | 6 (6.0) [9]                    |
| Abdominal abscess                                                    | 0                         | 1 (1.0) [1]                    |
| Diverticulitis                                                       | 0                         | 1 (1.0) [1]                    |
| Cellulitis                                                           | 0                         | 1 (1.0) [1]                    |
| Oesophageal candidiasis                                              | 0                         | 1 (1.0) [1]                    |
| Oral candidiasis                                                     | 0                         | 1 (1.0) [1]                    |
| COVID-19                                                             | 2 (1.9) [2]               | 1 (1.0) [1]                    |
| COVID-19 pneumonia                                                   | 2 (1.9) [2]               | 1 (1.0) [1]                    |
| Herpes simplex meningoencephalitis                                   | 1 (1.0) [1]               | 0                              |
| Pneumonia                                                            | 0                         | 1 (1.0) [1]                    |
| Sepsis                                                               | 0                         | 1 (1.0) [1]                    |
| Investigations                                                       | 0                         | 2 (2.0) [2]                    |
| Bacterial test positive                                              | 0                         | 1 (1.0) [1]                    |
| Lipase increased                                                     | 0                         | 1 (1.0) [1]                    |
| Musculoskeletal and connective tissue disorders                      | 0                         | 1 (1.0) [1]                    |
| Musculoskeletal chest pain                                           | 0                         | 1 (1.0) [1]                    |
| Neoplasms benign, malignant, and unspecified (incl cysts and polyps) | 0                         | 1 (1.0) [1]                    |
| Basal cell carcinoma                                                 | 0                         | 1 (1.0) [1]                    |
| Nervous system disorders                                             | 9 (8.7) [10]              | 2 (2.0) [3]                    |
| Cerebral haemorrhage                                                 | 1 (1.0) [1]               | 0                              |
| Myasthenia gravis                                                    | 8 (7.8) [9]               | 2 (2.0) [3]                    |
| Pregnancy, puerperium, and perinatal conditions                      | 1 (1.0) [1]               | 0                              |
| Hyperemesis gravidarum                                               | 1 (1.0) [1]               | 0                              |
| Respiratory, thoracic, and mediastinal disorders                     | 1 (1.0) [1]               | 1 (1.0) [1]                    |
| Chronic obstructive pulmonary disease                                | 1 (1.0) [1]               | 0                              |

<div style=\"page-break-after: always\"></div>

| MedDRA v24.0 SOC PT   |   Placebo N=103 n (%) [#] | ZLP 0.3mg/kg N=100 n (%) [#]   |
|-----------------------|---------------------------|--------------------------------|
| Pulmonary embolism    |                         0 | 1 (1.0) [1]                    |

## AEs of interest

## Infections (non-serious)

Table 36: Incidence of nonserious infection TEAEs (Pool S2A)

| MedDRA SOC HLT PT                         | v24.0 Placebo N=118 n (%) [#]   | ZLP 0.1mg/kg+0.3mg/kg N=127 n (%) [#]   |
|-------------------------------------------|---------------------------------|-----------------------------------------|
| Infections and infestations               | 17 (14.4) [23]                  | 33 (26.0) [40]                          |
| Abdominal and gastrointestinal infections | 1 (0.8) [1]                     | 0                                       |
| Diverticulitis                            | 1 (0.8) [1]                     | 0                                       |
| Bacterial infections NEC                  | 0                               | 1 (0.8) [1]                             |
| Cellulitis                                | 0                               | 1 (0.8) [1]                             |
| Candida infections                        | 1 (0.8) [1]                     | 1 (0.8) [1]                             |
| Vulvovaginal candidiasis                  | 1 (0.8) [1]                     | 1 (0.8) [1]                             |
| Coronavirus infections                    | 2 (1.7) [2]                     | 2 (1.6) [2]                             |
| COVID-19                                  | 2 (1.7) [2]                     | 2 (1.6) [2]                             |
| Dental and oral soft tissue infections    | 2 (1.7) [2]                     | 1 (0.8) [1]                             |
| Gingival abscess                          | 0                               | 1 (0.8) [1]                             |
| Gingivitis                                | 1 (0.8) [1]                     | 0                                       |
| Tooth infection                           | 1 (0.8) [1]                     | 0                                       |
| Ear infections                            | 1 (0.8) [1]                     | 0                                       |
| Ear infection                             | 1 (0.8) [1]                     | 0                                       |
| Escherichia infections                    | 0                               | 1 (0.8) [1]                             |
| Escherichia urinary tract infection       | 0                               | 1 (0.8) [1]                             |
| Eye and eyelid infections                 | 0                               | 1 (0.8) [1]                             |
| Conjunctivitis                            | 0                               | 1 (0.8) [1]                             |
| Female reproductive tract infections      | 1 (0.8) [2]                     | 0                                       |
| Vaginal infection                         | 1 (0.8) [2]                     | 0                                       |
| Fungal infections NEC                     | 0                               | 1 (0.8) [1]                             |
| Fungal skin infection                     | 0                               | 1 (0.8) [1]                             |
| Herpes viral infections                   | 0                               | 1 (0.8) [1]                             |
| Herpes zoster                             | 0                               | 1 (0.8) [1]                             |
| Infections NEC                            | 0                               | 1 (0.8) [1]                             |

<div style=\"page-break-after: always\"></div>

Table 36: Incidence of nonserious infection TEAEs (Pool S2A)

| MedDRA v24.0 SOC HLT PT                         | Placebo N=118 n (%) [#]   | ZLP 0.1mg/kg+0.3mg/kg N=127 n (%) [#]   |
|-------------------------------------------------|---------------------------|-----------------------------------------|
| Localised infection                             | 0                         | 1 (0.8) [1]                             |
| Influenza viral infections                      | 0                         | 1 (0.8) [1]                             |
| Influenza                                       | 0                         | 1 (0.8) [1]                             |
| Lower respiratory tract and lung infections     | 1 (0.8) [1]               | 2 (1.6) [2]                             |
| Bronchitis                                      | 0                         | 2 (1.6) [2]                             |
| Pneumonia                                       | 1 (0.8) [1]               | 0                                       |
| Pseudomonal infections                          | 1 (0.8) [1]               | 0                                       |
| Urinary tract infection pseudomonal             | 1 (0.8) [1]               | 0                                       |
| Sepsis, bacteraemia, viraemia and fungaemia NEC | 0                         | 1 (0.8) [1]                             |
| Sepsis                                          | 0                         | 1 (0.8) [1]                             |
| Upper respiratory tract infections              | 7 (5.9) [7]               | 16 (12.6) [16]                          |
| Nasopharyngitis                                 | 3 (2.5) [3]               | 7 (5.5) [7]                             |
| Sinusitis                                       | 0                         | 5 (3.9) [5]                             |
| Upper respiratory tract infection               | 3 (2.5) [3]               | 3 (2.4) [3]                             |
| Tonsillitis                                     | 0                         | 1 (0.8) [1]                             |
| Pharyngitis                                     | 1 (0.8) [1]               | 0                                       |
| Urinary tract infections                        | 4 (3.4) [4]               | 8 (6.3) [8]                             |
| Urinary tract infection                         | 4 (3.4) [4]               | 8 (6.3) [8]                             |
| Viral infections NEC                            | 1 (0.8) [1]               | 2 (1.6) [2]                             |
| Viral infection                                 | 0                         | 1 (0.8) [1]                             |
| Viral upper respiratory tract infection         | 1 (0.8) [1]               | 1 (0.8) [1]                             |

COVID-19=coronavirus disease 2019; HLT=High Level Term; ISS=Integrated Summary of Safety; MedDRA=Medical Dictionary for Regulatory Activities; NEC=not elsewhere classified; PT=Preferred Term; SOC=System Organ Class; TEAE=treatment-emergent adverse event; ZLP=zilucoplan

Note: n=number of participants reporting at least 1 TEAE within HLT/PT

Note: [#] is the number of individual occurrences of the TEAE

The overall incidence of nonserious infections was higher in the ZLP treatment group compared with the placebo treatment group. This was driven by a higher incidence of upper respiratory tract infections, which is considered an ADR for ZLP.

There was a slightly higher incidence of urinary tract infections in the ZLP group compared with the placebo group (8 study participants [6.3%] vs 4 study participants (3.4%), respectively) in the HLT Urinary tract infections and 1 study participant (0.8%) with PTs urinary tract infection pseudomonal and Escherichia urinary tract infection in the placebo and ZLP groups, respectively.

<div style=\"page-break-after: always\"></div>

## Serious infections

Table 37: Incidence of serious infection TEAEs (Pool S2A)

| MedDRA v24.0 SOC HLT PT                         | Placebo N=118 n (%) [#]   | ZLP 0.1mg/kg+0.3mg/kg N=127 n (%) [#]   |
|-------------------------------------------------|---------------------------|-----------------------------------------|
| Infections and infestations                     | 6 (5.1) [8]               | 6 (4.7) [9]                             |
| Abdominal and gastrointestinal infections       | 0                         | 1 (0.8) [2]                             |
| Abdominal abscess                               | 0                         | 1 (0.8) [1]                             |
| Diverticulitis                                  | 0                         | 1 (0.8) [1]                             |
| Bacterial infections NEC                        | 0                         | 1 (0.8) [1]                             |
| Cellulitis                                      | 0                         | 1 (0.8) [1]                             |
| Candida infections                              | 0                         | 1 (0.8) [2]                             |
| Oesophageal candidiasis                         | 0                         | 1 (0.8) [1]                             |
| Oral candidiasis                                | 0                         | 1 (0.8) [1]                             |
| Coronavirus infections                          | 3 (2.5) [4]               | 1 (0.8) [2]                             |
| COVID-19                                        | 2 (1.7) [2]               | 1 (0.8) [1]                             |
| COVID-19 pneumonia                              | 2 (1.7) [2]               | 1 (0.8) [1]                             |
| Herpes viral infections                         | 1 (0.8) [1]               | 0                                       |
| Herpes simplex meningoencephalitis              | 1 (0.8) [1]               | 0                                       |
| Lower respiratory tract and lung infections     | 0                         | 1 (0.8) [1]                             |
| Pneumonia                                       | 0                         | 1 (0.8) [1]                             |
| Rhinoviral infections                           | 1 (0.8) [1]               | 0                                       |
| Rhinovirus infection                            | 1 (0.8) [1]               | 0                                       |
| Sepsis, bacteraemia, viraemia and fungaemia NEC | 0                         | 1 (0.8) [1]                             |
| Sepsis                                          | 0                         | 1 (0.8) [1]                             |
| Urinary tract infections                        | 1 (0.8) [2]               | 0                                       |
| Urinary tract infection                         | 1 (0.8) [2]               | 0                                       |

COVID-19=coronadisease 2019; HLT=High Level Term; ISS=Invirus tegrated Summary of Safety; MedDRA=Medical Dictionary for Regulatory Activities; NEC=not elsewhere classified; PT=Preferred Term; SOC=System Organ Class; TEAE=treatment-emergent adverse event; ZLP=zilucoplan

Note: n=number of participants reporting a TEAE within HLT/PT.

Note: [#] is the number of individual occurrences of the TEAE.

In the placebo-controlled Pools S1A and S2A, the overall incidence of serious infections was similar in placebo and ZLP treatment groups.

Exposure-adjusted incidence rates and event rates for serious and nonserious infections decreased in the long-term Pools S1B and S2B as compared with the corresponding placebo-controlled Pools S1A and S2A.

## Neisseria infections

Background: Zilucoplan is  a  selective  immunosuppressant  with  a  mechanism  of  action  based  on  C5 inhibition. Deficiency of terminal complement components is associated with an increased incidence of

<div style=\"page-break-after: always\"></div>

infection with Neisseria species, in particular Neisseria meningitidis, as Neisseria bacteria are primarily cleared by the terminal complement components (Lewis and Ram, 2020; Skattum et al, 2011). This is supported by experience with approved drugs with a similar mechanism of action eculizumab (Soliris®) and  ravulizumab  (Ultomiris®),  and  evidence  from  patients  with  genetic  deficiencies  of  terminal complement  components.  Zilucoplan  does  not  inhibit  early  complement  components,  for  which deficiencies are associated with an increased susceptibility for a number of other infections, e.g., with other encapsulated bacteria (Lewis and Ram, 2020; Skattum et al, 2011).

No Neisseria infections were reported in the ZLP development programme as of the clinical cutoff date, where all study participants (N=591 including estimated exposure from non UCB sponsored studies) were required to be vaccinated against meningococcal infections and/or to use prophylactic antibiotics.

## Opportunistic infections

Potential opportunistic infections were identified through a medical review by checking event PTs or pathogens  mentioned  in  the  SAE  narrative  with  the  MedDRA  Standardized  MedDRA  Query  (SMQ) 'Opportunistic infections.'

In terms of potential opportunistic infections, 3 events of serious infections met the criteria for the narrow scope SMQ:

- Herpes simplex meningoencephalitis: the event started when the subject was on placebo in MG0010 and  was  reported  as  worsening  on  the  first  day  of  MG0011  (7 hours  after  the  first  ZLP administration), which is not suggestive for a causal involvement of ZLP.
- Endocarditis: different pathogens were identified including Candida albicans and Stenotrophomonas maltophilia . The event was attributed to a device (cardiac pacemaker) and the study participant had a Hickman catheter for total parenteral nutrition.
- Liver abscess: the event occurred in the context of a post-Endoscopic retrograde cholangiopancreatography  (ERCP)  pancreatitis  in  a  participant  with  a  history  of  cholecystitis; different pathogens were identified including Candida albicans .

Further medical review, also considering terms in the broad scope SMQ, that is known to include less specific terms, identified an additional 10 serious events in 7 study participants:

- Sepsis:  following  PLEX  treatment  for  a  myasthenic  crisis; Staphylococcus  aureus (methicillinsensitive) was identified.
- Staphylococcal infection: Methicillin-resistant Staphylococcus aureus infection post shoulder surgery. The participant also had a central catheter.
- Pneumonia: with coagulase-negative staphylococci and suspected bacteremia with Staphylococcus hominis ,  likely  due  to  contamination.  The  study  participant  likely  had  an  intravenous  line  to administer the vancomycin treatment for pneumonia.
- Bacteraemia with Acinetobacter, Corynebacterium, and Staphylococcus epidermidis , attributed most likely to an infected Hickman catheter for total parenteral nutrition.
- Pneumonia klebsiella: urinary tract infection/epididymitis with Klebsiella pneumoniae .
- Sepsis  (3  separate  events)  and  hepatitis  C:  1 sepsis  event  associated  to  a  pneumonia  with Enterobacter cloacae in blood cultures, 1 sepsis event related to COVID-19, and a post-procedural

<div style=\"page-break-after: always\"></div>

sepsis  event  in  the  frame  of  a  post-ERCP  pancreatitis.  Hepatitis  C  was  reported  as  a  chronic asymptomatic infection related to a needlestick injury, and the participant had a history of ongoing glucose tolerance impairment.

- Staphylococcal sepsis: Staphylococcus aureus sepsis with central catheter as probable origin.

In all of these cases, risk factors for opportunistic infections were present, e.g., use of dentures and history  of  candidiasis  in  the  case  of  esophageal  candidiasis,  and  also  included  concurrent  use  of prednisone or methotrexate.

Potential opportunistic infections occurred at a similar incidence in placebo and ZLP treatment groups in placebo-controlled  pools  and  were  overall  confounded  by  concurrent  use  of  immunosuppressants, medical history, presence of intravenous lines/catheters, invasive medical devices/procedures or other factors that are nonsuggestive for causal involvement of ZLP.

## Malignancies

In Pool S1A, any TEAEs related to malignant or unspecified tumours were reported by 3 study participants (3.0%) in the ZLP 0.1mg/kg+0.3mg/kg group and 0 study participants in the placebo treatment group. Two events of basal cell carcinoma; 1 mild and 1 moderate in intensity and 2 events of squamous cell carcinoma, both mild in intensity, were reported in the ZLP 0.1mg/kg+0.3mg/kg group. There were no malignancies reported in the IMNM study IMNM01.

In Pool S1B and Pool S2B, TEAEs of interest of malignant tumours were reported by 8 study participants (3.8%) and 8 study participants (3.4%) in All ZLP group, respectively. Preferred terms in this category were  basal  cell  carcinoma,  squamous  cell  carcinoma,  malignant  melanoma,  metastatic  malignant melanoma,  metastatic  neoplasm,  and  pancreatic  carcinoma.  The  most  frequently  reported  TEAE  of malignant or unspecified tumours in Pool S1B and Pool S2B was basal cell carcinoma (4 study participants [1.9%] and [1.7%] each).

## Injection site reactions

Table  38:  Incidence  of  Injection  site  reactions  (Pool  S1A  and  Pool  S2A  excluding  MG0009  study participants)

| MedDRA SOC PT                                    | v24.0 Pool S1A   | Pool S2A       | Pool S2A                   |                        |                            |
|--------------------------------------------------|------------------|----------------|----------------------------|------------------------|----------------------------|
| MedDRA SOC PT                                    | N=88 n (%)       | Placebo [#]    | ZLP 0.3mg/kg N=86 n (%)[#] | Placebo N=103 n (%)[#] | ZLP 0.3mg/kg N=98 n (%)[#] |
| Any Injection Site Reactions                     | 13 (14.8) [15]   | 23 (26.7) [33] |                            | 14 (13.6) [17]         | 26 (26.5) [36]             |
| General disorders administration site conditions | and 13           | (14.8) [15]    | 23 (26.7) [33]             | 14 (13.6) [17]         | 26 (26.5) [36]             |
| Injection site bruising                          | 8 (9.1) [10]     | 14 (16.3) [18] | 9 (8.7)                    | [12]                   | 14 (14.3) [18]             |
| Injection site pain                              | 3 (3.4) [3]      | 8 (9.3) [9]    | 3 (2.9)                    | [3]                    | 9 (9.2) [10]               |
| Injection site haematoma                         | 0                | 2 (2.3) [2]    | 0                          |                        | 2 (2.0) [2]                |
| Injection site rash                              | 2 (2.3) [2]      | 0              | 2 (1.9)                    | [2]                    | 0                          |
| Injection site haemorrhage                       | 0                | 1 (1.2) [1]    | 0                          |                        | 1 (1.0) [1]                |
| Injection site mass                              | 0                | 1 (1.2) [1]    | 0                          |                        | 1 (1.0) [1]                |
| Injection site nodule                            | 0                | 1 (1.2) [1]    | 0                          |                        | 1 (1.0) [1]                |
| Injection site reaction                          | 0                | 1 (1.2) [1]    | 0                          |                        | 1 (1.0) [1]                |

<div style=\"page-break-after: always\"></div>

| MedDRA SOC              | v24.0   | Pool S1A               | Pool S1A                   | Pool S2A               | Pool S2A                   |
|-------------------------|---------|------------------------|----------------------------|------------------------|----------------------------|
| PT                      |         | Placebo N=88 n (%) [#] | ZLP 0.3mg/kg N=86 n (%)[#] | Placebo N=103 n (%)[#] | ZLP 0.3mg/kg N=98 n (%)[#] |
| Injection site erythema |         | 0                      | 0                          | 0                      | 1 (1.0) [1]                |
| Injection site pruritus | 0       |                        | 0                          | 0                      | 1 (1.0) [1]                |

ISS=Integrated  Summary  of  Safety;  MedDRA=Medical  Dictionary  for  Regulatory  Activities;  PT=Preferred  Term;  SOC=System Organ Class; TEAE=treatment-emergent adverse event; ZLP=zilucoplan

Note: n=number of study participants reporting at least 1 TEAE within PT.

Note: [#] is the number of individual occurrences of the TEAE.

Note: Injection site reactions: TEAEs in MedDRA High Level Term 'Injection site reactions' or High Level Term 'Administration site reactions

In Pool S1A, the incidence of TEAEs of interest of Injection site reactions was higher in the ZLP 0.3mg/kg treatment group (23 study participants [26.7%]) compared with the placebo treatment group (13 study participants [14.8%]). The incidence of TEAEs of interest of Injection site reactions in Pool S2A was similar to Pool S1A (26 study participants [26.5%] in the ZLP 0.3mg/kg group and 14 study participants [13.6%] in the placebo treatment group). None of the TEAEs of interest in the event category of Injection site reactions were considered serious or severe, and none resulted in permanent withdrawal from IMP. Injection site reactions is considered an ADR for zilucoplan.

## Hypersensitivity reactions including anaphylaxis

In Pool S1A and S2A, incidences of Hypersensitivity reactions respectively were slightly higher and similar in  the  ZLP  0.1mg/kg+0.3mg/kg  group  (13  study  participants  [11.3%]  and  13  study  participants [10.2%])  compared  with  the  placebo  treatment  group  (9  study  participants  [8.7%]  and  10  study participants [8.5%]). No severe TEAEs of Hypersensitivity reactions were reported across the treatment groups.

The EAIRs and event rates for hypersensitivity reactions were lower or similar in the long-term Pools S1B and S2B as compared with the placebo-controlled Pools S1A and S2A. No events of anaphylactic reactions to ZLP were identified across the pools.

## Hepatic events

There were no signs of increased hepatic events compared to placebo.

## Skin and oral mucosal ulcerations

In the Phase 2 MG0009 study, study participants were monitored at each study visit for AEs due to skin or oral lesions, and study drug was to be permanently discontinued in the event of moderate or severe skin or oral lesions considered related to study drug. No such events occurred in MG0009.

<div style=\"page-break-after: always\"></div>

Table 39: Skin and oral mucosal ulcerations (Pool S2A)

| MedDRA v24.0 HLT PT       | Placebo N=118 n (%) [#]   | ZLP 0.1mg/kg+0.3mg/kg N=127 n (%) [#]   |
|---------------------------|---------------------------|-----------------------------------------|
| Stomatitis and ulceration | 2 (1.7) [2]               | 5 (3.9) [6]                             |
| Aphthous ulcer            | 0                         | 3 (2.4) [4]                             |
| Mouth ulceration          | 1 (0.8) [1]               | 2 (1.6) [2]                             |
| Lip ulceration            | 1 (0.8) [1]               | 0                                       |

ISS=Integrated  Summary  of  Safety;  HLT=high  level  term;  MedDRA=Medical  Dictionary  for  Regulatory  Activities; PT=Preferred Term; ZLP=zilucoplan

Note: n=number of participants reporting a TEAE within HLT/PT

Note: [#] is the number of individual occurrences of the TEAE

In the placebo-controlled Pools S1A and S2A, the overall incidence of skin and oral mucosal ulcerations was similar across the ZLP and placebo groups. No events of skin and oral mucosal ulcerations occurred in the Phase 2 IMNM01 study, so there are no differences in these events between Pools S2A and S1A. Exposure-adjusted incidence rates and event rates of skin and oral mucosal ulcerations decreased in the long-term Pools S1B and S2B as compared with the corresponding placebo-controlled Pools S1A and S2A.

## Morphoea

Morphoea, also known as localised scleroderma, is a rare idiopathic, inflammatory disorder that causes sclerotic changes in the skin, manifesting as painless, discoloured patches on the skin.

During the MA assessment procedure, a safety signal of morphoea was validated in Feb 2023 by the applicant due to the occurrence of 11 TEAEs of morphoea in 10 study participants in the ongoing openlabel Phase 3 study in generalised myasthenia gravis (gMG), MG0011. The time to onset was &gt;1 year, ranging from 430 to 1262 days from the first ZLP dose. The incidence rate of morphoea in the ZLP clinical development programme is 1.90 per 100 patient-years (1900 per 100,000 patient years; 2 TEAEs not included since they both occurred after the cut-off date of the Q1 2023 SSD) while the overall incidence rate  of  morphoea  in  the  general  population  reported  in  the  literature  ranged  from  0.34  (localised scleroderma in children) (Herrick et al, 2010) to 2.7 per 100,000 (Peterson et al, 1997). The applicant concludes that the incidence is considerably higher than reported for the general population. The time to  onset  is  compatible  with  a  drug-induced  morphoea,  as  other  drugs  implicated  as  a  trigger  for morphoea have observed longer latencies consistent with &gt;1 year.

The applicant concludes that although other autoimmune diseases (including scleroderma) are more common in patients with myasthenia gravis than in the general population, morphoea has previously only  been  described  in  isolated  case  reports  in  MG  patients.  This  may  partly  be  due  to  a  possible underreporting of morphoea related to the mild manifestations of the disease.

Confounding  factors  among  the  10  cases  were  previous  tick  bites  with  Lyme  disease  (N=1),  covid infection or covid vaccination (N=4).

Other C5 inhibitors, eculizumab and ravulizumab, are not labelled for morphoea or scleroderma as ADR in their respective EU SmPCs or US PI; however, there have been reports of morphoea or scleroderma in the post-marketing setting.

Based on the high incidence in the long-term FU study and a time-to-onset that is in line with other drug-induced cases of morphoea, the relation to treatment with zilucoplan is considered at least possible.

<div style=\"page-break-after: always\"></div>

Thus, morphoea is included in the SmPC section 4.8 Table of ADRs with a frequency of common and described below the ADR table as a selected ADR.

## 2.6.8.5. Laboratory findings

## Liver function tests

Post-Baseline for Pool S1A and Pool S2A, the incidence of elevated liver function tests was low and similar across treatment groups. No study participants met the laboratory criteria for potential drug-induced liver  injuries,  including  Hy's  law  criteria  ([aspartate  aminotransferase  or  alanine  aminotransferase &gt;3.0×ULN] and total bilirubin &gt;2.0×ULN and alkaline phosphatase &lt;2.0×ULN).

## Amylase and lipase increased

In  the  placebo-controlled  Pools  S1A  and  S2A,  the  overall  incidence  for  laboratory  abnormalities  of amylase increased and lipase increased were higher in the ZLP treatment group compared with placebo. The majority of study participants with laboratory amylase and lipase elevations had a normal Baseline value. Pancreatic enzyme elevations were generally transient and resolved over time with continuation of ZLP. Exposure-adjusted incidence rates for amylase and lipase elevations in these study participants decreased in the long-term Pools S1B and S2B as compared with the corresponding placebo-controlled Pools S1A and S2A.

Table  40:  Maximum  post-baseline  CTCAE  grade  in  study  participants  with  pancreatic  enzyme abnormalities (Pool S2A)

| Post- baseline laborator y abnormali ty   | Placebo N=118 n (%)   | Placebo N=118 n (%)   | Placebo N=118 n (%)   | ZLP 0.1mg/kg+0.3mg/kg N=127   | ZLP 0.1mg/kg+0.3mg/kg N=127   | ZLP 0.1mg/kg+0.3mg/kg N=127   |
|-------------------------------------------|-----------------------|-----------------------|-----------------------|-------------------------------|-------------------------------|-------------------------------|
| Post- baseline laborator y abnormali ty   | All Grades            | Grade 1-2             | Grade 3-4             | All Grades                    | Grade 1-2                     | Grade 3-4                     |
| Amylase increased                         | 22 (18.6)             | 22 (18.6)             | 0 (0)                 | 32 (25.2)                     | 24 (18.9)                     | 8 (6.3)                       |
| Lipase increased                          | 16 (13.6)             | 10 (8.5)              | 6 (5.1)               | 42 (33.1)                     | 27 (21.3)                     | 15 (11.8)                     |

CI=confidence  interval;  CTCAE=Common  Terminology  Criteria  for  Adverse  Events;  ISS=Integrated  Summary  of  Safety; ZLP=zilucoplan

Note: n=number of participants reporting a TEAE within SOC/PT.

Note: [#] is the number of individual occurrences of the TEAE.

Definitions of CTCAE grades (V.5): Grade 1 is &gt;ULN-1.5xULN, Grade 2 is &gt;1.5-2.0xULN, Grade 3 is &gt;2.0-5.0xULN, Grade 4 is &gt;5.0xULN.

One study participant (MG0011-122-145) discontinued ZLP due to a pancreatic enzyme elevation. This study participant with a history of rheumatoid arthritis and obesity experienced Grade 3 lipase/Grade 2 amylase with TEAEs of amylase increased and lipase increased reported 57 days after the first dose of ZLP along with other TEAEs of diarrhoea, dyspepsia, and nephrolithiasis. Zilucoplan was interrupted and pancreatic enzyme elevations resolved. After restarting ZLP, the study participant experienced a Grade 1 lipase increase with a TEAE of lipase increased reported along with other TEAEs of abdominal pain, diarrhoea, and vomiting. The participant received a COVID-19 vaccine 13 days prior to the second event of lipase increased. Zilucoplan was discontinued, and lipase elevation resolved. No TEAE of pancreatitis was reported. All TEAEs of amylase increased and lipase increased were considered treatment related by the Investigator. Although a positive rechallenge was observed, it is difficult to interpret the relevance due to the large variability of pancreatic enzyme values over time. This case was confounded by the nephrolithiasis, COVID-19 vaccine, and a history of rheumatoid arthritis.

<div style=\"page-break-after: always\"></div>

Three events of pancreatitis were reported, two serious, severe cases presented 24 hours after ERCP and  1  nonserious,  mild  case  occurred  7  days  after  receiving  a  COVID-19  vaccine.  Pancreatitis  is  a common severe complication of ERCP, and cases of pancreatitis have been reported in the literature after the COVID-19 vaccine (Arata et al, 2010; Parkash, 2021). Zilucoplan was continued in all cases with resolution of pancreatitis in 2 cases and no resolution in 1 case but normal pancreatic enzyme values at  the  time  of  Safety  Follow-Up  visit;  no  reoccurrence  of  pancreatitis  was  reported  in  these  study participants.

No  evidence  suggestive  of  ZLP-induced  pancreatitis  or  other  pancreas  pathologies  was  identified. Pancreatic enzyme elevations in other study participants were generally asymptomatic (not associated with  abdominal  pain),  and  none  of  these  met  the  diagnostic  criteria  for  acute  pancreatitis  per  the American College of Gastroenterology.

Events indicative of other pancreas pathologies included 3 events of pancreatic cyst, 2 events of pancreas infection, 1 event of pancreatic carcinoma, and 1 event of pancreatic mass. The majority of these events were serious, and all were considered not related (by the Investigator). Zilucoplan was continued in all cases, except for 1 study participant who withdrew ZLP due to a fatal pancreatic carcinoma. All remaining events resolved at the time of report, except for 1 pancreatic cyst and 1 pancreatic mass.

## Eosinophils increased

## Background

In the literature, a role for eosinophils in autoimmunity has been suggested (Diny et al, 2017). Case reports of simultaneous presentation of hypereosinophilic syndrome and myasthenia gravis have also been described (Avni et al, 2006; Ishida et al, 1996). Complement 5a is implicated in inducing eosinophil activation and extravasation (Zeck-Kapp and Kapp, 1995; Zeck Kapp et al, 1995); however the effect of C5 inhibition on eosinophils is unclear.

Laboratory assessments for eosinophils were required at Screening, Baseline, and at regularly scheduled intervals  in  clinical  studies  as  a  routine  haematology  laboratory  assessment.  In  MG0010,  a  higher incidence of blood eosinophil elevations was observed in the ZLP treatment group compared with the placebo treatment group, which prompted further review.

Hypereosinophilia is defined as eosinophils ≥ 1.5 × 109/L, and hypereosinophilic syndrome is defined as eosinophils ≥ 1.5 × 109/L  on  2  occasions ≥ 1  month  apart,  plus  organ  dysfunction  attributable  to eosinophilia (Weller and Klion, 2022).

## Results:

Table 41: Shift from baseline to maximum post-baseline result for eosinophils (Pool S2A)

| Shift from baseline to maximum post-Baseline   | Eosinophils         | Eosinophils                       |
|------------------------------------------------|---------------------|-----------------------------------|
| Shift from baseline to maximum post-Baseline   | Placebo N=118 n (%) | ZLP 0.1mg/kg+0.3mg/kg N=127 n (%) |
| Normal to High                                 | 1 (0.8)             | 21 (16.5)                         |
| High to High                                   | 1 (0.8)             | 0 (0)                             |
| Any to High                                    | 2 (1.7)             | 21 (16.5)                         |

ISS=Integrated Summary of Safety; ZLP=zilucoplan

<div style=\"page-break-after: always\"></div>

The high post-baseline eosinophils in 15 study participants were below 1.5 × 10 9 /L (13 study participants in the ZLP group and 2 study participants in the placebo group) and 6 study participants met the criterion of hypereosinophilia (eosinophils ≥ 1.5 × 10 9 /L), all in the ZLP treatment group.

Eosinophil elevations were generally transient and resolved with continuation of ZLP. The majority of participants  were  asymptomatic,  and  no  study  participants  experienced  clinically  significant  organ dysfunction, hypereosinophilic syndrome, or other eosinophilic pathologies. No eosinophils elevations led to permanent discontinuation or drug interruption of IMP.

## Vital signs, ECG

There were no clinically meaningful mean changes from Baseline in vital sign parameters or ECG results.

A separate TQT study (UP0093) was designed to study of the effects of a supratherapeutic dose of ZLP on cardiac repolarisation in healthy adult study participants. The results of UP0093 constitute a negative thorough QT (TQT) study for ZLP.

## 2.6.8.6. Safety in special populations

## Gender

The incidences of any TEAEs, treatment-related TEAEs (as determined by the Investigator), and serious TEAEs were higher and had a difference of ≥5 study participants in the ZLP 0.3mg/kg treatment group in female study participants (45 study participants [86.5%], 21 study participants [40.4%], and 9 study participants  [17.3%],  respectively)  compared  with  male  study  participants  (21  study  participants [61.8%], 7 study participants [20.6%], and 2 study participants [5.9%], respectively).

## Age

In the pooled data, 158 of subjects with gMG were in the age group 18-&lt;65 years, 50 were 65 to &lt;75 and 5 were 75 to &lt;85 years of age.

<div style=\"page-break-after: always\"></div>

Table 42: Summary of TEAEs overall and by age subgroups (S1A)

|                                                                       | Overall                | Overall                   | <65 years            | <65 years                 | ≥65 years              | ≥65 years                   |
|-----------------------------------------------------------------------|------------------------|---------------------------|----------------------|---------------------------|------------------------|-----------------------------|
| Category                                                              | Placebo 88=N n (%) [#] | ZLP 0.3mg/kg N=86 [#](%)u | Placebo N=62 n(%)[#] | ZLP 0.3mg/kg N=64 n(%)[#] | Placebo N=26 n (%) [#] | ZLP 0.3mg/kg N=22 n (%) [#] |
| Any TEAEs                                                             | 62 (70.5) [222]        | 66 (76.7) [291]           | 47 (75.8) [175]      | 53 (82.8) [236]           | 15 (57.7) [47]         | 13 (59.1) [55]              |
| Serious TEAEs                                                         | 13 (14.8) [18]         | 11 (12.8) [15]            | 12 (19.4) [17]       | 7 (10.9) [6]              | 1 (3.8) [1]            | 4 (18.2) [6]                |
| TEAEs resulting in permanent withdrawal from IMP a                    | 2 (2.3) [2]            | 4 (4.7) [4]               | 2 (3.2) [2]          | 3 (4.7) [3]               | 0                      | 1 (4.5) [1]                 |
| Treatment-related TEAEs                                               | 22 (25.0) [34]         | 28 (32.6) [55]            | 19 (30.6) [31]       | 25 (39.1) [51]            | 3 (11.5) [3]           | 3 (13.6) [4]                |
| Severe TEAEs                                                          | 11 (12.5) [14]         | 10 (11.6) [24]            | 11 (17.7) [14]       | 5 (7.8) [15]              | 0                      | 5 (22.7) [6]                |
| All deaths (number of study participants with AEs leading to death) b | 1                      | 1                         | 1                    | 1                         | 0                      | 0                           |
| Deaths (TEAEs leading to death)                                       | 1 (1.1) [1]            | 1 (1.2) [2]               | 1 (1.6) [1]          | 1 (1.6) [2]               | 0                      | 0                           |

Note: n=number of study participants reporting at least 1 TEAE in that category.

AE=adverse event; CTCAE=Common Terminology Criteria for Adverse Events; IMP=investigational medicinal product; SS=Safety Set; TEAE=treatment-emergent adverse event; ZLP=zilucoplan

Note: [#] is the number of individual occurrences of the TEAE in that category.

Note: Treatment-related TEAEs were considered to be related to IMP by the Investigator.

Note: Severe TEAEs were those with CTCAE Grade 3 or above or those without a CTCAE grading classified as *severe'by the Investigator.

b All deaths were based on all study participants screened and refers to all deaths that occurred on study.

Includes all deaths.

In the age subgroup of ≥65 years, trends between the treatment groups in the incidences of TEAEs, including TEAEs resulting in permanent withdrawal from IMP was similar to that observed in the overall population;  trends  in  the  incidences  of  any  TEAEs,  severe  TEAEs,  treatment-related  TEAEs  (as determined  by  the  Investigator),  and  serious  TEAEs  were  different  to  that  observed  in  the  overall population (Table 42).

## By body weight or BMI

There were no clinically meaningful differences within the subgroups of body weight or BMI.

## By disease duration, by MGFA disease class, by gMG refractory status

In the pivotal study MG0010, in the subgroup with ≥median disease duration at baseline, the incidences of TEAEs were higher compared with the subgroup with &lt;median disease duration. The same was true for patients with MGFA disease class III vs II and for those with a gMG refractory status.

## Extrinsic factors (Geographic region)

The study regions were East Asia, Europe, and North America.

In general, there were no clinically meaningful differences within the subgroup of geographic region.

<div style=\"page-break-after: always\"></div>

## Use in pregnancy and lactation

## Pregnancy

Animal  studies  did  not indicate direct or  indirect  harmful  effects  with  respect  to  pregnancy, embryonic/fetal development, parturition, or postnatal development.

Data collected from an ex-vivo closed-circuit human placental transfer model suggest low transfer rate of ZLP (0.5 to 1.0%) in the foetal compartment. The transfer rate of 0.5% was observed at a steady state  plasma  concentration  of  10µg/mL  ZLP,  corresponding  to  a  therapeutic  dose  of  0.3mg/kg.  The clinical relevance of these data in human pregnancies is unknown.

1 pregnancy case was reported with maternal exposure to ZLP. One study participant from MG0009, who was in the placebo group during the Main Portion of the study and in the ZLP 0.1mg/kg/day dose group in the Extension Portion of the study, became pregnant after discontinuation of ZLP 0.1mg/kg in the Extension Portion, with the date of last menstrual period 1 day before the last ZLP administration. The participant had been exposed to ZLP for more than a year. During pregnancy, the mother experienced gestational diabetes and went on to have an uncomplicated full-term, live birth of a healthy baby via an elective cesarean section. No congenital malformations, failure to thrive, or developmental delay were observed in a follow-up about 16 months after delivery.

## Lactation

No cases of lactation were reported with maternal exposure to ZLP. It is unknown whether ZLP is excreted in human milk or absorbed systemically after oral ingestion by the baby.

## 2.6.8.7. Immunological events

## AEs by ADA status and by anti-PEG antibody status

In pool S1B, 2 out of 169 study participants (1.2%) were treatment-emergent ADA positive. Both these subjects had TEAEs of injection site reactions: injection site pain (2 study participants) and injection site bruising (1 study participant).

In pool S1B, 10 out of 169 study participants (5.9%) were treatment-emergent APA positive. TEAEs of injection  site  reactions  were  reported  in  3  of  these  subjects  and  were  TEAEs  of  injection  site  lump, injection site haemorrhage, and injection site pain (1 study participant each). TEAEs of hypersensitivity reactions were reported in 3 study participants and were TEAEs of dermatitis contact, rash, rash pruritic, and urticaria (1 study participant each).

Overall, incidences of treatment -emergent ADA positive or APA positive study participants were low. Upon review of the available data, no evidence was identified of an association between positive ADA status or positive APA status and the incidence of TEAEs overall, or specifically with hypersensitivity reactions, injection site reactions or autoimmune disorders. Immunogenicity had no clinically meaningful impact on safety of ZLP.

## 2.6.8.8. Discontinuation due to adverse events

In Pool S1A, the number of participants reporting TEAEs leading to discontinuation was low overall and similar across treatment groups (ZLP 0.3mg/kg [4.0%] and placebo [1.9%]). No TEAEs leading to IMP discontinuation  were  reported  in  the  ZLP  0.1mg/kg  group.  Treatment-emergent  AEs  leading  to discontinuation  were  spread  across  SOCs  with  no  obvious  trend.  By  PT,  no  TEAE  leading  to  study discontinuation was reported by &gt;1 study participant in any treatment group.

<div style=\"page-break-after: always\"></div>

## 2.6.9. Discussion on clinical safety

The evaluation of safety of zilucoplan in the treatment of patients with gMG is based on data from the 3 studies included in the present application, the phase 2 study including both the 0.1 and 0.3 mg/kg dose, the phase 3 study with only the 0.3 mg/kg dose vs placebo and the ongoing open-label extension study with patients having completed the main studies. In addition, to enlarge the somewhat small safety database  for  zilucoplan,  patients  with  a  similar  disease,  IMNM  have  been  included  for  some  safety analyses.

For gMG, 91 subjects have been exposed for more than a year to the therapeutic dose of 0.3 mg/kg. Therefore, the applicant has created safety pool S2B to include subjects with IMNM, a disease with similar clinical characteristics. In safety pool S2B, 99 subjects have been exposed to zilucoplan for at least 12 months. Thus, when including patients with the similar disease IMNM, almost 100 patients have been exposed to zilucoplan for at least 12 months, which is in line with the recommendations for the size of the safety database.

Updated safety data from the ongoing MG0011 clinical trial through the September 8, 2022 cut-off date, provided by the applicant during the procedure did not raise any new safety issue. 139 patients were treated with ZLP for 1 year. This seems sufficient for long term data.

The applicant states that they consider gMG and IMNM studies similar in their randomised controlled trial design and the diseases also similar enough to justify pooling of safety. This may be concurred. However, the safety pools with only gMG patients are preferred in this safety report.

There was no increase in overall incidence of TEAEs or severe TEAEs for zilucoplan-treated patients compared to the placebo group.

The safety data in SmPC section 4.8 stems from Pool S1A with only patients with gMG. Urinary tract infection (UTI) is not included in 4.8 although 7.0% vs 3.9%, since a higher proportion of the zilucoplan study participants had risk factors for UTI compared to the placebo group.

The identified ADRs of zilucoplan for treatment of gMG are injection site reactions, upper respiratory tract infections, diarrhoea, and increased amylase, lipase and blood eosinophils. For the C5 monoclonal antibodies  Soliris  (eculizumab)  and  Ultomiris  (ravulizumab),  upper  respiratory  tract  infections  and diarrhoea are also included in the list of ADRs. Thus, these ADRs seem to be class effects. In addition, both these have headache as a very common ADR. However, headache has not been listed as an ADR for zilucoplan, since it was not more frequent in the treatment group than in the placebo group (19.1% vs 16.5% for placebo).

Since the dose range in the gMG and IMNM studies was narrow (0.1 and 0.3 mg/kg) and the number of patients treated with the 0.1 mg/kg dose was low (N=15), no dose-related safety has been identified.

The incidence of any TEAE decreased after the first month of treatment in both zilucoplan treatment groups and placebo groups. In the open-label long-term treatment safety pools, the incidence of any TEAE over time was generally stable, i.e. no meaningful differences in incidence of TEAEs by duration of treatment.

No apparent withdrawal effects after cessation of treatment have been observed in any ZLP study.

In the randomised controlled trials studies, there were 2 deaths, one in the zilucoplan treatment group (Covid-19 pneumonia, after 18 days exposure to zilucoplan) and one in the placebo group (cerebral haemorrhage). Nine deaths occurred during OLE periods (3 in MG0009, 5 in MG0011, and 1 in IMNM01) after a mean (median) exposure period of 10.9 (6.2) months (range 2.5-42.2 months) to zilucoplan. Among these 9 OLE deaths, 2 were related to covid-19 infection, in 3 cases the reported cause of death was cardiac arrest, 1 due to head injury, 2 had pancreatic carcinoma or probable pancreas cancer at the

<div style=\"page-break-after: always\"></div>

time of death, 1 was due to pneumonia. None of the deaths were considered treatment-related by the Investigator. There were several death cases in which the patient was described as having confounding factors related to metabolic syndrome; diabetes in 8 cases, hypertension in 7, hypercholesterolemia or hyperlipidaemia in 5, and obesity in 3.

Pancreatic events are interesting, since there were pancreatic events in the cynomolgus non-clinical studies and elevated amylase and lipase and 3 cases of pancreatitis in the clinical studies. However, the patients with pancreatic cancer had been on zilucoplan treatment at the 0.3 mg/kg dose for 230 and 241 days at the time of death, respectively. The pancreas cancer and pancreatic mass were diagnosed 6 months and 3 months after initiation of zilucoplan treatment, respectively, making zilucoplan treatment an unlikely cause or contributing factor for the malignancy.

The incidence of SAEs was equal between treated and placebo groups. However, within the various SOCs there were slightly more serious infections in the zilucoplan group, counterbalanced by more SAEs with the term myasthenia gravis in the placebo group, the latter being indicative of a positive treatment effect.

The number of TEAEs leading to discontinuation was overall low and similar across treatment groups.

Based on the experience from the C5 monoclonal antibodies eculizumab and ravulizumab and non-clinical studies  of  zilucoplan,  the  applicant  had  defined  several  AEs  of  interest,  which  included  infections, Neisseria  infections,  opportunistic  infections,  malignancies,  injection  site  reactions,  hypersensitivity reactions, hepatic events skin and oral mucosal ulcerations, and pancreatic events.

The overall incidence of non-serious infections was higher for zilucoplan-treated subjects than for placebo (26.0% vs 14.4%), which was driven by a higher incidence of upper respiratory tract infections (12.6% for ZLP vs 5.9% for placebo), which is considered an ADR for ZLP. The incidence of UTI was slightly higher in the ZLP group compared with the placebo group (6.3% vs 3.4%).

In the placebo-controlled Pools S1A and S2A, the overall incidence of serious infections was similar in placebo and ZLP treatment groups. Serious infections have been included as an important potential risk in the list of safety concerns in the context of the PSUR.

Meningococcal infections are the most important identified risk for C5 inhibition, since it is cleared via the MAC, the formation of which is inhibited by zilucoplan treatment. In the present studies, all study participants  were  required  to  be  vaccinated  against  Neisseria  Meningitidis  (meningococcal  infection) and/or to use prophylactic antibiotics. As a result, no meningococcal infections were reported in the ZLP development programme. Post-marketing, all patients are required to be vaccinated against Neisseria Meningitidis at least 2 weeks before zilucoplan treatment, or otherwise use antibiotics until at least 2 weeks have passed after the vaccination. Since patients with generalised myasthenia gravis are at higher risk of contracting infections due to their muscle weaknesses including the respiratory muscles, it would be prudent to be consistent with the immunisation recommendations in the SmPC even though no actual increase  in  the  risk  for  serious  infections  (other  than  Neisseria)  has  been  identified  for  zilucoplan. However, elderly as well as patients with diseases leading to muscle weakness (such as gMG) are often recommended to be vaccinated against pneumococcal infections. As a general precautionary principle and in line with the C5 antibodies and treatment guidelines, the following is added to the SmPC 4.4 text: 'Prior to initiating zilucoplan therapy, it is recommended that patients initiate immunizations according to current immunization guidelines.'

With regards to the risk of malignancy after zilucoplan treatment, no increased risk has been seen in non-clinical studies and in subjects with a genetic C5 deficiency. Malignant tumours were reported in 8 patients in the OLE studies, but these numbers were not considered increased compared to the normal population and did not include any cancer types that are known to be secondary to viral infection, such as HPV-related cervical cancer.

<div style=\"page-break-after: always\"></div>

The incidence of injection site reactions was higher in the zilucoplan 0.3 mg/kg treatment group than in the  placebo  group  (26.7%  vs  14.8%)  in  pool  S1A  with  similar  numbers  when  the  IMNM  study  was included  in  pool  S2A.  Injection  site  reactions  are  considered  ADRs  of  zilucoplan.  The  incidence  of hypersensitivity reactions was slightly higher in the zilucoplan treated groups than in the placebo groups over the randomised controlled trial pools. No severe hypersensitivity reactions including anaphylactic reactions occurred. Unlike the non-clinical cynomolgus toxicology studies, there were neither signs of hepatic events nor an increased incidence of skin and oral mucosal ulcerations in the clinical studies of zilucoplan.

Transient amylase and lipase elevations were seen without corresponding cases of pancreatitis.

Other C5 inhibitors, eculizumab and ravulizumab, are not labelled for any pancreatic events in their respective EU SmPCs; however, there have been reports of pancreatic events, including pancreatitis, pancreatic cysts, pancreatic carcinoma, pancreatic enzymes increased in the post-marketing setting, (FAERS dashboard, 2023).

The incidence of elevated liver function tests was low and similar across treatment groups. No study participants met criteria for potential drug induced liver injuries, including Hy's law criteria and no hepatic events occurred in the clinical studies.

In total, 12 pancreatic events in 9 subjects (8 men and 1 female), occurred. Infections were reported in the same patient prior to or during the pancreatic event in 10 of 12 cases, but no association between infectious agent and the pancreatic event was identified. 4 events of pancreatitis, of which 3 occurred in gMG  patients  and  1  occurred  in  an  ALS  study.  Of  these,  2  occurred  after  ERCP  and  1  after  covid vaccination. ERCP is a well-known risk for pancreatitis. Furthermore, of the pancreatic events, 5 were pancreatic cysts, of which 2 were pseudocysts, which may be a complication of ERCP, 1 was a benign epithelial cyst, 1 was a multifocal branch-duct intraductal papillary mucinous neoplasm (BD-IPMN, which shows a lower risk than main duct IPMN to develop into pancreatic cancer) and 1 unknown type. Known risk factors for acute pancreatitis are gallstones and the ERCP procedure to treat gallstones, alcohol abuse,  smoking,  diabetes,  obesity.  Taking  into  consideration  the  non-clinical findings of  both hepatobiliary and pancreatic changes, a common causative factor for hepatobiliary and pancreatic events would have been expected in the clinical studies. However, here was no trend for liver enzyme elevations of concern in the clinical studies, which otherwise could have suggested a common causative factor for the original hepatobiliary events treated with ERCP and the pancreatitis.

In conclusion, no common causative factor has been elucidated for severe pancreatic events including acute pancreatitis and pancreatic cancer. Nevertheless, the pancreatic findings in the non-clinical studies together  with  the  elevated  pancreatic  enzymes  in  the  human  studies  call  for  a  close  follow  up  of pancreatic events post-approval. Pancreatic events are included as an important potential risk in the list of safety concerns in the context of the PSUR.

A role for eosinophils in autoimmunity has been suggested and complement 5a is implicated in inducing eosinophil activation and extravasation. Case reports of simultaneous presentation of hypereosinophilic syndrome and myasthenia gravis have been described. In the zilucoplan studies, transient asymptomatic eosinophil elevations were observed without cases of hypereosinophilic syndrome.

There were no effects on vital signs or ECG. A negative TQT study was included during the submission.

Not surprisingly, a longer disease duration, a more severe disease, and a refractory disease were all related to a higher incidence of TEAEs in the pivotal study. This probably reflects both a more fragile status of the patient due to muscular weakness and patients with a longer disease duration previously having  been  exposed  to  more  immunosuppressive  medications  making  them  more  susceptible  to infections. There was also a trend for women having more TEAEs.

<div style=\"page-break-after: always\"></div>

The incidence of serious TEAEs in placebo vs zilucoplan-treated patients was variable in different BMI spans, with the higher incidence in zilucoplan vs placebo only in the BMI 30-40 kg/m 2  group. In the OLE study, the two groups with a BMI 30-40 kg/m 2  and &gt;40 kg/m 2  showed an increasing rate of serious TEAEs related to cardiac disorders and infections &amp; infestations.

The  applicant  claims  that  an  increasing  trend  for  the  SOCs  Cardiac  disorders  and  Infections  and infestations is expected since obese patients have an increased risk of morbidity and mortality for these types of disorders. According to the applicant, obesity and/or comorbid conditions were risk factors for an increased mortality in the types of TEAEs that led to death in all 8 study participants with a BMI &gt;30kg/m2 and that the presence of these risk factors are nonsuggestive for a contributory role of ZLP.

Animal studies did not indicate direct or indirect harmful effects with respect to pregnancy and an exvivo closed-circuit human placental transfer model suggest low transfer rate of ZLP (0.5 to 1.0%) in the foetal compartment. The clinical relevance of these data in human pregnancies is unknown.

1 pregnancy with maternal exposure to zilucoplan for a year before and with the last dose shortly after the last menstruation, giving birth to a healthy child. No reported cases of lactation while treated with zilucoplan.

The  applicant  has  presented  results  from  an ex  vivo placental  transfer  model  indicating  low  grade transfer of zilucoplan over placenta. However, the clinical relevance of this model is unknown and the data  from  the  literature  on  placental  transfer  of  peptides  and  pegylated  peptides  provided  by  the applicant did not shed further light on this issue. Thus, there is no clinical information that could justify a specific SmPC text for zilucoplan in section 4.6.

Incidences of treatment -emergent ADA positive or APA positive study participants were low in the longterm safety  pool  (1.2%  and  5.9%,  respectively).  There  was  no  evidence  of  an  association  between positive ADA status or positive APA status and the incidence of hypersensitivity reactions, injection site reactions or autoimmune disorders.

During the procedure, a safety signal of morphoea was validated in Feb 2023 by the applicant due to the occurrence of 11 TEAEs of morphoea in 10 study participants in the ongoing open-label Phase 3 study in gMG, MG0011. Based on the high incidence in the long-term FU study and a time-to-onset that is in line with other drug-induced cases of morphoea, the relation to treatment with zilucoplan is considered at least possible. Thus, morphoea is included in the SmPC section 4.8 Table of ADRs with a frequency of common and described below the ADR table as a selected ADR.

## 2.6.10. Conclusions on the clinical safety

The safety database is considered sufficient and the safety of zilucoplan in the treatment of gMG has been appropriately characterised. The safety profile is acceptable with Neisseria infection being the most important risk. Increases in amylase and lipase appear product specific. It should be further elucidated in PSURs whether pancreatic events including pancreatitis may be a risk for zilucoplan.

<div style=\"page-break-after: always\"></div>

## Risk Management Plan

## 2.6.11. Safety concerns

Table 43: Summary of safety concerns

| List of important risks and missing ginformation   | List of important risks and missing ginformation            |
|----------------------------------------------------|-------------------------------------------------------------|
| Important identified risks                         | None                                                        |
| Important potential risks                          | Neisseria infections, particularly meningococcal infections |
| Missing information                                | Use during pregnancy and lactation Long-term safety         |

## 2.6.12. Pharmacovigilance plan

Table 44: Ongoing and planned additional pharmacovigilance activities

| Study Status                                                                                                                  | Summary of objectives                                                                                                                                                                                                                                                                    | Safety concerns addressed                                                                                                                                          | Milestones                                                     | Due dates                                                                                                            |
|-------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------|
| Category 3 -- Required additional pharmacovigilance activities                                                                | Category 3 -- Required additional pharmacovigilance activities                                                                                                                                                                                                                           | Category 3 -- Required additional pharmacovigilance activities                                                                                                     | Category 3 -- Required additional pharmacovigilance activities | Category 3 -- Required additional pharmacovigilance activities                                                       |
| Observational secondary data PASS (MG0026) Planned                                                                            | To assess the implementation of the RMM, to evaluate any potential increase in the risk of serious infections for zilucoplan exposed gMG patients compared to gMG patients not exposed to zilucoplan(exposed to other gMG treatments) and to describe other safety outcomes of interest. | Important potential risk: Neisseria infections, particularly meningococcal infections Missing information: Use of zilucoplan during pregnancy and long-term safety | Protocol submission                                            | Will be submitted for PRAC review before initiation of the study (6 months after marketing authorisation in Europe). |
| Observational secondary data PASS (MG0026) Planned                                                                            | To assess the implementation of the RMM, to evaluate any potential increase in the risk of serious infections for zilucoplan exposed gMG patients compared to gMG patients not exposed to zilucoplan(exposed to other gMG treatments) and to describe other safety outcomes of interest. | Important potential risk: Neisseria infections, particularly meningococcal infections Missing information: Use of zilucoplan during pregnancy and long-term safety | Interim report submission                                      | 01 Jun 2026                                                                                                          |
| Observational secondary data PASS (MG0026) Planned                                                                            | To assess the implementation of the RMM, to evaluate any potential increase in the risk of serious infections for zilucoplan exposed gMG patients compared to gMG patients not exposed to zilucoplan(exposed to other gMG treatments) and to describe other safety outcomes of interest. | Important potential risk: Neisseria infections, particularly meningococcal infections Missing information: Use of zilucoplan during pregnancy and long-term safety | Final report submission                                        | 01 Dec 2028                                                                                                          |
| MG0011 (RAISE-XT)- - A Phase 3, multicentre, open- label extension study of zilucoplan in study participants with gMG Ongoing | To assess the long- term safety, tolerability, and efficacy of zilucoplan in study participants with gMG.                                                                                                                                                                                | Missing information: long-term safety                                                                                                                              | Final report submission                                        | 30 Nov 2026                                                                                                          |

<div style=\"page-break-after: always\"></div>

## 2.6.13. Risk minimisation measures

Table  45:  Summary  table  of  pharmacovigilance  activities  and  risk  minimisation  activities  by  safety concern

| Safety Concern                                              | Risk minimisation measures (RMMs)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Pharmacovigilance activities                                                                                                                                                                                                                                                                                                     |
|-------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Neisseria infections, particularly meningococcal infections | Routine RMMs: Zilucoplan is intended for use under the guidance and supervision by specialist healthcare professionals experienced in the management of patients with neuromuscular disorders (SmPC Section 4.2 Posology and method of administration). SmPC Section 4.3 (Contraindications). Measures such as meningococcal vaccination and antibiotic prophylaxis are discussed in SmPC Section 4.4 (Special warnings and precautions for use), PL Section 2 (What you need to know before you use Zilbrysq), and PL Section 3 (How to use Zilbrysq). Risk of Neisseria infections and information on signs and symptoms of meningococcal infections are discussed under SmPC Section 4.4 (Special warnings and precautions for use) and PL Section 2 (What you need to know before you use Zilbrysq). Additional RMMs for meningococcal infections: Controlled access programme Educational materials - Guide for HCPs - Patient Alert Card - Patient/Carer Guide | Routine PhV activities beyond adverse reactions reporting and signal detection: A specific adverse reaction follow-up questionnaire for 'meningococcal infections' will be utilised in the post-marketing setting. Additional PhV activities: Zilucoplan observational secondary data post- authorisation safety study (MG0026). |
| Missing information                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                  |
| Use during pregnancy and lactation                          | Routine RMMs: Zilucoplan is intended for use under the guidance and supervision by specialist healthcare professionals experienced in the management of patients with neuromuscular disorders (SmPC Section 4.2 Posology and method of administration). SmPC Section 4.6 (Fertility, Pregnancy, and Lactation). PL Section 2 (What you need to know before you use Zilbrysq) Additional RMMs: None                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Routine PhV activities beyond adverse reactions reporting and signal detection: None Additional PhV activities: Zilucoplan observational secondary data post- authorisation safety                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

| Long-term safety   | Routine RMMs: Zilucoplan is intended for use under the guidance and supervision by specialist healthcare professionals experienced in the management of patients with neuromuscular disorders (SmPC Section 4.2 Posology and method of administration). Additional RMMs: None   | Routine PhV activities beyond adverse reactions reporting and signal detection: None Additional PhV activities: Zilucoplan observational secondary data post- authorisation safety study (MG0026). Zilucoplan open-label extension study (MG0011/RAISE-XT)   |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

## 2.6.14. Conclusion

The CHMP considers that the risk management plan version 0.4 is acceptable.

## 2.7. Pharmacovigilance

## 2.7.1. Pharmacovigilance system

The CHMP considered that the pharmacovigilance system summary submitted by the applicant fulfils the requirements of Article 8(3) of Directive 2001/83/EC.

## 2.7.2. Periodic Safety Update Reports submission requirements

The requirements for submission of periodic safety update reports for this medicinal product are set out in the Annex II, Section C of the CHMP Opinion. The applicant did request alignment of the PSUR cycle with the international birth date IBD. The IBD is 12-11-2015. The new EURD list entry will therefore use the IBD to determine the forthcoming Data Lock Points.

## 2.8. Product information

## 2.8.1. User consultation

The results of the user consultation with target patient groups on the package leaflet submitted by the applicant show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use.

## 2.8.2. Additional monitoring

Pursuant  to  Article  23(1)  of  Regulation  No  (EU)  726/2004,  Zilbrysq  (zilucoplan)  is  included  in  the additional  monitoring  list  as  it  contains  a  new  active  substance  which,  on  1  January  2011,  was  not contained in any medicinal product authorised in the EU.

Therefore, the summary of product characteristics and the package leaflet includes a statement that this

<div style=\"page-break-after: always\"></div>

medicinal product is subject to additional monitoring and that this will allow quick identification of new safety information. The statement is preceded by an inverted equilateral black triangle.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

The applicant seeks approval for zilucoplan (Zilbrysq) in the following indication: for the treatment of gMG in adult patients who are anti-acetylcholine receptor (AChR) antibody positive and require treatment in addition to steroids or non-steroidal immunosuppressants.

MG is a rare disease characterised by the production of autoantibodies targeting proteins that are critical for the normal transmission of neurotransmitter signals from nerves to muscles. Approximately 80% of patients with MG are AChR antibody positive. Binding of anti-AChR auto-antibodies to AChR results in an activation of the classical complement pathway, culminating in the cleavage of C5 into C5a and C5b and deposition of the cytolytic MAC (C5b-9) on the post-synaptic membrane of the NMJ and subsequent injury to the neuromuscular endplate.

MG most commonly affects young adult women (under 40) and older men (over 60), but it can occur at any age. The prevalence of MG in Europe (EU) is estimated to be 1 per 5,000 population (Orphanet).

## 3.1.2. Available therapies and unmet medical need

First-line  therapy  for  symptomatic  gMG  is  treatment  with  acetylcholinesterase  inhibitors  such  as pyridostigmine.  Pyridostigmine  monotherapy  is  usually  insufficient  for  the  treatment  of  generalised weakness. Therefore, corticosteroids with or without systemic immunosuppressants are used off label. Immunosuppressants  used  frequently  in  gMG  include  azathioprine  and  mycophenolate  mofetil. Cyclosporine,  methotrexate,  tacrolimus,  cyclophosphamide,  and  rituximab  are  also  used.  These immunosuppressants have established short- and long-term toxicities. Surgical removal of the thymus may be recommended in patients with non-thymomatous gMG and moderate to severe symptoms, in an effort to reduce the production of AChR autoantibodies. IVIG and PLEX are typically used short-term to manage worsening MG symptoms and in patients with myasthenic crisis or life-threatening signs such as respiratory insufficiency or dysphagia.

Inhibition of C5 for the treatment of gMG has already been shown to be effective in 2 clinical studies with  the  C5-blocking  antibodies  eculizumab  and  ravulizumab.  The  most  recent  additions  to  the  MG treatment regimen, has been the introduction of efgartigimod (Vyvgart®), an IgG1 Fc fragment that targets FcRn, leading to reduced overall IgG recycling.

In spite of a number of MG medications used off-label and recently approved, an unmet medical need for new therapies due to insufficiencies of current treatment options due to insufficient effects, adverse effects, high costs, and poor patient access continues to persist. There is a need for improved therapeutic options, and in particular a more accessible and convenient C5 inhibitor such as zilucoplan for patients with gMG.

<div style=\"page-break-after: always\"></div>

## 3.1.3. Main clinical studies

The main clinical trials were the phase III trials MG0010 and its open label extension MG0011.

MG0010 was a single pivotal, placebo-controlled, double- blind parallel study comparing zilucoplan 0.3 mg/kg and placebo. Endpoints were measured at 12 weeks with MG-ADL change from baseline being the primary efficacy endpoint and change from baseline in QMG, MCG and MG-QOL15r as the most important secondary efficacy endpoints. One hundred and seventy-four patients were randomised, 88 to placebo and 86 to zilucoplan.

MG0011 was an open label study for participants who had completed MG0011 or the phase II study MG0009. All participants (N=199) were given zilucoplan 0.3 mg/kg. Efficacy at 24 weeks was obtained by combining the 12 weeks blinded data from MG0010, and 12 weeks open label data from MG0011.

## 3.2. Favourable effects

## Efficacy at 12 weeks: primary and key secondary endpoints

Study MG0010 was a single pivotal, randomised double blind PB-controlled parallel study comparing the efficacy  of  ZLP  0.3mg/kg  with  PB  at  12  weeks.  Patients  included  were  to  be  Acetylcholine-receptor antibody positive, MGFA II-IV, have at least an MG-ADL score of 6 and a QMG score of at least 12 with a score of at least 2 in at least 4 items. At baseline, MG-ADL was 10.6 and QMG was 19.1, 50.6% of participants were treatment refractory. After 12 weeks of treatment, the primary efficacy endpoint, MGADL change from baseline, was LSM -2.09 (95% CI -3.24, -0.95) in ZLP 0.3 mg/kg treated participants, corrected  for  CBL  in  PB  participants  (p&lt;0.001).  All  sensitivity  analyses  were  highly  significant  with estimates ranging between -2.02 and -2.35. The first key secondary efficacy endpoint, QMG change from baseline, was (LSM) -2.94 (95% CI -4.39, -1.49) corrected for CBL in PB participants (p&lt;0.001). Efficacy estimates in the two other key secondary endpoints, MGC and MG-QOL15r, were -3.20 (p=0.0023) and -2.49 (p=0.0128).

Study  MG0009  was  a  phase  II  randomised  double  blind  PB-controlled  parallel  study  comparing  the efficacy of ZLP 0.3mg/kg and ZLP 0.1mg/kg with PB at 12 weeks. In this study, QMG was the primary efficacy endpoint and MG-ADL one of the secondary endpoints. Baseline characteristics were similar to study MG0010. Efficacy (CBL in QMG) at 12 weeks was -2.8 corrected for CBL in PB treated participants (p=0.0538, one-sided p-value). MG-ADL change from baseline was -2.3 corrected for CBL in PB treated participants (p=0.0392, one-sided p-value). Efficacy estimates in the two other key secondary endpoints, MGC and MG-QOL15r, were -4.1  (p=0.0301,  one-sided  p-value)  and  -3.7  (p=0.0624,  one-sided  pvalue).

Study MG0011 was an OLE of Study MG0010 (and MG0009) where all participants received ZLP 0.3 mg/kg. After 12 weeks of open label ZLP 0.3 mg/kg treatment, the former MG0010 PB participants had reduced their MG-ADL with 2.87 points and QMG 3. 77 points. This can be compared to the CBL not corrected for PB in study MG0010, MG-ADL -4.68 and QMG -6.48.

## Additional efficacy data at 12 weeks

Proportions and odds ratio (ORs) were calculated for responders in Study MG0010: MG-ADL (achieving a ≥ 3-point reduction in MG-ADL score at Week 12 without rescue therapy), 73.1% (ZLP) vs 46.1% (PB), OR: 3.184; 95% CI: 1.662 to 6.101, QMG (achieving a ≥ 5-point reduction in QMG score at Week 12 without rescue therapy) 58.0% vs 33.0%, OR: 2.865; 95% CI: 1.518 to 5.409 and Minimal Symptom Expression (MG-ADL of 0 or 1, at Week 12 without rescue therapy) 14.0% vs 5.8%; OR: 2.608; 95% CI:  0.866  to  7.860.  MG-ADL responders and QMG responders were significant also after multiplicity control.

<div style=\"page-break-after: always\"></div>

The  cumulative  proportion  of  study  participants  receiving  rescue  therapy  by  Week  12  was  5%  (4 participants) in the ZLP 0.3mg/kg group and 12% (10 participants) in the placebo group (p=0.1003).

## Efficacy at 24 weeks: primary and key secondary endpoints

Efficacy at 24 weeks was estimated in participants who received ZLP 0.3 mg/kg blinded for 12 weeks in study MG0010 and continued ZLP 0.3 mg/kg in the OL study MG0011. After 24 weeks of active treatment, the  CBL  with  conservative  imputation  (participants  who  discontinued  or  used  rescue  therapy  were counted  as  treatment  failures  and  participants  who  died  were  given  the  maximum  score  for  each assessment scale) was -5.33 in MG-ADL and - 7.10 in QMG. CBL in MGC and MG-QOL15r was -9.91 and -8.06, respectively.

24 weeks efficacy data was also obtained from Study MG0009 when combining the 12-week blinded portion with the OL portion of the same study. CBL was -4.15 in MG-ADL, -7.50 in QMG, -7.6 in MGC, and -6.1 in MG-QOL15r.

## Long term efficacy

With conservative imputation (study participants who discontinued the study and participants who used rescue therapy were counted as treatment failures, study participants who died were imputed with the worst possible score from the time of death) mean change from double-blind study (MG0010) baseline to week 24 (week 12 of MG0011) and week 60 (week 48 of MG0011) in total scores were: MG-ADL 5.46 and -5.16, QMG -7.10 and -6.44, MGC -10.37 and -8.89, and MG QoL15r -8.09 and -7.22 in the initial PB group. Corresponding changes in the group treated with ZLP from MG0010 baseline were; MG ADL -5.20 and -4.37, QMG -7.19 and -6.15, MGC -11.12 and -9.02, and MG QoL15r -7.96 and -6.09.

## Subgroup analyses

In  the  pivotal  study  MG0010,  participants  aged  &lt;65  years  reduced  their  MG-ADL  with  4.56  points (placebo 2.75), and participants aged ≥65 years reduced their MG -ADL with 5.14 points (placebo 3.08), at 12 weeks. MG-QOL15r was reduced 7.02 points (placebo 3.65) in the younger participants and 3.02 points (placebo 4.54) in the older participants. In MG0011, the corresponding reduction in MG-ADL (not PB corrected) after 12 weeks of ZLP treatment in the former PB participants was 3.57 in participants &lt;65 years an d  2.36  in  participants  ≥65  years;  the  MG -QOL15r reduction was 6.11 and 2.55 points respectively. In post hoc analyses with data imputation (rescue therapy, myasthenic crisis, or death were imputed as treatment failure), LSM change in MG-ADL was -2.22 in participants aged &lt;65 years and 1.99 in participants aged ≥65 years, MG -QOL15r LSM change in was -3.52 in the younger participants and +0.26 in the older participants. At week 24 in MG0011, MG-QOL15r was reduced with 9.39 points in the younger participants and 4.29 in the older participants.

Participants in MG0010 with MGADL ≤9 at baseline, reduced MG -ADL with 3.88 points (placebo 2.48) and participants with MG-ADL &gt;9 at baseline reduced MG-ADL with 5.24 points (placebo 3.06) at 12 weeks. Corresponding reductions in MG0011 (not PB corrected) were 1.76 and 6.06 in the former PB participants at 12 weeks and 0.56 and 4.33 in the former ZLP participants (i.e. their last 12 weeks of ZLP treatment). In post hoc analysis  using  imputation  (scores  after  rescue  therapy  or  any  death  or myasthenic crisis were imputed based on baseline score or on the last available score, whichever was worst) participants with baseline MG-ADL &lt;9, 9&lt;12, and ≥12, reduced their MG -ADL score with 4.41, 3.49  and  5.59  points  respectively  (not  corrected  for  BP).  Efficacy  data  based  on  MG-ADL  were  not provided for 24 weeks follow up.

Participants with QMG ≤17 at baseline vs ≥18 at MG0010 baseline reduced their MG -ADL with 4.19 points (placebo 2.81) and 5.11 points (placebo 2.88), respectively. Corresponding numbers in MG0011 (i. e. not PB corrected) were -2.43 and -5.05 in the former PB participants at 12 weeks and -0.50 and 3.80 in the former ZLP participants (i.e. their last 12 weeks of ZLP treatment). In post hoc analysis using

<div style=\"page-break-after: always\"></div>

imputation  (scores  after  rescue  therapy  or  any  death  or  myasthenic  crisis  were  imputed  based  on baseline score or on the last available score, whichever was worst) participants with baseline QMG ≤16 and QMG &gt;16 (note the different subgroup limits than in the original analyses), reduced their MG-ADL with 3.88 and 4.61 points respectively (not corrected for PB). Efficacy data based on QMG were not provided for 24 week follow up.

Participants  classified  as  MG  refractory yes versus no reduced  their  MG-ADL  with  2.63  and  1.08 respectively, (corrected for PB). Corresponding numbers in MG0011 (i. e. not PB corrected) were -3.87 and -2.67 in the former PB participants at 12 weeks and -0.97 and -1.39 in the former ZLP participants (i.e. their last 2 weeks of ZLP treatment).

## 3.3. Uncertainties and limitations about favourable effects

The requirements of the disease manifestations, as expressed in the inclusion criteria of studies MG0009 and MG0010, decrease the proportion of patients with mild disease. This can be seen in the baseline disease characteristics where more than 70% of participants had at least moderate weakness according to  the  MGFA  classification,  mean  MG-ADL  was  10.6  and  mean  QMG  (all  participants)  was  19.1.  For comparison, the cohort of patients selected from the MG-registry for the external reference of study MG0011 (requirement of baseline MGADL ≥ 6), had a baseline MG -ADL of 7.4 and QMG of 12.9. The two cohorts from the MGTX study included in the modelling for the reference group, had an index mean QMG of 13.0 and mean MG-ADL of 8.0 before using Odds  Weighting. Subgroup analyses based on dichotomous groups of disease severity (MGADL ≤9 vs &gt;9, QMG ≤17 vs ≥ 18) indicate that participants in the groups with less severe disease improved numerically less than participants more affected by their gMG disease. This is seen in the PB controlled study MG0010 at 12 weeks and the difference between less and more affected participants, albeit not corrected for PB effect, is even larger after 24 weeks in study MG0011. However, post hoc subgroup analyses which used data imputation (scores after rescue therapy or any death or myasthenic crisis were imputed based on baseline score or on the last available score, whichever was worst) as opposed to the original subgroup analyses, did not confirm the initial findings. In explored subgroups (based on MG-ADL at baseline, QMG at baseline and MGFA at baseline), no clear correlation was observed between the effect size (CBL, responder rate) of zilucoplan and disease severity. 24 weeks efficacy data in subgroups based on MG-ADL and QMG were not provided.

As  pointed  out  earlier  in  scientific  advice,  a  12-week  PB-controlled  study  may  not  be  of  sufficient duration, given the expected long-term treatment and the fact that myasthenia gravis fluctuates over time. Twenty-four weeks data were obtained by combining the 12-week double-blind Study MG0010 with the first 12 weeks of the OL study MG0011. The main issue with the last 12 weeks being that in a setting that lacks a concurrent randomised control, treatment efficacy cannot be isolated, and the true treatment efficacy cannot be separated from e.g., subject-expectancy effect or spontaneous disease fluctuations. Nevertheless, supplementary analyses support that there is treatment efficacy after the 12 weeks of open label study (in total 24 weeks) despite other sources of clinical improvement.

In  study  MG0011,  at  12  weeks,  there  is  a  numerical  difference  with  smaller  efficacy  magnitude  in participants ≥ 65 years of age in the former PB participants. The difference is minor in the MG-ADL score, but quite evident in the secondary efficacy endpoints. In Study MG0010, elderly participants seemed to benefit less than younger only when looking at the quality-of-life score, MG-QOL15. In an additional post hoc analysis  using  imputation  (discontinuation,  rescue  and  death  imputed  with  treatment  failure)  a difference in efficacy between age groups in MG0010 was still seen in QMG; -3.42 versus -1.84, and MGQOL15r -3.52 versus +0.26. A more conservative analysis (death imputed with worst score of each scale) was performed on data from MG0011 and a notable difference between age groups was then only seen for MG-QOL15r in participants treated for 24 weeks.

<div style=\"page-break-after: always\"></div>

## 3.4. Unfavourable effects

The most well-characterised risk of C5-inhibition, known from subjects with genetic C5 deficiency and treatment with the approved C5-blocking monoclonal antibodies eculizumab and ravulizumab is the risk of Neisseria infection,  and  especially  that  of  Neisseria  Meningitidis  (meningococcal  meningitis). Therefore, all subjects in the clinical studies were vaccinated against meningococcal infection and no such cases occurred.

The overall incidence of AEs was similar between study arms (80.9% zilucoplan versus 73.4% placebo) in the phase 2 and 3 studies (Pool S1A), most of them mild-moderate AEs (severe AEs 13.9% zilucoplan versus  13.6%  placebo)  and  34.8%  in  zilucoplan  versus  26.2%  in  placebo  considered  related  to treatment. In Pool S1A, incidences of serious TEAEs were similar in the ZLP 0.1mg/kg+0.3mg/kg group (13.9%) and in the placebo group (15.5%). The incidence of AEs leading to treatment discontinuation was also low (4.0% zilucoplan 0.3 mg/kg versus 1.9% placebo, 0 in zilucoplan 0.1 mg/kg group). In the two randomised clinical trials, there were 2 deaths, one in the zilucoplan treatment group (Covid-19 pneumonia) and one in the placebo group (cerebral haemorrhage). Eight deaths occurred during OLE periods of gMG studies (3 in MG0009, 5 in MG0011).

Headache  (19.1%  versus  16.5%  of  patients  for  zilucoplan  and  placebo,  respectively),  injection  site bruising  (13.9%  versus  9.7%),  myasthenia  gravis  (12.2%  versus  12.6%),  diarrhoea  (9.6%  versus 2.9%), (procedural) contusion (7.8% versus 3.9%), injection site pain (7.0% versus 3.9%), urinary tract infection (7.0% versus 3.9%), amylase increased (6.1% versus 2.9%), lipase increased (5.2% versus 2.9%), nasopharyngitis (5.2% versus 2.9%), oedema peripheral (4.3% versus 1.0%), were the most frequently reported AEs both in zilucoplan and placebo groups. During the open-label extension headache  (23.0%),  myasthenia  gravis  (19.7%),  and  diarrhoea  (15.0%).  were  the  most  frequently reported  AEs.  ARDs  for  zilucoplan  (pool  S2A)  were  injection  site  reactions  (25.2%  for  all  zilucoplan treated versus 14.4% for placebo), upper respiratory tract infections (13.4% versus 6.8%), diarrhoea (8.7% versus 2.5%), amylase increased (6.3% versus 2.5%), lipase increased (4.7% versus 2.5%), and blood eosinophils increased (0.8% versus 0).

## 3.5. Uncertainties and limitations about unfavourable effects

The main uncertainties of the unfavourable effects derive from the limitations of the safety database, particularly long-term safety data with a total of 138 gMG patients exposed for ≥6 months and 91 gMG patients exposed for more than a year, of which 87 at the therapeutic dose 0.3mg/kg). When patients with  IMNM were  included,  99  subjects  have  been  exposed  to  zilucoplan  for  ≥12  months. These uncertainties are mitigated to some extent by the long-standing post-marketing experience with other C5 related products. In addition, clinical reviews of rare cases with inherited C5 deficiency show that an increased  risk  of  recurrent Neisseria infections  appears  to  be  the  only  clinical  consequence  of  C5 deficiency (Schejbel et al., Primary complement C5 deficiencies - Molecular characterisation and clinical review of two families,2013). Updated safety data from the ongoing MG0011 clinical trial through the September 8, 2022 cut-off date, provided by the applicant during the procedure did not raise any new safety issue. 139 patients were treated with ZLP for 1 year. That seems sufficient for long term data.

The  total  number  of  study  participants  in  the  ZLP  0.1mg/kg  treatment  group  (N=15)  was  limited compared with the number of study participants in the placebo (N=118) and ZLP 0.3mg/kg (N=112) treatment groups. This has impeded the detection of potential dose response with respect to safety, since the dose range was narrow between the two doses used in clinical studies and the numbers were too small to draw any meaningful conclusions. Overall, no dose response has been observed with respect to safety.

<div style=\"page-break-after: always\"></div>

Due to the limited number of patients enrolled in some categories, it is not possible to obtain any reliable conclusions  about  different  safety  profile  in  specific  subgroups.  Nevertheless,  a  trend  for  a  higher incidence of severe and serious AEs is noted in the elderly population and for all AEs and serious AEs for female versus male subjects.

Meningococcal infections are the most important identified risk for C5 inhibition, since it is cleared via the MAC, the formation of which is inhibited by zilucoplan treatment. In the present studies, all study participants  were  required  to  be  vaccinated  against Neisseria  Meningitidis (meningococcal  infection) and/or to use prophylactic antibiotics. As a result, no meningococcal infections were reported in the ZLP development programme. However, upper respiratory tract infections were observed at an increased incidence in the zilucoplan group versus placebo and UTIs were slightly more common. Since patients with gMG may also be more susceptible to infections due to their background disease with respiratory muscular  weakness,  a  recommendation  that  patients  initiate  immunisations  according  to  current immunisation guidelines before treatment with zilucoplan is included in SmPC 4.4.

Serious infections have been included as an important potential risk in the list of safety concerns in the context of the PSUR.

No  common  causative  factor  has  been  elucidated  for  severe  pancreatic  events  including  acute pancreatitis  and  pancreatic  cancer.  Nevertheless,  the  pancreatic  findings  in  the  non-clinical  studies together  with  the  elevated  pancreatic  enzymes  in  the  human  studies  call  for  a  close  follow  up  of pancreatic events post-approval. Accordingly, pancreatic events have been included as an important potential risk in the list of safety concerns in the context of the PSUR.

## 3.6. Effects Table

Table 46: Effects table for Zilbrysq (zilucoplan) for the treatment of generalised myasthenia gravis

The database for the interim Clinical Study Report of MG0011 is based on a clinical data cut-off date of 18 Feb 2022.

| Effect             | Short Description                                                | Unit               | Treatment                   | Control            | Uncertainties/ Strength of evidence                                                                       | Refere nces        |
|--------------------|------------------------------------------------------------------|--------------------|-----------------------------|--------------------|-----------------------------------------------------------------------------------------------------------|--------------------|
| Favourable Effects | Favourable Effects                                               | Favourable Effects | Favourable Effects          | Favourable Effects | Favourable Effects                                                                                        | Favourable Effects |
|                    |                                                                  |                    | Zilucoplan 0.3 mg/kg groups | Placebo            |                                                                                                           |                    |
| MG-ADL             | 8-item (0-24p) Patient reported outcome                          | CBL week 12        | -4.39                       | -2.30              | p<0.001 for MG-ADL (primary EP) and QMG first key secondary EP. MGC and MG-QOL15r had p<0.05. Sensitivity | MG0010             |
| QMG                | Standardised and validated quantitative strength scoring (0-39p) | CBL week 12        | -6.19                       | -3.25              | analyses with similar estimates and statistical significance.                                             | MG0010             |
| MGC                | Combination of examination and patient reported symptoms         | CBL week 12        | -8.62                       | -5.42              | Few discontinued the study.                                                                               | MG0010             |
| MG- QOL15r         | Patient reported QOL                                             | CBL week 12        | -5.65                       | -3.16              | Few discontinued the study.                                                                               | MG0010             |

<div style=\"page-break-after: always\"></div>

Effect

MG-ADL

QMG

MGC

MG-

Short

Description

8-item (0-24p)

Patient reported outcome

Standardised and

validated quantitative

strength scoring (0-39p)

Combination  of examination

and patient

reported symptoms

Patient reported

QOL15r

QOL

## Unfavourable Effects

|                                           |                                                                                | %   |   Zilucoplan 0.3 and 0.1 mg/kg groups |   Placebo | Percentages calculated based on available data from patients on zilucoplan and patients on PBO.   | Pool S1A (MG0009 /MG0010 combined safety analysis)   |
|-------------------------------------------|--------------------------------------------------------------------------------|-----|---------------------------------------|-----------|---------------------------------------------------------------------------------------------------|------------------------------------------------------|
| All AEs                                   |                                                                                | %   |                                  80.9 |      73.4 |                                                                                                   |                                                      |
| Treatmen t-related AEs                    |                                                                                | %   |                                  34.8 |      26.2 |                                                                                                   |                                                      |
| Severe AEs                                |                                                                                | %   |                                  13.9 |      13.6 |                                                                                                   |                                                      |
| AEs leading to treatment discontin uation |                                                                                | %   |                                   3.5 |       1.9 |                                                                                                   |                                                      |
| Headache                                  |                                                                                | %   |                                  19.1 |      16.5 |                                                                                                   |                                                      |
| Injection site reactions                  |                                                                                | %   |                                  26.7 |      14.8 |                                                                                                   |                                                      |
| Upper respirator y tract infections       | Nasopharyngiti s, sinusitis, upper respiratory infections. Viral and bacterial | %   |                                  13.4 |       6.8 | Pool S2A                                                                                          |                                                      |
| Diarrhoea                                 |                                                                                | %   |                                   9.6 |       2.9 |                                                                                                   |                                                      |
| UTI                                       |                                                                                | %   |                                   7   |       3.9 |                                                                                                   |                                                      |
| Amylase increased                         |                                                                                | %   |                                   6.1 |       2.9 |                                                                                                   |                                                      |
| Lipase increased                          |                                                                                | %   |                                   5.2 |       2.9 |                                                                                                   |                                                      |

Unit

CBL

week

E12/

week

24

CBL

week

E12/

week

24

CBL

week

E12/

week

24

CBL

week

E12/

week

24

Treatment

-5.33

-7.10

-9.91

-8.06

Control

-

-

-

-

Uncertainties/

Strength of evidence

Open  label.  No  placebo control.  Rescue  therapy

or discontinuation

counted as

treatment failure  and  imputed  with

last observation

or baseline  score  whichever

was worst.

Death was

imputed with worst score possible for each scale.

Refere nces

MG0011

Interim analysis

,  cut-off date  08

Sep

2022

<div style=\"page-break-after: always\"></div>

| Effect       | Short Description   | Unit   |   Treatment | Control   | Uncertainties/ Strength of evidence   | Refere nces           |
|--------------|---------------------|--------|-------------|-----------|---------------------------------------|-----------------------|
| ADA          |                     | %      |         1.2 | N/A       |                                       | Pool S1B:             |
| Anti-PEG- Ab |                     | %      |         5.9 | N/A       |                                       | (Long- term gMG pool) |

Abbreviations: CBL change from baseline

Notes:

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

## Efficacy at 12 weeks

The primary efficacy endpoint in the phase III trials was change from baseline in MG-ADL. MG-ADL score is a based on the patient's subjective reporting of function and impairment during activities of daily living and a reduction of 2 points indicates clinical improvement (Muppidi et  al ).  The  efficacy found in the pivotal Study MG0010, a reduction of 2.09 points, can thus be regarded as a clinically relevant effect.

The first key secondary endpoint, change from baseline in QMG, is an important efficacy endpoint as it is based on the physician's examination findings at a specific medical visit when the patient has been off acetylcholine esterase inhibitor medication for a certain number of hours, usually at least 10 hours. It is in that sense objective, as opposed to MG-ADL. It has been found that treatment must produce more than 2.6 units of change in QMG to be of clinical significance. QMG score changes of up to 2.6 units are expected  to  occur  due  to  variability  of  repeated  observations  (Bahron et  al ).  Further,  the  minimal clinically important difference (from baseline) in QMG score has been stated to be dependent on baseline QMG. If baseline QMG &gt;16, a reduction of 2.75 points can be regarded as minimal clinically important difference (Katzberg et al ). According to the MGFA, recent data support the use of a 2- or 3- point of change in QMG as a criterion for minimal clinically significant change and depending on MG severity; in mild (QMG 0-9) to moderate disease (QMG 10-16), a 2-point change is clinically significant and a 3-point change is significant for severe MG (QMG &gt;16) (https://myasthenia.org/Professionals/Resources-forProfessionals Jan 8, 2023). In the pivotal trial, QMG was reduced with 2.94 points and therefore can be regarded a clinically relevant effect.

MGC, one of the other two secondary endpoints, requires a reduction of 3 points to be considered to reflect clinical improvement and meaningful to the patient. The change from baseline in the pivotal study was -3.20 at 12 weeks. What represents a clinically meaning full change in MG-QOL15r has not been defined.

Based on the above discussion what improvements are required to represent a clinically relevant efficacy, the magnitude of efficacy at 12 weeks in the studied population can be regarded as meaningful. These results  were  highly  significant  and  robust  as  sensitivity  analyses  show  similar  results  with  statistical significance.

## Efficacy at 24 weeks

It was advised to conduct a 24week placebo controlled phase III trial as MG fluctuates over time and treatment is anticipated to be long lasting. Study MG0011, was an open label extension of the 12-week pivotal study and 60 weeks of active treatment was obtained by adding these together. The main issue with the last 48 weeks is that in a setting that lacks a concurrent randomised control, treatment efficacy

<div style=\"page-break-after: always\"></div>

cannot be isolated, and the true treatment efficacy cannot be separated from e.g., subject-expectancy effect or spontaneous disease fluctuations. Nevertheless, supplementary analyses support that there is treatment efficacy after the 12 weeks of open label study (in total 60 weeks) despite other sources of clinical improvement.

## Efficacy in patients with mild gMG and patients with MGFA V

Patients included in the ZLP studies were more affected by their disease than in most other published gMG studies. This is likely due to the requirement QMG ≥12 and at least four QMG items of at least score 2, which was not required e. g. in the studies of other authorised gMG products. In subgroup analyses of study MG0010, there was a pattern of smaller magnitude of efficacy in participants with a milder disease. This pattern was also seen in the OL Study MG0011, with the largest difference between patients with mild and moderate-severe disease in participants assessed after the longer treatment duration of 24 weeks. This raised a concern regarding efficacy in patients with mild gMG. Disease severity in gMG can be assessed in several ways and there is no consensus on what should be considered mild disease. In post hoc subgroup analyses on data from studies MG0010 and MG0011 using data imputation, no clear correlation was observed between the effect size (CBL, responder rate) of zilucoplan and disease severity (based on MGFA, MG-ADL and QMG). The indication may not be restricted to the pivotal study population, who had QMG ≥ 12 and at least four QMG items of at least score 2, as it is considered that efficacy can be extrapolated to patients with less severe disease but who are still symptomatic despite standard of care, based on the mechanism of action with reduced complement dependent cytotoxicity.

Patients with severe and life-threatening disease, MGFA V, were excluded from the studies. In line with other authorised gMG products, it is highlighted in the product information that there is no experience in patients of MGFA class V.

## Efficacy depending on age and age at disease onset

Subgroup  analyses  in  MG0010  and  MG0011  raised  some  concern  regarding  efficacy  among  elderly participants. In post hoc analyses using data imputation (discontinuation, rescue treatment or death imputed as treatment failure) there is a numerical difference at 24 weeks of treatment in MG-QOL15r, other  endpoints  not  showing  anything  notable.  As  there  is  no  rationale  why  efficacy  would  differ depending on age as such, efficacy analyses based on age at disease onset was performed. MG has traditionally  been  divided  in  early  onset  (dominated  by  women,  typically  generalised  with  clear fluctuations) and late onset (increase proportion of men, more ocular symptoms and less pronounced fluctuations). Lately, division into three subgroups based on age at onset has shown purposeful, early &lt;50, late ≥ 50 to &lt;65 years, very late ≥ 65 years (Cortés-Vicente et al , 2020). Post hoc efficacy analyses with conservative imputation show a variability in placebo response which may be due to a variability in the regression to the mean in a study of patients with a fluctuating disease and strict inclusion criteria (Benatar et al 2012). Efficacy assessed after ZLP treatment is more stable and seemingly at a relevant size. Efficacy resulting from inhibition of CDC in AChR antibody mediated disease, should likely not be affected by age or age at onset. Most data point to a fair effect in elderly patients and in patients with late and very late onset of disease and a restriction to the indication is not justified.

## Efficacy in treatment refractory patients

The  estimated  efficacy  in  participants  who  at  baseline  were  classified  as  treatment  refractory,  was numerically larger than in participants not classified as refractory. This may partly be due to refractory participants having a more severe disease, but the result is important as this group of patients is in particular need for a treatment alternative.

<div style=\"page-break-after: always\"></div>

## Other comments regarding efficacy

Compared to the two other C5 inhibitors recently approved in the EU which are administered IV (every 1 to 2 months), Zilucoplan is administered SC every day. The SC route may be more convenient to patients despite the need for daily injections, and may reduce the burden on healthcare.

## Safety

The C5 inhibition caused by zilucoplan especially increases the risk of Neisseria infection. However, to increase the awareness among the treating neurologists, the SmPC 4.4 wording is recommended to be updated  related  to  recommendation  to  adhere  to  immunisation  programmes  for  patients  with neuromuscular disorders with muscular weakness or patients above the age of 65.

Although the mechanism of action of zilucoplan is well-known from approved C5 monoclonal antibodies, zilucoplan is a different type of molecule and may have a somewhat different safety profile, as indicated by various non-clinical findings (e.g. epithelial degeneration and mononuclear cell infiltrates in various tissues and cases of pancreatitis) . From the clinical studies, the non-clinical findings are in general not reflected, but there are remaining uncertainties related to observed various severe pancreatic adverse events  and  their  possible  causal  relation  to  zilucoplan  treatment,  which  will  be  followed  up  by  the applicant in future PSURs.

## 3.7.2. Balance of benefits and risks

The benefit/risk balance is positive.

The favourable effects on a number of different gMG-related endpoints are robust for placebo-controlled treatment up to 12 weeks and long-term efficacy is supported by open label data up to 60 weeks of zilucoplan treatment. Efficacy can be extrapolated to patients not included in the studies with less severe disease but who are still symptomatic despite standard of care. The unfavourable effects are in general mild to moderate and manageable.

## 3.7.3. Additional considerations on the benefit-risk balance

Not applicable.

## 3.8. Conclusions

The  overall  benefit/risk  balance  of  Zilbrysq  is  positive,  subject  to  the  conditions  stated  in  section 'Recommendations'.

## 4. Recommendations

## Similarity with authorised orphan medicinal products

The CHMP by consensus is of the opinion that Zilbrysq is not similar to Soliris and Vyvgart within the meaning of Article 3 of Commission Regulation (EC) No. 847/2000. See Appendix on Similarity

## Outcome

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considers by consensus that the benefit-risk balance of Zilbrysq is favourable in the following indication(s):

<div style=\"page-break-after: always\"></div>

Zilbrysq  is  indicated  as  an  add-on  to  standard  therapy  for  the  treatment  of  generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.

The CHMP therefore recommends the granting of the marketing authorisation subject to the following conditions:

## Conditions or restrictions regarding supply and use

Medicinal  product  subject  to  restricted  medical  prescription  (see  Annex  I:  Summary  of  Product Characteristics, section 4.2).

## Other conditions and requirements of the marketing authorisation

## · Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## · Risk Management Plan (RMP)

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.
- Additional risk minimisation measures

Prior to the launch of zilucoplan in each Member State, the MAH must agree about the content and format  of  the  controlled  access  programme  and  educational  programme,  including  communication media, distribution modalities, and any other aspects of the programme, with the National Competent Authority.

The  controlled  access  programme  and  educational  programme  are  aimed  at  further  minimizing  the important potential risk of meningococcal infection by reinforcing the key safety information available in the Summary of Product Characteristics and the package leaflet.

The MAH shall ensure that in each Member State where zilucoplan is marketed, healthcare professionals (HCPs) and patients/caregivers who are expected to prescribe/use zilucoplan are provided with/have access to the following educational materials:

- Guide for HCPs
- Patient alert card
- Patient/carer guide

## The physician education material should contain:

- The Summary of Product Characteristics

<div style=\"page-break-after: always\"></div>

- Guide for HCPs

The guide for HCPs should contain the following key elements:

- A concise introduction to zilucoplan and the purpose of the guide for HCPs.
- The HCP should educate the patient/caregiver on the risk described in the guide for HCPs and ensure the patient/caregiver is provided with a patient alert card and a patient/carer guide.
- Key information on the important potential risk of meningococcal infection.
- o Treatment with zilucoplan may increase the risk of meningococcal infection.
- o Emphasise requirement of meningococcal vaccination and potentially antibiotic prophylaxis and  that  meningococcal  vaccines  reduce  but  do  not  completely  eliminate  the  risk  of meningococcal infection.
- o Inform HCPs on how to comply with the controlled access programme to ensure that only patients who have been vaccinated against Neisseria meningitidis have access to zilucoplan.
- o Importance of monitoring for meningococcal infection and educate patients/caregivers on signs and symptoms of meningococcal infection and when to seek medical attention.
- o Recommendation for measures to take in case of suspected meningococcal infection.
- Emphasise importance to patients/caregivers that the patient alert card needs to be carried at all times and to be presented to all HCPs.
- Reminding the need for and how to report suspected adverse reactions.

## The patient/caregiver information pack should contain:

- Package leaflet
- Patient alert card
- Patient/carer guide

The patient alert card should contain the following key elements:

- A concise introduction to the potential risk of meningococcal infections with zilucoplan as a C5 inhibitor.
- A warning message for HCPs, including in conditions of emergency, that the patient is using zilucoplan.
- Signs and symptoms of meningococcal infection and when to seek medical attention.
- The importance of carrying the patient alert card at all times and presenting it to all HCPs.
- Contact details of the zilucoplan prescriber.

## The patient/care guide should contain the following key elements:

- An introduction to zilucoplan treatment and a description of the correct use of zilucoplan including key information for safe self-administration.
- Zilucoplan may increase the risk of meningococcal infection.
- Requirement of meningococcal vaccinations  (initial  and  booster  vaccinations)  and  potentially antibiotic  prophylaxis  to  minimise  the  risk  of  meningococcal  infections.  Emphasise  that

<div style=\"page-break-after: always\"></div>

meningococcal  vaccines  reduce  but  do  not  completely  eliminate  the  risk  of  meningococcal infection.

- A controlled access programme is in place to ensure that only patients who have been vaccinated against meningococcal infection have access to zilucoplan.
- Signs and symptoms of meningococcal infection and when to seek medical attention.
- The importance of carrying the patient alert card at all times and presenting it to all HCPs.
- Reminding the need for and how to report suspected adverse reactions.

The MAH shall send annually a letter to prescribing physicians to remind them to verify and ensure that their  patient's  vaccination  against  meningococcal  infection  is  still  current  according  to  relevant vaccination guidelines.

The  MAH  shall  implement  in  each  Member  State  where  Zilbrysq  is  marketed,  a  controlled  access programme to ensure that only patients who have been vaccinated against Neisseria meningitidis have access to zilucoplan. Verification of vaccination is achieved via written confirmation from the prescriber.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product to be implemented by the Member States

Not applicable.

## New active substance status

Based on the CHMP review of the available data, the CHMP considers that zilucoplan is to be qualified as a new active substance in itself as it is not a constituent of a medicinal product previously authorised within the European Union.

Refer to Appendix on new active substance (NAS).